CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
HCV-Single Disease Content  
Live CME Meetings

HCV Alliance Series

The goal of the HCV Alliance program is to provide small group education in order to improve patient outcomes. The HCV ALLIANCE program will provide 2 sessions of in-depth, structured clinical guidance and support to select community-based gastroenterologists while providing a "hands-on" consultative approach to education and training.

HCV Advances Series

The goal of the HCV Advances series is to provide important clinical data on issues related to the management of HCV. This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, physician assistants, and nurse practitioners involved in the care of patients with HCV.

Liver Summit Series

The goal of the Liver Summit series is to educate primary care providers involved in the diagnosis and management of patients with chronic liver disease and help them achieve a level of competency that leads to improved outcomes to tens of thousands of patients with liver disorders.

Webcasts
     
Treatment of HCV GT 1,4,5,6 Patients - Jordan Feld   Educational Webcast
Treatment of HCV GT 2 and GT 3 Patients - Eric Lawitz   Educational Webcast
Trial By Jury: Current Controversies in HCV   CME Webcast
Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient   Educational Webcast
Latest Treatment Updates for GT 1 Patients   Educational Webcast
Latest Treatment Updates for GT 2/3 Patients   Educational Webcast
Disease Burden and Treatment Overview   CME Webcast
HCV Treatment Update: Sofosbuvir   CME Webcast
HCV Treatment Update: Simeprevir   CME Webcast
HCV Treatment Update: ABT-450r + ABT-267 + ABT 333 and Daclatasvir+ Sofofsbuvir   CME Webcast
Hepatology News Tonight: Managing Complications of Cirrhosis   CME Webcast
Best of HCV From AASLD 2013   Educational Webcast
Next wave of IFN-containing regimens   Educational Webcast
Autoimmune hepatitis: When first line therapy does not work   Educational Webcast
Hepatitis C: Management of previous nonresponders with first line protease inhibitors   Educational Webcast
Next wave of IFN-containing regimens   Educational Webcast
All oral regimens: How far away are they?   Educational Webcast
HCV: Highlights from EASL 2013   Educational Webcast
HCV: Highlights from EASL 2013   Educational Webcast
HCV: Highlights from EASL 2013   Educational Webcast
HCV: Highlights from EASL 2013   Educational Webcast
HCV Case Study: Optimizing Outcomes with Current Therapies   Educational Webcast
HCV Case Study: Treat Now or Wait for New Therapies   CME Webcast
Hepatology News Tonight: Special Report on HCV   CME Webcast
Emerging Therapies for HCV: Highlights from AASLD 2012   CME Webcast
Current CDC Guidelines on HCV Testing   Educational Webcast
Hepatitis C: Emerging Therapies   CME Webcast
2011 Update on HCV   Educational Webcast
CME eNewsletter
     
  Newsletter  
     
  Credit Designation  
  1.0 AMA PRA  
  Category 1 Credit(s)  
  Download  
     
  ACHS  
  Jointly sponsored by The Annenberg Center for Health Sciences and the Chronic Liver Disease Foundation.

This activity supported by:
Janssen Therapeutics
Vertex Pharmaceuticals
 
     
 
 
Hepatitis C Emerging Therapy Update: Reports From the Liver Meeting 2012
 
Target Audience
This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, physician assistants, and nurse practitioners involved in the care of patients with chronic liver disease.
 
Statement of Need/Program Overview
To provide important clinical data on issues related to the management of HCV.
 
Educational Objectives
Upon completion of this activity, participants should be better able to:
To assess the efficacy and safety of new antiviral agents currently under development for the treatment of chronic hepatitis C
To recognize the advantages offered by the new antiviral agents currently under development for the treatment of chronic hepatitis C when compared to current therapy with boceprevir or telaprevir + PegIFN + RBV
 
Accreditation Statement
Please see page 1 of the newsletter for full accreditation statement.
 
 
 
Dynamic CME Resource Library
     
Hepatitis C: Emerging Therapies   Educational eNewsletter
Slide Library
HCV Slides
   Released: 2014
Webcast
Treatment of HCV GT 1, 4, 5, 6 Patients
57 slides
 
 
   Released: 2014
Webcast
Treatment of HCV GT 2 and GT 3 Patients
34 slides
 
 
   Released: 2014
Webcast
Trial By Jury: Current Controversies in HCV
108 slides
 
 
   Released: 2014
Webcast
HCV Management Update 2014
85 slides
 
 
   Released: 2013
Webcast
HCV Alliance Program
38 slides
 
 
   Released: 2013
Webcast
HCV Alliance Program
30 slides
 
 
   Released: 2013
Webcast
Update on the Management of HCV: Focus on Novel Treatments
67 slides
 
 
   Released: 2013
Webcast
Best of HCV From AASLD 2013
61 slides
 
 
   Released: 2013
Webcast
Autoimmune hepatitis: When first line therapy does not work
29 slides
 
 
   Released: 2013
Webcast
Hepatitis C: Management of treatment naïve patients with first line protease inhibitors
18 slides
 
 
   Released: 2013
Webcast
Hepatitis C: Management of previous nonresponders with first line protease inhibitors
33 slides
 
 
   Released: 2013
Webcast
Next wave of IFN-containing regimens
32 slides
 
 
   Released: 2013
Webcast
All oral regimens: How far away are they?
27 slides
 
 
   Released: 2012
Webcast
HCV: Highlights from EASL 2013
33 slides
 
 
   Released: 2012
Webcast
Hepatitis C: Emerging Therapies
79 slides
 
 
   Released: 2012
Webcast
Hepatology News Tonight- Special Report on HCV
54 slides
 
 
   Released: 2012
Webcast
HCV Highlights from AASLD 2012
65 slides
 
 
   Released: 2012
Webcast
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)
66 slides
 
 
   Released: 2012
Webcast
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
46 slides
 
 
   Released: 2012
Webcast
Emerging Therapies for HCV: Highlights from AASLD- Part 1
39 slides
 
 
   Released: 2012
Webcast
Emerging Therapies for HCV: Highlights from AASLD- Part 2
31 slides
 
 
   Released: 2012
Webcast
HCV Case Study: Treat Now or Wait for New Therapies
31 slides
 
 
   Released: 2012
Webcast
HCV Case Study: Optimizing Outcomes with Current Therapies
18 slides
 
 
   Released: 2012
Webcast
Current CDC Guidelines on Treating HCV
14 slides
 
 
   Released: 2012
Webcast
Advances in the Management of HCV
59 slides
 
 
   Released: 2011
Webcast
Current Breakthroughs in the Management of Hepatitis C
11 slides
 
 
   Released: 2010
Webcast
Current Perspectives on Chronic Liver Disease
11 slides
 
 
     
 
 
Abstract Library
  1. Resolute efforts to cure hepatitis C: Understanding patients' reasons for completing antiviral treatment
    Clark JA1, Gifford AL2. Health (London). 2014 Nov 5. pii: 1363459314555237. [Epub ahead of print]


  2. Outcomes in Liver Transplantation: Does Sex Matter?
    Sarkar M1, Watt KD2, Terrault N3, Berenguer M4. J Hepatol. 2014 Nov 26. pii: S0168-8278(14)00872-1. doi: 10.1016/j.jhep.2014.11.023. [Epub ahead of print]


  3. Liver Stiffness Measurement among Patients with Chronic Hepatitis B and C: Results from a 5-Year Prospective Study
    Christiansen KM, Mössner BK, Hansen JF, Jarnbjer EF, Pedersen C, Christensen PB. PLoS One. 2014 Nov 4;9(11):e111912. doi: 10.1371/journal.pone.0111912. eCollection 2014.


  4. An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
    Kwo PY1, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X N Engl J Med. 2014 Nov 11. [Epub ahead of print]


  5. A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing
    Baumert TF1, Fauvelle C2, Chen DY3, Lauer GM4. J Hepatol. 2014 Nov;61(1S):S34-S44. doi: 10.1016/j.jhep.2014.09.009. Epub 2014 Nov 3.


  6. Are selective serotonin reuptake inhibitors associated with hepatocellular carcinoma in patients with hepatitis C?
    Pocha C1, Knott A, Rector TS, Dieperink E. J Clin Psychiatry. 2014 Oct;75(10):e1122-6. doi: 10.4088/JCP.13m08877.


  7. The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17 000 HCV-infected transplant recipients
    Younossi Z1, Stepanova M, Saab S, Trimble G, Mishra A, Henry L. Aliment Pharmacol Ther. 2014 Nov 21. doi: 10.1111/apt.13027. [Epub ahead of print]


  8. Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study
    Wu T1, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ. Dig Dis. 2014;32(6):791-9. doi: 10.1159/000368024. Epub 2014 Oct 29.


  9. Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy
    Tada T1, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabtake S, Ito T. J Gastroenterol. 2014 Nov 7. [Epub ahead of print]


  10. Chronic Hepatitis B and Liver Cancer Risks among Asian Immigrants in New York City: Results from a Large, Community-Based Screening, Evaluation, and Treatment Program
    Pollack HJ1, Kwon SC2, Wang SH3, Wyatt LC2, Trinh-Shevrin C2; AAHBP Coalition. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2229-39. doi: 10.1158/1055-9965.EPI-14-0491.


  11. Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
    Charlton M1, Gane E2, Manns MP3, Brown RS Jr4, Curry MP5, Kwo PY6, Fontana RJ7, Gilroy R8, Teperman L9, Muir AJ10, McHutchison JG11, Symonds WT11, Brainard D11, Kirby B11, Dvory-Sobol H11, Denning J11, Arterburn S11, Samuel D12, Forns X13, Terrault NA14. Gastroenterology. 2014 Oct 7. pii: S0016-5085(14)01194-9. doi: 10.1053/j.gastro.2014.10.001. [Epub ahead of print]


  12. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies
    Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print]


  13. Concordance of Sustained Virologic Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir-Containing Regimens for Hepatitis C Virus
    Yoshida EM1, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, Jacobson IM, Reddy KR, Lawitz E. Hepatology. 2014 Oct 14. doi: 10.1002/hep.27366. [Epub ahead


  14. Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis
    Stine JG1, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, Northup PG. Dig Dis Sci. 2014 Nov 6. [Epub ahead of print]


  15. Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study
    Poordad F1, Agarwal K2, Younes Z3, Cohen D4, Xie W4, Podsadecki T4. Clin Infect Dis. 2014 Nov 2. pii: ciu865. [Epub ahead of print]


  16. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C
    Stirnimann G. Expert Opin Pharmacother. 2014 Dec;15(17):2609-22. doi: 10.1517/14656566.2014.972364. Epub 2014 Oct 27.


  17. The continuum of hepatitis C testing and care
    Viner K1, Kuncio D, Newbern EC, Johnson CC. Hepatology. 2014 Oct 28. doi: 10.1002/hep.27584. [Epub ahead of print]


  18. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies
    Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print]


  19. Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment
    Huang F1, Moschetti V2, Lang B3, Halabi A4, Petersen-Sylla M4, Yong CL5, Elgadi M6. Antimicrob Agents Chemother. 2014 Oct 27. pii: AAC.03359-14. [Epub ahead of print]


  20. Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care
    Muir AJ. Top Antivir Med. 2014 Sep-Oct;22(4):685-9.


  21. Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013
    Kim HY, Kim W. World J Gastroenterol. 2014 Oct 28;20(40):14581-14588.


  22. Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
    Svarovskaia ES1, Dvory-Sobol H1, Parkin N2, Hebner C1, Gontcharova V1, Martin R1, Ouyang W1, Han B1, Xu S1, Ku K1, Chiu S1, Gane E3, Jacobson IM4, Nelson DR5, Lawitz E6, Wyles DL7, Bekele N1, Brainard D1, Symonds WT1, McHutchison JG1, Miller MD1, Mo H1. Clin Infect Dis. 2014 Sep 28. pii: ciu697. [Epub ahead of print]


  23. Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis
    Luo YQ1, Wu XX, Ling ZX, Cheng YW, Yuan L, Xiang C. J Zhejiang Univ Sci B. 2014 Oct;15(10):900-6. doi: 10.1631/jzus.B1400073.


  24. Evaluating a hepatitis c quality gap: missed opportunities for HCV-related cares
    Liu Y, Lawrence RH, Falck-Ytter Y, Watts B, Hirsch AA1. Am J Manag Care. 2014 Jul 1;20(7):e257-64.


  25. Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs
    Schackman BR1, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR, Freedberg KA, Linas BP. Addiction. 2014 Oct 8. doi: 10.1111/add.12754. [Epub ahead of print]


  26. Hepatitis C core antigen testing: a reliable, quick and potentially cost-effective alternative to Hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection
    Cresswell FV1, Fisher M2, Hughes DJ1, Shaw SG1, Homer G3, Hassan-Ibrahim MO3. Clin Infect Dis. 2014 Oct 9. pii: ciu782. [Epub ahead of print]


  27. Hepatitis B knowledge and preventive practices of Chinese American immigrants in Southern California
    Zhao X1, Edwards QT, Patel N, Hicks RW. J Am Assoc Nurse Pract. 2014 Oct 6. doi: 10.1002/2327-6924.12173. [Epub ahead of print]


  28. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection
    Zuo SR1, Zuo XC, Wang CJ, Ma YT, Zhang HY, Li ZJ, Song LY, Deng ZZ, Liu SK. J Clin Pharmacol. 2014 Oct 7. doi: 10.1002/jcph.409. [Epub ahead of print]


  29. Sofosbuvir (Sovaldi) for the treatment of hepatitis C
    Lam B1, Henry L, Younossi Z. Expert Rev Clin Pharmacol. 2014 Sep;7(5):555-66. doi: 10.1586/17512433.2014.928196. Epub 2014 Jun 11.


  30. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
    McDonald SA1, Innes HA2, Hayes PC3, Dillon JF4, Mills PR5, Goldberg DJ6, Barclay S7, Allen S8, Fox R5, Fraser A9, Kennedy N10, Bhattacharyya D11, Hutchinson SJ2. J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00635-7. doi: 10.1016/j.jhep.2014.08.046. [Epub ahead of print]


  31. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients
    Meissner EG1, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Hepatology. 2014 Sep 9. doi: 10.1002/hep.27424. [Epub ahead of print]


  32. Simeprevir (TMC435) with Peginterferon/Ribavirin in Patients Coinfected with HCV Genotype-1 and HIV-1: A Phase III Study
    Dieterich D1, Rockstroh JK2, Orkin C3, Gutiérrez F4, Klein MB5, Reynes J6, Shukla U7, Jenkins A8, Lenz O9, Ouwerkerk-Mahadevan S10, Peeters M9, De La Rosa G7, Tambuyzer L9, Jessner W9. Clin Infect Dis. 2014 Sep 5. pii: ciu675. [Epub ahead of print]


  33. Hepatitis C drugs: The end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: A concise review
    Yau AH, Yoshida EM. Can J Gastroenterol Hepatol. 2014 Sep;28(8):445-51.


  34. Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach
    Lanini S1, Mammone A, Puro V, Girardi E, Bruzzi P, Ippolito G. New Microbiol. 2014 Jul;37(3):263-76. Epub 2014 Jul 1.


  35. Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection
    Patel R1, Mikuls T, Richards JS, Kerr G, Cannon G, Baker JF. Arthritis Care Res (Hoboken). 2014 Sep 3. doi: 10.1002/acr.22463. [Epub ahead of print]


  36. Current Practices of Screening for Incident Hepatitis C Virus Infection among HIV- Infected, HCV-Uninfected Individuals in Primary Care
    Freiman JM1, Huang W1, White L2, Geng EH3, Hurt CB4, Taylor LE5, Overton ET6, Cachay ER7, Kitahata MM8, Moore RD9, Rodriguez B10, Mayer KH11, Linas BP12. Clin Infect Dis. 2014 Sep 3. pii: ciu698. [Epub ahead of print]


  37. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C
    Younossi ZM1, Stepanova M2, Henry L3, Gane E4, Jacobson IM5, Lawitz E6, Nelson D7, Gerber L2, Nader F8, Hunt S2. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6.


  38. Prevalence and correlates of hepatitis C virus infection among inmates at two New York State correctional facilities
    Alvarez KJ1, Befus M2, Herzig CT3, Larson E3. J Infect Public Health. 2014 Aug 30. pii: S1876-0341(14)00118-X. doi: 10.1016/j.jiph.2014.07.018. [Epub ahead of print]


  39. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis
    Huang H, Kang R, Zhao Z. PLoS One. 2014 Sep 3;9(9):e106376. doi: 10.1371/journal.pone.0106376. eCollection 2014.


  40. Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus
    Summers BB1, Beavers JW, Klibanov OM. J Pharm Pharmacol. 2014 Aug 31. doi: 10.1111/jphp.12294. [Epub ahead of print]


  41. Management of hepatitis C virus and human immunodeficiency virus coinfection
    O'neil CR1, Coffin CS. Minerva Gastroenterol Dietol. 2014 Sep;60(3):165-75.


  42. Follow-up testing for hepatitis C virus infection: an analysis of massachusetts surveillance data, 2007-2010
    Barton K, Church D, Onofrey S, Cocoros N, DeMaria A Jr. Public Health Rep. 2014 Sep;129(5):403-7.


  43. BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion
    Grady BP1, Prins M, Rebers S, Molenkamp R, Geskus RB, Schinkel J. J Viral Hepat. 2014 Sep 1. doi: 10.1111/jvh.12303. [Epub ahead of print]


  44. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department
    Galbraith JW1, Franco RA, Donnelly JP, Rodgers JB, Morgan JM, Viles AF, Overton ET, Saag MS, Wang HE. Hepatology. 2014 Sep 1. doi: 10.1002/hep.27410. [Epub ahead of print]


  45. Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring-predictors and predictive models of disease progression
    Konerman MA1, Yapali S, Lok AS. Aliment Pharmacol Ther. 2014 Aug 28. doi: 10.1111/apt.12921. [Epub ahead of print]


  46. Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes
    Liu T, Howell GT, Turner L, Corace K, Garber G, Cooper C. Can J Gastroenterol Hepatol. 2014 Jul-Aug;28(7):381-4.


  47. A Pilot Study Examining the Safety and Tolerability of Valacyclovir in Veterans With Hepatitis C Virus/Herpes Simplex Virus Type 2 Coinfection
    Burton MJ1, Penman A, Sunesara I, McGuire BM, Hook EW 3rd. Am J Med Sci. 2014 Aug 26. [Epub ahead of print]


  48. Liver inflammation is a Risk Factor for Prediabetes in At-Risk Latinos with and without Hepatitis C Infection
    Burman BE1, Bacchetti P, Ayala CE, Gelman N, Melgar J, Khalili M. Liver Int. 2014 Aug 23. doi: 10.1111/liv.12676. [Epub ahead of print]


  49. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection
    Flanagan S1, Crawford-Jones A, Orkin C. Expert Rev Clin Pharmacol. 2014 Sep 11:1-14. [Epub ahead of print]


  50. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection
    Scott J1, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L.


  51. Treating hepatitis C in the elderly: the future is near?
    Conti F1, Vitale G, Andreone P. Expert Opin Pharmacother. 2014 Oct;15(14):2019-28. doi: 10.1517/14656566.2014.945422. Epub 2014 Aug 26.


  52. An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials
    Wendt A1, Bourlière M2. Ther Adv Infect Dis. 2013 Dec;1(6):191-208. doi: 10.1177/2049936113502647.


  53. Lack of Clinically Significant Pharmacokinetic Interaction Between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir
    Wire MB1, Fang L2, Hussaini A3, Kleha JF4, Theodore D4. Antimicrob Agents Chemother. 2014 Aug 25. pii: AAC.03091-14. [Epub ahead of print]


  54. Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring-predictors and predictive models of disease progression
    Konerman MA1, Yapali S, Lok AS. Aliment Pharmacol Ther. 2014 Aug 28. doi: 10.1111/apt.12921. [Epub ahead of print]


  55. The frequency and determinants of liver stiffness measurement failure: a retrospective study of
    Ji D1, Shao Q1, Han P2, Li F1, Li B1, Zang H3, Niu X1, Li Z1, Xin S3, Chen G1. PLoS One. 2014 Aug 14;9(8):e105183. doi: 10.1371/journal.pone.0105183. eCollection 2014.


  56. Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance
    Chang ML1, Tsou YK2, Hu TH3, Lin CH2, Lin WR2, Sung CM2, Chen TH2, Cheng ML4, Chang KC3, Chiu CT2, Yeh CT2, Pang JH5, Shiao MS4. PLoS One. 2014 Aug 14;9(8):e104783. doi: 10.1371/journal.pone.0104783. eCollection 2014.


  57. Daclatasvir + Asunaprevir: first global approval
    Poole RM. Drugs. 2014 Sep;74(13):1559-71. doi: 10.1007/s40265-014-0279-4.


  58. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for Sofosbuvir
    Donaldson EF1, Harrington PR, O'Rear JJ, Naeger LK. Hepatology. 2014 Aug 14. doi: 10.1002/hep.27375. [Epub ahead of print]


  59. Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C
    Evon DM1, Esserman DE2, Howell MA3, Ruffin RA1. Pharmacopsychiatry. 2014 Sep;47(6):195-201. doi: 10.1055/s-0034-1385929. Epub 2014 Aug 14.


  60. Hepatitis C in African Americans
    Saab S1, Jackson Md Facg C2, Nieto DO Facg Facp J3, Francois Md MSc Facg F4. Am J Gastroenterol. 2014 Sep 2. doi: 10.1038/ajg.2014.243. [Epub ahead of print]


  61. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
    Hayashi N1, Mobashery N, Izumi N. J Gastroenterol. 2014 Aug 13. [Epub ahead of print]


  62. Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C
    Lawitz E1, Gruener D, Marbury T, Hill J, Webster L, Hassman D, Nguyen AH, Pflanz S, Mogalian E, Gaggar A, Massetto B, Subramanian GM, McHutchison JG, Jacobson IM, Freilich B, Rodriguez-Torres M. Antivir Ther. 2014 Aug 8. doi: 10.3851/IMP2845. [Epub ahead of print]


  63. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis c virus
    Eley T1, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, Gardiner D, Grasela DM, Bertz R, Bifano M. Clin Drug Investig. 2014 Sep;34(9):661-71. doi: 10.1007/s40261-014-0219-9.


  64. Treatment of hepatitis C: a systematic review
    Kohli A1, Shaffer A2, Sherman A2, Kottilil S2. JAMA. 2014 Aug 13;312(6):631-40. doi: 10.1001/jama.2014.7085.


  65. Ending hepatitis C in the United States: the role of screening
    Coffin PO1, Reynolds A2. Hepat Med. 2014 Jul 3;6:79-87. doi: 10.2147/HMER.S40940. eCollection 2014.


  66. Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting
    Price JC1, Murphy RC, Shvachko VA, Pauly MP, Manos MM. Dig Dis Sci. 2014 Aug 8. [Epub ahead of print]


  67. Pegylated-IFN?2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new
    Bichoupan K1, Dieterich DT. Expert Opin Biol Ther. 2014 Sep;14(9):1369-78. doi: 10.1517/14712598.2014.943180.


  68. Modeling viral evolutionary dynamics after telaprevir-based treatment
    Haseltine EL1, De Meyer S2, Dierynck I2, Bartels DJ1, Ghys A2, Davis A1, Zhang EZ1, Tigges AM1, Spanks J1, Picchio G3, Kieffer TL1, Sullivan JC1. PLoS Comput Biol. 2014 Aug 7;10(8):e1003772. doi: 10.1371/journal.pcbi.1003772. eCollection 2014.


  69. Performance Comparison of the Versant HCV Genotype 2.0 Assay (LiPA) and the Abbott Realtime HCV Genotype II for Detecting Hepatitis C Virus Genotype 6
    Yang R1, Cong X1, Du S1, Fei R1, Rao H1, Wei L2. J Clin Microbiol. 2014 Aug 6. pii: JCM.00882-14. [Epub ahead of print]


  70. The role played by gender in viral hepatitis
    Bernabucci V1, Villa E. Scand J Clin Lab Invest Suppl. 2014;74(244):90-4. doi: 10.3109/00365513.2014.936695.


  71. Global epidemiology and genotype distribution of the hepatitis C virus infection
    Gower E1, Estes C C1, Hindman S1, Razavi-Shearer K1, Razavi H2. J Hepatol. 2014 Jul 30. pii: S0168-8278(14)00526-1. doi: 10.1016/j.jhep.2014.07.027. [Epub ahead of print]


  72. The changing burden of hepatitis C virus infection in the United States: model-based predictions
    Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. Ann Intern Med. 2014 Aug 5;161(3):170-80. doi: 10.7326/M14-0095.


  73. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz and tenofovir
    Sabo JP1, Kort J1, Ballow C2, Haschke M3, Battegay M3, Fuhr R4, Girlich B5, Schobelock M6, Feifel U7, Lang B8, Li Y1, Elgadi M9. Clin Infect Dis. 2014 Aug 4. pii: ciu616. [Epub ahead of print]


  74. Clinical outcomes of compensated and decompensated cirrhosis: A long term study
    Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. World J Hepatol. 2014 Jul 27;6(7):504-12. doi: 10.4254/wjh.v6.i7.504.


  75. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
    Petta S1, Cabibbo G1, Enea M2, Macaluso FS1, Plaia A2, Bruno R3, Gasbarrini A4, Bruno S5, Craxì A1, Cammà C6; on behalf of the WEF study group. Dig Liver Dis. 2014 Jul 22. pii: S1590-8658(14)00422-8. doi: 10.1016/j.dld.2014.06.009. [Epub ahead of print]


  76. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
    Lawitz E1, Sulkowski MS2, Ghalib R3, Rodriguez-Torres M4, Younossi ZM5, Corregidor A6, DeJesus E7, Pearlman B8, Rabinovitz M9, Gitlin N10, Lim JK11, Pockros PJ12, Scott JD13, Fevery B14, Lambrecht T15, Ouwerkerk-Mahadevan S14, Callewaert K14, Symonds WT16, Picchio G17, Lindsay KL17, Beumont M14, Jacobson IM18. Lancet. 2014 Jul 26. pii: S0140-6736(14)61036-9. doi: 10.1016/S0140-6736(14)61036-9. [Epub ahead of print]


  77. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
    Manns M1, Pol S2, Jacobson IM3, Marcellin P4, Gordon SC5, Peng CY6, Chang TT7, Everson GT8, Heo J9, Gerken G10, Yoffe B11, Towner WJ12, Bourliere M13, Metivier S14, Chu CJ15, Sievert W16, Bronowicki JP17, Thabut D18, Lee YJ19, Kao JH20, McPhee F21, Kopit J21, Mendez P22, Linaberry M22, Hughes E22, Noviello S22; on behalf of the HALLMARK-DUAL Study Team. Lancet. 2014 Jul 26. pii: S0140-6736(14)61059-X. doi: 10.1016/S0140-6736(14)61059-X. [Epub ahead of print]


  78. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection
    Saab S1, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Aliment Pharmacol Ther. 2014 Jul 28. doi: 10.1111/apt.12871. [Epub ahead of print]


  79. Severity of liver disease among chronic hepatitis C patients: an observational study of 4594 patients in 5 EU countries
    Marcellin P1, Grotzinger K, Theodore D, Demuth D, Manns M, Bañares Cañizares R, Pike J, Forssen UM. J Gastroenterol Hepatol. 2014 Aug 4. doi: 10.1111/jgh.12698. [Epub ahead of print]


  80. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
    Hézode C1, Hirschfield GM2, Ghesquiere W3, Sievert W4, Rodriguez-Torres M5, Shafran SD6, Thuluvath PJ7, Tatum HA8, Waked I9, Esmat G10, Lawitz EJ11, Rustgi VK12, Pol S13, Weis N14, Pockros PJ15, Bourlière M16, Serfaty L17, Vierling JM18, Fried MW19, Weiland O20, Brunetto MR21, Everson GT22, Zeuzem S23, Kwo PY24, Sulkowski M25, Bräu N26, Hernandez D27, McPhee F27, Wind-Rotolo M28, Liu Z29, Noviello S28, Hughes EA28, Yin PD27, Schnittman S27. Gut. 2014 Jul 30. pii: gutjnl-2014-307498. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print]


  81. New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment
    Zimner-Rapuch S1, Janus N, Deray G, Launay-Vacher V. Drugs. 2014 Jul 25. [Epub ahead of print]


  82. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)
    Loras C1, Gisbert JP2, Saro MC3, Piqueras M4, Sánchez-Montes C5, Barrio J6, Ordás I7, Montserrat A8, Ferreiro R9, Zabana Y1, Chaparro M2, Fernández-Bañares F1, Esteve M10; for the REPENTINA study, GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). J Crohns Colitis. 2014 Jul 19. pii: S1873-9946(14)00206-2. doi: 10.1016/j.crohns.2014.06.009. [Epub ahead of print]


  83. Costs of Telaprevir-based Triple Therapy for Hepatitis C: $189,000 per Sustained Virologic Response
    Bichoupan K1, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Perumalswami PV, Schiano TD, Odin JA, Liu L, Moskowitz AJ, Dieterich DT, Branch AD. Hepatology. 2014 Jul 28. doi: 10.1002/hep.27340. [Epub ahead of print]


  84. Delivery of treatment for hepatitis C virus infection in the primary care setting
    Baker D1, Alavi M, Erratt A, Hill S, Balcomb A, Hallinan R, Siriragavan S, Richmond D, Smart J, Keats J, Doong N, Marks P, Grebely J, Dore GJ. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):1003-9. doi: 10.1097/MEG.0000000000000150.


  85. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
    Gentile I1, Buonomo AR1, Zappulo E1, Minei G1, Morisco F2, Borrelli F1, Coppola N3, Borgia G1. Ther Clin Risk Manag. 2014 Jun 26;10:493-504. doi: 10.2147/TCRM.S66731. eCollection 2014.


  86. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection
    Sulkowski MS1, Naggie S2, Lalezari J3, Fessel WJ4, Mounzer K5, Shuhart M6, Luetkemeyer AF7, Asmuth D8, Gaggar A9, Ni L9, Svarovskaia E9, Brainard DM9, Symonds WT9, Subramanian GM9, McHutchison JG9, Rodriguez-Torres M10, Dieterich D11; PHOTON-1 Investigators. JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734.


  87. Assessment of Hepatitis C Risk Factors and Infection Prevalence in a Jail Population
    Wenger PJ1, Rottnek F, Crippin JS, Parker T. Am J Public Health. 2014 Jul 17:e1-e6. [Epub ahead of print]


  88. The Effect of HIV-Hepatitis C Co-Infection on Bone Mineral Density and Fracture: A Meta-Analysis
    O'Neill TJ1, Rivera L1, Struchkov V2, Zaheen A3, Thein HH4. PLoS One. 2014 Jul 17;9(7):e101493. doi: 10.1371/journal.pone.0101493. eCollection 2014.


  89. Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients
    Liu X1, Wang Y2, Zhang G1, Li N3, Zhu Q3, Chang H1, Han Q3, Lv Y4, Liu Z5. Int J Antimicrob Agents. 2014 Jun 10. pii: S0924-8579(14)00163-0. doi: 10.1016/j.ijantimicag.2014.04.018. [Epub ahead of print]


  90. Concordance of risk behavior reporting within HCV serodiscordant injecting partnerships of young injection drug users in San Francisco, CA
    Evans JL1, Morris MD2, Yu M2, Page K2, Hahn JA2. Drug Alcohol Depend. 2014 Jul 4. pii: S0376-8716(14)00955-7. doi: 10.1016/j.drugalcdep.2014.06.028. [Epub ahead of print]


  91. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C
    Bronowicki JP1, Ratziu V2, Gadano A3, Thuluvath PJ4, Bessone F5, Martorell CT6, Pol S7, Terg R8, Younes Z9, He B10, Eley T10, Cohen D11, Yu F11, Hernandez D11, McPhee F11, Mendez P10, Hughes E10. J Hepatol. 2014 Jul 16. pii: S0168-8278(14)00480-2. doi: 10.1016/j.jhep.2014.07.011. [Epub ahead of print]


  92. Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965
    Cartwright EJ1, Rentsch C, Rimland D. BMC Res Notes. 2014 Jul 14;7(1):449. doi: 10.1186/1756-0500-7-449.


  93. Antiviral treatment of hepatitis C
    Feeney ER1, Chung RT2. BMJ. 2014 Jul 7;349:g3308. doi: 10.1136/bmj.g3308.


  94. MicroRNA and hepatitis C virus- challenges in investigation and translation: a review of the literature
    Waldron PR1, Holodniy M2. Diagn Microbiol Infect Dis. 2014 Jun 5. pii: S0732-8893(14)00243-0. doi: 10.1016/j.diagmicrobio.2014.05.024. [Epub ahead of print]


  95. An overview of hepatitis C vaccines
    Garcia A, Fernandez S, Toro F, De Sanctis JB1. Recent Pat Inflamm Allergy Drug Discov. 2014;8(2):85-91.


  96. Hepatic Retransplant: What Have We Learned?
    Kitchens WH1, Yeh H2, Markmann JF3. Clin Liver Dis. 2014 Aug;18(3):731-751. doi: 10.1016/j.cld.2014.05.010.


  97. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential
    Lauffenburger JC1, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Eur J Gastroenterol Hepatol. 2014 Jul 10. [Epub ahead of print]


  98. Oral manifestations of hepatitis C virus infection
    Carrozzo M, Scally K. World J Gastroenterol. 2014 Jun 28;20(24):7534-7543.


  99. Association between chronic hepatitis C virus infection and low muscle mass in US adults
    Gowda C1, Compher C, Amorosa VK, Lo Re V 3rd. J Viral Hepat. 2014 Jul 2. doi: 10.1111/jvh.12273. [Epub ahead of print]


  100. Estimating the true prevalence of hepatitis C in rhode island
    Kinnard EN1, Taylor LE2, Galárraga O3, Marshall BD4. R I Med J (2013). 2014 Jul 1;96(7):19-24.


  101. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis
    Yehia BR1, Schranz AJ2, Umscheid CA3, Lo Re V 3rd4. PLoS One. 2014 Jul 2;9(7):e101554. doi: 10.1371/journal.pone.0101554. eCollection 2014.


  102. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis
    García-Álvarez M1, Pineda-Tenor D, Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, Resino S. Hepatology. 2014 Jun 27. doi: 10.1002/hep.27281. [Epub ahead of print]


  103. Viral kinetic modeling: state of the art
    Canini L1, Perelson AS. J Pharmacokinet Pharmacodyn. 2014 Jun 25. [Epub ahead of print]


  104. Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs
    Hayes B, Briceno A, Asher A, Yu M, Evans JL, Hahn JA, Page K. BMC Public Health. 2014 Jun 25;14(1):645. [Epub ahead of print]


  105. Emerging therapeutic options for the management of hepatitis C infection
    Thompson JR. World J Gastroenterol. 2014 Jun 21;20(23):7079-7088.


  106. Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study
    Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print]


  107. Risk of hepatitis C virus exposure in orthopedic surgery: is universal screening needed?
    DelSole EM, Mercuri JJ, Stachel A, Phillips MS, Zuckerman JD1. Am J Orthop (Belle Mead NJ). 2014 Jun;43(6):E117-23.


  108. Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program
    Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print]


  109. Natural history and management of hepatitis C: does sex play a role?
    Baden R1, Rockstroh JK2, Buti M3. Infect Dis. 2014 Jul 15;209 Suppl 3:S81-5. doi: 10.1093/infdis/jiu057.


  110. Restricting liver transplant recipients to younger donors does not increase wait-list time or drop-out rate: The hepatitis C experience
    Flemming JA1, Vagefi PA, Freise CE, Yao FY, Terrault NA. Liver Transpl. 2014 Jun 25. doi: 10.1002/lt.23937. [Epub ahead of print]


  111. Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study
    Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print]


  112. Risk of hepatitis C virus exposure in orthopedic surgery: is universal screening needed?
    DelSole EM, Mercuri JJ, Stachel A, Phillips MS, Zuckerman JD1. Am J Orthop (Belle Mead NJ). 2014 Jun;43(6):E117-23.


  113. Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program
    Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print]


  114. Natural history and management of hepatitis C: does sex play a role?
    Baden R1, Rockstroh JK2, Buti M3. Infect Dis. 2014 Jul 15;209 Suppl 3:S81-5. doi: 10.1093/infdis/jiu057.


  115. Restricting liver transplant recipients to younger donors does not increase wait-list time or drop-out rate: The hepatitis C experience
    Flemming JA1, Vagefi PA, Freise CE, Yao FY, Terrault NA. Liver Transpl. 2014 Jun 25. doi: 10.1002/lt.23937. [Epub ahead of print]


  116. Incidence and Management of Rash in Telaprevir-Treated Patients: Lessons for Simeprevir?
    Smith MA1, Johnson HJ2, Chopra KB2, Dunn MA2, Ulrich AM2, Mohammad RA3. Ann Pharmacother. 2014 Jun 17. pii: 1060028014539274. [Epub ahead of print]


  117. New insight into the enhanced effect of pegylated IFN-alpha
    Abe H1, Hayes CN, Chayama K. Hepatology. 2014 Jun 18. doi: 10.1002/hep.27269. [Epub ahead of print]


  118. Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model
    Ikeda K1, Kawamura Y, Kobayashi M, Fukushima T, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Oncology. 2014 Jun 7;86(5-6):295-302. [Epub ahead of print]


  119. High Post-Transplant Virologic Response in Hepatitis C Virus Infected Patients Treated with Pre-Transplant Protease Inhibitor-Based Triple Therapy
    Verna EC1, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, Fox AN, Dove LM, Brown RS. Liver Int. 2014 Jun 6. doi: 10.1111/liv.12616. [Epub ahead of print]


  120. Outbreaks of Infections Associated With Drug Diversion by US Health Care Personnel
    Schaefer MK1, Perz JF2. Mayo Clin Proc. 2014 May 30. pii: S0025-6196(14)00342-5. doi: 10.1016/j.mayocp.2014.04.007. [Epub ahead of print]


  121. Validation of the fatigue severity scale in chronic hepatitis C
    Rosa K, Fu M, Gilles L, Cerri K, Peeters M, Bubb J, Scott J. Health Qual Life Outcomes. 2014 Jun 11;12(1):90. [Epub ahead of print]


  122. IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response
    Lin JC1, Habersetzer F2, Rodriguez-Torres M3, Afdhal N4, Lawitz EJ5, Paulson MS6, Zhu Y6, Subramanian GM6, McHutchison JG6, Sulkowski M7, Wyles DL1, Schooley RT1. J Infect Dis. 2014 Jun 6. pii: jiu325. [Epub ahead of print]


  123. Long term changes in liver histology following treatment of chronic hepatitis C virus
    Shiffman ML1, Sterling RK2, Contos M3, Hubbard S2, Long A1, Luketic VA2, Stravitz RT2, Fuchs M2, Sanyal AJ2. Ann Hepatol. 2014 Jul-Aug;13(4):340-9.


  124. Pushing to a cure by harnessing innate immunity against hepatitis C virus
    Ireton RC1, Gale M Jr2. Antiviral Res. 2014 Jun 4. pii: S0166-3542(14)00149-1. doi: 10.1016/j.antiviral.2014.05.012. [Epub ahead of print]


  125. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
    Manns M1, Marcellin P2, Poordad F3, de Araujo ES4, Buti M5, Horsmans Y6, Janczewska E7, Villamil F8, Scott J9, Peeters M10, Lenz O10, Ouwerkerk-Mahadevan S11, De La Rosa G12, Kalmeijer R12, Sinha R10, Beumont-Mauviel M10. Lancet. 2014 Jun 3. pii: S0140-6736(14)60538-9. doi: 10.1016/S0140-6736(14)60538-9. [Epub ahead of print]


  126. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort
    Tracy D1, Hahn JA2, Fuller Lewis C1, Evans J3, Briceño A3, Morris MD3, Lum PJ4, Page K3. BMJ Open. 2014 May 29;4(5):e004988. doi: 10.1136/bmjopen-2014-004988.


  127. Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals
    Bichoupan K1, Dieterich DT. Drugs. 2014 May 28. [Epub ahead of print]


  128. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
    Jacobson IM1, Dore GJ2, Foster GR3, Fried MW4, Radu M5, Rafalsky VV6, Moroz L7, Craxi A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, De La Rosa G11, Kalmeijer R11, Scott J12, Sinha R9, Beumont-Mauviel M9. Lancet. 2014 Jun 3. pii: S0140-6736(14)60494-3. doi: 10.1016/S0140-6736(14)60494-3. [Epub ahead of print]


  129. Response-Guided Therapy for Hepatitis C Genotype 2 and 3 in Those with HIV Coinfection
    Win LL1, James P, Wong DK. Dig Dis Sci. 2014 May 21. [Epub ahead of print]


  130. The current state and future prospects of chronic hepatitis C virus infection treatment
    Moore C1, Levitsky J. Curr Infect Dis Rep. 2014 Aug;16(8):413. doi: 10.1007/s11908-014-0413-1.


  131. Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects
    Lawitz EJ1, Membreno FE. J Gastroenterol Hepatol. 2014 May 22. doi: 10.1111/jgh.12632. [Epub ahead of print]


  132. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes
    Linas BP1, Barter DM2, Leff JA3, Assoumou SA2, Salomon JA4, Weinstein MC5, Kim AY6, Schackman BR3. PLoS One. 2014 May 19;9(5):e97317. doi: 10.1371/journal.pone.0097317. eCollection 2014.


  133. My Treatment Approach to Chronic Hepatitis C Virus
    Shiffman ML1, Long AG2, James A2, Alexander P2. Mayo Clin Proc. 2014 May 24. pii: S0025-6196(14)00372-3. doi: 10.1016/j.mayocp.2014.04.013. [Epub ahead of print]


  134. Resistance to hepatitis C virus protease inhibitors
    Kieffer TL1, George S2. Curr Opin Virol. 2014 May 19;8C:16-21. doi: 10.1016/j.coviro.2014.04.008. [Epub ahead of print]


  135. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C
    Elkrief L1, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D. Hepatology. 2014 May 20. doi: 10.1002/hep.27228. [Epub ahead of print]


  136. Advances in newly developing therapy for chronic hepatitis C virus infection
    Pockros PJ. Front Med. 2014 Jun;8(2):166-74. doi: 10.1007/s11684-014-0334-2. Epub 2014 May 29.


  137. Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity
    Flamm SL1, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM. J Clin Gastroenterol. 2014 May 13. [Epub ahead of print]


  138. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study
    Frimpong JA1, D'Aunno T, Jiang L. Am J Public Health. 2014 Jun;104(6):e75-82. doi: 10.2105/AJPH.2013.301827. Epub 2014 Apr 17.


  139. Is Screening Baby Boomers for HCV Enough? A Call to Screen for Hepatitis C Virus in Persons from Countries of High Endemicity
    Asselah T1, Perumalswami PV, Dieterich D. Liver Int. 2014 May 20. doi: 10.1111/liv.12599. [Epub ahead of print]


  140. Lower life expectancy among people with an HCV notification: a population-based linkage study
    Alavi M1, Law MG, Grebely J, Thein HH, Walter S, Amin J, Dore GJ. J Viral Hepat. 2014 Jun;21(6):e10-8. doi: 10.1111/jvh.12245.


  141. Epidemiology of hepatitis C virus in pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings
    Larney S1, Mahowald MK, Scharff N, Flanigan TP, Beckwith CG, Zaller ND. Am J Public Health. 2014 Jun;104(6):e69-74. doi: 10.2105/AJPH.2014.301943. Epub 2014 Apr 17.


  142. Adherence During Antiviral Treatment Regimens for Chronic Hepatitis C: A Qualitative Study of Patient-reported Facilitators and Barriers
    Evon DM1, Golin CE, Bonner JE, Grodensky C, Velloza J. J Clin Gastroenterol. 2014 May 13. [Epub ahead of print]


  143. Predictors of donor follow-up after living donor liver transplantation
    Brown RS Jr1, Smith A, Dew MA, Gillespie BW, Hill-Callahan M, Ladner DP. Liver Transpl. 2014 May 13. doi: 10.1002/lt.23912. [Epub ahead of print]


  144. Multiplex Protein Analysis to determine Fibrosis Stage and Progression in Patients with Chronic Hepatitis C
    Patel K1, Remlinger KS2, Walker TG3, Leitner P4, Lucas JE5, Gardner SD2, McHutchison JG6, Irving W7, Guha IN7. Clin Gastroenterol Hepatol. 2014 May 7. pii: S1542-3565(14)00672-7. doi: 10.1016/j.cgh.2014.04.037. [Epub ahead of print]


  145. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters
    van der Meer AJ1, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Ieluzzi D, Zeuzem S, Hofmann WP, de Knegt RJ, Veldt BJ, Janssen HL. Gut. 2014 May 9. doi: 10.1136/gutjnl-2013-305357. [Epub ahead of print]


  146. ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV Genotype 1b Infection
    Andreone P1, Colombo MG2, Enejosa JV3, Koksal I4, Ferenci P5, Maieron A6, Müllhaupt B7, Horsmans Y8, Weiland O9, Reesink HW10, Rodrigues L Jr3, Hu YB3, Podsadecki T3, Bernstein B3. Gastroenterology. 2014 May 9. pii: S0016-5085(14)00603-9. doi: 10.1053/j.gastro.2014.04.045. [Epub ahead of print]


  147. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
    Zeuzem S1, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; the VALENCE Investigators. N Engl J Med. 2014 May 4. [Epub ahead of print]


  148. Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment
    Abdelrahman T1, Hughes J, Main J, McLauchlan J, Thursz M, Thomson E. Hepatology. 2014 May 2. doi: 10.1002/hep.27192. [Epub ahead of print]


  149. Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
    Sofia MJ. Antiviral Res. 2014 May 2. pii: S0166-3542(14)00114-4. doi: 10.1016/j.antiviral.2014.04.008. [Epub ahead of print]


  150. A US Multicenter Study of Hepatitis C Treatment of Liver Transplant Recipients with Protease-Inhibitor Triple Therapy
    Burton JR Jr1, O'Leary JG2, Verna EC3, Saxena V4, Dodge JL4, Stravitz RT5, Levitsky J6, Trotter JF2, Everson GT1, Brown RS Jr3, Terrault NA7. J Hepatol. 2014 May 3. pii: S0168-8278(14)00300-6. doi: 10.1016/j.jhep.2014.04.037. [Epub ahead of print]


  151. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model - Arizona and utah, 2012-2014
    Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, Box T, Carroll C, Holtzman D, Ward JW; Division of Viral Hepatitis, National Center for National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. MMWR Morb Mortal Wkly Rep. 2014 May 9;63(18):393-8.


  152. Frontiers in the treatment of hepatitis C virus infection
    Ahn J, Flamm SL. Gastroenterol Hepatol (N Y). 2014 Feb;10(2):90-100.


  153. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
    Stedman C. Therap Adv Gastroenterol. 2014 May;7(3):131-140.


  154. All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection
    Wyles DL1, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS. Hepatology. 2014 Feb 5. doi: 10.1002/hep.27053. [Epub ahead of print]


  155. Interferon-free strategies with a nucleoside/nucleotide analogue
    Feld JJ. Semin Liver Dis. 2014 Feb;34(1):37-46. doi: 10.1055/s-0034-1371009. Epub 2014 Apr 29.


  156. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals
    Hagan LM1, Sulkowski MS, Schinazi RF. Hepatology. 2014 Mar 28. doi: 10.1002/hep.27151. [Epub ahead of print]


  157. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type
    Matsuura K1, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M. J Viral Hepat. 2013 Sep 3. doi: 10.1111/jvh.12171. [Epub ahead of print]


  158. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy
    Miller MH1, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF. Aliment Pharmacol Ther. 2014 Apr 22. doi: 10.1111/apt.12764. [Epub ahead of print]


  159. The role of interferon in the new era of hepatitis C treatments
    Parekh PJ1, Shiffman ML. Expert Rev Gastroenterol Hepatol. 2014 Apr 23. [Epub ahead of print]


  160. Drugs Aging. 2014 May;31(5):339-47. doi: 10.1007/s40266-014-0170-8.
    Malnick S1, Maor Y, Melzer E, Tal S. Drugs Aging. 2014 May;31(5):339-47. doi: 10.1007/s40266-014-0170-8.


  161. CXCL10 levels identify individuals with rapid fibrosis at 12 months post-transplant for hepatitis C virus and predict treatment response
    Joshi D1, Carey I, Foxton M, Al-Freah M, Bruce M, Heaton N, Quaglia A, O'Grady J, Aluvihare V, Agarwal K. Clin Transplant. 2014 Apr 21. doi: 10.1111/ctr.12354. [Epub ahead of print]


  162. Combination of Racial/Ethnic and Etiology/Disease-Specific Factors are associated with Lower Survival following Liver Transplantation in African Americans: An Analysis from UNOS/OPTN Database
    Wong RJ1, Ahmed A. Clin Transplant. 2014 Apr 21. doi: 10.1111/ctr.12374. [Epub ahead of print]


  163. Patient-Reported Outcomes Assessment in Chronic Hepatitis C Treated with Sofosbuvir and Ribavirin: The VALENCE Study
    Younossi ZM1, Stepanova M2, Zeuzem S3, Dusheiko G4, Esteban R5, Hezode C6, Reesink HW7, Weiland O8, Nader F9, Hunt SL2. J Hepatol. 2014 Apr 5. pii: S0168-8278(14)00220-7. doi: 10.1016/j.jhep.2014.04.003. [Epub ahead of print]


  164. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
    Afdhal N1, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; the ION-1 Investigators. N Engl J Med. 2014 Apr 11. [Epub ahead of print]


  165. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens
    Younossi ZM1, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, Lawitz E, Hunt SL. Hepatology. 2014 Apr 8. doi: 10.1002/hep.27161. [Epub ahead of print]


  166. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
    Afdhal N1, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.


  167. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
    Kowdley KV1, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; the ION-3 Investigators. N Engl J Med. 2014 Apr 10. [Epub ahead of print]


  168. The Rapid Evolution of Treatment Strategies for Hepatitis C
    Muir AJ. Am J Gastroenterol. 2014 Apr 15. doi: 10.1038/ajg.2014.66. [Epub ahead of print]


  169. Curing Chronic Hepatitis C - The Arc of a Medical Triumph
    Chung RT1, Baumert TF. N Engl J Med. 2014 Apr 10. [Epub ahead of print]


  170. How can we improve tracking of transplanted tissue in the United States?
    Mahajan R1, Kuehnert MJ. Cell Tissue Bank. 2013 Nov 27. [Epub ahead of print]


  171. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study
    Barocas JA1, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Harm Reduct J. 2014 Jan 14;11:1. doi: 10.1186/1477-7517-11-1.


  172. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission
    Paintsil E1, Binka M, Patel A, Lindenbach BD, Heimer R. J Infect Dis. 2014 Apr;209(8):1205-11. doi: 10.1093/infdis/jit648. Epub 2013 Nov 23.


  173. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men
    Fierer DS1, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, van Seggelen WO, Hijdra RM, Cassagnol DG; New York Acute Hepatitis C Surveillance Network. Clin Infect Dis. 2014 Mar;58(6):873-9. doi: 10.1093/cid/cit799. Epub 2013 Dec 13.


  174. Maternal-fetal transmission of hepatitis C infection: what is so special about babies?
    Wen JW1, Haber BA. J Pediatr Gastroenterol Nutr. 2014 Mar;58(3):278-82. doi: 10.1097/MPG.0000000000000258.


  175. Impact of Provider Type on Hepatitis C Outcomes With Boceprevir-based and Telaprevir-based Regimens
    Backus LI1, Belperio PS, Shahoumian TA, Mole LA. J Clin Gastroenterol. 2014 Mar 24. [Epub ahead of print]


  176. Hepatitis C virus: a silent killer relevant to dentistry
    Carrozzo M. Oral Dis. 2014 Mar 26. doi: 10.1111/odi.12240. [Epub ahead of print]


  177. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals
    Hagan LM1, Sulkowski MS, Schinazi RF. Hepatology. 2014 Mar 28. doi: 10.1002/hep.27151. [Epub ahead of print]


  178. Boceprevir In Liver Transplant Recipients
    Saab S1, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M, Han S, Busuttil RW. Liver Int. 2014 Mar 26. doi: 10.1111/liv.12548. [Epub ahead of print]


  179. Second wave Anti-HCV Protease Inhibitors: Too little too late?
    De Nicola S1, Aghemo A. Liver Int. 2014 Mar 20. doi: 10.1111/liv.12543. [Epub ahead of print]


  180. The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine
    Haznedar J1, Moreira S, Marbury T, Robson R, Smith W, Kulkarni R, Munson ML, Thommes JA, Lemenuel-Diot A, Washington C, Smith P, Chen YC. Drug Dev Res. 2013 Dec 26. doi: 10.1002/ddr.21166. [Epub ahead of print]


  181. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188)
    Deuffic-Burban S1, Schwarzinger M2, Obach D3, Mallet V4, Pol S5, Pageaux GP6, Canva V7, Deltenre P8, Roudot-Thoraval F9, Larrey D10, Dhumeaux D11, Mathurin P12, Yazdanpanah Y13. J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00155-X. doi: 10.1016/j.jhep.2014.03.011. [Epub ahead of print]


  182. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study
    Eg Hansen AB1, Haukali Omland L2, Krarup H3, Obel N2; on behalf of the DANVIR cohort study. J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00151-2. doi: 10.1016/j.jhep.2014.03.007. [Epub ahead of print]


  183. Barriers to HCV treatment in the era of triple therapy: A prospective multi-centered study in clinical practice
    Crespo J1, Cabezas J, Sacristán B, Olcoz JL, Pérez R, de la Vega J, García R, García-Pajares F, Sáez-Royuela F, González JM, Jiménez F, Rodríguez S, Cuadrado A, López-Arias MJ, García I, Milla A, García-Riesco E, Muñoz M, Sánchez-Antolín G, Jorquera F. Liver Int. 2014 Mar 20. doi: 10.1111/liv.12536. [Epub ahead of print]


  184. Hepatitis C treatment: an incipient therapeutic revolution
    Delemos AS1, Chung RT2. Trends Mol Med. 2014 Mar 10. pii: S1471-4914(14)00023-9. doi: 10.1016/j.molmed.2014.02.002. [Epub ahead of print]


  185. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C
    Ponziani FR1, Viganò R2, Iemmolo RM3, Donato MF4, Rendina M5, Toniutto P6, Pasulo L7, Morelli MC8, Burra P9, Miglioresi L10, Merli M11, Di Paolo D12, Fagiuoli S7, Gasbarrini A13, Pompili M13; on behalf of AISF RECOLT-C Group, Belli L, Gerunda GE, Marino M, Montalti R, Di Benedetto F, De Ruvo N, Rigamonti C, Colombo M, Rossi G, Di Leo A, Lupo L, Memeo V, Bringiotti R, Zappimbulso M, Bitetto D, Vero V, Colpani M, Fornasiere E, Pinna AD, Morelli MC, Bertuzzo V, De Martin E, Senzolo M, Ettorre GM, Visco-Comandini U, Antonucci G, Angelico M, Tisone G, Giannelli V, Giusto M. Dig Liver Dis. 2014 Mar 10. pii: S1590-8658(14)00207-2. doi: 10.1016/j.dld.2014.01.157. [Epub ahead of print]


  186. Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis
    Sato M1, Kondo M1, Tateishi R1, Fujiwara N1, Kato N2, Yoshida H1, Taguri M3, Koike K1. PLoS One. 2014 Mar 17;9(3):e91822. doi: 10.1371/journal.pone.0091822. eCollection 2014.


  187. Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV-HIV Coinfected Liver Transplant Recipients
    Terrault N1, Reddy KR, Poordad F, Curry M, Schiano T, Johl J, Shaikh O, Dove L, Shetty K, Millis M, Schiff E, Regenstein F, Barnes D, Barin B, Peters M, Roland M, Stock P; for the HIVTR Investigators. Am J Transplant. 2014 Mar 17. doi: 10.1111/ajt.12668. [Epub ahead of print]


  188. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score
    Virlogeux V1, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F. J Viral Hepat. 2014 Feb 25. doi: 10.1111/jvh.12237. [Epub ahead of print]


  189. HCV Genotype 3 is Associated with an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans with HCV
    Kanwal F1, Kramer JR, Ilyas J, Duan Z, El-Serag HB. Hepatology. 2014 Feb 24. doi: 10.1002/hep.27095. [Epub ahead of print]


  190. Review article: HCV genotype 3 - the new treatment challenge
    Ampuero J1, Romero-Gómez M, Reddy KR. Aliment Pharmacol Ther. 2014 Feb 20. doi: 10.1111/apt.12646. [Epub ahead of print]


  191. Prospective evaluation of Fibrotest®, Fibrometer® and Hepascore® for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C
    Leroy V1, Sturm N2, Faure P3, Trocme C4, Marlu A5, Hilleret MN6, Morel F4, Zarski JP6. J Hepatol. 2014 Mar 11. pii: S0168-8278(14)00137-8. doi: 10.1016/j.jhep.2014.02.029. [Epub ahead of print]


  192. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
    Kumada H1, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Hepatology. 2014 Mar 6. doi: 10.1002/hep.27113. [Epub ahead of print]


  193. Simeprevir with Peginterferon and Ribavirin Leads to High Rates of SVR in Patients with HCV Genotype 1 Who Relapsed After Previous Therapy: a Phase 3 Trial
    Forns X1, Lawitz E2, Zeuzem S3, Gane E4, Bronowicki JP5, Andreone P6, Horban A7, Brown A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, Scott J11, De La Rosa G12, Kalmeijer R12, Sinha R9, Beumont-Mauviel M9. Gastroenterology. 2014 Mar 3. pii: S0016-5085(14)00293-5. doi: 10.1053/j.gastro.2014.02.051. [Epub ahead of print]


  194. Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial
    Su KP1, Lai HC2, Yang HT3, Su WP2, Peng CY2, Chang JP4, Chang HC5, Pariante CM6. Biol Psychiatry. 2014 Jan 24. pii: S0006-3223(14)00047-X. doi: 10.1016/j.biopsych.2014.01.008. [Epub ahead of print]


  195. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
    Wyles DL1, Gutierrez JA. J Viral Hepat. 2014 Apr;21(4):229-40. doi: 10.1111/jvh.12230.


  196. Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy
    Hwang JP1, Suarez-Almazor ME, Torres HA, Palla SL, Huang DS, Fisch MJ, Lok AS. J Oncol Pract. 2014 Mar 4. [Epub ahead of print]


  197. Impact of birth cohort screening for hepatitis C
    Asrani SK1, Davis GL. Curr Gastroenterol Rep. 2014 Apr;16(4):381. doi: 10.1007/s11894-014-0381-5.


  198. Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design
    Ozen A1, Sherman W2, Schiffer CA1. J Chem Theory Comput. 2013 Dec 10;9(12):5693-5705.


  199. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining
    Varan AK1, Mercer DW1, Stein MS1, Spaulding AC2. Public Health Rep. 2014 Mar;129(2):187-95.


  200. Hepatitis C virus: Here comes all-oral treatment
    Dugum M1, O'Shea R. Cleve Clin J Med. 2014 Mar;81(3):159-72. doi: 10.3949/ccjm.81a.13155.


  201. Disease dependent qualitative and quantitative differences in the inflammatory response to ascites occurring in cirrhotics
    Attar BM, George M, Ion-Nedelcu N, Ramadori G, Thiel DH. World J Hepatol. 2014 Feb 27;6(2):85-91. doi: 10.4254/wjh.v6.i2.85.


  202. Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment
    Aggarwal J1, Vera-Llonch M, Donepudi M, Suthoff E, Younossi Z, Goss TF. J Viral Hepat. 2014 Feb 16. doi: 10.1111/jvh.12227. [Epub ahead of print]


  203. Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence
    Thomas DL. Top Antivir Med. 2013 Dec;21(5):152-6.


  204. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness
    Sheahan T1, Imanaka N1, Marukian S2, Dorner M1, Liu P1, Ploss A1, Rice CM3. Cell Host Microbe. 2014 Feb 12;15(2):190-202. doi: 10.1016/j.chom.2014.01.007.


  205. The fragile relationship between hepatitis C virus and its human host
    Schooley RT. Top Antivir Med. 2013 Dec;21(5):148-51.


  206. HCV Core Residues Critical for Infectivity Are Also Involved in Core-NS5A Complex Formation
    Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD, Gallay PA. PLoS One. 2014 Feb 12;9(2):e88866. doi: 10.1371/journal.pone.0088866. eCollection 2014.


  207. Transarterial Therapies for Primary Liver Tumors
    Talenfeld AD1, Sista AK1, Madoff DC2. Surg Oncol Clin N Am. 2014 Apr;23(2):323-351. doi: 10.1016/j.soc.2013.11.002.


  208. Hepatitis C virus infection and insulin resistance
    Bose SK, Ray R. World J Diabetes. 2014 Feb 15;5(1):52-58.


  209. Modeling the impact of hepatitis C viral clearance on end-stage liver disease in an HIV co-infected cohort with targeted maximum likelihood estimation
    Schnitzer ME1, Moodie EE, van der Laan MJ, Platt RW, Klein MB. Biometrics. 2013 Nov 13. doi: 10.1111/biom.12105. [Epub ahead of print]


  210. Racial Disparities in the Proportion of Current, Unresolved Hepatitis C Virus Infections in the United States, 2003-2010
    Liu G1, Holmberg SD, Kamili S, Xu F. Dig Dis Sci. 2014 Feb 27. [Epub ahead of print


  211. Hepatitis C and Work Impairment: A Review of Current Literature
    Manne V, Sassi K, Allen R, Saab S. J Clin Gastroenterol. 2014 Jan 31. [Epub ahead of print]


  212. Screening for hepatitis C virus infection in a high prevalence country by an antigen/antibody combination assay versus a rapid test
    Tagny CT1, Mbanya D1, Murphy EL2, Lefrère JJ3, Laperche S4. J Virol Methods. 2014 Jan 30. pii: S0166-0934(14)00012-3. doi: 10.1016/j.jviromet.2014.01.002. [Epub ahead of print]


  213. Hepatitis C screening trends in a large integrated health system
    Linas BP1, Hu H2, Barter DM3, Horberg M2. Am J Med. 2014 Jan 28. pii: S0002-9343(14)00078-3. doi: 10.1016/j.amjmed.2014.01.012. [Epub ahead of print]


  214. Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients
    Zeuzem S1, Demasi R2, Baldini A3, Coate B2, Luo D2, Mrus J4, Witek J2. J Hepatol. 2014 Jan 28. pii: S0168-8278(14)00059-2. doi: 10.1016/j.jhep.2014.01.013. [Epub ahead of print]


  215. A New Laboratory Based Algorithm to Predict Development of Hepatocellular Carcinoma in Patients with Hepatitis C and Cirrhosis
    El-Serag HB1, Kanwal F2, Davila JA3, Kramer J4, Richardson P5. Gastroenterology. 2014 Jan 23. pii: S0016-5085(14)00104-8. doi: 10.1053/j.gastro.2014.01.045. [Epub ahead of print]


  216. Acute hepatitis C: management in the rapidly evolving world of HCV
    Sharma SA, Feld JJ. Curr Gastroenterol Rep. 2014 Feb;16(2):371. doi: 10.1007/s11894-014-0371-7.


  217. Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection
    Picchio G1, De Meyer S2, Dierynck I2, Ghys A2, Gritz L3, Kieffer TL3, Bartels DJ3, Witek J4, Bengtsson L3, Luo D4, Kauffman RS3, Adda N5, Sarrazin C6. J Clin Virol. 2014 Jan 6. pii: S1386-6532(13)00542-8. doi: 10.1016/j.jcv.2013.12.011. [Epub ahead of print]


  218. Clearance of Hepatitis C infection is associated with early appearance of broad neutralizing antibody responses
    Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. Hepatology. 2014 Jan 15. doi: 10.1002/hep.27013. [Epub ahead of print]


  219. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
    Lok AS1, Gardiner DF2, Hézode C3, Lawitz EJ4, Bourlière M5, Everson GT6, Marcellin P7, Rodriguez-Torres M8, Pol S9, Serfaty L10, Eley T2, Huang SP11, Li J11, Wind-Rotolo M11, Yu F12, McPhee F12, Grasela DM2, Pasquinelli C2. J Hepatol. 2013 Oct 26. pii: S0168-8278(13)00744-7. doi: 10.1016/j.jhep.2013.10.019. [Epub ahead of print]


  220. Acute hepatitis C: A 24 week-course of Peg-Interferon alpha-2b versus a 12 week-course of Peg-Interferon alpha-2b alone or with ribavirin
    Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Perri GD, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Hepatology. 2014 Jan 18. doi: 10.1002/hep.26991. [Epub ahead of print]


  221. Distinct Features in Natural History and Outcomes of Acute Hepatitis C
    Bunchorntavakul C, Jones LM, Kikuchi M, Valiga ME, Kaplan DE, Nunes FA, Aytaman A, Reddy KR, Chang KM. J Clin Gastroenterol. 2014 Jan 22. [Epub ahead of print]


  222. The impact of hepatitis C burden: an evidence-based approach
    Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. Aliment Pharmacol Ther. 2014 Jan 26. doi: 10.1111/apt.12625. [Epub ahead of print]


  223. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
    Vince B1, Hill JM2, Lawitz EJ3, O'Riordan W4, Webster LR5, Gruener DM6, Mofsen RS7, Murillo A8, Donovan E9, Chen J9, McCarville JF9, Sullivan-Bólyai JZ9, Mayers D9, Zhou XJ10. J Hepatol. 2014 Jan 13. pii: S0168-8278(14)00014-2. doi: 10.1016/j.jhep.2014.01.003. [Epub ahead of print]


  224. Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
    Kris V. Kowdley, M.D., Eric Lawitz, M.D., Fred Poordad, M.D., Daniel E. Cohen, M.D., David R. Nelson, M.D., Stefan Zeuzem, M.D., Gregory T. Everson, M.D., Paul Kwo, M.D., Graham R. Foster, F.C.R.P., Mark S. Sulkowski, M.D., Wangang Xie, Ph.D., Tami Pilot-Matias, Ph.D., George Liossis, B.A., Lois Larsen, Ph.D., Amit Khatri, Ph.D., Thomas Podsadecki, M.D., and Barry Bernstein, M.D.


  225. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6
    Wantuck JM, Ahmed A, Nguyen MH. Aliment Pharmacol Ther. 2014 Jan;39(2):137-47. doi: 10.1111/apt.12551. Epub 2013 Nov 19.


  226. An overview of emerging therapies for the treatment of chronic hepatitis C
    Ilyas JA, Vierling JM. Med Clin North Am. 2014 Jan;98(1):17-38. doi: 10.1016/j.mcna.2013.10.011.


  227. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
    Mark S. Sulkowski, M.D., David F. Gardiner, M.D., Maribel Rodriguez-Torres, M.D., K. Rajender Reddy, M.D., Tarek Hassanein, M.D., Ira Jacobson, M.D., Eric Lawitz, M.D., Anna S. Lok, M.D., Federico Hinestrosa, M.D., Paul J. Thuluvath, M.D., Howard Schwartz, M.D., David R. Nelson, M.D., Gregory T. Everson, M.D., Timothy Eley, Ph.D., Megan Wind-Rotolo, Ph.D., Shu-Pang Huang, Ph.D., Min Gao, Ph.D., Dennis Hernandez, Ph.D., Fiona McPhee, Ph.D., Diane Sherman, M.S., Robert Hindes, M.D., William Symonds, Pharm.D., Claudio Pasquinelli, M.D., Ph.D., and Dennis M. Grasela, Pharm.D., Ph.D. for the AI444040 Study Group


  228. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy
    Cooper C, Shafran S, Greenbloom S, Enns R, Farley J, Hilzenrat N, Williams K, Elkashab M, Abadir N, Neuman M. Can J Gastroenterol. 2014 Jan;28(1):35-40. Epub 2013 Nov 8.


  229. Hepatitis C virus infection and type 2 diabetes
    Fallahi P, Ferrari SM, Colaci M, Ruffilli I, Vita R, Azzi A, Ferri C, Antonelli A, Ferrannini E. Clin Ter. 2013;164(5):e393-404. doi: 10.7417/CT.2013.1620.


  230. Hepatitis C virus and type 1 diabetes
    Fallahi P, Di Domenicantonio A, Mazzi V, Santini F, Fabiani S, Sebastiani M, Zignego AL, Ferri C, Antonelli A. Clin Ter. 2013;164(5):e437-44. doi: 10.7417/CT.2013.1624.


  231. After the Cure: Management of HCV After Achievement of SVR
    Zator ZA, Chung RT. Curr HIV/AIDS Rep. 2013 Dec;10(4):428-35. doi: 10.1007/s11904-013-0181-9.


  232. Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection
    Lattimore S, Irving W, Collins S, Penman C, Ramsay M; On behalf of the collaboration for the sentinel surveillance of blood-borne virus testing. Hepatology. 2013 Nov 9. doi: 10.1002/hep.26926. [Epub ahead of print]


  233. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection
    Rodríguez-Torres M. Expert Rev Anti Infect Ther. 2013 Dec;11(12):1269-79. doi: 10.1586/14787210.2013.855126.


  234. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Lancet. 2013 Nov 1. pii: S0140-6736(13)62121-2. doi: 10.1016/S0140-6736(13)62121-2. [Epub ahead of print]


  235. Hepatitis C transmission and treatment in contact networks of people who inject drugs
    Rolls DA, Sacks-Davis R, Jenkinson R, McBryde E, Pattison P, Robins G, Hellard M. PLoS One. 2013 Nov 1;8(11):e78286. doi: 10.1371/journal.pone.0078286.


  236. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort
    Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Aliment Pharmacol Ther. 2014 Jan;39(1):93-103. doi: 10.1111/apt.12546. Epub 2013 Nov 10.


  237. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?
    Grasso A, Malfatti F, Testa R. World J Gastroenterol. 2013 Nov 7;19(41):6947-56. doi: 10.3748/wjg.v19.i41.6947.


  238. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis
    Park C, Jiang S, Lawson KA. J Clin Pharm Ther. 2014 Feb;39(1):14-24. doi: 10.1111/jcpt.12106. Epub 2013 Nov 16.


  239. HCV and host lipids: an intimate connection
    Schaefer EA, Chung RT. Semin Liver Dis. 2013 Nov;33(4):358-68. doi: 10.1055/s-0033-1358524. Epub 2013 Nov 12.


  240. Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies
    Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, Sloss A, McCaughan GW, Dore GJ, Thompson A, Crawford DH, Sievert W, Weltman M, Cheng W, George J; Australian Liver Association Clinical Research Network. J Gastroenterol Hepatol. 2014 Jan;29(1):179-84. doi: 10.1111/jgh.12424.


  241. Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
    Rockstroh JK, Bhagani S. BMC Med. 2013 Nov 1;11:234. doi: 10.1186/1741-7015-11-234.


  242. Isaacs D, Abdelaziz N, Keller M, Tibble J, Haq I. Hepat Res Treat. 2013;2013:910519. doi: 10.1155/2013/910519. Epub 2013 Oct 7.
    Isaacs D, Abdelaziz N, Keller M, Tibble J, Haq I. Hepat Res Treat. 2013;2013:910519. doi: 10.1155/2013/910519. Epub 2013 Oct 7.


  243. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature
    Fusco F, D'Anzeo G, Rossi A, Sciorio C, Buonomo AR, d'Emmanuele di Villa Bianca R, Borgia G, Mirone V, Gentile I. Expert Opin Pharmacother. 2013 Dec;14(18):2533-44. doi: 10.1517/14656566.2013.850073. Epub 2013 Nov 12.


  244. New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
    Yadav AD, Chang YH, Aqel BA, Byrne TJ, Chakkera HA, Douglas DD, Mulligan DC, Rakela J, Vargas HE, Carey EJ. J Transplant. 2013;2013:269096. doi: 10.1155/2013/269096. Epub 2013 Sep 24.


  245. Does Chemotherapy Cause Viral Relapse in Cancer Patients With Hepatitis C Infection Successfully Treated With Antivirals?
    Mahale P1, Okhuysen PC2, Torres HA3. Clin Gastroenterol Hepatol. 2013 Nov 7. pii: S1542-3565(13)01726-6. doi: 10.1016/j.cgh.2013.10.034. [Epub ahead of print]


  246. Can Antidepressants Prevent Pegylated Interferon-?/Ribavirin-Associated Depression in Patients with Chronic Hepatitis C: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials?
    Hou XJ, Xu JH, Wang J, Yu YY. PLoS One. 2013 Oct 30;8(10):e76799. doi: 10.1371/journal.pone.0076799.


  247. Hepatitis C and alcohol exacerbate liver injury by suppression of FOXO3
    Tumurbaatar B, Tikhanovich I, Li Z, Ren J, Ralston R, Kuravi S, Campbell R, Chaturvedi G, Huang TT, Zhao J, Hao J, O'Neil M, Weinman SA. Am J Pathol. 2013 Dec;183(6):1803-14. doi: 10.1016/j.ajpath.2013.08.013. Epub 2013 Nov 11.


  248. Is the genotype 3 of the hepatitis C virus the new villain?
    Goossens N, Negro F. Hepatology. 2013 Oct 24. doi: 10.1002/hep.26905. [Epub ahead of print]


  249. Association between vitamin D and hepatitis C virus infection: a meta-analysis
    Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. World J Gastroenterol. 2013 Sep 21;19(35):5917-24. doi: 10.3748/wjg.v19.i35.5917.


  250. Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of Sustained Viral Response in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis
    Rodriguez-Torres M1, Stoehr A2, Gane EJ3, Serfaty L4, Lawitz E5, Zhou A6, Bourque M6, Bhanja S6, Strizki J6, Barnard RJ6, Hwang PM6, Dinubile MJ6, Mobashery N7. Clin Gastroenterol Hepatol. 2013 Oct 10. pii: S1542-3565(13)01519-X. doi: 10.1016/j.cgh.2013.09.067. [Epub ahead of print]


  251. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype
    Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. J Med Virol. 2013 Oct 28. doi: 10.1002/jmv.23824. [Epub ahead of print]


  252. Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and -experienced patients
    Goralczyk AD, Cameron S, Amanzada A. BMC Gastroenterol. 2013 Oct 14;13:148. doi: 10.1186/1471-230X-13-148.


  253. Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy
    Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, Bansal M, Dieterich DT, Branch AD. Liver Int. 2013 Oct 1. doi: 10.1111/liv.12342. [Epub ahead of print]


  254. Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
    Zeuzem S1, Berg T2, Gane E3, Ferenci P4, Foster GR5, Fried MW6, Hezode C7, Hirschfield GM8, Jacobson I9, Nikitin I10, Pockros PJ11, Poordad F12, Scott J13, Lenz O14, Peeters M14, Sekar V15, De Smedt G14, Sinha R14, Beumont-Mauviel M14. Gastroenterology. 2013 Nov 1. pii: S0016-5085(13)01576-X. doi: 10.1053/j.gastro.2013.10.058. [Epub ahead of print]


  255. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?
    Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. J Infect Dis. 2014 Jan;209(1):38-45. doi: 10.1093/infdis/jit541. Epub 2013 Oct 14.


  256. Hepatitis C and pregnancy
    Floreani A. World J Gastroenterol. 2013 Oct 28;19(40):6714-20. doi: 10.3748/wjg.v19.i40.6714.


  257. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection
    van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. J Viral Hepat. 2013 Oct 10. doi: 10.1111/jvh.12185. [Epub ahead of print]


  258. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients
    Péres DP, Cheinquer H, Wolf FH, Cheinquer N, Falavigna M, Péres LD. Ann Hepatol. 2013 Nov-Dec;12(6):871-5.


  259. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b
    Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y. J Gastroenterol Hepatol. 2014 Jan;29(1):144-50. doi: 10.1111/jgh.12402.


  260. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy
    Afdhal NH1, Dusheiko GM2, Giannini EG3, Chen PJ4, Han KH5, Mohsin A6, Rodriguez-Torres M7, Rugina S8, Bakulin I9, Lawitz E10, Shiffman ML11, Tayyab GU12, Poordad F10, Kamel YM13, Brainsky A14, Geib J14, Vasey SY14, Patwardhan R14, Campbell FM13, Theodore D15. Gastroenterology. 2013 Oct 12. pii: S0016-5085(13)01436-4. doi: 10.1053/j.gastro.2013.10.012. [Epub ahead of print]


  261. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
    Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Hepatology. 2013 Oct 12. doi: 10.1002/hep.26892. [Epub ahead of print]


  262. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C
    Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, Cornberg M, Wedemeyer H. Aliment Pharmacol Ther. 2013 Dec;38(11-12):1365-72. doi: 10.1111/apt.12523. Epub 2013 Oct 16.


  263. Daclatasvir: potential role in hepatitis C
    Lee C. Drug Des Devel Ther. 2013 Oct 16;7:1223-33. doi: 10.2147/DDDT.S40310.


  264. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
    Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM. Liver Int. 2013 Aug 2. doi: 10.1111/liv.12300. [Epub ahead of print]


  265. Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
    Macaluso FS1, Maida M2, Cammà C2, Cabibi D3, Alessi N2, Cabibbo G2, Di Marco V2, Craxì A2, Petta S2. Clin Gastroenterol Hepatol. 2013 Oct 7. pii: S1542-3565(13)01507-3. doi: 10.1016/j.cgh.2013.09.059. [Epub ahead of print]


  266. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype
    Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. J Med Virol. 2013 Oct 28. doi: 10.1002/jmv.23824. [Epub ahead of print]


  267. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. J Med Econ. 2014 Jan;17(1):65-76. doi: 10.3111/13696998.2013.860033. Epub 2013 Nov 18.


  268. Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C
    Arase Y, Kobayashi M, Kawamura Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Kobayashi T. J Med Virol. 2014 Jan;86(1):169-75. doi: 10.1002/jmv.23777. Epub 2013 Oct 24.


  269. Screening for Hepatitis C Virus Infection in Adults
    John M. Eisenberg Center for Clinical Decisions and Communications Science.


  270. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature
    Cacopardo B, Benanti F, Pinzone MR, Nunnari G. BMC Res Notes. 2013 Oct 30;6(1):437. [Epub ahead of print]


  271. Hepatitis C Direct-acting Antiviral Agents: Changing the Paradigm of Hepatitis C Treatment in HIV-infected Patients
    Martel-Laferrière V, Bichoupan K, Dieterich DT. J Clin Gastroenterol. 2013 Oct 28. [Epub ahead of print]


  272. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
    Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New Paradigm of HCV Therapy Meeting Participants. J Viral Hepat. 2013 Nov;20(11):745-60. doi: 10.1111/jvh.12173.


  273. Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor
    de Bruijne J, Thomas XV, Rebers SP, Weegink CJ, Treitel MA, Hughes E, Bergmann JF, de Knegt RJ, Janssen HL, Reesink HW, Molenkamp R, Schinkel J. J Viral Hepat. 2013 Nov;20(11):779-89. doi: 10.1111/jvh.12104. Epub 2013 Jun 27.


  274. The experience of hepatitis C treatment for people with a history of mental health problems: An interpretative phenomenological analysis
    Ware K, Davies J, Rowse G, Whittaker S. J Health Psychol. 2013 Oct 22. [Epub ahead of print]


  275. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy
    Liang CM, Hu TH, Lu SN, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM. J Viral Hepat. 2013 Nov;20(11):761-9. doi: 10.1111/jvh.12097. Epub 2013 Apr 7.


  276. A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C
    Ferreira Cda S, Abreu RM, da Silva MC, Ferreira AS, Nasser PD, Carrilho FJ, Ono SK. PLoS One. 2013 Oct 22;8(10):e78142. doi: 10.1371/journal.pone.0078142.


  277. Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment
    Ackefors M, Nyström J, Wernerson A, Gjertsen H, Sönnerborg A, Weiland O. J Viral Hepat. 2013 Nov;20(11):770-8. doi: 10.1111/jvh.12099. Epub 2013 Apr 23.


  278. Interferon-Free Regimens for Hepatitis C: Combine and Conquer
    Martel-Laferrière V, Bichoupan K, Dieterich DT. BioDrugs. 2013 Oct 30. [Epub ahead of print]


  279. Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis
    Di Marco V, Covolo L, Calvaruso V, Levrero M, Puoti M, Suter F, Gaeta GB, Ferrari C, Raimondo G, Fattovich G, Santantonio T, Alberti A, Bruno R, Mussini C, Mondelli M, Donato F, Craxì A; Multicenter Italian Group for the Study of Hepatitis C. J Viral Hepat. 2013 Nov;20(11):790-800. doi: 10.1111/jvh.12106. Epub 2013 Sep 15.


  280. Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity
    Han H, Agarwal R, Martel-Laferriere V, Dieterich DT. Clin Liver Dis. 2013 Nov;17(4):657-70, ix. doi: 10.1016/j.cld.2013.07.007. Epub 2013 Sep 4.


  281. Boceprevir Plus Peginterferon α-2b/Ribavirin in Chronic Hepatitis C Genotype 1: Impact of Baseline Viral Load on Sustained Virologic Response
    Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ. J Clin Gastroenterol. 2013 Oct 30. [Epub ahead of print]


  282. Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: A systematic review and meta-analysis
    Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, Chen X, Chen L. Clin Res Hepatol Gastroenterol. 2013 Oct 28. pii: S2210-7401(13)00187-3. doi: 10.1016/j.clinre.2013.08.013. [Epub ahead of print]


  283. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
    Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Hepatology. 2013 Oct 12. doi: 10.1002/hep.26892. [Epub ahead of print]


  284. Association between vitamin D and hepatitis C virus infection: a meta-analysis
    Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. World J Gastroenterol. 2013 Sep 21;19(35):5917-24. doi: 10.3748/wjg.v19.i35.5917.


  285. Clinical Outcomes of Hepatitis C Treated with Pegylated Interferon and Ribavirin via Telemedicine Consultation in Northern California
    Rossaro L, Torruellas C, Dhaliwal S, Botros J, Clark G, Li CS, Minoletti MM. Dig Dis Sci. 2013 Dec;58(12):3620-5. doi: 10.1007/s10620-013-2810-y. Epub 2013 Oct 24.


  286. Longitudinal Effects of Selective Serotonin Reuptake Inhibitor Therapy and Cytokine-Related Depression on Hepatitis C Viral Logs During Antiviral Therapy
    Sims OT, Whalen CC, Nackerud LG, Bride BE. J Clin Psychopharmacol. 2013 Oct 16. [Epub ahead of print]


  287. Simeprevir for the treatment of chronic hepatitis C
    You DM, Pockros PJ. Expert Opin Pharmacother. 2013 Dec;14(18):2581-9. doi: 10.1517/14656566.2013.850074. Epub 2013 Oct 19.


  288. "To Share or Not to Share?" Serosorting by Hepatitis C Status in the Sharing of Drug Injection Equipment Among NHBS-IDU2 Participants
    Smith BD, Jewett A, Burt RD, Zibbell JE, Yartel AK, Dinenno E. J Infect Dis. 2013 Dec;208(12):1934-42. doi: 10.1093/infdis/jit520. Epub 2013 Oct 16.


  289. Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir
    Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, Viciana P, Espinosa N, Castillo-Ferrando JR, Lopez-Cortes LF. Clin Infect Dis. 2013 Nov 8. [Epub ahead of print]


  290. Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. J Infect Dis. 2014 Jan;209(1):38-45. doi: 10.1093/infdis/jit541. Epub 2013 Oct 14.
    Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. J Infect Dis. 2014 Jan;209(1):38-45. doi: 10.1093/infdis/jit541. Epub 2013 Oct 14.


  291. Variation of transaminases, HCV-RNA levels and Th1/Th2 cytokine production during the post-partum period in pregnant women with chronic hepatitis C
    Ruiz-Extremera A, Muñoz-Gámez JA, Abril-Molina A, Salmerón-Ruiz MA, Muñoz-de-Rueda P, Pavón-Castillero EJ, Quiles-Pérez R, Carazo A, Gila A, Jimenez-Ruiz SM, Casado J, Martín AB, Sanjuán-Núñez L, Ocete-Hita E, Viota JL, León J, Salmerón J. PLoS One. 2013 Oct 10;8(10):e75613. doi: 10.1371/journal.pone.0075613.


  292. Novel therapeutic approaches for hepatitis C
    Au JS1, Pockros PJ2. Clin Pharmacol Ther. 2013 Jan;95(1):78-88. doi: 10.1038/clpt.2013.206. Epub 2013 Oct 14.


  293. Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease
    García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, Domínguez-Díez A, Rodríguez de Cía J, Sáez A, Porrero JL, Vargas-Castrillón J, Chávez-Jiménez E, Soto-Fernández S, Díaz A, Gallego-Durán R, Madejón A, Miquilena-Colina ME. Eur J Clin Invest. 2014 Jan;44(1):65-73. doi: 10.1111/eci.12192. Epub 2013 Nov 23.


  294. The State of Infectious Diseases Clinical Trials: A Systematic Review of ClinicalTrials.gov
    Goswami ND, Pfeiffer CD, Horton JR, Chiswell K, Tasneem A, Tsalik EL. PLoS One. 2013 Oct 16;8(10):e77086. doi: 10.1371/journal.pone.0077086.


  295. Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses
    Guo X, Yang G, Yuan J, Ruan P, Zhang M, Chen X, Zhou B. PLoS One. 2013 Oct 17;8(10):e77911. doi: 10.1371/journal.pone.0077911.


  296. A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers
    Real LM, Caruz A, Rivero-Juarez A, Soriano V, Neukam K, Rivero A, Cifuentes C, Mira JA, Macías J, Pineda JA. Liver Int. 2013 Sep 25. doi: 10.1111/liv.12330. [Epub ahead of print]


  297. Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation
    Rose R, Markov PV, Lam TT, Pybus OG. Infect Genet Evol. 2013 Dec;20:418-21. doi: 10.1016/j.meegid.2013.09.029. Epub 2013 Oct 16.


  298. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy
    Afdhal NH1, Dusheiko GM2, Giannini EG3, Chen PJ4, Han KH5, Mohsin A6, Rodriguez-Torres M7, Rugina S8, Bakulin I9, Lawitz E10, Shiffman ML11, Tayyab GU12, Poordad F10, Kamel YM13, Brainsky A14, Geib J14, Vasey SY14, Patwardhan R14, Campbell FM13, Theodore D15. Gastroenterology. 2013 Oct 12. pii: S0016-5085(13)01436-4. doi: 10.1053/j.gastro.2013.10.012. [Epub ahead of print]


  299. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C
    Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, Cornberg M, Wedemeyer H. Aliment Pharmacol Ther. 2013 Dec;38(11-12):1365-72. doi: 10.1111/apt.12523. Epub 2013 Oct 16.


  300. Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents
    Kittner JM, Weiss NM, Wiltink J, Schattenberg JM, Grambihler A, Thieringer F, Weinmann A, Zimmermann T, Koch S, Schuchmann M, Galle PR. Dig Liver Dis. 2013 Oct 11. pii: S1590-8658(13)00424-6. doi: 10.1016/j.dld.2013.08.139. [Epub ahead of print]


  301. Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort
    Aronsohn A, Ancuta I, Caruntu F, Coppola C, Delic D, Digiacomo A, Dusheiko GM, Lengyel G, Marcellin P, Orlandini A, Pruthi J, Silva GF, Tallarico L, Schmitz M, Tatsch F, Korner E, Cheinquer H. J Viral Hepat. 2013 Oct 17. doi: 10.1111/jvh.12179. [Epub ahead of print]


  302. Clinical characteristics, treatment patterns and survival outcome of hepatocellular carcinoma patients aged 70 years or older: a single-center retrospective study from China
    Fan C, Jin G, Sun C, Ma D, Chen C, Qiao P, Wu D. Aging Clin Exp Res. 2013 Oct 16. [Epub ahead of print]


  303. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study
    Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Aliment Pharmacol Ther. 2013 Nov;38(9):1076-85. doi: 10.1111/apt.12494. Epub 2013 Sep 17.


  304. Liver stiffness predicts hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy
    Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T. J Gastroenterol Hepatol. 2013 Oct 3. doi: 10.1111/jgh.12401. [Epub ahead of print]


  305. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C
    Calès P, Boursier J, Ducancelle A, Oberti F, Hubert I, Hunault G, de Lédinghen V, Zarski JP, Salmon D, Lunel F; the ANRS HC EP 23 Fibrostar Study. Liver Int. 2013 Sep 19. doi: 10.1111/liv.12327. [Epub ahead of print]


  306. The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection
    Kawaguchi-Suzuki M, Frye RF. Pharmacotherapy. 2013 Sep 30. doi: 10.1002/phar.1349. [Epub ahead of print]


  307. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients
    Péres DP, Cheinquer H, Wolf FH, Cheinquer N, Falavigna M, Péres LD. Ann Hepatol. 2013 Nov-Dec;12(6):871-5.


  308. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with HCV genotype 1b
    Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y. J Gastroenterol Hepatol. 2013 Oct 3. doi: 10.1111/jgh.12402. [Epub ahead of print]


  309. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4
    Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y. Liver Int. 2013 Sep 16. doi: 10.1111/liv.12321. [Epub ahead of print]


  310. Hepatitis C Virus Genotype 5: Prospective Evaluation of Peginterferon/Ribavirin Treatment Efficacy and Predictive Value of On-treatment Virological Responses for Sustained Virological Response
    Papastergiou V, Skorda L, Lisgos P, Stampori M, Ntetskas G, Papakonstantinou L, Prodromidou K, Karatapanis S. J Clin Gastroenterol. 2013 Oct 4. [Epub ahead of print]


  311. A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects
    Gardner S, Cutrell A, Elko-Simms C, Adkison K, Hamatake R, Walker J, Rodriguez-Torres M, Hong Z. Liver Int. 2013 Sep 25. doi: 10.1111/liv.12334. [Epub ahead of print]


  312. Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C
    Catanzaro R, Milazzo M, Arona S, Sapienza C, Vasta D, Arcoria D, Marotta F. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):500-7.


  313. Emerging treatments for hepatitis C
    Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Expert Opin Emerg Drugs. 2013 Dec;18(4):461-75. doi: 10.1517/14728214.2013.847089. Epub 2013 Oct 8.


  314. Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis
    Al-Omari A, Cowan J, Turner L, Cooper C. Can J Gastroenterol. 2013 Oct;27(10):575-81.


  315. Impact of coffee on liver diseases: a systematic review
    Saab S, Mallam D, Cox Ii GA, Tong MJ. Liver Int. 2013 Aug 12. doi: 10.1111/liv.12304. [Epub ahead of print]


  316. Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
    Macaluso FS, Maida M, Cammà C, Cabibi D, Alessi N, Cabibbo G, Di Marco V, Craxì A, Petta S. Clin Gastroenterol Hepatol. 2013 Oct 7. pii: S1542-3565(13)01507-3. doi: 10.1016/j.cgh.2013.09.059. [Epub ahead of print]


  317. Hepatitis B and C in the armed forces
    Freshwater DA. J R Army Med Corps. 2013 Sep;159(3):169-74. doi: 10.1136/jramc-2013-000096. Epub 2013 Jun 3.


  318. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource
    Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Hepatology. 2013 Oct 1. doi: 10.1002/hep.26744. [Epub ahead of print]


  319. Preparing the patient for success: treat or wait?
    Buti M, Esteban R. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S332-6. doi: 10.1016/j.dld.2013.07.013.


  320. Safety of direct antiviral agents in real life
    D'Ambrosio R, Colombo M. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S363-6. doi: 10.1016/j.dld.2013.07.012.


  321. Evaluation of Hepatitis C Virus as a Risk Factor for HIV-Associated Neuroretinal Disorder
    Branch AD, Drye LT, Van Natta ML, Sezgin E, Fishman SL, Dieterich DT, Meinert CL, Jabs DA. Clin Infect Dis. 2013 Dec;57(11):1618-25. doi: 10.1093/cid/cit550. Epub 2013 Sep 30.


  322. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C
    Liu YL, Du XF, Chen XY, Ma LN, Guo DD, Lu JF, Cao ZH, Zhang YH. Scand J Infect Dis. 2013 Dec;45(12):939-43. doi: 10.3109/00365548.2013.835067. Epub 2013 Oct 3.


  323. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response
    Furusyo N, Ogawa E, Murata M, Toyoda K, Ohnishi H, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Kainuma M, Okada K, Hayashi J. J Antimicrob Chemother. 2013 Oct 3. [Epub ahead of print]


  324. Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study
    Chang SC, Hung CT, Li SF, Lee HM, Chung YC, Pai LW, Yang SS. J Formos Med Assoc. 2013 Sep 30. pii: S0929-6646(13)00296-9. doi: 10.1016/j.jfma.2013.08.011. [Epub ahead of print]


  325. Treatment of chronic hepatitis C virus infection after liver transplantation
    Agarwal K, Barnabas A. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S349-54. doi: 10.1016/j.dld.2013.07.014.


  326. Emerging concepts in immunity to hepatitis C virus infection
    Rosen HR. J Clin Invest. 2013 Oct 1;123(10):4121-30. doi: 10.1172/JCI67714. Epub 2013 Oct 1.


  327. Association of the interleukin-28B gene polymorphism with development of hepatitis virus-related hepatocellular carcinoma and liver cirrhosis: a meta-analysis
    Suo GJ, Zhao ZX. Genet Mol Res. 2013 Sep 19;12(3):3708-17. doi: 10.4238/2013.September.19.1.


  328. Host-targeting agents in the treatment of hepatitis C: A beginning and an end?
    Baugh JM, Garcia-Rivera JA, Gallay PA. Antiviral Res. 2013 Nov;100(2):555-61. doi: 10.1016/j.antiviral.2013.09.020. Epub 2013 Sep 30.


  329. Optimizing treatment in HIV/HCV coinfection
    Puoti M, Rossotti R, Travi G, Panzeri C, Morreale M, Chiari E, Cocca G, Orso M, Moioli MC. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S355-62. doi: 10.1016/j.dld.2013.09.001.


  330. Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity
    Han H, Agarwal R, Martel-Laferriere V, Dieterich DT. Clin Liver Dis. 2013 Nov;17(4):657-70, ix. doi: 10.1016/j.cld.2013.07.007. Epub 2013 Sep 4.


  331. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy
    Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Br J Cancer. 2013 Oct 29;109(9):2481-8. doi: 10.1038/bjc.2013.564. Epub 2013 Oct 1.


  332. A new subtype of hepatitis C virus genotype 3: analysis of available evidence
    Salehi Moghadam F, Mohebbi SR, Hosseini SM, Damavand B, Zali MR. Hepat Mon. 2013 Aug 17;13(8):e13380. doi: 10.5812/hepatmon.13380


  333. Genotype impact on HCV RNA levels determined with the VERSANT HCV RNA 1.0 assay (kPCR)
    Kessler HH, Hübner M, Konrad PM, Stelzl E, Stübler MM, Baser MH, Santner BI. J Clin Virol. 2013 Nov;58(3):522-7. doi: 10.1016/j.jcv.2013.09.005. Epub 2013 Sep 12.


  334. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study
    Kielland KB, Delaveris GJ, Rogde S, Eide TJ, Amundsen EJ, Dalgard O. J Hepatol. 2013 Oct 2. pii: S0168-8278(13)00682-X. doi: 10.1016/j.jhep.2013.09.022. [Epub ahead of print]


  335. The importance of drug-drug interactions in the DAA era
    Back D, Else L. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S343-8. doi: 10.1016/j.dld.2013.07.008.


  336. Management of anaemia and other treatment complications
    Hézode C. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S337-42. doi: 10.1016/j.dld.2013.07.010.


  337. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients
    Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, Kuo HT, Huang JF, Chang JM, Chen HC, Juo SH, Hwang SJ, Chuang WL; FORMOSA-LIKE group. J Hepatol. 2013 Oct 2. pii: S0168-8278(13)00683-1. doi: 10.1016/j.jhep.2013.09.023. [Epub ahead of print]


  338. Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C
    García-Martín E, Agúndez JA, Maestro ML, Suárez A, Vidaurreta M, Martínez C, Fernández-Pérez C, Ortega L, Ladero JM. PLoS One. 2013 Sep 20;8(9):e74764. doi: 10.1371/journal.pone.0074764.


  339. Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C
    Sugawara K, Inao M, Nakayama N, Mochida S. J Gastroenterol. 2013 Oct 1. [Epub ahead of print]


  340. Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA
    Campo M, Shrestha A, Oren E, Thiede H, Duchin J, Narita M, Crothers K. Epidemiol Infect. 2013 Sep 25:1-8. [Epub ahead of print]


  341. Less-established risk factors are common in asian americans with hepatitis C virus: a case-controlled study
    Kin KC, Lin B, Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Levitt BS, da Silveira EB, Nguyen MH. Dig Dis Sci. 2013 Nov;58(11):3342-7. doi: 10.1007/s10620-013-2884-6. Epub 2013 Oct 1.


  342. Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase
    Najera I. Curr Opin Virol. 2013 Oct;3(5):508-13. doi: 10.1016/j.coviro.2013.08.011. Epub 2013 Sep 24.


  343. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment
    Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, Solsky J, Nieforth K, Wat C, Grippo JF. Antimicrob Agents Chemother. 2013 Dec;57(12):6097-105. doi: 10.1128/AAC.00608-13. Epub 2013 Sep 30.


  344. Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B
    Schoenfeld RC, Bourdet DL, Brameld KA, Chin E, de Vicente J, Fung A, Harris SF, Lee EK, Le Pogam S, Leveque V, Li J, Lui AS, Najera I, Rajyaguru S, Sangi M, Steiner S, Talamas FX, Taygerly JP, Zhao J. J Med Chem. 2013 Oct 10. [Epub ahead of print]


  345. Hepatitis C virus infection, microRNA and liver disease progression
    Shrivastava S, Mukherjee A, Ray RB. World J Hepatol. 2013 Sep 27;5(9):479-486.


  346. Lambda Interferon Serum Levels in Patients with Chronic Hepatitis C Virus Infection According to Their Response to Therapy with Pegylated Interferon and Ribavirin
    Torres C, Brahm J, Venegas M. J Interferon Cytokine Res. 2013 Sep 26. [Epub ahead of print]


  347. Hepatitis C genotype 6: A concise review and response-guided therapy proposal
    Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. World J Hepatol. 2013 Sep 27;5(9):496-504.


  348. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region
    Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, Nakatani SM, Ono SK, Takahashi-Nakaguchi A, Gonoi T, Yokosuka O. PLoS One. 2013 Sep 17;8(9):e73615. doi: 10.1371/journal.pone.0073615.


  349. Diagnostics and Treatment of Cryoglobulinaemia: It Takes Two to Tango
    Damoiseaux J, Cohen Tervaert JW. Clin Rev Allergy Immunol. 2013 Sep 26. [Epub ahead of print]


  350. The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus
    Shankar H, Bichoupan K, Dieterich DT. Expert Opin Drug Metab Toxicol. 2013 Nov;9(12):1647-57. doi: 10.1517/17425255.2013.840290. Epub 2013 Oct 1.


  351. The discovery and development of boceprevir
    Rotella DP. Expert Opin Drug Discov. 2013 Nov;8(11):1439-47. doi: 10.1517/17460441.2013.843525. Epub 2013 Sep 30.


  352. New triple therapy for chronic hepatitis C: real life clinical experience in a community setting
    Akiyama MJ, Piotrowski JI, Roytman MM, Chan SM, Hong LK, Huddleston L, Trujillo R, Tsai NC. Hawaii J Med Public Health. 2013 Sep;72(9 Suppl 4):6-13.


  353. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
    Aizawa N, Enomoto H, Takashima T, Sakai Y, Iwata K, Ikeda N, Tanaka H, Iwata Y, Saito M, Imanishi H, Iijima H, Nishiguchi S. J Gastroenterol. 2013 Sep 25. [Epub ahead of print]


  354. Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor
    Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J. Antimicrob Agents Chemother. 2013 Dec;57(12):6034-49. doi: 10.1128/AAC.01176-13. Epub 2013 Sep 23.


  355. Hepatitis C: A mouse at the end of the tunnel
    Binder M, Bartenschlager R. Cell Res. 2013 Sep 24. doi: 10.1038/cr.2013.132. [Epub ahead of print]


  356. Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis
    Laurito MP, Parise ER. Braz J Infect Dis. 2013 Sep-Oct;17(5):555-63. doi: 10.1016/j.bjid.2013.02.009. Epub 2013 Sep 19.


  357. The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis
    Khairy M, Fouad R, Mabrouk M, El-Akel W, Awad AB, Salama R, Elnegouly M, Shaker O. Hepat Mon. 2013 Jul 17;13(7):e10509. doi: 10.5812/hepatmon.10509.


  358. Predictors of consent to pharmacogenomics testing in the IDEAL study
    Jazwinski AB, Clark PJ, Thompson AJ, Gordon SC, Lawitz EJ, Noviello S, Brass CA, Pedicone LD, Albrecht JK, Sulkowski MS, Muir AJ. Pharmacogenet Genomics. 2013 Nov;23(11):619-23. doi: 10.1097/FPC.0000000000000002.


  359. Histopathologic distinction between fibrosing cholestatic hepatitis C and biliary obstruction
    Salomao M, Verna EC, Lefkowitch JH, Moreira RK. Am J Surg Pathol. 2013 Dec;37(12):1837-44. doi: 10.1097/PAS.0b013e31829b626c.


  360. A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3-Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate
    Rivero-Juarez A, López-Cortés LF, Camacho A, Mira JA, Téllez F, Marquez M, Merino D, Pineda JA, Rivero A; for the Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR), part of the Sociedad Andaluza de Enfermedades Infecciosas. Clin Infect Dis. 2013 Oct 21. [Epub ahead of print]


  361. Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
    Silva GF, Villela-Nogueira CA, Mello CE, Soares EC, Coelho HS, Ferreira PR, Ruiz FJ; Brazilian HCV-Related Advanced Fibrosis Study Group. Braz J Infect Dis. 2013 Sep 20. pii: S1413-8670(13)00202-X. doi: 10.1016/j.bjid.2013.05.007. [Epub ahead of print]


  362. Complexities of HCV management in the new era of direct-acting antiviral agents
    Rosenberg WM, Tanwar S, Trembling P. QJM. 2013 Sep 23. [Epub ahead of print]


  363. Decreased level of intracellular cholesterol in peripheral blood mononuclear cells is associated with chronic hepatitis C virus infection
    Sidorkiewicz M, Grek M, Jozwiak B, Piekarska A. Virus Res. 2013 Dec 26;178(2):539-42. doi: 10.1016/j.virusres.2013.09.019. Epub 2013 Sep 18.


  364. An Association of Virus Infection with Type 2 Diabetes and Alzheimer's Disease
    Karim S, Mirza Z, Kamal MA, Abuzenadah AM, Azhar EI, Al-Qahtani MH, Sohrab SS. CNS Neurol Disord Drug Targets. 2013 Sep 19. [Epub ahead of print]


  365. Development and Validation of a Comorbidity Scoring System for Patients With Cirrhosis
    Jepsen P, Vilstrup H, Lash TL. Gastroenterology. 2013 Sep 18. pii: S0016-5085(13)01347-4. doi: 10.1053/j.gastro.2013.09.019. [Epub ahead of print]


  366. Treatment decisions and contemporary versus pending treatments for hepatitis C
    Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM.


  367. Is universal screening for hepatitis C infection (HCV) prior to commencing anti-TNF-? therapy necessary?
    Reid CT, De Gascun C, Hall W, Collins P, Lally A, Kirby B. Br J Dermatol. 2013 Aug 21. doi: 10.1111/bjd.12598. [Epub ahead of print]


  368. Targeted hepatitis C screening among ex-injection drug users in the community
    Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, Szeto KJ, Tsang S, Wu SH, Yan KK, Hui AY, Yiu DC, Wu BB, Cheung D, Chung CS, Lai CW, Chan HL. J Gastroenterol Hepatol. 2013 Aug 22. doi: 10.1111/jgh.12355. [Epub ahead of print]


  369. MicroRNA profile before and after antiviral therapy in liver transplant recipients for Hepatitis C virus cirrhosis
    Gelley F, Zadori G, Nemes B, Fassan M, Lendvai G, Sarvary E, Doros A, Gerlei Z, Nagy P, Schaff Z, Kiss A. J Gastroenterol Hepatol. 2013 Aug 22. doi: 10.1111/jgh.12362. [Epub ahead of print]


  370. The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010
    Younossi ZM, Stepanova M, Mishra A, Venkatesan C, Henry L, Hunt S. Aliment Pharmacol Ther. 2013 Nov;38(9):1065-75. doi: 10.1111/apt.12485. Epub 2013 Sep 12.


  371. Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy
    Lee TH, Tillmann HL, Patel K. Mol Diagn Ther. 2013 Sep 11. [Epub ahead of print]


  372. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction
    Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, Jamalidoust M, Hamidpour L. Hepat Mon. 2013 May 30;13(6):e9147. doi: 10.5812/hepatmon.9147.


  373. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis C (and congenital bleeding disorders): where do we stand?
    Coppola A, Di Capua M, Conca P, Cimino E, Tufano A, Cerbone AM, Di Minno G, Tarantino G. Semin Thromb Hemost. 2013 Oct;39(7):803-15. doi: 10.1055/s-0033-1354421. Epub 2013 Sep 10.


  374. Protective effects of higher cognitive reserve for neuropsychological and daily functioning among individuals infected with hepatitis C
    Sakamoto M, Woods SP, Kolessar M, Kriz D, Anderson JR, Olavarria H, Sasaki AW, Chang M, Flora KD, Loftis JM, Huckans M. J Neurovirol. 2013 Oct;19(5):442-51. doi: 10.1007/s13365-013-0196-4. Epub 2013 Sep 10.


  375. Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease
    Himoto T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, Senda S, Haba R, Ueno M, Yamaoka G, Masaki T. Diabetol Metab Syndr. 2013 Sep 9;5(1):51. [Epub ahead of print]


  376. Birth cohort testing for hepatitis C virus: implications for clinical social workers in health care settings
    Sims OT, Whalen CC, Nackerud LG, Bride BE. Soc Work Health Care. 2013;52(8):689-703. doi: 10.1080/00981389.2013.806385.


  377. The ins and outs of hepatitis C virus entry and assembly
    Lindenbach BD, Rice CM. Nat Rev Microbiol. 2013 Oct;11(10):688-700. doi: 10.1038/nrmicro3098. Epub 2013 Sep 10.


  378. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
    Karino Y, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Toyota J. J Viral Hepat. 2013 Aug 25. doi: 10.1111/jvh.12162. [Epub ahead of print]


  379. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration
    Castera L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, Asselineau J, Dabis F, Degos F, Salmon D. HIV Med. 2013 Sep 6. doi: 10.1111/hiv.12082. [Epub ahead of print]


  380. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study
    Hayashi N, Seto C, Kato M, Komada Y, Goto S. J Gastroenterol. 2013 Sep 5. [Epub ahead of print]


  381. Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument
    Anderson RT, Baran RW, Dietz B, Kallwitz E, Erickson P, Revicki DA. Qual Life Res. 2013 Sep 5. [Epub ahead of print]


  382. Hepatitis C virus-associated thrombocytopenia in pregnancy: impact upon multidisciplinary care provision
    Monteith C, Ainle FN, Cooley S, Lambert JS, Kelleher B, Jackson V, Eogan M. J Perinat Med. 2013 Sep 4:1-4. doi: 10.1515/jpm-2013-0080. [Epub ahead of print]


  383. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear)
    Lawitz EJ, Rodriguez-Torres M, Denning J, Mathias A, Mo H, Gao B, Cornpropst MT, Berrey MM, Symonds WT. J Viral Hepat. 2013 Oct;20(10):699-707. doi: 10.1111/jvh.12091. Epub 2013 Mar 31.


  384. Hepatitis C Virus Induces Interleukin-1? (IL-1?)/IL-18 in Circulatory and Resident Liver Macrophages
    Shrivastava S, Mukherjee A, Ray R, Ray RB. J Virol. 2013 Nov;87(22):12284-90. doi: 10.1128/JVI.01962-13. Epub 2013 Sep 4.


  385. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons
    Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W 4th, Cheng G. Antiviral Res. 2013 Nov;100(2):439-45. doi: 10.1016/j.antiviral.2013.08.018. Epub 2013 Sep 5.


  386. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
    Tapper EB, Afdhal NH. J Viral Hepat. 2013 Oct;20(10):669-77. doi: 10.1111/jvh.12168.


  387. Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients
    Saludes V, Bascuñana E, Jordana-Lluch E, Casanovas S, Ardèvol M, Soler E, Planas R, Ausina V, Martró E. PLoS One. 2013 Aug 28;8(8):e72600. doi: 10.1371/journal.pone.0072600.


  388. Antidepressant Pretreatment for the Prevention of Interferon Alfa-Associated Depression: A Systematic Review and Meta-Analysis
    Sarkar S, Schaefer M. Psychosomatics. 2013 Sep 4. pii: S0033-3182(13)00130-8. doi: 10.1016/j.psym.2013.06.015. [Epub ahead of print]


  389. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents
    Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F. J Infect. 2013 Sep 4. pii: S0163-4453(13)00251-X. doi: 10.1016/j.jinf.2013.08.019. [Epub ahead of print]


  390. Viral Breakthrough Is Associated With Resistance Using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection
    Zhou K, Ferguson J, Bau S, Saab S. J Clin Gastroenterol. 2013 Sep 16. [Epub ahead of print]


  391. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults
    Chen EY, North CS, Fatunde O, Bernstein I, Salari S, Day B, Jain MK. J Viral Hepat. 2013 Oct;20(10):708-14. doi: 10.1111/jvh.12095. Epub 2013 Apr 1.


  392. Locations and reasons for initial testing for hepatitis C infection--chronic hepatitis cohort study, United States, 2006-2010
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2013 Aug 16;62(32):645-8.


  393. Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study
    Memon MS, Arain ZI, Naz F, Zaki M, Kumar S, Burney AA. J Diabetes Res. 2013;2013:539361. doi: 10.1155/2013/539361. Epub 2013 Aug 1.


  394. Spleen stiffness correlates with the presence of ascites but not esophageal varices in chronic hepatitis C patients
    Mori K, Arai H, Abe T, Takayama H, Toyoda M, Ueno T, Sato K. Biomed Res Int. 2013;2013:857862. doi: 10.1155/2013/857862. Epub 2013 Aug 1.


  395. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial
    Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. JAMA. 2013 Aug 28;310(8):804-11. doi: 10.1001/jama.2013.109309.


  396. A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C
    Gentile I, Coppola N, Pasquale G, Liuzzi R, D'Armiento M, Di Lorenzo ME, Capoluongo N, Buonomo AR, Sagnelli E, Morisco F, Caporaso N, Borgia G. Hepat Mon. 2013 May 8;13(5):e8352. doi: 10.5812/hepatmon.8352. eCollection 2013.


  397. Metabolic factors and chronic hepatitis C: a complex interplay
    Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Biomed Res Int. 2013;2013:564645. doi: 10.1155/2013/564645. Epub 2013 Jul 17.


  398. Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: A metabolomics analysis
    Saito T, Sugimoto M, Igarashi K, Saito K, Shao L, Katsumi T, Tomita K, Sato C, Okumoto K, Nishise Y, Watanabe H, Tomita M, Ueno Y, Soga T. Metabolism. 2013 Nov;62(11):1577-86. doi: 10.1016/j.metabol.2013.07.002. Epub 2013 Aug 15.


  399. Many Patients with IL28B Genotypes Associated with Response to Therapy are Ineligible for Treatment Because of Comorbidities
    Kanwal F, White DL, Tavakoli-Tabasi S, Jiao L, Lin D, Ramsey DJ, Spiegelman A, Kuzniarek J, El-Serag HB. Clin Gastroenterol Hepatol. 2013 Aug 23. pii: S1542-3565(13)01236-6. doi: 10.1016/j.cgh.2013.08.034. [Epub ahead of print]


  400. Association of the IFNL4-?G Allele With Impaired Spontaneous Clearance of Hepatitis C Virus
    Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, Astemborski J, Plankey M, Villacres MC, Peters MG, Desai S, Seaberg EC, Edlin BR, Strickler HD, Thomas DL, Prokunina-Olsson L, Sharp GB, O'Brien TR. J Infect Dis. 2013 Sep 4. [Epub ahead of print]


  401. Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance
    Calvaruso V, Di Marco V, Ferraro D, Petta S, Calì A, Grazia Bavetta M, Conte E, Luigi Almasio P. Hepat Mon. 2013 May 11;13(5):e7176. doi: 10.5812/hepatmon.7176. eCollection 2013.


  402. Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes
    Arnaud C, Pradat P, Spaziante M, Berthillon P, Maynard M, Taliani G, Chemin I, Trépo C, Petit MA. Antivir Ther. 2013 Aug 15. doi: 10.3851/IMP2671. [Epub ahead of print]


  403. Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients
    Retamozo S, Díaz-Lagares C, Bosch X, Bové A, Brito-Zerón P, Gómez ME, Yagüe J, Forns X, Cid MC, Ramos-Casals M. Medicine (Baltimore). 2013 Aug 22. [Epub ahead of print]


  404. Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study
    Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F, Sansonno D. Medicine (Baltimore). 2013 Aug 26. [Epub ahead of print]


  405. The role of chemokines in acute and chronic hepatitis C infection
    Fahey S, Dempsey E, Long A. Cell Mol Immunol. 2013 Aug 19. doi: 10.1038/cmi.2013.37. [Epub ahead of print]


  406. Evaluation of commercialized rapid diagnostic testing for some Hepatitis B biomarkers in an area of intermediate endemicity
    El-Ghitany EM, Farghaly AG. J Virol Methods. 2013 Sep 1;194(1-2):190-193. doi: 10.1016/j.jviromet.2013.08.026. [Epub ahead of print]


  407. The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse
    Bodeau S, Durand-Maugard C, Lemaire-Hurtel AS, François C, Castelain S, Helle F, Andréjak M, Nguyen-Khac E, Duverlie G, Brochot E. Ther Drug Monit. 2013 Aug 12. [Epub ahead of print]


  408. HCV infected prisoners: should they be still considered a difficult to treat population?
    Iacomi F, Iannicelli G, Franceschini A, Migliorisi P, Rosati S, Piselli P, Scognamiglio P, De Carli G, Marcellini S, Palmieri F. BMC Infect Dis. 2013 Aug 14;13:374. doi: 10.1186/1471-2334-13-374.


  409. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial
    Rusu E, Jinga M, Enache G, Rusu F, Dragomir AD, Ancuta I, Dragu? R, Parpala C, Nan R, Sima I, Ateia S, Stoica V, Che?a DM, Radulian G. Nutr J. 2013 Aug 14;12:119. doi: 10.1186/1475-2891-12-119.


  410. IL28B gene polymorphisms and US liver fatty changes in patients who spontaneously cleared hepatitis C virus infection
    Taliani G, Spaziante M, Biliotti E, Borro M, Palazzo D, Grieco S, Franchi C, Iaiani G, Furlan C, Gallinaro V, Simmaco M. PLoS One. 2013 Aug 1;8(8):e67301. doi: 10.1371/journal.pone.0067301. Print 2013.


  411. Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients
    Aghemo A, Degasperi E, Rumi MG, Galmozzi E, Valenti L, De Francesco R, De Nicola S, Cheroni C, Grassi E, Colombo M. Biomed Res Int. 2013;2013:580796. doi: 10.1155/2013/580796. Epub 2013 Jul 9.


  412. Pathological characteristics of patients who develop hepatocellular carcinoma with negative results of both serous hepatitis B surface antigen and hepatitis C virus antibody
    Kondo R, Nakashima O, Sata M, Imazeki F, Yokosuka O, Tanikawa K, Kage M, Yano H; The Liver Cancer Study Group of Kyushu. Hepatol Res. 2013 Aug 13. doi: 10.1111/hepr.12219. [Epub ahead of print]


  413. Interferon-stimulated genes and their role in controlling hepatitis C virus
    Metz P, Reuter A, Bender S, Bartenschlager R. J Hepatol. 2013 Aug 8. pii: S0168-8278(13)00548-5. doi: 10.1016/j.jhep.2013.07.033. [Epub ahead of print]


  414. Faldaprevir and deleobuvir for HCV genotype 1 infection
    Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Böcher WO, Mensa FJ. N Engl J Med. 2013 Aug 15;369(7):630-9. doi: 10.1056/NEJMoa1213557.


  415. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection
    Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W, Tsuda Y, Steinmann G, Omata M. Liver Int. 2013 Jun 19. doi: 10.1111/liv.12254. [Epub ahead of print]


  416. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons
    Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. BMJ Open. 2013 Aug 13;3(8). pii: e003153. doi: 10.1136/bmjopen-2013-003153.


  417. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE
    Ferrín G, Ranchal I, Llamoza C, Rodríguez-Perálvarez ML, Romero-Ruiz A, Aguilar-Melero P, López-Cillero P, Briceño J, Muntané J, Montero-Álvarez JL, De la Mata M. Liver Int. 2013 Jul 22. doi: 10.1111/liv.12277. [Epub ahead of print]


  418. Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results
    Lacombe K, Valin N, Stitou H, Gozlan J, Thibault V, Boyd A, Poirier JM, Meynard JL, Valantin MA, Bottero J, Girard PM. AIDS. 2013 May 15;27(8):1356-9. doi: 10.1097/QAD.0b013e32836138d0.


  419. AST/ALT ratio is not an index of liver fibrosis in chronic hepatitis C when aminotransferase activities are determinate according to the international recommendations
    Guéchot J, Boisson RC, Zarski JP, Sturm N, Calès P, Lasnier E; the ANRS HCEP 23 Fibrostar Group. Clin Res Hepatol Gastroenterol. 2013 Aug 7. pii: S2210-7401(13)00146-0. doi: 10.1016/j.clinre.2013.07.003. [Epub ahead of print]


  420. Polypharmacy and Comorbidity Are Associated with a Lower Early Virologic Response in Hepatitis C Patients Treated with First Generation Protease Inhibitor Triple Therapy: A Preliminary Analysis
    Juneja M, Euliano R, Satoskar R, Lewis JH. Dig Dis Sci. 2013 Aug 8. [Epub ahead of print]


  421. Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection
    Kanwal F, Hoang T, Chrusciel T, Kramer JR, El-Serag HB, Durfee J, Dominitz JA, Yano EM, Asch SM. Dig Dis Sci. 2013 Aug 10. [Epub ahead of print]


  422. The impact of network medicine in gastroenterology and hepatology
    Baffy G. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1240-4. doi: 10.1016/j.cgh.2013.07.033. Epub 2013 Aug 7.


  423. Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C
    Brochot E, Riachi G, Plantier JC, Guillemard C, Vabret A, Mathurin P, Nguyen-Khac E, Duverlie G; G4 group. J Med Virol. 2013 Jul;85(7):1191-8. doi: 10.1002/jmv.23592.


  424. Health related quality of life among patients with chronic hepatitis C: a cross-sectional study of sociodemographic, psychopathological and psychiatric determinants
    Fábregas BC, de Ávila RE, Faria MN, Moura AS, Carmo RA, Teixeira AL. Braz J Infect Dis. 2013 Jul 31. pii: S1413-8670(13)00167-0. doi: 10.1016/j.bjid.2013.03.008. [Epub ahead of print]


  425. Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients
    Petta S, Marchesini G, Caracausi L, Macaluso FS, Cammà C, Ciminnisi S, Cabibi D, Porcasi R, Craxì A, Di Marco V. J Hepatol. 2013 Aug 6. pii: S0168-8278(13)00553-9. doi: 10.1016/j.jhep.2013.07.037. [Epub ahead of print]


  426. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection
    Herbst DA, Reddy KR. Expert Opin Investig Drugs. 2013 Oct;22(10):1337-46. doi: 10.1517/13543784.2013.826189. Epub 2013 Aug 9.


  427. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection-A Randomized Trial
    Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators. Gastroenterology. 2013 Nov;145(5):1035-1044.e5. doi: 10.1053/j.gastro.2013.07.051. Epub 2013 Aug 4.


  428. Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV
    Tempestilli M, Milano E, D'Offizi G, Montalbano M, D'Avolio A, Gasperi T, Narciso P, Ascenzi P, Pucillo LP. IUBMB Life. 2013 Sep;65(9):800-5. doi: 10.1002/iub.1197. Epub 2013 Jul 29.


  429. Hepatitis C virus induced up-regulation of microRNA-27: A novel mechanism for hepatic steatosis
    Singaravelu R, Chen R, Lyn RK, Jones DM, O'Hara S, Rouleau Y, Cheng J, Srinivasan P, Nasheri N, Russell RS, Lorne D, Pezacki JP. Hepatology. 2013 Jul 29. doi: 10.1002/hep.26634. [Epub ahead of print]


  430. A Unique Model for Treating Chronic Hepatitis C in Patients With Psychiatric Disorders, Substance Abuse, and/or Housing Instability
    Ho CJ, Preston C, Fredericks K, Doorley SL, Kramer RJ, Kwan L, Kamal A. J Addict Med. 2013 September/October;7(5):320-324.



  431. Brunings P, Klar S, Butt G, Nijkamp MD, Buxton JA. Gastroenterol Nurs. 2013 Jul-Aug;36(4):249-57. doi: 10.1097/SGA.0b013e31829f3f9e.


  432. Antiviral activity and resistance of HCV NS5A replication complex inhibitors
    Gao M. Curr Opin Virol. 2013 Oct;3(5):514-520. doi: 10.1016/j.coviro.2013.06.014. Epub 2013 Jul 27.


  433. Effects of metabolic syndrome on fibrosis in chronic viral hepatitis
    Yoon H, Lee JG, Yoo JH, Son MS, Kim DY, Hwang SG, Rim KS. Gut Liver. 2013 Jul;7(4):469-74. doi: 10.5009/gnl.2013.7.4.469. Epub 2013 Jun 20.


  434. Iron and proinflammatory cytokines in chronic hepatitis C virus infection
    López-Prieto J, González-Reimers E, Alemán-Valls MR, de la Vega-Prieto MJ, Abreu-González P, Pelazas-González R, Hernández-Luis R, Jorge-Ripper C, Santolaria-Fernández F. Biol Trace Elem Res. 2013 Oct;155(1):5-10. doi: 10.1007/s12011-013-9760-2. Epub 2013 Jul 28.


  435. Efficacy and Safety of Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease
    Allen AM, Kim WR, Larson J, Loftus EV Jr. Clin Gastroenterol Hepatol. 2013 Jul 23. pii: S1542-3565(13)01055-0. doi: 10.1016/j.cgh.2013.07.014. [Epub ahead of print]


  436. Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1
    Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M, Culp A, Goljer I, Spreen W.


  437. The role of ultrasound elastographic techniques in chronic liver disease: Current status and future perspectives
    Piscaglia F, Marinelli S, Bota S, Serra C, Venerandi L, Leoni S, Salvatore V. Eur J Radiol. 2013 Jul 23. pii: S0720-048X(13)00326-4. doi: 10.1016/j.ejrad.2013.06.009. [Epub ahead of print]


  438. Vitamin D in liver diseases: from mechanisms to clinical trials
    Han YP, Kong M, Zheng S, Ren Y, Zhu L, Shi H, Duan Z. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:49-55. doi: 10.1111/jgh.12016.


  439. Anesthetic management of totally robotic right lobe living-donor hepatectomy: new tools ask for perioperative care
    Martucci G, Burgio G, Spada M, Arcadipane AF. Eur Rev Med Pharmacol Sci. 2013 Jul;17(14):1974-7.


  440. Nucleotide prodrugs for the treatment of HCV infection
    Sofia MJ. Adv Pharmacol. 2013;67:39-73. doi: 10.1016/B978-0-12-405880-4.00002-0.


  441. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment
    Paul D, Hoppe S, Saher G, Krijnse-Locker J, Bartenschlager R. J Virol. 2013 Oct;87(19):10612-27. doi: 10.1128/JVI.01370-13. Epub 2013 Jul 24.


  442. Hepatic stellate cells, liver innate immunity, and hepatitis C virus
    Wang Y, Li J, Wang X, Sang M, Ho W. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:112-5. doi: 10.1111/jgh.12023.


  443. Characterization of Hepatitis C Virus Resistance from a Multiple Dose Clinical Trial of the novel NS5A Inhibitor GS-5885
    Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H. Antimicrob Agents Chemother. 2013 Jul 22. [Epub ahead of print]


  444. Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study
    Berger KL, Lagacé L, Triki I, Cartier M, Marquis M, Lawetz C, Bethell R, Scherer J, Kukolj G. Antimicrob Agents Chemother. 2013 Oct;57(10):4928-36. doi: 10.1128/AAC.00822-13. Epub 2013 Jul 22.


  445. Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community
    Perumalswami PV, Miller FD, Orabee H, Regab A, Adams M, Kapelusznik L, Aljibawi F, Pagano W, Tong V, Dieterich DT. Liver Int. 2013 Jun 22. doi: 10.1111/liv.12259. [Epub ahead of print]


  446. What are the costs and benefits of patient notification exercises following poor infection control practices in dentistry?
    Close RM, Gray S, Bennett S, Appleby S, Khan F, Payne C, Oliver I. Public Health. 2013 Jul 20. pii: S0033-3506(13)00164-9. doi: 10.1016/j.puhe.2013.04.029. [Epub ahead of print]


  447. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor
    Pearlman BL, Ehleben C. Hepatology. 2013 Jul 19. doi: 10.1002/hep.26624. [Epub ahead of print]


  448. Explaining differences in hepatitis C between U.S. veterans and nonveterans in treatment for substance abuse: results from a regression decomposition
    Heslin KC, Guerrero EG, Mitchell MN, Afable MK, Dobalian A. Subst Use Misuse. 2013 Jul;48(10):854-62. doi: 10.3109/10826084.2013.808222.


  449. Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients
    Subramanian V, Bharat A, Vachharajani N, Crippin J, Shenoy S, Mohanakumar T, Chapman WC. HPB (Oxford). 2013 Jul 22. doi: 10.1111/hpb.12128. [Epub ahead of print]


  450. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C
    Hara T, Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Kumada H. J Med Virol. 2013 Oct;85(10):1746-53. doi: 10.1002/jmv.23673. Epub 2013 Jul 16.


  451. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail
    Morcos PN, Chang L, Kulkarni R, Giraudon M, Shulman N, Brennan BJ, Smith PF, Tran JQ. Eur J Clin Pharmacol. 2013 Jul 20. [Epub ahead of print]


  452. Assessment of health-related quality of life predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C
    Matsushita H, Ikeda F, Iwasaki Y, Seki H, Nanba S, Takeuchi Y, Moritou Y, Yasunaka T, Onishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K. J Gastroenterol Hepatol. 2013 Jul 22. doi: 10.1111/jgh.12337. [Epub ahead of print]


  453. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C
    Stättermayer AF, Rutter K, Beinhardt S, Wrba F, Scherzer TM, Strasser M, Hofer H, Steindl-Munda P, Trauner M, Ferenci P. Liver Int. 2013 Jun 27. doi: 10.1111/liv.12269. [Epub ahead of print]


  454. Molecular evolution in court: analysis of a large hepatitis C virus outbreak from an evolving source
    González-Candelas F, Bracho MA, Wróbel B, Moya A. BMC Biol. 2013 Jul 19;11:76. doi: 10.1186/1741-7007-11-76.


  455. Direct Acting Antiviral Agents and the Path to Interferon Independence
    Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Clin Gastroenterol Hepatol. 2013 Jul 17. pii: S1542-3565(13)01036-7. doi: 10.1016/j.cgh.2013.06.024. [Epub ahead of print]


  456. Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin
    Par G, Szereday L, Berki T, Palinkas L, Halasz M, Miseta A, Hegedus G, Szekeres-Bartho J, Vincze A, Hunyady B, Par A. PLoS One. 2013 Jul 9;8(7):e67770. doi: 10.1371/journal.pone.0067770. Print 2013.


  457. Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations
    Romero-Gómez M, Berenguer M, Molina E, Calleja JL. J Hepatol. 2013 Jul 15. pii: S0168-8278(13)00461-3. doi: 10.1016/j.jhep.2013.07.014. [Epub ahead of print]


  458. Management algorithm for genotype 1 hepatitis C virus
    Kim AY. F1000Prime Rep. 2013 Jul 1;5:24. doi: 10.12703/P5-24. Print 2013.


  459. Vitamin D status and serum ferritin concentration in chronic hepatitis C virus type 1 infection
    Amanzada A, Goralczyk AD, Moriconi F, van Thiel DH, Ramadori G, Mihm S.


  460. Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype
    Han H, Noureddin M, Witthaus M, Park YJ, Hoofnagle JH, Liang TJ, Rotman Y. J Hepatol. 2013 Jul 10. pii: S0168-8278(13)00451-0. doi: 10.1016/j.jhep.2013.07.004. [Epub ahead of print]


  461. Excellent liver retransplantation outcomes in hepatitis C-infected recipients
    Kressel A, Therapondos G, Bohorquez H, Borg B, Bruce D, Carmody I, Cohen A, Girgrah N, Joshi S, Reichman T, Loss GE. Clin Transplant. 2013 Jul;27(4):E512-20. doi: 10.1111/ctr.12182. Epub 2013 Jul 16.


  462. Hepatitis C virus screening and management of seroconversions in hemodialysis facilities
    Mbaeyi C, Thompson ND. Semin Dial. 2013 Jul-Aug;26(4):439-46. doi: 10.1111/sdi.12097. Epub 2013 May 31.


  463. Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C
    Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arastéh K, Bourlière M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G; BI 207127 Study Group. Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35. doi: 10.1128/AAC.00565-13. Epub 2013 Jul 15.


  464. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection
    Hazuda DJ, Burroughs M, Howe AY, Wahl J, Venkatraman S. Ann N Y Acad Sci. 2013 Jul;1291:69-76. doi: 10.1111/nyas.12218.


  465. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection
    Beinhardt S, Payer BA, Datz C, Strasser M, Maieron A, Dorn L, Grilnberger-Franz E, Dulic-Lakovic E, Stauber R, Laferl H, Aberle JH, Holzmann H, Krall C, Vogel W, Ferenci P, Hofer H. J Hepatol. 2013 Jul 10. pii: S0168-8278(13)00446-7. doi: 10.1016/j.jhep.2013.06.028. [Epub ahead of print]


  466. In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellualr carcimona, with better tolerance and similar survival
    Shingina A, Hashim AM, Haque M, Suen M, Yoshida EM, Gill S, Donnellan F, Weiss AA. Can J Gastroenterol. 2013 Jul;27(7):393-6.


  467. Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
    Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC. Radiology. 2013 Jul 17. [Epub ahead of print]


  468. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen
    Cachay ER, Wyles DL, Torriani FJ, Ballard C, Colwell B, Lin JC, Hill L, Mathews WC. AIDS. 2013 Jul 24. [Epub ahead of print]


  469. A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir
    Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. Curr Med Chem. 2013;20(30):3733-42.


  470. Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection
    Druyts E, Thorlund K, Humphreys S, Lion M, Cooper CL, Mills EJ. Clin Epidemiol. 2013 Jun 20;5:173-83. doi: 10.2147/CLEP.S44273. Print 2013.


  471. Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C
    Tajiri H, Tanaka Y, Takano T, Suzuki M, Abukawa D, Miyoshi Y, Shimizu T, Brooks S. Hepatol Res. 2013 Jul 11. doi: 10.1111/hepr.12206. [Epub ahead of print]


  472. Factors contributing to health disparities in liver transplantation in a Hispanic population
    Rivera MN, Jowsey S, Alsina AE, Torres EA. P R Health Sci J. 2012 Dec;31(4):199-204.


  473. Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C
    Gavilán JC, Ojeda G, Arnedo R, Puerta S. Eur J Intern Med. 2013 Jul 9. pii: S0953-6205(13)00175-1. doi: 10.1016/j.ejim.2013.06.010. [Epub ahead of print]


  474. Effect of hepatitis C virus infection on erythropoiesis in patients on hemodialysis
    Saifan C, El-Charabaty E, Kleiner M, El-Sayegh S. Int J Nephrol Renovasc Dis. 2013 Jun 28;6:121-4. doi: 10.2147/IJNRD.S44656. Print 2013.


  475. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives
    Chae HB, Park SM, Youn SJ. ScientificWorldJournal. 2013 Jun 5;2013:704912. doi: 10.1155/2013/704912.


  476. Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C
    Lin CY, Sheen IS, Chen JY, Huang CW, Huang CH, Jeng WJ, Chen WT. J Clin Gastroenterol. 2013 Oct;47(9):794-9. doi: 10.1097/MCG.0b013e31829d2064.


  477. Current progress in development of hepatitis C virus vaccines
    Liang TJ. Nat Med. 2013 Jul;19(7):869-78. doi: 10.1038/nm.3183.


  478. Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis
    Ji F, Zhang S, Huang N, Deng H, Li Z. Braz J Infect Dis. 2013 Jul 2. pii: S1413-8670(13)00146-3. doi: 10.1016/j.bjid.2013.02.004. [Epub ahead of print]


  479. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection
    Sagrini E, Ardoino I, Marano G, Gianstefani A, Orlandini A, Sebastiani G, Donati G, Cucchetti A, Pelosi G, Ferrari C, Alberti A, Biganzoli E, Piscaglia F, Bolondi L. Eur J Gastroenterol Hepatol. 2013 Jul 3. [Epub ahead of print]


  480. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
    Scheel TK, Rice CM. Nat Med. 2013 Jul;19(7):837-49. doi: 10.1038/nm.3248.


  481. Regulation of hepatic innate immunity by hepatitis C virus
    Horner SM, Gale M Jr. Nat Med. 2013 Jul;19(7):879-88. doi: 10.1038/nm.3253.


  482. Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients
    Lee HS, Kweon YO, Tak WY, Park SY, Kang EJ, Lee YL, Yang HM, Park HW. Clin Mol Hepatol. 2013 Jun;19(2):148-55. doi: 10.3350/cmh.2013.19.2.148. Epub 2013 Jun 27.


  483. Non-invasive assessment of liver fibrosis using magnetic resonance elastography in liver transplant recipients with hepatitis C
    Crespo S, Bridges M, Nakhleh R, McPhail A, Pungpapong S, Keaveny AP. Clin Transplant. 2013 Jul 10. doi: 10.1111/ctr.12180. [Epub ahead of print]


  484. Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients
    Ciccarelli N, Fabbiani M, Grima P, Falasca K, Tana M, Baldonero E, Colafigli M, Silveri MC, Vecchiet J, Cauda R, Di Giambenedetto S. Infection. 2013 Jul 10. [Epub ahead of print]


  485. Lack of Access to Treatment as a Barrier to HCV Screening: A Facility-Based Assessment in the Indian Health Service
    Reilley B, Leston J, Redd JT, Geiger R. J Public Health Manag Pract. 2013 Jul 8. [Epub ahead of print]


  486. Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C
    Goldhaber-Fiebert JD, Barnett PG, Dally S, Asch SM, Liu S, Cipriano L, Owens DK, Miake-Lye IM, Beroes JM, Shekelle PG.


  487. Women with chronic hepatitis C virus infection: recommendations for clinical practice
    Burton MJ, Brock JB, Geraci SA. South Med J. 2013 Jul;106(7):422-6. doi: 10.1097/SMJ.0b013e31829b99f5.


  488. Hepatitis C--an update
    Holmes J, Thompson A, Bell S. Aust Fam Physician. 2013 Jul;42(7):452-6.


  489. Sequencing of the Hepatitis C Virus: A Systematic Review
    Jacka B, Lamoury F, Simmonds P, Dore GJ, Grebely J, Applegate T. PLoS One. 2013 Jun 27;8(6):e67073. Print 2013.


  490. Hepatitis C treatment in patients with kidney disease
    Fabrizi F, Aghemo A, Messa P. Kidney Int. 2013 Jul 3. doi: 10.1038/ki.2013.264. [Epub ahead of print]


  491. Insulin resistance is associated with DNA damage in peripheral blood cells in non-diabetic patients with genotype 1 chronic hepatitis C
    Sakae PN, Ihara SS, Ribeiro DA, de Carvalho L, Parise ER. Free Radic Res. 2013 Sep;47(9):750-6. doi: 10.3109/10715762.2013.821700. Epub 2013 Jul 29.


  492. Value of Interleukin 28B Genetic Polymorphism on Retreatment Outcomes of Chronic Hepatitis C Genotype 1 Relapsers by Peginterferon Alfa plus Ribavirin
    Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ. J Gastroenterol Hepatol. 2013 Jul 5. doi: 10.1111/jgh.12329. [Epub ahead of print]


  493. Global control of hepatitis C: where challenge meets opportunity
    Thomas DL. Nat Med. 2013 Jul;19(7):850-8. doi: 10.1038/nm.3184.


  494. Epidemiological factors affecting
    Diomidous M, Zimeras S, Elefsiniotis IS. Stud Health Technol Inform. 2013;190:261-3.


  495. Drug-drug interactions during antiviral therapy for chronic hepatitis C
    Kiser JJ, Burton JR Jr, Everson GT. Nat Rev Gastroenterol Hepatol. 2013 Jul 2. doi: 10.1038/nrgastro.2013.106. [Epub ahead of print]


  496. Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link
    Hernández-Bartolomé A, López-Rodríguez R, Rodríguez-Muñoz Y, Martín-Vílchez S, Borque MJ, García-Buey L, González-Moreno L, Real Y, Moreno-Otero R, Sanz-Cameno P. PLoS One. 2013 Jun 18;8(6):e66143. Print 2013.


  497. Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit
    Vafiadis I, Trilianos P, Vlachogiannakos J, Karagiorga M, Hatziliami A, Voskaridou E, Ladas SD. Ann Hepatol. 2013 Jul-Aug;12(4):532-8.


  498. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir
    Mauss S, Hueppe D, Alshuth U. Hepatology. 2013 Jun 28. doi: 10.1002/hep.26602. [Epub ahead of print]


  499. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin
    Yen YH, Wang JC, Hung CH, Lu SN, Wang JH, Hu TH, Kee KM, Hsiao CC, Lee CM. J Formos Med Assoc. 2013 Jun 26. pii: S0929-6646(13)00163-0. doi: 10.1016/j.jfma.2013.04.013. [Epub ahead of print]


  500. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C
    Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-Escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-Santos R, Solà R. J Hepatol. 2013 Jun 26. pii: S0168-8278(13)00435-2. doi: 10.1016/j.jhep.2013.06.019. [Epub ahead of print]


  501. Marijuana Smoking Does Not Accelerate Progression of Liver Disease in HIV-Hepatitis C Coinfection: A Longitudinal Cohort Analysis
    Brunet L, Moodie EE, Rollet K, Cooper C, Walmsley S, Potter M, Klein MB; Canadian Co-infection Cohort Investigators. Clin Infect Dis. 2013 Sep;57(5):663-70. doi: 10.1093/cid/cit378. Epub 2013 Jun 28.


  502. Intravenous Interferon Administered During Liver Transplantation Is Not Effective in Preventing Hepatitis C Reinfection
    Russo MW, Narang T, Eskind L, Hayes D, Casingal V, Purdum PP, Hanson JS, Ahrens W, Norton J, Bonkovsky H. Dig Dis Sci. 2013 Jun 29. [Epub ahead of print]


  503. Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection
    Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES. Gastroenterology. 2013 Jun 26. pii: S0016-5085(13)00995-5. doi: 10.1053/j.gastro.2013.06.051. [Epub ahead of print]


  504. Impact of Hepatitis C Virus (HCV) infection on biomolecular markers influencing the pathogenesis of bladder cancer
    Hemmaid KZ, Awadalla A, Elsawy E, Hussein AA, Abdel-Aziz A, Shokeir AA, El-Hefnawy AS, Abol-Enein H. Infect Agent Cancer. 2013 Jun 28;8(1):24. doi: 10.1186/1750-9378-8-24.


  505. Non-invasive assessment of liver fibrosis using ARFI with pathological correlation, a prospective study
    Yap WW, Kirke R, Yoshida EM, Owen D, Harris AC. Ann Hepatol. 2013 Jul-Aug;12(4):608-15.


  506. Hepatitis B and C in African Americans: Current Status and Continued Challenges
    Forde KA, Tanapanpanit O, Reddy KR. Clin Gastroenterol Hepatol. 2013 Jun 28. pii: S1542-3565(13)00865-3. doi: 10.1016/j.cgh.2013.06.006. [Epub ahead of print]


  507. Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis
    Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C, Zeuzem S, Hofmann WP. PLoS One. 2013 Aug 1;8(8):e71262. doi: 10.1371/journal.pone.0071262. Print 2013.


  508. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma
    Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. World J Hepatol. 2013 Jun 27;5(6):332-5. doi: 10.4254/wjh.v5.i6.332.


  509. A report from the 26th International Conference on Antiviral Research (May 11-15, San Francisco, California, USA)
    Rabasseda X. Drugs Today (Barc). 2013 Jun;49(6):411-7. doi: 10.1358/dot.2013.49.6.2002838.


  510. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C
    Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. J Viral Hepat. 2013 Aug;20(8):550-5. doi: 10.1111/jvh.12080. Epub 2013 Mar 25.


  511. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles
    Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, Lin IL, Lin ZY, Chen SC, Wang LY, Chuang WL, Yu ML, Tung HD. J Gastroenterol Hepatol. 2013 Jun 28. doi: 10.1111/jgh.12313. [Epub ahead of print]


  512. Is There any Difference Between the Glomerular Filtration Rate of Patients With Chronic Hepatitis B and C and Patients With Cirrhosis?
    Gluhovschi C, Velciov S, Buzas R, Petrica L, Bozdog G, Gadalean F, Gluhovschi A, Balgradean C, Vernic C, Sporea I. Hepat Mon. 2013 Apr 15;13(4):e6789. doi: 10.5812/hepatmon.6789. Print 2013 Apr.


  513. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C
    Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, Marrone A, Macera M, Sagnelli E, Perrone L, Adinolfi LE, Miraglia del Giudice E. J Viral Hepat. 2013 Aug;20(8):517-23. doi: 10.1111/jvh.12053. Epub 2013 Jan 7.


  514. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting
    Manos MM, Darbinian J, Rubin J, Ray GT, Shvachko V, Denis B, Velez F, Quesenberry C. J Manag Care Pharm. 2013 Jul-Aug;19(6):438-47.


  515. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C
    Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM. J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.


  516. Long-term clearance of hepatitis C virus following interferon ?-2b or peginterferon ?-2b, alone or in combination with ribavirin
    Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM, Bárcena R, Schiff ER, Shaikh OS, Bacon B, Marcellin P, Deng W, Esteban-Mur R, Poynard T, Pedicone LD, Brass CA, Albrecht JK, Gordon SC. J Viral Hepat. 2013 Aug;20(8):524-9. doi: 10.1111/jvh.12074. Epub 2013 Mar 3.


  517. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence
    Evon DM, Esserman DA, Bonner JE, Rao T, Fried MW, Golin CE. J Viral Hepat. 2013 Aug;20(8):536-49. doi: 10.1111/jvh.12079. Epub 2013 Feb 25.


  518. Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial
    Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, Ghys A, Luo D, Picchio GR, Beumont M. J Infect Dis. 2013 Jul 11. [Epub ahead of print]


  519. Performance of unidimensional transient elastography in staging chronic hepatitis C. Results from a cohort of 1,202 biopsied patients from one single center
    Lupsor Platon M, Stefanescu H, Feier D, Maniu A, Badea R. J Gastrointestin Liver Dis. 2013 Jun;22(2):157-66.


  520. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan
    Hsu CS, Kao JH, Chao YC, Lin HH, Fan YC, Huang CJ, Tsai PS. Aliment Pharmacol Ther. 2013 Aug;38(4):415-23. doi: 10.1111/apt.12391. Epub 2013 Jun 26.


  521. Patient perspectives on hepatitis C and its treatment
    North CS, Devereaux R, Pollio DE, Hong BA, Jain MK. Eur J Gastroenterol Hepatol. 2013 Jun 19. [Epub ahead of print]


  522. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: A randomized controlled trial
    Chapplain JM, Bellissant E, Guyader D, Molina JM, Poizot-Martin I, Perré P, Pialoux G, Turlin B, Mouchel C, Renault A, Michelet C; ANRS HC-12 Study Group. J Infect. 2013 Jun 22. pii: S0163-4453(13)00152-7. doi: 10.1016/j.jinf.2013.05.007. [Epub ahead of print]


  523. Infection status outcome, machine learning method and virus type interact to affect the optimised prediction of hepatitis virus immunoassay results from routine pathology laboratory assays in unbalanced data
    Richardson AM, Lidbury BA. BMC Bioinformatics. 2013 Jun 25;14:206. doi: 10.1186/1471-2105-14-206.


  524. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse
    Lagging M, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Färkkilä M, Hellstrand K, Langeland N, Lindh M, Westin J, Norkrans G. Scand J Gastroenterol. 2013 Jul;48(7):839-47. doi: 10.3109/00365521.2013.793389.


  525. Prediction of hepatic fibrosis in patients coinfected with human immunodeficiency virus and hepatitis C virus based on genetic markers
    Fernández-Rodríguez A, Berenguer J, Jiménez-Sousa MA, Guzmán-Fulgencio M, Micheloud D, Miralles P, López JC, Bellón JM, Aldamiz-Echevarria T, García-Broncano P, Carrero A, Alvarez E, Resino S. J Acquir Immune Defic Syndr. 2013 Jun 21. [Epub ahead of print]


  526. Modelling the prevalence of HCV amongst people who inject drugs: An investigation into the risks associated with injecting paraphernalia sharing
    Corson S, Greenhalgh D, Taylor A, Palmateer N, Goldberg D, Hutchinson S. Drug Alcohol Depend. 2013 Jun 19. pii: S0376-8716(13)00189-0. doi: 10.1016/j.drugalcdep.2013.05.014. [Epub ahead of print]


  527. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C
    Bronowicki JP, Pol S, Thuluvath PJ, Larrey D, Martorell CT, Rustgi VK, Morris DW, Younes Z, Fried MW, Bourlière M, Hézode C, Reddy KR, Massoud O, Abrams GA, Ratziu V, He B, Eley T, Ahmad A, Cohen D, Hindes R, McPhee F, Reilly B, Mendez P, Hughes E. Antivir Ther. 2013 Jun 26. doi: 10.3851/IMP2660. [Epub ahead of print]


  528. Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment
    Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O. Int J Med Sci. 2013 Jun 15;10(8):1015-21. doi: 10.7150/ijms.6402. Print 2013.


  529. Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy
    Jadali Z. Indian J Endocrinol Metab. 2013 Jan;17(1):69-75. doi: 10.4103/2230-8210.107856.


  530. Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with HCV Genotype 1
    Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. J Clin Microbiol. 2013 Jun 19. [Epub ahead of print]


  531. Hepatitis C in men who have sex with men in London - a community survey
    Price H, Gilson R, Mercey D, Copas A, Parry J, Nardone A, Hart G. HIV Med. 2013 Jun 18. doi: 10.1111/hiv.12050. [Epub ahead of print]


  532. Role of IL28B Gene Polymorphism and Cell-Mediated Immunity in Spontaneous Resolution of Acute Hepatitis C
    Spada E, Amoroso P, Taliani G, Zuccaro O, Chiriacò P, Maio P, Maio G, Esposito ML, Mariano C, Rinaldi R, Bellissima P, Tosti ME, Del Porto P, Francavilla R, Mellace V, Garbuglia AR, Folgori A, Mele A; for the Acute Hepatitis Italian Study Group. Clin Infect Dis. 2013 Jul 9. [Epub ahead of print]


  533. Interleukin-28B genetic variations and spontaneous clearance of hepatitis C antibody-positive blood donors in China
    Liu Y, Ma H, Chen S, Wang J, Liu G, Xu M, Ke L, He M. Transfusion. 2013 Jun 19. doi: 10.1111/trf.12305. [Epub ahead of print]


  534. Analysis of Site Performance in Academic-based and Community-based Centers in the IDEAL Study
    Jou JH, Sulkowski MS, Noviello S, Long J, Pedicone LD, McHutchison JG, Muir AJ. J Clin Gastroenterol. 2013 Jun 19. [Epub ahead of print]


  535. Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study
    Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, Guzman L, Kletter E, Seewald RM, Des-Jarlais DC, Sorensen JL, Perlman DC. Harm Reduct J. 2013 Jun 20;10:10. doi: 10.1186/1477-7517-10-10.


  536. Outbreak of hepatitis C virus infections at an outpatient hemodialysis facility: the importance of infection control competencies
    Rao AK, Luckman E, Wise ME, MacCannell T, Blythe D, Lin Y, Xia G, Drobeniuc J, Noble-Wang J, Arduino MJ, Thompson ND, Patel PR, Wilson LE. Nephrol Nurs J. 2013 Mar-Apr;40(2):101-10, 164; quiz 111.


  537. Half a Diagnosis: Gap in Confirming Infection among Hepatitis C Antibody-positive Patients
    McGibbon E, Bornschlegel K, Balter S. Am J Med. 2013 Aug;126(8):718-22. doi: 10.1016/j.amjmed.2013.01.031. Epub 2013 Jun 17.


  538. Evaluation of the significance of pretreatment liver biopsy and baseline mental health disorder diagnosis on hepatitis C treatment completion rates at a veterans affairs medical center
    Kluck J, O'Flynn RM, Kaplan DE, Chang KM. Hepat Res Treat. 2013;2013:653976. doi: 10.1155/2013/653976. Epub 2013 May 16.


  539. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis
    Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N. Virology. 2013 Sep 1;443(2):278-84. doi: 10.1016/j.virol.2013.05.013. Epub 2013 Jun 10.


  540. Comparative Analysis of T-Cell Depletion Method for Clinical Immunotherapy-Anti-Hepatitis C Effects of Natural Killer Cells Via Interferon-? Production
    Ohira M, Nishida S, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, Ricordi C, Ohdan H, Tzakis AG. http://www.ncbi.nlm.nih.gov/pubmed/23769105#


  541. Socioeconomic status in HCV infected patients - risk and prognosis
    Omland LH, Osler M, Jepsen P, Krarup H, Weis N, Christensen PB, Roed C, Sørensen HT, Obel N. Clin Epidemiol. 2013 May 31;5:163-72. doi: 10.2147/CLEP.S43926. Print 2013.


  542. Acceptability of Psychotherapy, Pharmacotherapy, and Self-Directed Therapies in Australians Living with Chronic Hepatitis C
    Stewart BJ, Turnbull D, Mikocka-Walus AA, Harley HA, Andrews JM. http://www.ncbi.nlm.nih.gov/pubmed/23756631#


  543. IL-4 -590C/T Polymorphism and Susceptibility to Liver Disease: A Meta-Analysis and Meta-Regression
    Zheng Z, Li X, Li Z, Ma XC. DNA Cell Biol. 2013 Aug;32(8):443-50. doi: 10.1089/dna.2013.2020. Epub 2013 Jun 15.


  544. Comparative analysis of viral protein interaction networks in Hepatitis B Virus and Hepatitis C Virus infected HCC
    Yuan W, Huang T, Yu J, Zeng L, Lian B, He Q, Li Y, Zhang X, Zhou F, Xie L.


  545. Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma
    Littera R, Zamboni F, Tondolo V, Fantola G, Chessa L, Orrù N, Sanna M, Valentini D, Cappai L, Mulargia M, Caocci G, Arras M, Floris A, Orrù S, La Nasa G, Carcassi C. Hum Immunol. 2013 Jun 10. pii: S0198-8859(13)00148-1. doi: 10.1016/j.humimm.2013.05.007. [Epub ahead of print]


  546. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres
    Cazzagon N, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Del Poggio P, Rapaccini G, Di Nolfo AM, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Svegliati Baroni G, Morisco F, Pecorelli A, Farinati F; for the ITA.LI.CA Group. Liver Int. 2013 May 9. doi: 10.1111/liv.12208. [Epub ahead of print]


  547. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection
    Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y. J Med Virol. 2013 Sep;85(9):1523-33. doi: 10.1002/jmv.23626. Epub 2013 Jun 17.


  548. Donor notification and counseling - Experience and challenges
    Kaur G, Kaur P, Basu S, Kaur R, Sharma S. Transfus Apher Sci. 2013 Jun 12. pii: S1473-0502(13)00164-X. doi: 10.1016/j.transci.2013.05.005. [Epub ahead of print]


  549. Direct-Acting Antiviral-Associated Dermatitis During Chronic Hepatitis C Virus Treatment
    Biesbroeck LK, Scott JD, Taraska C, Moore E, Falsey RR, Shinohara MM. Am J Clin Dermatol. 2013 Jun 18. [Epub ahead of print]


  550. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
    Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators. Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.


  551. The AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations
    Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA. Hepatology. 2013 Jun 14. doi: 10.1002/hep.26578. [Epub ahead of print]


  552. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
    Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Antiviral Res. 2013 Jun 7;99(3):214-220. doi: 10.1016/j.antiviral.2013.05.015. [Epub ahead of print]


  553. Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C
    Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sällberg M. Mol Ther. 2013 Jun 11. doi: 10.1038/mt.2013.119. [Epub ahead of print]


  554. Global confluence of infectious and non-communicable diseases - The case of type 2 diabetes
    Magee MJ, Narayan KM. Prev Med. 2013 Jun 6. pii: S0091-7435(13)00190-4. doi: 10.1016/j.ypmed.2013.05.027. [Epub ahead of print]


  555. Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia
    Charles ED, Orloff MI, Nishiuchi E, Marukian S, Rice CM, Dustin LB. Arthritis Rheum. 2013 Jun 10. doi: 10.1002/art.38041. [Epub ahead of print]


  556. Hepatitis C therapy at home: a hospital and home care partnership
    Jack K, Barnett J, Holiday A, Heard G, Thomson B. Br J Nurs. 2013 May 9-22;22(9):518-23


  557. Outcome After Liver Transplantation for Cirrhosis Due to Alcohol and Hepatitis C: Comparison to Alcoholic Cirrhosis and Hepatitis C Cirrhosis
    Singal AK, Hmoud BS, Guturu P, Kuo YF. J Clin Gastroenterol. 2013 Jun 6. [Epub ahead of print]


  558. Efficacy and Safety of Pegylated Interferon Alfa-2b and Ribavirin Combination Therapy Versus Pegylated Interferon Monotherapy in Hemodialysis Patients: A Comparison of 2 Sequentially Treated Cohorts
    Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH. Am J Kidney Dis. 2013 Jun 5. pii: S0272-6386(13)00782-8. doi: 10.1053/j.ajkd.2013.03.037. [Epub ahead of print]


  559. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C
    Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. J Hepatol. 2013 Jun 7. pii: S0168-8278(13)00376-0. doi: 10.1016/j.jhep.2013.05.043. [Epub ahead of print]


  560. Depression and Fatigue in Chronic Hepatitis C Patients with and Without HIV Co-Infection
    Tavakkoli M, Ferrando SJ, Rabkin J, Marks K, Talal AH. Psychosomatics. 2013 Jun 4. pii: S0033-3182(13)00047-9. doi: 10.1016/j.psym.2013.02.009. [Epub ahead of print]


  561. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice
    Niederau C, Mauss S, Böker K, Lutz T, Heyne R, Moog G, John C, Witthöft T, Alshuth U, Hüppe D. Eur J Gastroenterol Hepatol. 2013 Jun 11. [Epub ahead of print]


  562. Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection
    Lamontagne A, Long RE, Comunale MA, Hafner J, Rodemich-Betesh L, Wang M, Marrero J, Di Bisceglie AM, Block T, Mehta A. PLoS One. 2013 Jun 4;8(6):e64992. doi: 10.1371/journal.pone.0064992. Print 2013.


  563. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
    Bartenschlager R, Lohmann V, Penin F. Nat Rev Microbiol. 2013 Jul;11(7):482-96. doi: 10.1038/nrmicro3046. Epub 2013 Jun 10.


  564. Increasing Hepatitis C Prevalence and Associated Risk Behaviors among Incarcerated Young Adults
    McNamara BC, Losikoff PT, Huguenin L, Macalino GE, Rich JD, Gregory SH. J Urban Health. 2013 May 31. [Epub ahead of print]


  565. A multicentre survey of hepatitis C awareness in a high-risk population
    Kanaan T, Liu A, Leroi M, Nanan R. J Paediatr Child Health. 2013 Jun 7. doi: 10.1111/jpc.12259. [Epub ahead of print]


  566. Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
    Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. World J Gastroenterol. 2013 Jun 7;19(21):3199-206. doi: 10.3748/wjg.v19.i21.3199.


  567. The impact of infectious diseases consultation on oncology practice
    Granwehr BP, Kontoyiannis DP. Curr Opin Oncol. 2013 Jul;25(4):353-9. doi: 10.1097/CCO.0b013e3283622c32.


  568. Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients
    Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Matsunaga K, Taki K, Asahina Y, Izumi N. Hepatol Res. 2013 Jun 6. doi: 10.1111/hepr.12179. [Epub ahead of print]


  569. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation
    Ponziani FR, Annicchiarico EB, Siciliano M, D'Aversa F, Pompili M, Gasbarrini A. World J Gastroenterol. 2013 Jun 7;19(21):3255-62. doi: 10.3748/wjg.v19.i21.3255.


  570. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
    Heim MH. Nat Rev Immunol. 2013 Jun 7;13(7):535-42. doi: 10.1038/nri3463. Epub 2013 Jun 7.


  571. Therapy of chronic hepatitis C with PEG-IFN ?-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses
    Fabris P, Carlotto A, Bianco TD, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A. Eur J Gastroenterol Hepatol. 2013 Jun 19. [Epub ahead of print]


  572. Editorial: killing two birds with one stone: screening for chronic hepatitis C at the time of colonoscopy in the baby boomer cohort
    Torres DM, Harrison SA. Am J Gastroenterol. 2013 Jun;108(6):990-2. doi: 10.1038/ajg.2013.54.


  573. Autoantibody profile in individuals with chronic hepatitis C
    Marconcini ML, Fayad L, Shiozawa MB, Dantas-Correa EB, Lucca Schiavon Ld, Narciso-Schiavon JL. Rev Soc Bras Med Trop. 2013;46(2). pii: S0037-86822013000200147. doi: 10.1590/0037-8682-0039-2013.


  574. A multicentre survey of hepatitis C awareness in a high-risk population
    Kanaan T, Liu A, Leroi M, Nanan R. J Paediatr Child Health. 2013 Jun 7. doi: 10.1111/jpc.12259. [Epub ahead of print]


  575. Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
    Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. World J Gastroenterol. 2013 Jun 7;19(21):3199-206. doi: 10.3748/wjg.v19.i21.3199.


  576. The impact of infectious diseases consultation on oncology practice
    Granwehr BP, Kontoyiannis DP. Curr Opin Oncol. 2013 Jul;25(4):353-9. doi: 10.1097/CCO.0b013e3283622c32.


  577. Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients
    Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Matsunaga K, Taki K, Asahina Y, Izumi N. Hepatol Res. 2013 Jun 6. doi: 10.1111/hepr.12179. [Epub ahead of print]


  578. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation
    Ponziani FR, Annicchiarico EB, Siciliano M, D'Aversa F, Pompili M, Gasbarrini A. World J Gastroenterol. 2013 Jun 7;19(21):3255-62. doi: 10.3748/wjg.v19.i21.3255.


  579. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
    Heim MH. Nat Rev Immunol. 2013 Jun 7;13(7):535-42. doi: 10.1038/nri3463. Epub 2013 Jun 7.


  580. Therapy of chronic hepatitis C with PEG-IFN ?-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses
    Fabris P, Carlotto A, Bianco TD, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A. Eur J Gastroenterol Hepatol. 2013 Jun 19. [Epub ahead of print]


  581. Editorial: killing two birds with one stone: screening for chronic hepatitis C at the time of colonoscopy in the baby boomer cohort
    Torres DM, Harrison SA. Am J Gastroenterol. 2013 Jun;108(6):990-2. doi: 10.1038/ajg.2013.54.


  582. Autoantibody profile in individuals with chronic hepatitis C
    Marconcini ML, Fayad L, Shiozawa MB, Dantas-Correa EB, Lucca Schiavon Ld, Narciso-Schiavon JL. Rev Soc Bras Med Trop. 2013;46(2). pii: S0037-86822013000200147. doi: 10.1590/0037-8682-0039-2013.


  583. Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients
    Petta S, Grimaudo S, Marco VD, Scazzone C, Macaluso FS, Cammà C, Cabibi D, Pipitone R, Craxì A. J Viral Hepat. 2013 Jul;20(7):486-93. doi: 10.1111/jvh.12072. Epub 2013 Mar 25.


  584. Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development
    Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY; Hiroshima Liver Study Group; Swiss Hepatitis C Cohort Study Group. PLoS One. 2013 May 29;8(5):e64053. doi: 10.1371/journal.pone.0064053. Print 2013.


  585. Role of T cell immunity in hepatitis C virus infections
    Claassen MA, Janssen HL, Boonstra A. Curr Opin Virol. 2013 Jun 1. pii: S1879-6257(13)00066-7. doi: 10.1016/j.coviro.2013.05.006. [Epub ahead of print]


  586. Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection
    Adeyemo O, Doi H, Rajender Reddy K, Kaplan DE. J Viral Hepat. 2013 Jul;20(7):453-62. doi: 10.1111/jvh.12050. Epub 2013 Apr 12.


  587. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies
    Pedersen J, Carlsen TH, Prentoe J, Ramirez S, Jensen TB, Forns X, Alter H, Foung SK, Law M, Gottwein J, Weis N, Bukh J. Hepatology. 2013 May 31. doi: 10.1002/hep.26524. [Epub ahead of print]


  588. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation
    García-Reyne A, Lumbreras C, Fernández I, Colina F, Abradelo M, Magan P, San-Juan R, Manrique A, López-Medrano F, Fuertes A, Lizasoain M, Moreno E, Aguado JM. Transpl Infect Dis. 2013 Jun 3. doi: 10.1111/tid.12097. [Epub ahead of print]


  589. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection
    Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, Fung J, Lai CL, Yuen MF. J Viral Hepat. 2013 Jul;20(7):470-7. doi: 10.1111/jvh.12047. Epub 2013 Apr 12.


  590. Project ECHO: Replicating a Novel Model to Enhance Access to Hepatitis C Care in a Community Health Center
    Khatri K, Haddad M, Anderson D. J Health Care Poor Underserved. 2013;24(2):850-8. doi: 10.1353/hpu.2013.0093.


  591. Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements
    Grebely J, Matthews GV, Lloyd AR, Dore GJ. Clin Infect Dis. 2013 Jun 27. [Epub ahead of print]


  592. Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan
    Torii H, Sueki H, Kumada H, Sakurai Y, Aoki K, Yamada I, Ohtsuki M. J Dermatol. 2013 Jun 5. doi: 10.1111/1346-8138.12199. [Epub ahead of print]


  593. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C
    Shah N, Pierce T, Kowdley KV. Expert Opin Investig Drugs. 2013 Jun 4. [Epub ahead of print]


  594. Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration
    Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB. Clin Gastroenterol Hepatol. 2013 May 22. pii: S1542-3565(13)00705-2. doi: 10.1016/j.cgh.2013.05.014. [Epub ahead of print]


  595. Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Clin Pharmacokinet. 2013 May 24. [Epub ahead of print]


  596. SOCS-1 Promoter Methylation and Treatment Response in Chronic Hepatitis C Patients Receiving Pegylated-Interferon/Ribavirin
    Tseng KC, Chou JL, Huang HB, Tseng CW, Wu SF, Chan MW. J Clin Immunol. 2013 May 24. [Epub ahead of print]


  597. Side effects of antiviral therapy in hepatitis C virus infection-sarcoidosis - case report
    Teodor D, Teodor A, Grigore L, Jug?nariu G, Dorob?? CM, Miftode E, Azoic?i D. Rev Med Chir Soc Med Nat Iasi. 2012 Oct-Dec;116(4):1039-43.


  598. Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy
    Trimoulet P, Pinson P, Papuchon J, Foucher J, Vergniol J, Chermak F, Wittkop L, Castaing N, Merrouche W, Reigadas S, Molimard M, Kann M, Fleury H, de Lédinghen V. Antivir Ther. 2013 May 23. doi: 10.3851/IMP2632. [Epub ahead of print]


  599. Current and future disease progression of the chronic HCV population in the United States
    Zalesak M, Francis K, Gedeon A, Gillis J, Hvidsten K, Kidder P, Li H, Martyn D, Orne L, Smith A, Kwong A. PLoS One. 2013 May 21;8(5):e63959. doi: 10.1371/journal.pone.0063959. Print 2013.


  600. Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C
    Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, Nobili B, Pasquale G, Maione S, Adinolfi LE, Perrone L, Sagnelli E, Del Giudice EM, Rossi F. Clin Gastroenterol Hepatol. 2013 May 21. pii: S1542-3565(13)00687-3. doi: 10.1016/j.cgh.2013.05.008. [Epub ahead of print]


  601. Osteopontin: Versatile modulator of liver diseases
    Nagoshi S. Hepatol Res. 2013 May 22. doi: 10.1111/hepr.12166. [Epub ahead of print]


  602. Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection
    Fusfeld L, Aggarwal J, Dougher C, Vera-Llonch M, Bubb S, Donepudi M, Goss TF. BMC Infect Dis. 2013 May 23;13(1):234. [Epub ahead of print]


  603. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis
    Noureddin M, Wright EC, Alter H, Clark S, Thomas E, Chen R, Zhao X, Conry-Cantilena C, Kleiner D, Liang TJ, Ghany MG. Hepatology. 2013 May 23. doi: 10.1002/hep.26506. [Epub ahead of print]


  604. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
    Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A; WEF Study Group. J Hepatol. 2013 May 23. pii: S0168-8278(13)00350-4. doi: 10.1016/j.jhep.2013.05.019. [Epub ahead of print]


  605. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy
    Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. J Hepatol. 2013 May 23. pii: S0168-8278(13)00348-6. doi: 10.1016/j.jhep.2013.05.017. [Epub ahead of print]


  606. Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV: A Randomized Trial
    Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Ann Intern Med. 2013 May 17. doi: 10.7326/0003-4819-159-2-201307160-00654. [Epub ahead of print]


  607. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays
    Ogawa E, Furusyo N, Murata M, Toyoda K, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Okada K, Kainuma M, Hayashi J. Antiviral Res. 2013 May 14;99(2):119-124. doi: 10.1016/j.antiviral.2013.05.002. [Epub ahead of print]


  608. Sustained virological response: A milestone in the treatment of chronic hepatitis C
    Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.


  609. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons ?-2a and ?-2b, plus ribavirin
    Dogan UB, Akin MS, Yalaki S. Eur J Gastroenterol Hepatol. 2013 May 15. [Epub ahead of print]


  610. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation
    Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Liver Transpl. 2013 Jul;19(7):690-700. doi: 10.1002/lt.23669. Epub 2013 Jun 3.


  611. Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in chronic hepatitis C
    Boursier J, de Ledinghen V, Sturm N, Amrani L, Bacq Y, Sandrini J, Le Bail B, Chaigneau J, Zarski JP, Gallois Y, Leroy V, Al Hamany Z, Oberti F, Fouchard-Hubert I, Dib N, Bertrais S, Rousselet MC, Calès P; Multicentre group ANRS HC EP23 FIBROSTAR. J Gastroenterol. 2013 May 17. [Epub ahead of print]


  612. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1
    Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T. J Gastroenterol. 2013 May 21. [Epub ahead of print]


  613. IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection
    Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. J Gastroenterol. 2013 May 22. [Epub ahead of print]


  614. Genetic analysis of interferon induced thyroiditis (IIT): Evidence for a key role for MHC and apoptosis related genes and pathways
    Hasham A, Zhang W, Lotay V, Haggerty S, Stefan M, Concepcion E, Dieterich DT, Tomer Y. J Autoimmun. 2013 May 15. pii: S0896-8411(13)00049-8. doi: 10.1016/j.jaut.2013.04.002. [Epub ahead of print]


  615. Prevalence of Hepatitis C Virus Infection in Alcoholic Patients: Cohort Study and Systematic Review
    Novo-Veleiro I, Calle CD, Domínguez-Quibén S, Pastor I, Marcos M, Laso FJ. Alcohol Alcohol. 2013 May 19. [Epub ahead of print]


  616. Donor risk index for african american liver transplant recipients with hepatitis C virus
    Shores NJ, Dodge JL, Feng S, Terrault NA. Hepatology. 2013 May 20. doi: 10.1002/hep.26478. [Epub ahead of print]


  617. Ever closer to a prophylactic vaccine for HCV
    Swadling L, Klenerman P, Barnes E. Expert Opin Biol Ther. 2013 May 7. [Epub ahead of print]


  618. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir
    Benito JM, Sánchez-Parra C, Maida I, Aguilera A, Rallón NI, Rick F, Labarga P, Fernández-Montero JV, Barreiro P, Soriano V. Antivir Ther. 2013 May 3. doi: 10.3851/IMP2614. [Epub ahead of print]


  619. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
    De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G. J Viral Hepat. 2013 Jun;20(6):395-403. doi: 10.1111/jvh.12046. Epub 2013 Jan 10.


  620. Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: an analysis of trial effect.
    Kelly EM, Cooper CL. Eur J Gastroenterol Hepatol. 2013 May 4. [Epub ahead of print]


  621. Synthesis and evaluation of a new phosphorylated ribavirin prodrug
    Dong SD, Lin CC, Schroeder M. Antiviral Res. 2013 Apr 24;99(1):18-26. doi: 10.1016/j.antiviral.2013.04.014. [Epub ahead of print]


  622. Impact of sustained virologic response on quality of life in chronic HVC carriers
    Daltro-Oliveira R, Morais-de-Jesus M, Pettersen KM, Paraná R, Quarantini LC.


  623. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a
    Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, Duberg AS, Lennerstrand J. Antiviral Res. 2013 May 3;99(1):12-17. doi: 10.1016/j.antiviral.2013.04.018. [Epub ahead of print]


  624. The association of non-O blood group and severity of liver fibrosis in patients with chronic hepatitis C infection
    Shavakhi A, Hajalikhani M, Minakari M, Norian A, Riahi R, Azarnia M, Liaghat L. J Res Med Sci. 2012 May;17(5):466-9.


  625. Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach
    Laouénan C, Guedj J, Mentré F. BMC Med Res Methodol. 2013 Apr 25;13:60. doi: 10.1186/1471-2288-13-60.


  626. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors
    Harris M, Rhodes T. Harm Reduct J. 2013 May 7;10(1):7. [Epub ahead of print]


  627. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis
    Rangnekar AS, Fontana RJ. J Viral Hepat. 2013 Jun;20(6):377-84. doi: 10.1111/jvh.12039. Epub 2013 Jan 7.


  628. Response of hepatitis C virus to long-term passage in the presence of interferon-?. Multiple mutations and a common phenotype
    Perales C, Beach NM, Gallego I, Soria ME, Quer J, Esteban JI, Rice C, Domingo E, Sheldon J. J Virol. 2013 May 1. [Epub ahead of print]


  629. Increasing Hepatitis C Knowledge Among Homeless Adults: Results of a Community-Based, Interdisciplinary Intervention
    Tyler D, Nyamathi A, Stein JA, Koniak-Griffin D, Hodge F, Gelberg L. J Behav Health Serv Res. 2013 Apr 25. [Epub ahead of print]


  630. A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis
    Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R. Clin Infect Dis. 2013 May 14. [Epub ahead of print]


  631. Poor response to hepatitis C treatment in elderly patients
    Silva I, Carvalho Filho R, Feldner AC, Zaros I, Silva AE, Ferraz ML. Ann Hepatol. 2013 May-Jun;12(3):392-8.


  632. Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight u.s. Sites, 2005-2011
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):357-61.


  633. Maintenance of Th1 HCV-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment
    Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group. J Gastroenterol Hepatol. 2013 May 10. doi: 10.1111/jgh.12265. [Epub ahead of print]


  634. Testing for HCV infection: an update of guidance for clinicians and laboratorians
    Centers for Disease Control and Prevention (CDC).


  635. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C
    Stasi C, Arena U, Zignego AL, Corti G, Monti M, Triboli E, Pellegrini E, Renzo S, Leoncini L, Marra F, Laffi G, Milani S, Pinzani M. Dig Liver Dis. 2013 May 6. pii: S1590-8658(13)00143-6. doi: 10.1016/j.dld.2013.03.023. [Epub ahead of print]


  636. The impact of nutritional supplementation on quality of life in patients infected with hepatitis C virus
    Boulhosa RS, Oliveira LP, Jesus RP, Cavalcante LN, Lemaire DC, Vinhas L, Lyra LG, Lyra AC. J Hum Nutr Diet. 2013 May 9. doi: 10.1111/jhn.12087. [Epub ahead of print]


  637. Education and counseling of pregnant patients with chronic hepatitis B: pespectives from obstetricians and perinatal nurses in santa clara county, california.
    Yang EJ, Cheung CM, So SK, Chang ET, Chao SD. Asian Pac J Cancer Prev. 2013;14(3):1707-13.


  638. Efficacy and Tolerability of Peginterferon ? -2a and Peginterferon ? -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
    Yang Z, Zhuang L, Yang L, Chen X. Gastroenterol Res Pract. 2013;2013:739029. doi: 10.1155/2013/739029. Epub 2013 Apr 11.


  639. Development of oleanane-type triterpenes as a new class of HCV entry inhibitors
    Yu F, Wang Q, Zhang Z, Peng Y, Qiu Y, Shi Y, Zheng Y, Xiao S, Wang H, Huang X, Zhu L, Chen K, Zhao C, Zhang C, Yu M, Sun D, Zhang L, Zhou D. J Med Chem. 2013 Jun 13;56(11):4300-19. doi: 10.1021/jm301910a. Epub 2013 May 28.


  640. Estimating the prevalence of hepatitis C infection in New York City using surveillance data
    Balter S, Stark JH, Kennedy J, Bornschlegel K, Konty K. Epidemiol Infect. 2013 May 9:1-8. [Epub ahead of print]


  641. Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome
    Pedersen J, Jensen TB, Carlsen TH, Schønning K, Christensen PB, Laursen AL, Krarup H, Bukh J, Weis N. PLoS One. 2013 May 7;8(5):e62674. doi: 10.1371/journal.pone.0062674. Print 2013.


  642. Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors
    Londoño MC, Crespo G, Forns X. Curr Opin Organ Transplant. 2013 Jun;18(3):271-8. doi: 10.1097/MOT.0b013e3283614aca.


  643. Pathogenic Role of Iron Deposition in Reticuloendothelial Cells during the Development of Chronic Hepatitis C
    Mitsuyoshi H, Yasui K, Yamaguchi K, Minami M, Okanoue T, Itoh Y. Int J Hepatol. 2013;2013:686420. doi: 10.1155/2013/686420. Epub 2013 Apr 4.


  644. Injecting practices in sexual partnerships: Hepatitis C transmission potentials in a 'risk equivalence' framework
    Harris M, Rhodes T. Drug Alcohol Depend. 2013 May 7. pii: S0376-8716(13)00141-5. doi: 10.1016/j.drugalcdep.2013.04.012. [Epub ahead of print]


  645. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma
    Lange CM, Bibert S, Dufour JF, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Müllhaupt B, Negro F, Semela D, Moradpour D, Kutalik Z, Bochud PY; Swiss Hepatitis C Cohort Study Group. J Hepatol. 2013 May 8. pii: S0168-8278(13)00287-0. doi: 10.1016/j.jhep.2013.04.032. [Epub ahead of print]


  646. Amiodarone inhibits the entry and assembly steps of Hepatitis C virus life cycle
    Cheng YL, Lan KH, Lee WP, Tseng SH, Hung LR, Lin HC, Lee FY, Lee SD, Lan KH. Clin Sci (Lond). 2013 May 9. [Epub ahead of print]


  647. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis
    Rangnekar AS, Fontana RJ. J Viral Hepat. 2013 Jun;20(6):377-84. doi: 10.1111/jvh.12039. Epub 2013 Jan 7


  648. Response of hepatitis C virus to long-term passage in the presence of interferon-?. Multiple mutations and a common phenotype
    Perales C, Beach NM, Gallego I, Soria ME, Quer J, Esteban JI, Rice C, Domingo E, Sheldon J. J Virol. 2013 May 1. [Epub ahead of print]


  649. Increasing Hepatitis C Knowledge Among Homeless Adults: Results of a Community-Based, Interdisciplinary Intervention
    Tyler D, Nyamathi A, Stein JA, Koniak-Griffin D, Hodge F, Gelberg L. J Behav Health Serv Res. 2013 Apr 25. [Epub ahead of print]


  650. A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis
    Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R. Clin Infect Dis. 2013 May 14. [Epub ahead of print]


  651. Poor response to hepatitis C treatment in elderly patients
    Silva I, Carvalho Filho R, Feldner AC, Zaros I, Silva AE, Ferraz ML. Ann Hepatol. 2013 May-Jun;12(3):392-8.


  652. A Small Percentage of Patients with Hepatitis C Receive Triple Therapy with Boceprevir or Telaprevir
    Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM. Clin Gastroenterol Hepatol. 2013 Apr 16. pii: S1542-3565(13)00482-5. doi: 10.1016/j.cgh.2013.03.032. [Epub ahead of print]


  653. High tumor necrosis factor-?/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C
    Aroucha DC, do Carmo RF, Moura P, Silva JL, Vasconcelos LR, Cavalcanti MS, Muniz MT, Aroucha ML, Siqueira ER, Cahú GG, Pereira LM, Coêlho MR. Cytokine. 2013 Jun;62(3):421-5. doi: 10.1016/j.cyto.2013.03.024. Epub 2013 Apr 16.


  654. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis
    Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, Chen Y, Lv Y, Liu X, Liu Z. Antiviral Res. 2013 Jun;98(3):373-9. doi: 10.1016/j.antiviral.2013.04.009. Epub 2013 Apr 16.


  655. Sofosbuvir for previously untreated chronic hepatitis C infection
    Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. N Engl J Med. 2013 May 16;368(20):1878-87. doi: 10.1056/NEJMoa1214853. Epub 2013 Apr 23.


  656. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study. N Engl J Med. 2013 May 16;368(20):1867-77. doi: 10.1056/NEJMoa1214854. Epub 2013 Apr 23.


  657. aProspective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8900 high-risk patients
    Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, Curley SA. HPB (Oxford). 2013 Apr 22. doi: 10.1111/hpb.12080. [Epub ahead of print]


  658. Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre
    Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla Y, Sakhuja V. Trop Gastroenterol. 2012 Jul-Sep;33(3):189-92.


  659. Hepatic triglyceride lipase plays an essential role in changing the lipid metabolism in genotype 1b hepatitis C virus replicon cells and hepatitis C patients
    Shinohara Y, Imajo K, Yoneda M, Tomeno W, Ogawa Y, Fujita K, Kirikoshi H, Takahashi J, Funakoshi K, Ikeda M, Kato N, Nakajima A, Saito S. Hepatol Res. 2013 Jan 14. doi: 10.1111/hepr.12072. [Epub ahead of print]


  660. The missing mass of morality: A new fitpack design for hepatitis C prevention in sexual partnerships
    Fraser S. Int J Drug Policy. 2013 May;24(3):212-9. doi: 10.1016/j.drugpo.2013.03.009. Epub 2013 Apr 18.


  661. Peg-IFN?/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
    Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Ann Rheum Dis. 2013 Apr 20. [Epub ahead of print]


  662. Peg-IFN?/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
    Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Ann Rheum Dis. 2013 Apr 20. [Epub ahead of print]


  663. Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings?
    Chakravarti A, Chauhan MS, Dogra G, Banerjee S. Braz J Infect Dis. 2013 May-Jun;17(3):369-74. doi: 10.1016/j.bjid.2012.10.028. Epub 2013 Apr 18.


  664. Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis
    Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Niinomi T, Ito T, Hasegawa R, Ando Y, Yamamoto K, Tanaka T. Hepatol Res. 2013 Mar 29. doi: 10.1111/hepr.12120. [Epub ahead of print]


  665. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening
    Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. BMC Infect Dis. 2013 Apr 18;13(1):181. [Epub ahead of print]


  666. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations
    Spaulding AS, Kim AY, Harzke AJ, Sullivan JC, Linas BP, Brewer A, Dickert J, McGovern BH, Strick LB, Trestman R, Ferguson WJ. Top Antivir Med. 2013 Feb-Mar;21(1):27-35.


  667. Missed opportunities for hepatitis C testing in opioid treatment programs
    Frimpong JA. Am J Public Health. 2013 Jun;103(6):1028-30. doi: 10.2105/AJPH.2012.301129. Epub 2013 Apr 18.


  668. Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort
    Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, Boscarino JA, Henkle EM, Gordon SC; for the Chronic Hepatitis Cohort Study (CHeCS) Investigators. Clin Infect Dis. 2013 May 8. [Epub ahead of print]


  669. Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance
    Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. ACS Chem Biol. 2013 May 1. [Epub ahead of print]


  670. Hepatitis C virus: virology and life cycle
    Kim CW, Chang KM. Clin Mol Hepatol. 2013 Mar;19(1):17-25. doi: 10.3350/cmh.2013.19.1.17. Epub 2013 Mar 25.


  671. Hepatitis C virus targets the interferon-? JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes
    Stevenson NJ, Bourke NM, Ryan EJ, Binder M, Fanning L, Johnston JA, Hegarty JE, Long A, O'Farrelly C. FEBS Lett. 2013 May 21;587(10):1571-8. doi: 10.1016/j.febslet.2013.03.041. Epub 2013 Apr 12.


  672. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease
    Ward JW. Top Antivir Med. 2013 Feb-Mar;21(1):15-9.


  673. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: Meta-analysis of clinical studies
    Fabrizi F, Dixit V, Messa P. J Med Virol. 2013 Jun;85(6):1019-27. doi: 10.1002/jmv.23562.


  674. Mutual Antagonism between Circadian Protein Period 2 and Hepatitis C Virus Replication in Hepatocytes
    Benegiamo G, Mazzoccoli G, Cappello F, Rappa F, Scibetta N, Oben J, Greco A, Williams R, Andriulli A, Vinciguerra M, Pazienza V. PLoS One. 2013 Apr 8;8(4):e60527. doi: 10.1371/journal.pone.0060527. Print 2013.


  675. CCR5-?32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection
    Suppiah V, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Nattermann J, Mueller T, Riordan S, Stewart GJ, George J, Booth DR, Ahlenstiel G; and the International Hepatitis C Genetics Consortium (IHCGC), Michalk M, Malik B, McClure P, Smith S, Sheridan D, Snape E, Fragomeli V, Norris R, How-Chow D, Jonsson JR, Barrie H, Stelzer-Braid S, Fletcher S, Applegate T, Grebely J, Matthews G, Bharadwaj M, Smedile A. Genes Immun. 2013 Apr 18. doi: 10.1038/gene.2013.15. [Epub ahead of print]


  676. Presentation, Outcomes, and Response to Therapy Among Patients with Acute Exacerbation of Chronic Hepatitis C
    Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N. Clin Gastroenterol Hepatol. 2013 Apr 13. pii: S1542-3565(13)00466-7. doi: 10.1016/j.cgh.2013.03.025. [Epub ahead of print]


  677. Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
    Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Clin Infect Dis. 2013 May 7. [Epub ahead of print]


  678. T cell receptor variable ? gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia
    Russi S, Lauletta G, Serviddio G, Sansonno S, Conteduca V, Sansonno L, De Re V, Sansonno D. Clin Exp Immunol. 2013 May;172(2):254-62. doi: 10.1111/cei.12035.


  679. Emerging Therapeutic Targets for Hepatitis C Virus Infection
    Jesudian AB, de Jong YP, Jacobson IM. Clin Gastroenterol Hepatol. 2013 Apr 11. pii: S1542-3565(13)00457-6. doi: 10.1016/j.cgh.2013.04.003. [Epub ahead of print]


  680. Syndecan-1 Serves as the Major Receptor for Attachment of Hepatitis C Virus to the surface of hepatocytes
    Shi Q, Jiang J, Luo G. J Virol. 2013 Apr 10. [Epub ahead of print]


  681. Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review
    Sublette VA, Douglas MW, McCaffery K, George J, Perry KN. Liver Int. 2013 Feb 18. doi: 10.1111/liv.12138. [Epub ahead of print]


  682. Validation of a solid-phase electrochemical array for genotyping hepatitis C virus
    Sam SS, Steinmetz HB, Tsongalis GJ, Tafe LJ, Lefferts JA. Exp Mol Pathol. 2013 Apr 11;95(1):18-22. doi: 10.1016/j.yexmp.2013.04.001. [Epub ahead of print]


  683. Treatment of hepatitis C virus infection in the future
    Kanda T, Yokosuka O, Omata M. Clin Transl Med. 2013 Apr 11;2(1):9. doi: 10.1186/2001-1326-2-9.


  684. Hepatitis C Virus Core Protein Down-Regulates p21(Waf1/Cip1) and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells
    Shiu TY, Huang SM, Shih YL, Chu HC, Chang WK, Hsieh TY. PLoS One. 2013;8(4):e61089. doi: 10.1371/journal.pone.0061089. Epub 2013 Apr 8.


  685. Meta-analysis: pegylated interferon ?-2a achieves higher early virological responses than ?-2b in chronic hepatitis C
    Romero-Gómez M, Planas R, Ampuero J, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Turnes J. Aliment Pharmacol Ther. 2013 Jun;37(11):1065-73. doi: 10.1111/apt.12314. Epub 2013 Apr 14.


  686. Sustained Hyperresponsiveness of Dendritic Cells is Associated with Spontaneous Resolution of Acute Hepatitis C
    Pelletier S, Bédard N, Said E, Ancuta P, Bruneau J, Shoukry NH. J Virol. 2013 Apr 10. [Epub ahead of print]


  687. Risk factors for recurrence after curative resection of hepatitis C-related hepatocellular carcinoma in patients without postoperative interferon therapy
    Yamashita YI, Shirabe K, Toshima T, Tsuijita E, Takeishi K, Harimoto N, Ikegami T, Yoshizumi T, Ikeda T, Soejima Y, Maehara Y. Hepatol Res. 2013 Mar 27. doi: 10.1111/hepr.12091. [Epub ahead of print]


  688. Hepatitis C virus therapy update 2013
    Casey LC, Lee WM. Curr Opin Gastroenterol. 2013 May;29(3):243-9. doi: 10.1097/MOG.0b013e32835ff972.


  689. Telaprevir-related dermatitis
    Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. JAMA Dermatol. 2013 Feb;149(2):152-8.


  690. In vitro detection of hepatitis C virus in platelets from uninfected individuals exposed to the virus
    Padovani JL, Corvino SM, Drexler JF, Silva GF, Pardini MI, Grotto RM. Rev Soc Bras Med Trop. 2013 Apr 2:0. [Epub ahead of print]


  691. The role of natural killer cells in hepatitis C infection
    Howell J, Visvanathan K. Antivir Ther. 2013 Apr 4. doi: 10.3851/IMP2565. [Epub ahead of print]


  692. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin
    Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Wang LY, Huang JF, Juo SH, Lin YC, Dai CY, Chuang WL, Yu ML. J Gastroenterol Hepatol. 2013 Apr 5. doi: 10.1111/jgh.12211. [Epub ahead of print]


  693. Interferon-lambda polymorphisms and hepatitis C virus clearance revisited
    Lupberger J, Felmlee DJ, Baumert TF. Hepatology. 2013 Apr 8. doi: 10.1002/hep.26443. [Epub ahead of print]


  694. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients
    Jiménez-Sousa MA, Berenguer J, Rallón N, Guzmán-Fulgencio M, López JC, Soriano V, Fernández-Rodríguez A, Cosín J, Restrepo C, García-Álvarez M, Miralles P, Benito JM, Resino S. J Viral Hepat. 2013 May;20(5):358-66. doi: 10.1111/jvh.12041. Epub 2012 Dec 20.


  695. Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
    Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Böcher WO, Mensa FJ. Antivir Ther. 2013 Apr 4. doi: 10.3851/IMP2567. [Epub ahead of print]


  696. Hepatocyte destruction with enhanced collagen synthesis: characteristic feature of chronic hepatitis C patients on haemodialysis
    Ue M, Ikebe N, Munekage K, Ochi T, Hirose A, Kataoka H, Fujimoto S, Kikuchi K, Okuhara Y, Ono M, Saibara T. J Viral Hepat. 2013 May;20(5):350-7. doi: 10.1111/jvh.12031. Epub 2012 Dec 11.


  697. The role of the hepatitis viruses in cholangiocarcinoma
    Ralphs S, Khan SA. J Viral Hepat. 2013 May;20(5):297-305. doi: 10.1111/jvh.12093.


  698. Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma
    Costantini S, Capone F, Maio P, Guerriero E, Colonna G, Izzo F, Castello G. Oncol Rep. 2013 Jun;29(6):2163-8. doi: 10.3892/or.2013.2378. Epub 2013 Apr 3.


  699. ?-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
    Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. Hepatology. 2013 Apr 8. doi: 10.1002/hep.26442. [Epub ahead of print]


  700. Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interactions
    Kiang TK, Wilby KJ, Ensom MH. Clin Pharmacokinet. 2013 Apr 4. [Epub ahead of print]


  701. Hepatitis C virus adaptation to T-cell immune pressure
    Plauzolles A, Lucas M, Gaudieri S. ScientificWorldJournal. 2013;2013:673240. doi: 10.1155/2013/673240. Epub 2013 Mar 11.


  702. Hepatitis C and recurrent treatment-resistant acute ischemic stroke
    Saxsena A, Tarsia J, Dunn C, Aysenne A, Shah B, Moore DF. Proc (Bayl Univ Med Cent). 2013 Apr;26(2):182-4.


  703. HCV RNA viral load assessments in the era of direct-acting antivirals
    Cobb B, Pockros PJ, Vilchez RA, Vierling JM. Am J Gastroenterol. 2013 Apr;108(4):471-5. doi: 10.1038/ajg.2012.248.


  704. Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review
    Modabbernia A, Poustchi H, Malekzadeh R. Hepat Mon. 2013 Jan;13(1):e8340. doi: 10.5812/hepatmon.8340. Epub 2013 Jan 7.


  705. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response
    Neukam K, Barreiro P, Rivero-Juárez A, Caruz A, Mira JA, Camacho A, Macías J, Rivero A, Soriano V, Pineda JA. J Infect. 2013 Mar 28. pii: S0163-4453(13)00066-2. doi: 10.1016/j.jinf.2013.03.010. [Epub ahead of print]


  706. Survival after surgery for hepatocellular carcinoma in relation to presence or absence of viral infection
    Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Am J Surg. 2013 Mar 30. pii: S0002-9610(13)00132-3. doi: 10.1016/j.amjsurg.2012.08.011. [Epub ahead of print]


  707. Genome-wide analysis of host mRNA translation during hepatitis C virus infection
    Colman H, Le Berre-Scoul C, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C. J Virol. 2013 Apr 3. [Epub ahead of print]


  708. Management of the Extrahepatic Symptoms of Chronic Hepatitis C: Feasibility of a Randomized Controlled Trial of Exercise
    McKenna O, Cunningham C, Gissane C, Blake C. Am J Phys Med Rehabil. 2013 Apr 2. [Epub ahead of print]


  709. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study
    Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M. J Gastroenterol. 2013 Mar 30. [Epub ahead of print]


  710. Systematic review: Asian patients with chronic hepatitis C infection
    Nguyen LH, Nguyen MH. Aliment Pharmacol Ther. 2013 May;37(10):921-36. doi: 10.1111/apt.12300. Epub 2013 Apr 5.


  711. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review
    Bota S, Sporea I, Sirli R, Popescu A, Neghin? AM, D?nil? M, Str?in M. World J Hepatol. 2013 Mar 27;5(3):120-6. doi: 10.4254/wjh.v5.i3.120.


  712. SIGMA-1 RECEPTOR REGULATES EARLY STEPS OF VIRAL RNA REPLICATION AT THE ONSET OF HEPATITIS C VIRUS INFECTION
    Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. J Virol. 2013 Mar 27. [Epub ahead of print]


  713. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States
    Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. PLoS One. 2013;8(3):e58975. doi: 10.1371/journal.pone.0058975. Epub 2013 Mar 22.


  714. Treatment of HCV infection by targeting microRNA
    Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27.


  715. Development and evaluation of an internet and personal health record training program for low-income patients with HIV or hepatitis C
    McInnes DK, Solomon JL, Shimada SL, Petrakis BA, Bokhour BG, Asch SM, Nazi KM, Houston TK, Gifford AL. Med Care. 2013 Mar;51(3 Suppl 1):S62-6. doi: 10.1097/MLR.0b013e31827808bf.


  716. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management
    Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. J Hepatol. 2013 Mar 27. pii: S0168-8278(13)00197-9. doi: 10.1016/j.jhep.2013.03.018. [Epub ahead of print]


  717. Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-Analysis
    Bota S, Sporea I, Sirli R, Neghin? AM, Popescu A, Str?in M. Clin Drug Investig. 2013 May;33(5):325-31. doi: 10.1007/s40261-013-0074-0.


  718. Combination therapy of natural human interferon-beta and ribavirin for chronic hepatitis C patients with injection drug use
    Morikawa H, Kozuka R, Fujii H, Iwai S, Enomoto M, Tamori A, Saito S, Kawada N. Hepatol Res. 2013 Mar 27. doi: 10.1111/hepr.12066. [Epub ahead of print]


  719. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature
    Salk A, Stobaugh DJ, Deepak P, Ehrenpreis ED. Ann Pharmacother. 2013 Apr;47(4):537-42. doi: 10.1345/aph.1R526. Epub 2013 Mar 27.


  720. Telaprevir: Changing the standard of care of chronic hepatitis C
    Rajani AK, Ravindra BK, Dkhar SA. J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493.


  721. Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus
    Tayel SS, Helmy AA, Ahmed R, Esmat G, Hamdi N, Abdelaziz AI. Arch Virol. 2013 Mar 23. [Epub ahead of print]


  722. Incident Hepatitis C Virus Infection in Men Who Have Sex With Men: A Prospective Cohort Analysis, 1984-2011
    Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, Jacobson LP, Detels R, Thio CL. Clin Infect Dis. 2013 Apr 22. [Epub ahead of print]


  723. Prediction of efficacy to pegylated interferon-?-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks
    Wada Y, Tamai H, Uno A, Kawashima A, Shingaki N, Mori Y, Moribata K, Miyata K, Higashi K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Hepatol Res. 2013 Feb 25. doi: 10.1111/hepr.12101. [Epub ahead of print]


  724. Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients
    Huang CF, Dai CY, Yeh ML, Huang JF, Huang CI, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Lin YC, Yu ML. PLoS One. 2013;8(3):e58882. doi: 10.1371/journal.pone.0058882. Epub 2013 Mar 19.


  725. The Diagnostic Accuracy of Fibroscan for Cirrhosis is Influenced by Liver Morphometry in HCV Patients with a Sustained Virological Response
    D'Ambrosio R, Aghemo A, Fraquelli M, Grazia Rumi M, Francesca Donato M, Paradis V, Bedossa P, Colombo M. J Hepatol. 2013 Mar 22. pii: S0168-8278(13)00191-8. doi: 10.1016/j.jhep.2013.03.013. [Epub ahead of print]


  726. Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin
    Hulskotte E, Feng HP, Xuan F, Gupta S, van Zutven M, O'Mara E, Wagner J, Butterton J. Antimicrob Agents Chemother. 2013 Mar 25. [Epub ahead of print]


  727. Patterns of Interferon-alpha Induced Thyroid Dysfunction Vary with Ethnicity, Sex, Smoking Status and Pre-Treatment TSH in an International Cohort of Patients Treated for Hepatitis C
    Mammen JS, Ghazarian SR, Rosen A, Ladenson PW. Thyroid. 2013 Mar 21. [Epub ahead of print]


  728. A health technology assessment of Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in adult liver disease
    Steadman R, Myers RP, Leggett L, Lorenzetti D, Noseworthy T, Rose S, Sutherland L, Clement F. Can J Gastroenterol. 2013 Mar;27(3):149-58.


  729. A novel strategy to inhibit the reproduction and translation of hepatitis C virus
    Duan A, Ning L, Li C, Hou Y, Yang N, Sun L, Li G. Sci China Life Sci. 2013 Apr;56(4):293-7. doi: 10.1007/s11427-013-4468-2. Epub 2013 Mar 20.


  730. Hepatitis C virus-induced mitochondrial dysfunctions
    Brault C, Levy PL, Bartosch B. Viruses. 2013 Mar 21;5(3):954-80. doi: 10.3390/v5030954.


  731. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin
    Webster DP, Wojcikiewicz T, Keller M, Castelnovo D, Mistry H, Gilleece Y, Tibble J, Fisher M. Int J STD AIDS. 2013 Mar 20. [Epub ahead of print]


  732. Simultaneous detection of hepatitis c virus antigen and antibodies in dried blood spots
    Brandão CP, Marques BL, Marques VA, Villela-Nogueira CA, Do Ó KM, de Paula MT, Lewis-Ximenez LL, Lampe E, Sá Ferreira JA, Villar LM. J Clin Virol. 2013 Mar 18. pii: S1386-6532(13)00075-9. doi: 10.1016/j.jcv.2013.02.014. [Epub ahead of print]


  733. Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
    Rong L, Guedj J, Dahari H, Coffield DJ Jr, Levi M, Smith P, Perelson AS. PLoS Comput Biol. 2013 Mar;9(3):e1002959. doi: 10.1371/journal.pcbi.1002959. Epub 2013 Mar 14.


  734. Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis C
    Tanaka T, Therapondos G, Selzner N, Renner EL, Lilly LB. Can J Gastroenterol. 2013 Mar;27(3):131-6.


  735. Management of Hepatitis C Virus Infection in Heavy Drinkers
    Costentin CE, Trabut JB, Mallet V, Darbeda S, Thépot V, Nalpas B, Badin de Montjoye B, Lavielle B, Vallet-Pichard A, Sogni P, Pol S. Alcohol Alcohol. 2013 Mar 21. [Epub ahead of print]


  736. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial
    Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H; for The Hep-Net Acute HCV-III Study Group. Lancet Infect Dis. 2013 Mar 21. pii: S1473-3099(13)70059-8. doi: 10.1016/S1473-3099(13)70059-8. [Epub ahead of print]


  737. Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection
    Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. J Clin Oncol. 2013 Mar 18. [Epub ahead of print]


  738. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
    McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26388. [Epub ahead of print]


  739. The incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis
    Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD, van den Bergh BJ, Degenhardt L. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26387. [Epub ahead of print]


  740. Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review
    Testino G, Sumberaz A, Leone S, Borro P. Minerva Med. 2013 Apr;104(2):225-32.


  741. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation
    Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. PLoS One. 2013;8(3):e58380. doi: 10.1371/journal.pone.0058380. Epub 2013 Mar 7.


  742. Sustained Virological Response following Chronic Hepatitis C treatment is associated with improvement in Insulin Resistance (Insulin Resistance in Hepatitis C)
    Chan CH, Hansen RD, Gilliver RS, Jones BE. Intern Med J. 2013 Mar 19. doi: 10.1111/imj.12136. [Epub ahead of print]


  743. Prevalence and predictors of hepatitis B virus co-infection in a united states cohort of hepatitis C virus-infected patients
    Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Hepatology. 2013 Mar 16. doi: 10.1002/hep.26400. [Epub ahead of print]


  744. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection
    El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, Elakel WA, Esmat G. Liver Int. 2013 Feb 15. doi: 10.1111/liv.12139. [Epub ahead of print]


  745. Birth Cohort Screening for Chronic Hepatitis During Colonoscopy Appointments
    Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Am J Gastroenterol. 2013 Mar 19. doi: 10.1038/ajg.2013.50. [Epub ahead of print]


  746. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know
    Kim YH, Kim do Y. Oncology. 2013;84 Suppl 1:34-9. doi: 10.1159/000345887. Epub 2013 Feb 20.


  747. Hepatitis C virus vaccines - Progress and perspectives
    Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Microb Pathog. 2013 Mar 7. pii: S0882-4010(13)00025-9. doi: 10.1016/j.micpath.2013.02.005. [Epub ahead of print]


  748. Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis
    Poustchi H, Eslami M, Ostovaneh MR, Modabbernia A, Saeedian FS, Taslimi S, George J, Malekzadeh R, Zamani F. Hepatol Res. 2013 Feb 7. doi: 10.1111/hepr.12088. [Epub ahead of print]


  749. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Lancet Infect Dis. 2013 Mar 14. pii: S1473-3099(13)70033-1. doi: 10.1016/S1473-3099(13)70033-1. [Epub ahead of print]


  750. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet. 2013 Mar 14. pii: S0140-6736(13)60247-0. doi: 10.1016/S0140-6736(13)60247-0. [Epub ahead of print]


  751. A Comparison of Modified Directly Observed Therapy to Standard Care for Chronic Hepatitis C
    Cioe PA, Stein MD, Promrat K, Friedmann PD. J Community Health. 2013 Mar 8. [Epub ahead of print]


  752. IL-28B (IFN-?3) and IFN-? synergistically inhibit HCV replication
    Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. J Viral Hepat. 2013 Apr;20(4):281-9. doi: 10.1111/j.1365-2893.2012.01649.x. Epub 2012 Aug 7.


  753. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study
    Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. J Viral Hepat. 2013 Apr;20(4):e107-14. doi: 10.1111/jvh.12017. Epub 2012 Dec 4.


  754. 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype-3a infection and do not predict sustained virological response after 24 weeks of therapy
    Bucci C, von Delft A, Cristian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. J Gen Virol. 2013 Mar 13. [Epub ahead of print]


  755. Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance
    Kuwashiro T, Mizuta T, Kawaguchi Y, Iwane S, Takahashi H, Oza N, Oeda S, Isoda H, Eguchi Y, Ozaki I, Anzai K, Fujimoto K. J Gastroenterol. 2013 Mar 16. [Epub ahead of print]


  756. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience
    Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, Hassanain M, Paraskevas S, Chaudhury P, Tchervenkov JI. HPB (Oxford). 2013 Mar 14. doi: 10.1111/hpb.12041. [Epub ahead of print]


  757. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
    Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Virol J. 2013 Mar 5;10:72. doi: 10.1186/1743-422X-10-72.


  758. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know
    Kim YH, Kim do Y. Oncology. 2013;84 Suppl 1:34-9. doi: 10.1159/000345887. Epub 2013 Feb 20.


  759. Hepatitis C virus vaccines - Progress and perspectives
    Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Microb Pathog. 2013 Mar 7. pii: S0882-4010(13)00025-9. doi: 10.1016/j.micpath.2013.02.005. [Epub ahead of print]


  760. Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis
    Poustchi H, Eslami M, Ostovaneh MR, Modabbernia A, Saeedian FS, Taslimi S, George J, Malekzadeh R, Zamani F. Hepatol Res. 2013 Feb 7. doi: 10.1111/hepr.12088. [Epub ahead of print]


  761. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Lancet Infect Dis. 2013 Mar 14. pii: S1473-3099(13)70033-1. doi: 10.1016/S1473-3099(13)70033-1. [Epub ahead of print]


  762. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet. 2013 Mar 14. pii: S0140-6736(13)60247-0. doi: 10.1016/S0140-6736(13)60247-0. [Epub ahead of print]


  763. A Comparison of Modified Directly Observed Therapy to Standard Care for Chronic Hepatitis C
    Cioe PA, Stein MD, Promrat K, Friedmann PD. J Community Health. 2013 Mar 8. [Epub ahead of print]


  764. IL-28B (IFN-?3) and IFN-? synergistically inhibit HCV replication
    Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. J Viral Hepat. 2013 Apr;20(4):281-9. doi: 10.1111/j.1365-2893.2012.01649.x. Epub 2012 Aug 7.


  765. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study
    Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. J Viral Hepat. 2013 Apr;20(4):e107-14. doi: 10.1111/jvh.12017. Epub 2012 Dec 4.


  766. 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype-3a infection and do not predict sustained virological response after 24 weeks of therapy
    Bucci C, von Delft A, Cristian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. J Gen Virol. 2013 Mar 13. [Epub ahead of print]


  767. Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance
    Kuwashiro T, Mizuta T, Kawaguchi Y, Iwane S, Takahashi H, Oza N, Oeda S, Isoda H, Eguchi Y, Ozaki I, Anzai K, Fujimoto K. J Gastroenterol. 2013 Mar 16. [Epub ahead of print]


  768. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience
    Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, Hassanain M, Paraskevas S, Chaudhury P, Tchervenkov JI. HPB (Oxford). 2013 Mar 14. doi: 10.1111/hpb.12041. [Epub ahead of print]


  769. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
    Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Virol J. 2013 Mar 5;10:72. doi: 10.1186/1743-422X-10-72.


  770. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force
    Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Ann Intern Med. 2013 Jan 15;158(2):109-13.


  771. Diabetes and Infections-Hepatitis C: Is There Type 2 Diabetes Excess in Hepatitis C Infection?
    Naing C, Mak JW, Wai N, Maung M. Curr Diab Rep. 2013 Mar 7. [Epub ahead of print]


  772. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients
    Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA. Enferm Infecc Microbiol Clin. 2013 Feb 28. pii: S0213-005X(12)00443-0. doi: 10.1016/j.eimc.2012.12.004. [Epub ahead of print]


  773. The predictive value of steatosis in hepatitis C virus infection
    Adinolfi LE, Restivo L, Marrone A. Expert Rev Gastroenterol Hepatol. 2013 Mar;7(3):205-13. doi: 10.1586/egh.13.7.


  774. The Hepatitis C Self-Management Program: Sustainability of Primary Outcomes at 1 Year
    Groessl EJ, Ho SB, Asch SM, Stepnowsky CJ, Laurent D, Gifford AL. Health Educ Behav. 2013 Feb 27. [Epub ahead of print]


  775. Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study
    Hopwood M.


  776. The origin of hepatitis C virus
    Simmonds P. Curr Top Microbiol Immunol. 2013;369:1-15. doi: 10.1007/978-3-642-27340-7_1.


  777. A high MELD score, combined with the presence of hepatitis C, is associated with a poor prognosis in living donor liver transplantation
    Ikegami T, Shirabe K, Yoshiya S, Yoshizumi T, Yamashita YI, Harimoto N, Toshima T, Uchiyama H, Soejima Y, Maehara Y. Surg Today. 2013 Feb 23. [Epub ahead of print]


  778. Antiviral Activity of Boceprevir Monotherapy in Treatment-Naive Subjects With Chronic Hepatitis C Genotype 2/3
    Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA. J Hepatol. 2013 Feb 27. pii: S0168-8278(13)00140-2. doi: 10.1016/j.jhep.2013.02.018. [Epub ahead of print]


  779. Profile of alisporivir and its potential in the treatment of hepatitis C
    Gallay PA, Lin K. Drug Des Devel Ther. 2013;7:105-15. doi: 10.2147/DDDT.S30946. Epub 2013 Feb 15.


  780. Risk of Pancreatic Cancer in Relation to ABO Blood Group and Hepatitis C Virus Infection in Korea: A Case-Control Study
    Woo SM, Joo J, Lee WJ, Park SJ, Han SS, Kim TH, Koh YH, Kim HB, Hong EK. J Korean Med Sci. 2013 Feb;28(2):247-51. doi: 10.3346/jkms.2013.28.2.247. Epub 2013 Jan 29.


  781. Therapy for HCV Infection Increases Survival of Patients with Pre-Treatment Anemia
    Mohanty A, Erqou S, McGinnis KA, Vanasse G, Freiberg MS, Sherman KE, Butt AA. Clin Gastroenterol Hepatol. 2013 Jan 31. pii: S1542-3565(13)00166-3. doi: 10.1016/j.cgh.2013.01.023. [Epub ahead of print]


  782. A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots
    Shepherd SJ, Kean J, Hutchinson SJ, Cameron SO, Goldberg DJ, Carman WF, Gunson RN, Aitken C. J Clin Virol. 2013 Jan 28. pii: S1386-6532(13)00005-X. doi: 10.1016/j.jcv.2013.01.002. [Epub ahead of print]


  783. High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C
    Petta S, Handberg A, Marchesini G, Cammà C, Di Marco V, Cabibi D, Macaluso FS, Craxì A. J Viral Hepat. 2013 Mar;20(3):174-82. doi: 10.1111/j.1365-2893.2012.01641.x. Epub 2012 Jul 9.


  784. Serum fibrinogen alpha C-chain 5.9 kDa fragment (FIC 5.9) as a biomarker for early detection of hepatic fibrosis related to hepatitis C virus
    Sogawa K, Noda K, Umemura H, Seimiya M, Kuga T, Tomonaga T, Nishimura M, Kanai F, Imazeki F, Takizawa H, Yoneda M, Nakajima A, Tsutsumi M, Yokosuka O, Nomura F. Proteomics Clin Appl. 2013 Feb 4. doi: 10.1002/prca.201200094. [Epub ahead of print]


  785. The Association of IL28B Polymorphism and Graft Survival in Patients with Hepatitis C Undergoing Liver Transplantation
    Allam SR, Krüger B, Mehrotra A, Schiano T, Schröppel B, Murphy B. PLoS One. 2013;8(1):e54854. doi: 10.1371/journal.pone.0054854. Epub 2013 Jan 30.


  786. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
    Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. J Clin Virol. 2013 Feb 2. pii: S1386-6532(13)00007-3. doi: 10.1016/j.jcv.2012.12.020. [Epub ahead of print]


  787. Frequency of Thyroid Dysfunctions during Interferon Alpha Treatment of Single and Combination Therapy in Hepatitis C Virus-Infected Patients: A Systematic Review Based Analysis
    Nair Kesavachandran C, Haamann F, Nienhaus A. PLoS One. 2013;8(2):e55364. doi: 10.1371/journal.pone.0055364. Epub 2013 Feb 1.


  788. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting
    Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, Mix C, Kirschner J, Manns MP, Wedemeyer H, Cornberg M. PLoS One. 2013;8(2):e55285. doi: 10.1371/journal.pone.0055285. Epub 2013 Feb 1.


  789. A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors
    Chen EY, Lee WM, Hynan LS, Singal AG. J Clin Gastroenterol. 2013 Mar 6. [Epub ahead of print]


  790. The Efficacy and Safety of Telaprevir-based Regimens for Treating Chronic Hepatitis C Virus Genotype 1 Infection: A Meta-analysis of Randomized Trials
    Yang D, Liang HJ, Li D, Wei X, Ma L, Jia Z. Intern Med. 2013;52(6):653-60. Epub 2013 Mar 15.


  791. New therapeutic strategies in HCV: second-generation protease inhibitors
    Clark VC, Peter JA, Nelson DR. Liver Int. 2013 Feb;33 Suppl 1:80-4. doi: 10.1111/liv.12061.


  792. Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin
    Yi NJ, Choi JY, Suh KS, Cho JY, Baik M, Hong G, Lee KW, Kim W, Kim YJ, Yoon JH, Lee HS, Kim DG. J Gastroenterol. 2013 Mar 6. [Epub ahead of print]


  793. Equal efficacy between the two types of peginterferon on HCV: A matter of relapse?
    Brochot E, Nguyen-Khac E, Duverlie G. Antiviral Res. 2013 Feb 16;98(1):1-3. doi: 10.1016/j.antiviral.2013.02.006. [Epub ahead of print]


  794. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C
    Younossi ZM, Zheng L, Stepanova M, Venkatesan C, Mir HM. Aliment Pharmacol Ther. 2013 Apr;37(7):703-9. doi: 10.1111/apt.12265. Epub 2013 Feb 24.


  795. The impact of timing and prioritisation on the cost-effectiveness of birth-cohort testing and treatment for hepatitis C virus in the U.S
    McEwan P, Ward T, Yuan Y, Kim R, L'italien G. Hepatology. 2013 Feb 6. doi: 10.1002/hep.26304. [Epub ahead of print]


  796. Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study
    Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y. World J Gastroenterol. 2013 Feb 14;19(6):923-30. doi: 10.3748/wjg.v19.i6.923.


  797. Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor
    Duvoux C, Firpi R, Grazi GL, Levy G, Renner E, Villamil F. Transpl Int. 2013 Feb 18. doi: 10.1111/tri.12065. [Epub ahead of print]


  798. Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes
    Manos MM, Ho CK, Murphy RC, Shvachko VA. Patient. 2013;6(1):23-34. doi: 10.1007/s40271-013-0005-4.


  799. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
    Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. doi: 10.1073/pnas.1203110110. Epub 2013 Feb 19.


  800. Intrafamilial transmission of hepatitis C virus
    Indolfi G, Nesi A, Resti M. J Med Virol. 2013 Apr;85(4):608-14. doi: 10.1002/jmv.23522.


  801. Future therapies for chronic hepatitis C
    Dabbouseh NM, Jensen DM. Nat Rev Gastroenterol Hepatol. 2013 Feb 19. doi: 10.1038/nrgastro.2013.17. [Epub ahead of print]


  802. HIV and Hepatitis C Virus: Special Concerns for Patients With Cirrhosis.
    Curry MP. J Infect Dis. 2013 Mar;207 Suppl 1:S40-4. doi: 10.1093/infdis/jis763.


  803. Treatment Outcomes of Treatment-Naïve Hepatitis C Patients Co-Infected with HIV: A Systematic Review and Meta-Analysis of Observational Cohorts
    Davies A, Singh KP, Shubber Z, Ducros P, Mills EJ, Cooke G, Ford N. PLoS One. 2013;8(2):e55373. doi: 10.1371/journal.pone.0055373. Epub 2013 Feb 5.


  804. Association of Interleukin 28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C
    Hodo Y, Honda M, Tanaka A, Nomura Y, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Sasaki M, Nakanuma Y, Moriyama M, Kaneko S. Clin Cancer Res. 2013 Feb 20. [Epub ahead of print]


  805. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients
    Joshi D, Carey I, Agarwal K. Aliment Pharmacol Ther. 2013 Apr;37(7):659-71. doi: 10.1111/apt.12260. Epub 2013 Feb 21.


  806. Pegylated Interferon-?2a and Ribavirin versus Pegylated Interferon-?2b and Ribavirin in Chronic Hepatitis C : A Meta-Analysis
    Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, Daurès JP, Blanc P. Drugs. 2013 Mar;73(3):263-77. doi: 10.1007/s40265-013-0027-1.


  807. Hepatitis C virus in pregnancy
    Prasad MR, Honegger JR. Am J Perinatol. 2013 Feb;30(2):149-60. doi: 10.1055/s-0033-1334459. Epub 2013 Feb 6.


  808. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-?2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial
    Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY. Antivir Ther. 2013 Feb 12. doi: 10.3851/IMP2549. [Epub ahead of print]


  809. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C
    Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, Rodrigo M, Estrada V, López-Alonso G, Agúndez JA. Ann Hepatol. 2013 Mar;12(2):199-204.


  810. Highlights of the 2012 American Association for the Study of Liver Diseases meeting
    Osborn MK. r Med. 2012 Dec;20(5):180-4.


  811. Adherence and completion in hepatitis C management: a systematic review
    Redulla R, Dudley-Brown S. Gastroenterol Nurs. 2013 Jan;36(1):53-8. doi: 10.1097/SGA.0b013e318281634e.


  812. Management of hepatitis C virus infection: the basics
    Naggie S. Top Antivir Med. 2012 Dec;20(5):154-61.


  813. Hepatitis C virus vaccines in the era of new direct-acting antivirals
    Shi C, Ploss A. Expert Rev Gastroenterol Hepatol. 2013 Feb;7(2):171-85. doi: 10.1586/egh.12.72.


  814. Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B
    Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Hepatol Res. 2012 Oct 18. doi: 10.1111/hepr.12005. [Epub ahead of print]


  815. The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance
    Himoto T, Tani J, Miyoshi H, Yoneyama H, Mori H, Inukai M, Masugata H, Goda F, Senda S, Haba R, Masaki T. Nutr Res. 2013 Jan;33(1):27-33. doi: 10.1016/j.nutres.2012.11.007. Epub 2012 Dec 20.


  816. Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials
    Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.


  817. Safety and Effectiveness of a Nurse-Led Outreach Program for Assessment and Treatment of Chronic Hepatitis C in the Custodial Setting
    Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, Rudge G, Boonwaat L, Forrest G, Douglas J, Monkley D. Clin Infect Dis. 2013 Jan 29. [Epub ahead of print]


  818. Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy
    Lontok E, Mani N, Harrington PR, Miller V. Clin Infect Dis. 2013 Feb 12. [Epub ahead of print]


  819. Review of drug interactions with telaprevir and antiretrovirals
    van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Antivir Ther. 2013 Jan 23. doi: 10.3851/IMP2527. [Epub ahead of print]


  820. Influence of healthcare-associated factors on the efficacy of hepatitis C therapy
    Daw MA, Dau AA, Agnan MM. ScientificWorldJournal. 2012;2012:580216. doi: 10.1100/2012/580216. Epub 2012 Dec 27.


  821. Host genetic variants in the pathogenesis of hepatitis C
    Rau M, Baur K, Geier A. Viruses. 2012 Dec;4(12):3281-302.


  822. Polymorphisms near Interleukin 28B Gene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence
    Lee DH, Cho Y, Seo JY, Kwon JH, Cho EJ, Jang ES, Kwak MS, Cheong JY, Cho SW, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim CY, Shin HD, Kim YJ. Intervirology. 2013 Jan 22. [Epub ahead of print]


  823. Neurocognitive Deficits Associated With the Hepatitis C Virus Among Incarcerated Men
    Umaki TM, Denney RL. Clin Neuropsychol. 2013 Jan 24. [Epub ahead of print]


  824. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
    Arzumanyan A, Reis HM, Feitelson MA. Nat Rev Cancer. 2012 Dec 21;13(2):123-35. doi: 10.1038/nrc3449.


  825. Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy
    Kallwitz ER. World J Gastroenterol. 2013 Jan 14;19(2):158-60. doi: 10.3748/wjg.v19.i2.158.


  826. Economic burden and current managed care challenges associated with hepatitis c
    Mathis AS. Am J Manag Care. 2012 Dec;18(14 Suppl):s350-9


  827. Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness [Internet]
    Sun X, Patnode CD, Williams C, Senger CA, Kapka TJ, Whitlock EP.


  828. A Review of standard and newer treatment strategies in hepatitis c
    Tran TT. Am J Manag Care. 2012 Dec;18(14 Suppl):s340-9.


  829. Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis
    Gu L, Chen Q, Xie J, Yan Y, Wu G, Tan J, Liang B, Chen W, Wu P, Su L, Tang N. Pharmazie. 2012 Dec;67(12):963-72.


  830. Serum Apoptosis Markers Related to Liver Damage in Chronic Hepatitis C: sFas as a Marker of Advanced Fibrosis in Children and Adults While M30 of Severe Steatosis Only in Children
    Valva P, Casciato P, Lezama C, Galoppo M, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. PLoS One. 2013;8(1):e53519. doi: 10.1371/journal.pone.0053519. Epub 2013 Jan 11.


  831. Overview of epidemiology, diagnosis, and disease progression associated with hepatitis c
    Tran TT. Am J Manag Care. 2012 Dec;18(14 Suppl):s335-9.


  832. Prognostic Gene-Expression Signature for Patients with Hepatitis C-Related Early-Stage Cirrhosis
    Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Gastroenterology. 2013 Jan 17. pii: S0016-5085(13)00078-4. doi: 10.1053/j.gastro.2013.01.021. [Epub ahead of print]


  833. Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?
    Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Am J Gastroenterol. 2013 Jan 22. doi: 10.1038/ajg.2012.449. [Epub ahead of print]


  834. IL28B in the Era of Direct-acting Antivirals for Hepatitis C
    Muir AJ. J Clin Gastroenterol. 2013 Mar;47(3):222-7. doi: 10.1097/MCG.0b013e3182680221.


  835. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma
    Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R, Kato J. J Gastroenterol. 2013 Jan 19. [Epub ahead of print]


  836. Spleen stiffness: Towards a non-invasive portal sphygmomanometer?
    Abraldes JG, Reverter E, Berzigotti A. Hepatology. 2013 Jan 21. doi: 10.1002/hep.26239. [Epub ahead of print]


  837. Performance of liver stiffness measurements by Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in chronic hepatitis
    Ferraioli G, Tinelli C, Bello BD, Zicchetti M, Lissandrin R, Filice G, Filice C, Above E, Barbarini G, Brunetti E, Calderon W, Gregorio MD, Gulminetti R, Lanzarini P, Ludovisi S, Maiocchi L, Malfitano A, Michelone G, Minoli L, Mondelli M, Novati S, Patruno SF, Perretti A, Poma G, Sacchi P, Zanaboni D, Zaramella M. World J Gastroenterol. 2013 Jan 7;19(1):49-56. doi: 10.3748/wjg.v19.i1.49.


  838. Hepatitis C virus core antigen test in monitoring of dialysis patients
    Li Cavoli G, Zagarrigo C, Schillaci O, Servillo F, Tralongo A, Coglitore M, Spadaro F, Scimeca C, Li Destri N, Rotolo U. Hepat Res Treat. 2012;2012:832021. doi: 10.1155/2012/832021. Epub 2012 Dec 4.


  839. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices
    Di Marco V, Calvaruso V, Grimaudo S, Ferraro D, Pipitone RM, Di Stefano R, Craxì A. J Viral Hepat. 2013 Feb;20(2):113-21. doi: 10.1111/j.1365-2893.2012.01637.x. Epub 2012 Jul 25.


  840. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4
    Domagalski K, Paw?owska M, Tretyn A, Halota W, Pilarczyk M, Smukalska E, Linkowska K, Grzybowski T. Eur J Clin Microbiol Infect Dis. 2013 Jan 13. [Epub ahead of print]


  841. Portal Vein Thrombosis in Patients with End Stage Liver Disease Awaiting Liver Transplantation: Outcome of Anticoagulation
    Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, Harrison ME, Rakela J, Aqel BA. Dig Dis Sci. 2013 Jan 12. [Epub ahead of print]


  842. Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
    Pawlotsky JM. Curr Gastroenterol Rep. 2013 Feb;15(2):309. doi: 10.1007/s11894-012-0309-x.


  843. Association of tattooing and hepatitis C virus infection: A multicenter case-control study
    Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F. Hepatology. 2013 Jan 12. doi: 10.1002/hep.26245. [Epub ahead of print]


  844. Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection
    Bonilla-Abadía F, Echeverri AF, Izquierdo JH, Cañas F, Cañas CA. Case Report Rheumatol. 2012;2012:923897. doi: 10.1155/2012/923897. Epub 2012 Dec 16.


  845. Hepatitis C virus core antigen test in monitoring of dialysis patients
    Li Cavoli G, Zagarrigo C, Schillaci O, Servillo F, Tralongo A, Coglitore M, Spadaro F, Scimeca C, Li Destri N, Rotolo U. Hepat Res Treat. 2012;2012:832021. doi: 10.1155/2012/832021. Epub 2012 Dec 4.


  846. Optimal treatment with telaprevir for chronic HCV infection
    Jesudian AB, Jacobson IM. Liver Int. 2013 Feb;33 Suppl 1:3-13. doi: 10.1111/liv.12079.


  847. Hepatitis C virus diversity and hepatic steatosis
    Roingeard P. J Viral Hepat. 2013 Feb;20(2):77-84. doi: 10.1111/jvh.12035. Epub 2012 Nov 29.


  848. How to optimize HCV therapy in genotype 1 patients: management of side-effects
    Chopra A, Klein PL, Drinnan T, Lee SS. Liver Int. 2013 Feb;33 Suppl 1:30-4. doi: 10.1111/liv.12080.


  849. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting
    Seidenberg A, Rosemann T, Senn O. BMC Infect Dis. 2013 Jan 8;13(1):9. doi: 10.1186/1471-2334-13-9.


  850. Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy
    Caviglia GP, Abate ML, Manzini P, Danielle F, Ciancio A, Rosso C, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M. Hepat Mon. 2012 Nov;12(11):e7292. doi: 10.5812/hepatmon.7292. Epub 2012 Nov 30.


  851. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C
    Kraus MR, Schäfer A, Teuber G, Porst H, Paul K, Wollschläger S, Keicher C, Scheurlen M. Hepatology. 2013 Jan 8. doi: 10.1002/hep.26229. [Epub ahead of print]


  852. Current management and perspectives for HCV recurrence after liver transplantation
    Coilly A, Roche B, Samuel D. Liver Int. 2013 Feb;33 Suppl 1:56-62. doi: 10.1111/liv.12062.


  853. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C
    Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S. BMC Med. 2013 Jan 8;11(1):6. [Epub ahead of print]


  854. IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients
    Hsu CS, Hsu SJ, Liu WL, Liu CH, Chen CL, Liu CJ, Chen PJ, Chen DS, Kao JH. Antivir Ther. 2013 Jan 7. doi: 10.3851/IMP2502. [Epub ahead of print]


  855. Interferon free therapy with direct acting antivirals for HCV
    Asselah T, Marcellin P. Liver Int. 2013 Feb;33 Suppl 1:93-104. doi: 10.1111/liv.12076.


  856. HCV therapy in HIV-infected patients
    Sulkowski MS. Liver Int. 2013 Feb;33 Suppl 1:63-7. doi: 10.1111/liv.12082.


  857. How to optimize HCV therapy in genotype 4 patients
    Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M. Liver Int. 2013 Feb;33 Suppl 1:41-5. doi: 10.1111/liv.12059.


  858. How to optimize HCV therapy in genotype 2 patients
    Grassi E, Aghemo A. Liver Int. 2013 Feb;33 Suppl 1:35-40. doi: 10.1111/liv.12056.


  859. How to optimize HCV therapy in genotype 1 patients: predictors of response
    Petta S, Craxì A. Liver Int. 2013 Feb;33 Suppl 1:23-9. doi: 10.1111/liv.12053.


  860. How to optimize HCV therapy in genotype 1 patients with cirrhosis
    Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP. Liver Int. 2013 Feb;33 Suppl 1:46-55. doi: 10.1111/liv.12067.


  861. Best strategies for global HCV eradication
    Hagan LM, Schinazi RF. Liver Int. 2013 Feb;33 Suppl 1:68-79. doi: 10.1111/liv.12063.


  862. Optimal treatment with boceprevir for chronic HCV infection
    Maasoumy B, Manns MP. Liver Int. 2013 Feb;33 Suppl 1:14-22. doi: 10.1111/liv.12070.


  863. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C
    Shlomai A, Halfon P, Goldiner I, Zelber-Sagi S, Halpern Z, Oren R, Bruck R. J Viral Hepat. 2013 Feb;20(2):95-102. doi: 10.1111/j.1365-2893.2012.01628.x. Epub 2012 Aug 3.


  864. Hepatitis C treatment - better outcomes through partner support
    Chapman F, McManus A. Australas Med J. 2012;5(11):585-8. doi: 10.4066/AMJ.2012.1442. Epub 2012 Nov 30.


  865. Chronic hepatitis C virus (HCV) disease burden and cost in the United States
    Razavi H, El Khoury A, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Hepatology. 2012 Dec 22. doi: 10.1002/hep.26218. [Epub ahead of print]


  866. Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis
    Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, Guo Z, He X. PLoS One. 2012;7(12):e52158. doi: 10.1371/journal.pone.0052158. Epub 2012 Dec 20.


  867. Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C
    Shimoyama Y, Nozaki A, Morimoto M, Moriya S, Kondo M, Fukuda H, Numata K, Miyajima E, Oba MS, Taguri M, Morita S, Maeda S, Tanaka K. Hepatol Res. 2012 Dec 5. doi: 10.1111/hepr.12037. [Epub ahead of print]


  868. Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: Results from the national surveillance system
    Spada E, Mele A, Mariano A, Zuccaro O, Tosti ME; on behalf of SEIEVA collaborating group. J Med Virol. 2012 Dec 28. doi: 10.1002/jmv.23485. [Epub ahead of print]


  869. Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
    Yu ML, Liu CH, Huang CF, Tseng TC, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Kao JH. PLoS One. 2012;7(12):e52048. doi: 10.1371/journal.pone.0052048. Epub 2012 Dec 21.


  870. Polymorphisms of the core, NS3 and NS5A proteins of hepatitis C 1 virus genotype 1b associate with development of hepatocellular carcinoma
    El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, Hotta H. Hepatology. 2012 Dec 24. doi: 10.1002/hep.26205. [Epub ahead of print]


  871. Introduction of an automated system for the diagnosis and quantification of hepatitis B and hepatitis C viruses
    Cabezas-Fernandez M, Cabeza-Barrera M. Source Open Virol J. 2012;6:122-34. doi: 10.2174/1874357901206010122. Epub 2012 Nov 30.


  872. Low Oxygen Tension Enhances Hepatitis C Virus Replication
    Vassilaki N, Kalliampakou KI, Kotta-Loizou I, Befani C, Liakos P, Simos G, Mentis AF, Kalliaropoulos A, Doumba PP, Smirlis D, Foka P, Bauhofer O, Poenisch M, Windisch MP, Lee ME, Koskinas J, Bartenschlager R, Mavromara P. J Virol. 2012 Dec 26. [Epub ahead of print]


  873. Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C
    Komase K, Maekawa S, Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Hepatol Res. 2012 Nov 29. doi: 10.1111/hepr.12032. [Epub ahead of print]


  874. Predictors of Psychopathological Outcome During Peg-Interferon and Ribavirin Therapy in Patients with Chronic HCV-Correlated Hepatitis
    Dell'osso B, Prati G, Palazzo MC, Rumi MG, Cavallaro F, Aghemo A, Colombo M, Altamura AC. J Interferon Cytokine Res. 2013 Jan;33(1):9-14. doi: 10.1089/jir.2012.0060. Epub 2012 Dec 31.


  875. Combination treatment with HCV protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a and 3a virus
    Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J. Antimicrob Agents Chemother. 2012 Dec 28. [Epub ahead of print]


  876. Update on the treatment of patients with non-genotype 1 HCV infection
    Mangia A, Mottola L, Piazzolla V. Clin Infect Dis. 2012 Dec 27. [Epub ahead of print]


  877. Combinations of Interferon Lambda with Direct-Acting Antiviral Agents are Highly Efficient in Suppressing Hepatitis C Virus Replication
    Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, McPhee F. Antimicrob Agents Chemother. 2012 Dec 28. [Epub ahead of print]


  878. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study
    Loftis JM, Patterson AL, Wilhelm CJ, McNett H, Morasco BJ, Huckans M, Morgan T, Saperstein S, Asghar A, Hauser P. J Psychosom Res. 2013 Jan;74(1):57-63. doi: 10.1016/j.jpsychores.2012.10.012. Epub 2012 Nov 21.


  879. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review
    Donato MF, Fabrizi F, Fogazzi GB, Cresseri D, Passerini P, Martin P, Messa P. Int J Artif Organs. 2013 Jan 2:0. doi: 10.5301/ijao.5000166. [Epub ahead of print]


  880. New targets for treatment against HCV infection
    Pan Q, van der Laan LJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):505-15. doi: 10.1016/j.bpg.2012.10.002.


  881. Vitamin A deficiency is associated with HCV chronic infection and with unresponsiveness to interferon based antiviral therapy
    Bitetto D, Bortolotti N, Falleti E, Vescovo S, Fabris C, Fattovich G, Cussigh A, Cmet S, Fornasiere E, Ceriani E, Pirisi M, Toniutto P. Hepatology. 2012 Dec 5. doi: 10.1002/hep.26186. [Epub ahead of print]


  882. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations
    North CS, Hong BA, Adewuyi SA, Pollio DE, Jain MK, Devereaux R, Quartey NA, Ashitey S, Lee WM, Lisker-Melman M. Gen Hosp Psychiatry. 2012 Dec 6. pii: S0163-8343(12)00336-2. doi: 10.1016/j.genhosppsych.2012.11.002. [Epub ahead of print]


  883. The role of resistance in HCV treatment
    Vermehren J, Sarrazin C. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):487-503. doi: 10.1016/j.bpg.2012.09.011.


  884. Hepatitis C virus and natural compounds: a new antiviral approach?
    Calland N, Dubuisson J, Rouillé Y, Séron K. Viruses. 2012 Oct 17;4(10):2197-217. doi: 10.3390/v4102197.


  885. Genetic Variants of STAT-4 Affect the Development of Graft Fibrosis After Liver Transplantation for HCV-Induced Liver Disease
    Eurich D, Boas-Knoop S, Struecker B, Neuhaus R, Neuhaus P, Bahra M. Transplantation. 2013 Jan 15;95(1):203-8. doi: 10.1097/TP.0b013e318277e2f6.


  886. Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection
    Kant J, Möller B, Heyne R, Herber A, Böhm S, Maier M, Liebert UG, Mössner J, Berg T, Wiegand J. Eur J Gastroenterol Hepatol. 2012 Dec 3. [Epub ahead of print]


  887. Occupational Exposures and the Prevalence of Blood-Borne Pathogens in a Deployed Setting: Data from a US Military Trauma Center in Afghanistan
    Okulicz JF, Yun HC, Murray CK. Infect Control Hosp Epidemiol. 2013 Jan;34(1):74-9. doi: 10.1086/668784. Epub 2012 Nov 19.


  888. Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases
    Tomeno W, Yoneda M, Imajo K, Suzuki K, Ogawa Y, Shinohara Y, Mawatari H, Fujita K, Shibata W, Kirikoshi H, Maeda S, Nakajima A, Saito S. Hepatol Res. 2012 Nov 12. doi: 10.1111/hepr.12023. [Epub ahead of print]


  889. Project ECHO: a model for complex, chronic care in the Pacific Northwest region of the United States
    Scott JD, Unruh KT, Catlin MC, Merrill JO, Tauben DJ, Rosenblatt R, Buchwald D, Doorenbos A, Towle C, Ramers CB, Spacha DH. J Telemed Telecare. 2012;18(8):481-4. doi: 10.1258/jtt.2012.GTH113. Epub 2012 Dec 3.


  890. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers
    Bruggmann P. J Viral Hepat. 2012 Dec;19(12):829-35. doi: 10.1111/jvh.12008. Epub 2012 Oct 1.


  891. Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C
    Petta S, Rosso C, Leung R, Abate ML, Booth D, Salamone F, Gambino R, Rizzetto M, Caviglia P, Smedile A, Grimaudo S, Cammà C, Craxì A, George J, Bugianesi E. Clin Gastroenterol Hepatol. 2012 Dec 4. pii: S1542-3565(12)01422-X. doi: 10.1016/j.cgh.2012.11.022. [Epub ahead of print]


  892. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV
    Lewis H, Cunningham M, Foster G. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):471-85. doi: 10.1016/j.bpg.2012.09.008.


  893. Neutralizing antibodies and pathogenesis of hepatitis C virus infection
    Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF. Viruses. 2012 Oct 9;4(10):2016-30. doi: 10.3390/v4102016.


  894. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
    Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B., Ph.D., Robert H. Hyland, D.Phil., Xiao Ding, Ph.D., Evguenia Svarovskaia, Ph.D., William T. Symonds, Pharm.D., Robert G. Hindes, M.D., and M. Michelle Berrey, M.D., M.P.H. N Engl J Med 2013; 368:34-44January 3, 2013DOI: 10.1056/NEJMoa1208953


  895. Is there a benefit to a routine preoperative screening of infectivity for HIV, hepatitis B and C virus before elective orthopaedic operations?
    Weber P, Eberle J, Bogner JR, Schrimpf F, Jansson V, Huber-Wagner S. Infection. 2012 Dec 7. [Epub ahead of print]


  896. Pathogenesis of hepatitis C during pregnancy and childhood
    Le Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Viruses. 2012 Dec 6;4(12):3531-50. doi: 10.3390/v4123531.


  897. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
    Fred Poordad, M.D., Eric Lawitz, M.D., Kris V. Kowdley, M.D., Daniel E. Cohen, M.D., Thomas Podsadecki, M.D., Sara Siggelkow, R.N., Michele Heckaman, M.S., Lois Larsen, Ph.D., Rajeev Menon, Ph.D., Gennadiy Koev, Ph.D., Rakesh Tripathi, M.S., Tami Pilot-Matias, Ph.D., and Barry Bernstein, M.D. N Engl J Med 2013; 368:45-53January 3, 2013DOI: 10.1056/NEJMoa120880


  898. Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers
    Ponziani FR, Milani A, Gasbarrini A, Zaccaria R, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Cescon M, Burra P, Miglioresi L, Merli M, Paolo DD, Fagiuoli S, Pompili M; on behalf of AISF RECOLT-C Group. Transpl Int. 2012 Dec 11. doi: 10.1111/tri.12027. [Epub ahead of print]


  899. Viral hepatitis induces hepatocellular cancer: what can we learn from epidemiology comparing iran and worldwide findings?
    Smolle E, Zöhrer E, Bettermann K, Haybaeck J. Hepat Mon. 2012 Oct;12(10 HCC):e7879. doi: 10.5812/hepatmon.7879. Epub 2012 Oct 30.


  900. Effects of triple-drug therapy with nitazoxanide, high-dose ribavirin and peginterferon-?-2a in patients with chronic hepatitis C
    Basu PP, Rayapudi K, Shah NJ, Krishnaswamy N, Brown RS. Hepatol Res. 2012 Dec 5. doi: 10.1111/hepr.12013. [Epub ahead of print]


  901. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4
    Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, Hadad M, Abboud D, Sabah H, Bochud PY, Negro F. J Viral Hepat. 2013 Jan;20(1):59-64. doi: 10.1111/j.1365-2893.2012.01621.x. Epub 2012 May 24.


  902. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences
    Ng J, Wu J. Hepat Mon. 2012 Oct;12(10 HCC):e7635. doi: 10.5812/hepatmon.7635. Epub 2012 Oct 25.


  903. Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis
    Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Clin Infect Dis. 2012 Dec 27. [Epub ahead of print]


  904. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response
    Tedder RS, Tuke P, Wallis N, Wright M, Nicholson L, Grant PR. J Viral Hepat. 2013 Jan;20(1):65-71. doi: 10.1111/j.1365-2893.2012.01630.x. Epub 2012 Jul 4.


  905. Boceprevir and personalized medicine in hepatitis C virus infection
    Habersetzer F, Leboeuf C, Doffoël M, Baumert TF. Pharmgenomics Pers Med. 2012;5:125-37. doi: 10.2147/PGPM.S24259. Epub 2012 Sep 26.


  906. Rapid hepatitis C virus divergence among chronically infected individuals
    Cruz-Rivera M, Carpio-Pedroza JC, Escobar-Gutiérrez A, Lozano D, Vergara-Castaneda A, Rivera-Osorio P, Martinez-Guarneros A, Chacon CA, Fonseca-Coronado S, Vaughan G. J Clin Microbiol. 2012 Dec 5. [Epub ahead of print]


  907. Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection
    Lam JT, Jacob S. Am J Health Syst Pharm. 2012 Dec 15;69(24):2135-9. doi: 10.2146/ajhp110500.


  908. Relationship of ?-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis
    Taura N, Fukuda S, Ichikawa T, Miyaaki H, Shibata H, Honda T, Yamaguchi T, Kubota Y, Uchida S, Kamo Y, Yoshimura E, Isomoto H, Matsumoto T, Takeshima F, Tsutsumi T, Tsuruta S, Nakao K. Exp Ther Med. 2012 Dec;4(6):972-976. Epub 2012 Sep 17.


  909. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection
    Feld JJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):429-44. doi: 10.1016/j.bpg.2012.09.013.


  910. Natural history of acute and chronic hepatitis C
    Maasoumy B, Wedemeyer H. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):401-12. doi: 10.1016/j.bpg.2012.09.009.


  911. Interferon stimulated genes are associated with peginterferon plus ribavirin treatment response regardless IL28B alleles in HCV/HIV coinfected patients
    Rallon NI, Lopez-Fernandez LA, Garcia MI, Benguria A, Fiorante S, Soriano V, Benito JM. AIDS. 2012 Nov 28. [Epub ahead of print]


  912. The role of viral and host genetics in natural history and treatment of chronic HCV infection
    Doyle JS, Hellard ME, Thompson AJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):413-27. doi: 10.1016/j.bpg.2012.09.004.


  913. Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2
    Taura N, Ichikawa T, Miyaaki H, Kadokawa Y, Tsutsumi T, Tsuruta S, Kato Y, Inoue O, Kinoshita N, Ohba K, Kato H, Ohata K, Masuda J, Hamasaki K, Yatsuhashi H, Nakao K. Gastroenterol Res Pract. 2012;2012:317580. doi: 10.1155/2012/317580. Epub 2012 Nov 5.


  914. Exploratory study on telaprevir given every 8?h at 500?mg or 750?mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients
    Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H. Hepatol Res. 2012 Nov 29. doi: 10.1111/hepr.12009. [Epub ahead of print]


  915. A combined proteomics and computational approach provides a better understanding of HCV-induced liver disease
    Tripathi LP, Mizuguchi K. Expert Rev Proteomics. 2012 Oct;9(5):493-6. doi: 10.1586/epr.12.47.


  916. Immunology of hepatitis C virus infections
    Spaan M, Janssen HL, Boonstra A. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):391-400. doi: 10.1016/j.bpg.2012.09.005.


  917. The Impact of Hepatitis A Virus Infection on Hepatitis C Virus Infection: A Competitive Exclusion Hypothesis
    Amaku M, Coutinho FA, Chaib E, Massad E. Bull Math Biol. 2012 Nov 29. [Epub ahead of print]


  918. HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents
    Calle Serrano B, Manns MP. Antivir Ther. 2012;17(6 Pt B):1133-46. doi: 10.3851/IMP2425. Epub 2012 Oct 5.


  919. Response guided therapy in patients with chronic hepatitis C - Yesterday, today and tomorrow
    Ferenci P. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):463-9. doi: 10.1016/j.bpg.2012.09.002.


  920. Hepatitis C infection among men who have sex with men, san francisco, 2011
    Raymond HF, Chu P, Nieves-Rivera I, Louie B, McFarland W, Pandori M. Sex Transm Dis. 2012 Dec;39(12):985-6. doi: 10.1097/OLQ.0b013e3182716e59.


  921. Interferon Gamma With Peg-Interferon ? 2a and Ribavirin in Non Responder Patients With Chronic Hepatitis C (ANRS HC16 GAMMATRI)
    Couzigou P, Pérusat S, Bourlière M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chêne G; the ANRS HC16 GAMMATRI trial Group. J Gastroenterol Hepatol. 2012 Nov 28. doi: 10.1111/jgh.12060. [Epub ahead of print]


  922. Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients
    Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J. J Gastroenterol Hepatol. 2012 Nov 28. doi: 10.1111/jgh.12057. [Epub ahead of print]


  923. Virology of hepatitis C virus infection
    Chevaliez S, Pawlotsky JM. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):381-9. doi: 10.1016/j.bpg.2012.09.006.


  924. Telaprevir-Related Dermatitis
    Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. Arch Dermatol. 2012 Nov 19:1-7. doi: 10.1001/jamadermatol.2013.938. [Epub ahead of print]


  925. Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity
    Carlson A, Gregorich Z, Striker R. Clin Infect Dis. 2012 Dec 7. [Epub ahead of print]


  926. Sexual transmission of HCV among monogamous heterosexual couples: The HCV partners study
    Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish R, Busch M, Reingold AL, Alter MJ. Hepatology. 2012 Nov 23. doi: 10.1002/hep.26164. [Epub ahead of print]


  927. Natural killer cells in hepatitis C virus infection
    Bozzano F, Marras F, Biassoni R, Maria AD. Expert Rev Clin Immunol. 2012 Nov;8(8):775-88. doi: 10.1586/eci.12.71.


  928. None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis
    Jeng WJ, Lin CY, Chen JY, Huang CW, Huang CH, Sheen IS. PLoS One. 2012;7(11):e48217. doi: 10.1371/journal.pone.0048217. Epub 2012 Nov 16.


  929. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to hepatitis C virus seroprevalence
    Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Hepatology. 2012 Nov 21. doi: 10.1002/hep.26141. [Epub ahead of print]


  930. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation
    Du Y, Su T, Ding Y, Cao G. Hepat Mon. 2012 Oct;12(10 HCC):e6031. doi: 10.5812/hepatmon.6031. Epub 2012 Oct 20.


  931. The science of direct-acting antiviral and host-targeted agent therapy
    Pawlotsky JM. Antivir Ther. 2012;17(6 Pt B):1109-17. doi: 10.3851/IMP2423. Epub 2012 Oct 5.


  932. Public health issues of hepatitis C virus infection
    Papatheodoridis G, Hatzakis A. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):371-80. doi: 10.1016/j.bpg.2012.09.012.


  933. Protective and Pathological Properties of IL-22 in Liver Disease: Implications for Viral Hepatitis
    Cobleigh MA, Robek MD. Am J Pathol. 2012 Nov 14. pii: S0002-9440(12)00719-5. doi: 10.1016/j.ajpath.2012.08.043. [Epub ahead of print]


  934. Importance of IL-10 and IL-6 during chronic hepatitis c genotype-1 treatment and their relation with IL28B
    Pavón-Castillero EJ, Muñoz-de-Rueda P, López-Segura R, Gila A, Quiles R, Muñoz-Gámez JA, Carazo A, Martínez P, Ruiz-Extremera A, Salmerón J. Cytokine. 2012 Nov 15. pii: S1043-4666(12)00742-9. doi: 10.1016/j.cyto.2012.10.009. [Epub ahead of print]


  935. Virological Responses in Chronic Hepatitis C Patients Undergoing Prolonged Therapy with Low-Dose Peg-IFNα-2a
    Zhou JY, Jiang ZA, Zhou DF, Xing WL, Wang W, Wang YD. Hepatogastroenterology. 2012 Nov 16;60(122). doi: 10.5754/hge12272. [Epub ahead of print]


  936. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
    Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, Andreoli A, Marignani M, D Ambrosio C, Miglioresi L, Nosotti L, Mitidieri O, Gentilucci UV, Puoti C, Barbaro G, Barlattani A, Furlan C, Barbarini G. BMC Gastroenterol. 2012 Nov 16;12(1):162. [Epub ahead of print]


  937. Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection
    Adda N, Bartels DJ, Gritz L, Kieffer TL, Tomaka F, Bengtsson L, Luo D, Jacobson IM, Kauffman RS, Picchio G. Clin Gastroenterol Hepatol. 2012 Nov 14. pii: S1542-3565(12)01386-9. doi: 10.1016/j.cgh.2012.10.045. [Epub ahead of print]


  938. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis
    Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ. QJM. 2012 Nov 17. [Epub ahead of print]


  939. Current progress in the treatment of chronic hepatitis C
    Alexopoulou A, Papatheodoridis GV. World J Gastroenterol. 2012 Nov 14;18(42):6060-9. doi: 10.3748/wjg.v18.i42.6060.


  940. Cryoglobulinemia is an independent factor negatively associated with sustained virological response in chronic hepatitis C patients
    Fan XH, Wu CH, Wang LF, Zheng YY, Yao Y, Lu HY, Xu XY, Wei L. Chin Med J (Engl). 2012 Nov;125(22):4014-7.


  941. Pharmacokinetic Interactions Between the HCV Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir
    Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, Youngberg SP, Wagner JA, Butterton JR. Clin Infect Dis. 2012 Nov 15. [Epub ahead of print]


  942. Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders
    Honda T, Katano Y, Kuzuya T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Toyoda H, Kumada T, Yamamoto K, Matsushita T, Kojima T, Takamatsu J, Goto H. J Med Virol. 2012 Nov 14. doi: 10.1002/jmv.23444. [Epub ahead of print]


  943. Improved Inflammatory Activity With Peginterferon Alfa-2b Maintenance Therapy in Non-cirrhotic Prior Nonresponders: a Randomized Study
    Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK. J Hepatol. 2012 Nov 14. pii: S0168-8278(12)00831-8. doi: 10.1016/j.jhep.2012.11.001. [Epub ahead of print]


  944. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: A multicenter study
    Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N. J Med Virol. 2013 Jan;85(1):65-70. doi: 10.1002/jmv.23428.


  945. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?
    Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V. J Clin Virol. 2012 Nov 10. pii: S1386-6532(12)00390-3. doi: 10.1016/j.jcv.2012.10.009. [Epub ahead of print]


  946. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection
    Wyles DL. Top Antivir Med. 2012 Oct;20(4):139-45.


  947. Anthropometric and Clinical Factors Associated with Mortality in Subjects with Nonalcoholic Fatty Liver Disease
    Otgonsuren M, Stepanova M, Gerber L, Younossi ZM. Dig Dis Sci. 2012 Nov 10. [Epub ahead of print]


  948. Hepatitis C Testing, Infection, and Linkage to Care Among Racial and Ethnic Minorities in the United States, 2009-2010
    Tohme RA, Xing J, Liao Y, Holmberg SD. Am J Public Health. 2012 Nov 15. [Epub ahead of print]


  949. Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment
    Hernández-Guerra M, González-Méndez Y, de Molina P, Gimeno-García AZ, Carrillo M, Casanova C, Pumarola T, Jimenez A, Hernández-Porto M, Torres A, Quintero E. PLoS One. 2012;7(11):e48610. doi: 10.1371/journal.pone.0048610. Epub 2012 Nov 8.


  950. Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype
    Motomura T, Shirabe K, Furusyo N, Yoshizumi T, Ikegami T, Soejima Y, Akahoshi T, Tomikawa M, Fukuhara T, Hayashi J, Maehara Y. BMC Gastroenterol. 2012 Nov 12;12:158. doi: 10.1186/1471-230X-12-158.


  951. Discordance Among Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients, Aminotransferase to Platelet Ratio Index, and Histologic Assessments of Liver Fibrosis in Patients with Chronic Hepatitis C
    Gara N, Zhao X, Kleiner DE, Liang TJ, Hoofnagle JH, Ghany MG. Clin Gastroenterol Hepatol. 2012 Nov 7. pii: S1542-3565(12)01312-2. doi: 10.1016/j.cgh.2012.10.044. [Epub ahead of print]


  952. The changing face of hepatitis C in the new era of direct-acting antivirals
    Soriano V, Labarga P, Fernández-Montero JV, Benito JM, Poveda E, Rallon N, Sánchez C, Vispo E, Barreiro P. Antiviral Res. 2012 Nov 9. pii: S0166-3542(12)00251-3. doi: 10.1016/j.antiviral.2012.10.011. [Epub ahead of print]


  953. Managing adverse effects and complications in completing treatment for hepatitis C virus infection
    Sherman KE. Top Antivir Med. 2012 Oct;20(4):125-8.


  954. Association of caffeine intake and histological features of chronic hepatitis C
    Costentin CE, Roudot-Thoraval F, Zafrani ES, Medkour F, Pawlotsky JM, Mallat A, Hézode C. J Hepatol. 2011 Jun;54(6):1123-9. Epub 2011 Feb 24.


  955. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients
    Charlebois A, Lee L, Cooper E, Mason K, Powis J. J Viral Hepat. 2012 Dec;19(12):836-42. doi: 10.1111/j.1365-2893.2012.01648.x. Epub 2012 Jul 31.


  956. The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice
    Garcia-Saenz-de-Sicilia M, Mukherjee S. Expert Rev Clin Pharmacol. 2012 Sep;5(5):587-93. doi: 10.1586/ecp.12.49.


  957. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions
    Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, Larrey D, Nikitin I, Pol S, Puoti M, Romero-Gómez M, Wedemeyer H, Zeuzem S. J Hepatol. 2012 Nov 5. pii: S0168-8278(12)00828-8. doi: 10.1016/j.jhep.2012.10.027. [Epub ahead of print]


  958. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism
    Del Campo JA, Ampuero J, Rojas L, Conde M, Rojas A, Maraver M, Millán R, García-Valdecasas M, García-Lozano JR, González-Escribano MF, Romero-Gómez M. Aliment Pharmacol Ther. 2012 Nov 5. doi: 10.1111/apt.12113. [Epub ahead of print]


  959. Hepatitis C virus infection and autoimmune diseases
    Paroli M, Iannucci G, Accapezzato D. Int J Gen Med. 2012;5:903-7. doi: 10.2147/IJGM.S37580. Epub 2012 Oct 23.


  960. IL28B genetic variation and hepatitis C virus-specific CD4(+) T-cell responses in anti-HCV-positive blood donors
    Bes M, Sauleda S, Campos-Varela I, Rodriguez-Frias F, Casamitjana N, Homs M, Piron M, Quer J, Tabernero D, Guardia J, Puig L, Esteban JI. J Viral Hepat. 2012 Dec;19(12):867-871. doi: 10.1111/j.1365-2893.2012.01631.x. Epub 2012 Jul 4.


  961. Prospects for Interferon-Free Treatment of Hepatitis C
    Stedman CA. J Gastroenterol Hepatol. 2012 Nov 9. doi: 10.1111/jgh.12028. [Epub ahead of print]


  962. Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients
    Tanaka T, Selzner N, Therapondos G, Renner EL, Lilly LB. Transpl Int. 2012 Nov 8. doi: 10.1111/j.1432-2277.2012.01571.x. [Epub ahead of print]


  963. Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs
    White B, Madden A, Hellard M, Kerr T, Prins M, Page K, Dore GJ, Maher L. Drug Alcohol Rev. 2012 Nov 1. doi: 10.1111/dar.12000. [Epub ahead of print]


  964. Hepatitis C virus genotype 5: an orphan virus
    Antaki N, Abboud D, Antaki F, Craxi A. Antivir Ther. 2012 Oct 30. doi: 10.3851/IMP2449. [Epub ahead of print]


  965. Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis
    Terrier B, Karras A, Cluzel P, Collet JP, Sène D, Saadoun D, Cacoub P. Am J Cardiol. 2012 Oct 29. pii: S0002-9149(12)02206-0. doi: 10.1016/j.amjcard.2012.09.028. [Epub ahead of print]


  966. A simple strategy to identify acute HCV infection among newly incarcerated injection drug users
    Kim AY, Nagami EH, Birch CE, Bowen MJ, Lauer GM, McGovern BH. Hepatology. 2012 Oct 30. doi: 10.1002/hep.26113. [Epub ahead of print]


  967. Checkmate to liver biopsy in chronic hepatitis C?
    Trifan A, Stanciu C. World J Gastroenterol. 2012 Oct 21;18(39):5514-20. doi: 10.3748/wjg.v18.i39.5514.


  968. Hepatitis C and renal transplantation
    Morales JM, Aguado JM. Curr Opin Organ Transplant. 2012 Dec;17(6):609-15. doi: 10.1097/MOT.0b013e32835a2bac.


  969. Perspectives and challenges of interferon-free therapy for chronic hepatitis C
    Lange CM, Zeuzem S. J Hepatol. 2012 Oct 24. pii: S0168-8278(12)00818-5. doi: 10.1016/j.jhep.2012.10.019. [Epub ahead of print]


  970. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: A prospective, multicenter study
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J. J Hepatol. 2012 Oct 22. pii: S0168-8278(12)00816-1. doi: 10.1016/j.jhep.2012.10.017. [Epub ahead of print]


  971. Promotion of hepatocellular carcinoma by hepatitis C virus
    Bühler S, Bartenschlager R. Dig Dis. 2012;30(5):445-52. doi: 10.1159/000341688. Epub 2012 Oct 24.


  972. Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era
    Bruno S, Mangia A. Dig Liver Dis. 2012 Oct 24. pii: S1590-8658(12)00369-6. doi: 10.1016/j.dld.2012.09.011. [Epub ahead of print]


  973. Host factors determining the efficacy of hepatitis C treatment
    Chuang WL, Yu ML. J Gastroenterol. 2012 Oct 27. [Epub ahead of print]


  974. The Role of Attachment Style and Depression in Patients with Hepatitis C
    Sockalingam S, Blank D, Jarad AA, Alosaimi F, Hirschfield G, Abbey SE. J Clin Psychol Med Settings. 2012 Oct 30. [Epub ahead of print]


  975. Hepatitis C Virus Infection, Mixed Cryoglobulinemia, and Kidney Disease
    Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P. Am J Kidney Dis. 2012 Oct 25. pii: S0272-6386(12)01230-9. doi: 10.1053/j.ajkd.2012.08.040. [Epub ahead of print]


  976. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C
    Amorim TG, Staub GJ, Lazzarotto C, Silva AP, Manes J, Ferronato Mda G, Shiozawa MB, Narciso-Schiavon JL, Dantas-Correa EB, Schiavon Lde L. Ann Hepatol. 2012 Nov;11(6):855-61.


  977. Lipids and HCV
    Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Semin Immunopathol. 2012 Oct 31. [Epub ahead of print]


  978. Association Between Chronic Hepatitis C Virus Infection and Bone Mineral Density
    Lin JC, Hsieh TY, Wu CC, Chen PJ, Chueh TH, Chang WK, Chu HC. Calcif Tissue Int. 2012 Oct 5. [Epub ahead of print]


  979. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
    Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, Marcellin P, Diago M, Craxi A, Pockros P, Rizzetto M, Bernstein D, Shiffman ML, Lin A, Tatsch F, Hadziyannis S. J Viral Hepat. 2012 Nov;19(11):766-774. doi: 10.1111/j.1365-2893.2012.01624.x. Epub 2012 May 14.


  980. Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis
    Fabrizi F, Dixit V, Messa P, Martin P. J Viral Hepat. 2012 Nov;19(11):784-91. doi: 10.1111/j.1365-2893.2012.01607.x. Epub 2012 Mar 30.


  981. Allele-Specific PCR for Determination of IL28B Genotype
    Cook L, Diem K, Kim W, Scott JD, Jerome KR. J Clin Microbiol. 2012 Oct 10. [Epub ahead of print]


  982. Living donor liver transplantation for hepatitis C
    Takada Y, Uemoto S. Surg Today. 2012 Oct 6. [Epub ahead of print]


  983. Hepatitis C virus and other risk factors in hepatocellular carcinoma
    Schiefelbein E, Zekri AR, Newton DW, Soliman GA, Banerjee M, Hung ChW, Seifeldin IA, Lo AC, Soliman AS. Acta Virol. 2012;56(3):235-40.


  984. Cholestatic hepatitis C following liver transplantation: An outcome-based histological definition, clinical predictors and prognosis
    Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS Jr. Liver Transpl. 2012 Oct 18. doi: 10.1002/lt.23559. [Epub ahead of print]


  985. Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients
    Huang YW, Hu JT, Hu FC, Chang CJ, Chang HY, Kao JH, Yang SS, Chen DS. Antivir Ther. 2012 Oct 17. doi: 10.3851/IMP2441. [Epub ahead of print]


  986. Incidence of hepatitis C virus infection in patients on hemodialysis: A systematic review and meta-analysis
    Su Y, Norris JL, Zang C, Peng Z, Wang N. Hemodial Int. 2012 Oct 16. doi: 10.1111/j.1542-4758.2012.00761.x. [Epub ahead of print]


  987. Donor-Derived Infection: Epidemiology and Outcomes
    Kaul DR. Curr Infect Dis Rep. 2012 Oct 17. [Epub ahead of print]


  988. Why should infectious disease physicians care for the hepatitis C-infected patient?
    Godofsky E. Infect Dis Clin North Am. 2012 Dec;26(4):839-47. doi: 10.1016/j.idc.2012.08.001.


  989. Elevated Serum IL-8 Is Associated with the Presence of Hepatocellular Carcinoma and Independently Predicts Survival
    Welling TH, Fu S, Wan S, Zou W, Marrero JA. Cancer Invest. 2012 Oct 16. [Epub ahead of print]


  990. Staging of Liver Disease: Which Option is Right for My Patient?
    Bhogal H, Sterling RK. Infect Dis Clin North Am. 2012 Dec;26(4):849-61. doi: 10.1016/j.idc.2012.08.002.


  991. IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment
    Berger CT, Kim AY. Infect Dis Clin North Am. 2012 Dec;26(4):863-77. doi: 10.1016/j.idc.2012.08.010.


  992. Type III Interferons, IL-28 and IL-29, Are Increased in Chronic HCV Infection and Induce Myeloid Dendritic Cell-Mediated FoxP3+ Regulatory T Cells
    Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, Bala S, Szabo G. PLoS One. 2012;7(10):e44915. doi: 10.1371/journal.pone.0044915. Epub 2012 Oct 10.


  993. Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrations
    Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, Miller AH. Brain Behav Immun. 2012 Oct 13. pii: S0889-1591(12)00472-2. doi: 10.1016/j.bbi.2012.10.010. [Epub ahead of print]


  994. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy
    Yuan H, Adams-Huet B, Petersen T, Attar N, Lee WM, Jain MK. J Med Virol. 2012 Dec;84(12):1913-9. doi: 10.1002/jmv.23407.


  995. Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis C: A Systematic Review and Meta-analysis
    Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Ann Intern Med. 2012 Oct 16;157(8):558-66. doi: 10.7326/0003-4819-157-8-201210160-00006.


  996. Association between genetic mutations and the development of autoimmune thyroiditis in patients with chronic hepatitis C treated with interferon alpha
    Krupinska J, Urbanowicz W, Kaczmarczyk M, Kulig G, Sowinska-Przepiera EB, Andrysiak-Mamos EB, Syrenicz A. Thyroid Res. 2012 Oct 16;5(1):10. [Epub ahead of print]


  997. Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: A prospective cohort study
    Morimoto M, Numata K, Kondo M, Moriya S, Morita S, Maeda S, Tanaka K. Eur J Radiol. 2012 Oct 12. pii: S0720-048X(12)00450-0. doi: 10.1016/j.ejrad.2012.09.014. [Epub ahead of print]


  998. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: Analysis from the sprint-2 trial
    Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Reddy KR, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM. Hepatology. 2012 Oct 18. doi: 10.1002/hep.26096. [Epub ahead of print]


  999. Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy
    Martinez SM, Foucher J, Combis JM, Métivier S, Brunetto M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Lédinghen V. PLoS One. 2012;7(10):e47715. doi: 10.1371/journal.pone.0047715. Epub 2012 Oct 17.


  1000. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus
    Jenkins ET, Jensen DM. Infect Dis Clin North Am. 2012 Dec;26(4):879-91. doi: 10.1016/j.idc.2012.08.007.


  1001. Approach to the Treatment-naïve Patient with HCV Genotype 1 Infection
    Muir AJ. Infect Dis Clin North Am. 2012 Dec;26(4):893-901. doi: 10.1016/j.idc.2012.08.012.


  1002. Hepatitis C virus drug resistance: implications for clinical management
    Wyles DL. Infect Dis Clin North Am. 2012 Dec;26(4):967-78. doi: 10.1016/j.idc.2012.08.005.


  1003. Hepatitis C virus-host interactions, replication, and viral assembly
    Shulla A, Randall G. Curr Opin Virol. 2012 Oct 17. pii: S1879-6257(12)00159-9. doi: 10.1016/j.coviro.2012.09.013. [Epub ahead of print]


  1004. Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection
    Flemming JA, Terrault NA. Infect Dis Clin North Am. 2012 Dec;26(4):903-15. doi: 10.1016/j.idc.2012.08.008.


  1005. Future classes of hepatitis C virus therapeutic agents
    Chen JY, Chung RT. Infect Dis Clin North Am. 2012 Dec;26(4):949-66. doi: 10.1016/j.idc.2012.08.003.


  1006. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV
    Slim J, Afridi MS. Infect Dis Clin North Am. 2012 Dec;26(4):917-29. doi: 10.1016/j.idc.2012.08.006.


  1007. Diagnosis and treatment of acute hepatitis C virus infection
    Boesecke C, Wedemeyer H, Rockstroh JK. Infect Dis Clin North Am. 2012 Dec;26(4):995-1010. doi: 10.1016/j.idc.2012.08.011.


  1008. NK cells in hepatitis C: role in disease susceptibility and therapy
    Lunemann S, Schlaphoff V, Cornberg M, Wedemeyer H. Dig Dis. 2012;30 Suppl 1:48-54. doi: 10.1159/000341680. Epub 2012 Oct 11.


  1009. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response
    Weintraub SJ, Fleckenstein JF, Marion TN, Madey MA, Mahmoudi TM, Schechtman KB. Am J Clin Nutr. 2012 Sep 26. [Epub ahead of print]


  1010. Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program
    Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. J Subst Abuse Treat. 2012 Oct 2. pii: S0740-5472(12)00142-0. doi: 10.1016/j.jsat.2012.08.007. [Epub ahead of print]


  1011. Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis
    Jia Z, Ding Y, Tian S, Niu J, Jiang J. PLoS One. 2012;7(9):e45698. doi: 10.1371/journal.pone.0045698. Epub 2012 Sep 21.


  1012. Three polymorphisms in the IL-10 gene and the risk of HCV infection: a meta-analysis plus a Chinese Association Study involving 1140 subjects
    Li J, Liu Y, Xu F, Chen J, Chen Y. Epidemiol Infect. 2012 Sep 27:1-12. [Epub ahead of print]


  1013. Host-targeting agents for prevention and treatment of viral hepatitis C- perspectives and challenges
    Zeisel MB, Lupberger J, Fofana I, Baumert TF. J Hepatol. 2012 Oct 4. pii: S0168-8278(12)00753-2. doi: 10.1016/j.jhep.2012.09.022. [Epub ahead of print]


  1014. Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis
    Sogawa H, Shrager B, Jibara G, Tabrizian P, Roayaie S, Schwartz M. HPB (Oxford). 2012 Aug 30. doi: 10.1111/j.1477-2574.2012.00548.x. [Epub ahead of print]


  1015. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature
    Roed T, Lebech AM, Kjaer A, Weis N. Clin Physiol Funct Imaging. 2012 Nov;32(6):421-30. doi: 10.1111/j.1475-097X.2012.01152.x. Epub 2012 Jul 30.


  1016. Bone alterations in hepatitis C virus infected patients
    Pelazas-González R, González-Reimers E, Alemán-Valls MR, Santolaria-Fernández F, López-Prieto J, González-Díaz A, Gómez-Sirvent JL, de la Vega-Prieto MJ. Eur J Intern Med. 2012 Sep 29. pii: S0953-6205(12)00245-2. doi: 10.1016/j.ejim.2012.09.007. [Epub ahead of print]


  1017. Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients : an indirect comparison using Bayesian network meta-analysis
    Cure S, Diels J, Gavart S, Bianic F, Jones E. Curr Med Res Opin. 2012 Sep 27. [Epub ahead of print]


  1018. Improvement of Thrombocytopenia in Hepatitis C-Related Advanced Fibrosis Patients After Sustained Virological Response
    Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN. Source Dig Dis Sci. 2012 Sep 22. [Epub ahead of print]


  1019. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C
    Cie?la A, Boci?ga-Jasik M, Sobczyk-Krupiarz I, G?owacki MK, Owczarek D, Cibor D, Sanak M, Mach T. World J Gastroenterol. 2012 Sep 21;18(35):4892-7.


  1020. Effectiveness of a Risk Screener in Identifying Hepatitis C Virus in a Primary Care Setting
    Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Southern WN. Am J Public Health. 2012 Nov;102(11):e115-e121. Epub 2012 Sep 20.


  1021. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population
    Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. J Med Virol. 2012 Nov;84(11):1744-50. doi: 10.1002/jmv.23399.


  1022. Clinical relevance of HCV antiviral drug resistance
    Welsch C, Zeuzem S. Curr Opin Virol. 2012 Sep 21. pii: S1879-6257(12)00134-4. doi: 10.1016/j.coviro.2012.08.008. [Epub ahead of print]


  1023. IL28B polymorphism in hepatitis C and liver transplantation
    Duarte-Rojo A, Deneke MG, Charlton MR. Liver Transpl. 2012 Sep 24. doi: 10.1002/lt.23554. [Epub ahead of print]


  1024. Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea
    Kim HI, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG. Hepat Mon. 2012 Jul;12(7):430-6. Epub 2012 Jul 30.


  1025. BASELINE CHARACTERISTICS AND MORTALITY AMONG PEOPLE IN CARE FOR CHRONIC VIRAL HEPATITIS: THE CHRONIC HEPATITIS COHORT STUDY (CHeCS)
    Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, Lu M, Nerenz DR, Nakasato CC, Boscarino JA, Henkle EM, Oja-Tebbe NJ, Xing J, Ward JW, Holmberg SD; for the Chronic Hepatitis Cohort Study (CHeCS) Investigators. Clin Infect Dis. 2012 Sep 18. [Epub ahead of print]


  1026. Predictive factors of sustained virological response for recurrent hepatitis C virus after liver transplantation: the hungarian experience
    Nemes B, Gelley F, Zádori G, Kiss A, Nagy P, Gerlei Z, Lengyel G, Sárváry E. Transplant Proc. 2012 Sep;44(7):2162-3. doi: 10.1016/j.transproceed.2012.07.099.


  1027. Rapid and sharp decline in hepatitis C virus upon monotherapy with NS3 protease inhibitor, ACH-1625
    Agarwal A, Zhang B, Olek E, Robison H, Robarge L, Deshpande M. Antivir Ther. 2012 Sep 13. doi: 10.3851/IMP2359. [Epub ahead of print]


  1028. Prediction of a favorable clinical course in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study
    Nishimura T, Yamaguchi K, Fujii H, Okada Y, Yokomizo C, Niimi T, Sumida Y, Yasui K, Mitsuyoshi H, Minami M, Umemura A, Shima T, Okanoue T, Itoh Y. Hepatol Res. 2012 Sep 14. doi: 10.1111/j.1872-034X.2012.01091.x. [Epub ahead of print]


  1029. Monitoring the natural evolution and response to treatment of post liver transplant recurrent hepatitis C using Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients: preliminary results
    Bellido-Muñoz F, Giráldez-Gallego A, Roca-Oporto C, García-Cayuela T, Pascasio-Acevedo JM, Sousa-Martín JM. Transplant Proc. 2012 Sep;44(7):2082-6. doi: 10.1016/j.transproceed.2012.07.090.


  1030. Measurement and Clinical Significance of Interleukin 28B in Hepatitis C Virus-Infected Liver Transplant Patients
    Gerlei Z, Sárváry E, Lengyel G, Görög D, Fehérvári I, Nemes B, Kóbori L, Langer RM. Transplant Proc. 2012 Sep;44(7):2154-6. doi: 10.1016/j.transproceed.2012.07.101.


  1031. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection
    Himoto T, Masaki T. Clin Dev Immunol. 2012;2012:871401. Epub 2012 Sep 5. Department of Gastroenterology and Neurology, Kagawa University School of Medicine, Kagawa, Japan ; Department of Integrated Medicine, Kagawa University School of Medicine, 1750-1, Ikenobe, Miki-Cho, Kita-Gun, Kagawa 761-0793, Japan.


  1032. Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C
    Chang MH, Gordon LA, Fung HB. Clin Ther. 2012 Sep 10. pii: S0149-2918(12)00490-0. doi: 10.1016/j.clinthera.2012.08.009. [Epub ahead of print]


  1033. Chronic Pain Treatment and Health Service Utilization of Veterans with Hepatitis C Virus Infection
    Lovejoy TI, Dobscha SK, Cavanagh R, Turk DC, Morasco BJ.


  1034. Ribavirin Enhances the Action of Interferon-? against Hepatitis C Virus by Promoting the p53 Activity through the ERK1/2 Pathway
    Liu WL, Yang HC, Su WC, Wang CC, Chen HL, Wang HY, Huang WH, Chen DS, Lai MY. PLoS One. 2012;7(9):e43824. Epub 2012 Sep 4.


  1035. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study
    Kielland KB, Skaug K, Amundsen EJ, Dalgard O. J Hepatol. 2012 Sep 4. [Epub ahead of print]


  1036. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)
    Sheridan DA, Neely RD, Bassendine MF. Clin Res Hepatol Gastroenterol. 2012 Sep 5. [Epub ahead of print]


  1037. High Predictability of a Sustained Virological Response (87%) in Chronic Hepatitis C Virus Genotype 1 Infection Treatment by Combined IL28B Genotype Analysis and ?-Glutamyltransferase/Alanine Aminotransferase Ratio: A Retrospective Single-Center Study
    Amanzada A, Goralczyk AD, Schneider S, Moriconi F, Lindhorst A, Mihm S, Van Thiel DH, Ramadori G. Digestion. 2012 Sep 5;86(3):218-227. [Epub ahead of print]


  1038. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C
    Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Lenaour G, Vaillant JC, Ratziu V, Charlotte F; the Fibrosis-TAGS group. Clin Res Hepatol Gastroenterol. 2012 Sep 5. [Epub ahead of print]


  1039. Quantifying the fraction of cirrhosis attributable to alcohol among chronic HCV patients: Implications for treatment cost-effectiveness
    Innes HA, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A, Goldberg DJ, Mills PR, McDonald SA, Morris J, Stanley A, Hayes P; on behalf of the Hepatitis C Clinical Database Monitoring Committee. Hepatology. 2012 Sep 7. doi: 10.1002/hep.26051. [Epub ahead of print]


  1040. Racial Differences in the Association Between Adiposity Measures and the Risk of Hepatitis C-related Liver Disease
    White DL, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ, El-Serag HB. J Clin Gastroenterol. 2012 Oct;46(9):779-788.


  1041. Short report: Telaprevir-based triple therapy in liver transplanted HCV patients: A 12 week pilot study providing safety and efficacy
    Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Liver Transpl. 2012 Sep 1. doi: 10.1002/lt.23542. [Epub ahead of print]


  1042. Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor
    Matthews SJ, Lancaster JW.Clin Ther. 2012 Aug 27. [Epub ahead of print]


  1043. A new tool to study ribavirin-induced haemolysis
    Brochot E, François C, Castelain S, Helle F, Van Nhien AN, Duchaussoy I, Capron D, Nguyen-Khac E, Duverlie G. Antivir Ther. 2012 Sep 5. doi: 10.3851/IMP2308. [Epub ahead of print]


  1044. Intensified Peginterferon ?-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein
    Harrison SA, Abdurakhmanov D, Shiffman ML, Bakulin I, Mazur W, Rodriguez-Torres M, Silva GF, Cheinquer H, Messinger D, Connell EV, McKenna M, Tatsch F, Reddy KR; on behalf of the PROGRESS Investigators. J Clin Gastroenterol. 2012 Aug 30. [Epub ahead of print]


  1045. Interferon-free hepatitis C therapy: how close are we?
    Pockros PJ. Drugs. 2012 Oct 1;72(14):1825-31. doi: 10.2165/11635560-000000000-00000.


  1046. Assessment of the quality of evidence underlying international guidelines in liver disease
    Rowe IA, Parker R, Armstrong MJ, King AL, Houlihan DD, Mutimer D. Am J Gastroenterol. 2012 Sep;107(9):1276-82. doi: 10.1038/ajg.2012.71.


  1047. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis
    Liu JY, Sheng YJ, Hu HD, Zhong Q, Wang J, Tong SW, Zhou Z, Zhang DZ, Hu P, Ren H. Virol J. 2012 Sep 6;9(1):186. [Epub ahead of print]


  1048. Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C
    Kondo R, Yano H, Nakashima O, Tanikawa K, Nomura Y, Kage M. J Gastroenterol. 2012 Aug 22. [Epub ahead of print]


  1049. Hepatitis C virus infection and nonalcoholic steatohepatitis
    Patel A, Harrison SA. Gastroenterol Hepatol (N Y). 2012 May;8(5):305-12.


  1050. Insulin resistance in chronic hepatitis C: the search for effective drug treatment continues
    Harrison SA, Lincoln MJ, Roberts KK. Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):401-3.


  1051. Genomic variation-guided management in chronic hepatitis C
    Hsu CS, Kao JH. Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):497-506.


  1052. Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response
    Gupta S, Singh R. PLoS One. 2012;7(7):e41209. Epub 2012 Jul 24.


  1053. Infectious disease. Calling all baby boomers: get your hepatitis C test
    Cohen J. Science. 2012 Aug 24;337(6097):903.


  1054. The ongoing impacts of hepatitis c - a systematic narrative review of the literature
    Miller ER, McNally S, Wallace J, Schlichthorst M. BMC Public Health. 2012 Aug 18;12(1):672. [Epub ahead of print]


  1055. HCV-Related Nervous System Disorders
    Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. Clin Dev Immunol. 2012;2012:236148. Epub 2012 Jul 30.


  1056. Liver transplantation and hepatitis C
    Akamatsu N, Sugawara Y. Int J Hepatol. 2012;2012:686135. Epub 2012 Jul 26.


  1057. New developments in the management of hepatitis C virus infection: focus on boceprevir
    Berenguer M, López-Labrador FX. Biologics. 2012;6:249-56. Epub 2012 Aug 3.


  1058. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
    Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32.


  1059. Performance of an antigen-antibody combined assay for hepatitis C virus testing without venipuncture
    Larrat S, Bourdon C, Baccard M, Garnaud C, Mathieu S, Quesada JL, Signori-Schmuck A, Germi R, Blanc M, Leclercq P, Hilleret MN, Leroy V, Zarski JP, Morand P. J Clin Virol. 2012 Aug 14. [Epub ahead of print]


  1060. Progress toward prevention and control of hepatitis C virus infection - egypt, 2001-2012
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep.2012 Jul 27;61:545-9.


  1061. Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence
    Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, Nakasato C, Boscarino JA, Henkle EM, Nerenz DR, Denniston MM, Holmberg SD; the Chronic Hepatitis Cohort Study (CHeCS) Investigators. Clin Infect Dis. 2012 Aug 8. [Epub ahead of print]


  1062. Process of Care for HCV Infection Is Linked to Treatment Outcome and Virologic Response
    Kanwal F, Hoang T, Chrusciel T, Kramer J, El-Serag H, Dominitz J, Asch SM. Clin Gastroenterol Hepatol. 2012 Jul 24. [Epub ahead of print]


  1063. Immunological HCV-Associated Thrombocytopenia: Short Review
    Dimitroulis D, Valsami S, Stamopoulos P, Kouraklis G. Clin Dev Immunol. 2012;2012:378653. Epub 2012 Jul 10.


  1064. An Examination of Liver Offers to Candidates on the Liver Transplant Wait-List
    Lai JC, Feng S, Roberts JP. Gastroenterology. 2012 Jul 26. [Epub ahead of print]


  1065. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor Daclatasvir
    Pelosi LA, Voss S, Liu M, Gao M, Lemm JA. Antimicrob Agents Chemother. 2012 Jul 30. [Epub ahead of print]


  1066. Hepatitis C virus infection and mixed cryoglobulinemia
    Lauletta G, Russi S, Conteduca V, Sansonno L. Clin Dev Immunol. 2012;2012:502156. Epub 2012 Jul 10.


  1067. Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis
    Farci P, Wollenberg K, Diaz G, Engle RE, Lai ME, Klenerman P, Purcell RH, Pybus OG, Alter HJ. Proc Natl Acad Sci U S A. 2012 Jul 24. [Epub ahead of print]


  1068. Therapeutic Approach to the Treatment-Naive Patient With Hepatitis C Virus Genotype 1 Infection: A Step-by-Step Approach
    Sherman KE. Clin Infect Dis. 2012 Aug 8. [Epub ahead of print]


  1069. Telaprevir and boceprevir in african americans with genotype 1 chronic hepatitis C: implications for patients and providers
    Burton MJ, Passarella MJ, McGuire BM. South Med J. 2012 Aug;105(8):431-6.


  1070. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients
    Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. J Hepatol. 2012 Aug 4. [Epub ahead of print]


  1071. Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection
    Joseph AM. Ther Adv Musculoskelet Dis. 2012 Feb;4(1):35-40.


  1072. Review of Patient-Reported Outcome Measures in Chronic Hepatitis C
    Kleinman L, Mannix S, Yuan Y, Kummer S, L'italien G, Revicki D. Health Qual Life Outcomes. 2012 Aug 7;10(1):92. [Epub ahead of print]


  1073. Vitamin D for Your Patients with Chronic Hepatitis C?
    Rahman AH, Branch AD. J Hepatol. 2012 Aug 4. [Epub ahead of print]


  1074. New Pharmacotherapy for Hepatitis C
    Assis DN, Lim JK. Clin Pharmacol Ther. 2012 Aug 1. doi: 10.1038/clpt.2012.103. [Epub ahead of print]


  1075. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin
    Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C. J Viral Hepat. 2012 Sep;19(9):615-22. doi: 10.1111/j.1365-2893.2011.01584.x. Epub 2012 Feb 9.


  1076. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?
    Fabrizi F, Dixit V, Messa P. J Viral Hepat. 2012 Sep;19(9):601-7. doi: 10.1111/j.1365-2893.2012.01633.x. Epub 2012 Jul 17.


  1077. Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation
    Ackefors M, Gjertsen H, Wernerson A, Weiland O. J Viral Hepat. 2012 Sep;19(9):635-9. doi: 10.1111/j.1365-2893.2012.01587.x. Epub 2012 Feb 17.


  1078. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus
    Feinstone SM, Hu DJ, Major ME. Clin Infect Dis. 2012 Jul;55 Suppl 1:S25-32.


  1079. Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality
    Singal AK, Kuo YF, Anand BS. Eur J Gastroenterol Hepatol. 2012 Jun 24. [Epub ahead of print]


  1080. Effect of discounting on estimation of benefits determined by hepatitis C treatment.
    Messori A, Fadda V, Maratea D, Trippoli S. World J Gastroenterol. 2012 Jun 21;18(23):3032-4.


  1081. Laboratory diagnostics for hepatitis C virus infection
    Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Clin Infect Dis. 2012 Jul;55 Suppl 1:S43-8.


  1082. Global burden of hepatitis C: considerations for healthcare providers in the United States
    Averhoff FM, Glass N, Holtzman D. Clin Infect Dis. 2012 Jul;55 Suppl 1:S10-5.


  1083. Evolving epidemiology of hepatitis C virus in the United States
    Klevens RM, Hu DJ, Jiles R, Holmberg SD. Clin Infect Dis. 2012 Jul;55 Suppl 1:S3-9.


  1084. New perspectives in occult hepatitis C virus infection
    Carreño V, Bartolomé J, Castillo I, Quiroga JA. World J Gastroenterol. 2012 Jun 21;18(23):2887-94.


  1085. Symptomatic Treatment of Interferon-?-Induced Depression in Hepatitis C: A Systematic Review
    Baraldi S, Hepgul N, Mondelli V, Pariante CM. J Clin Psychopharmacol. 2012 Aug;32(4):531-43.


  1086. New perspectives in occult hepatitis C virus infection
    Carreño V, Bartolomé J, Castillo I, Quiroga JA. World J Gastroenterol. 2012 Jun 21;18(23):2887-94.


  1087. Centers for disease control and prevention initiatives to prevent hepatitis C virus infection: a selective update
    Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Clin Infect Dis. 2012 Jul;55 Suppl 1:S49-53.


  1088. Investigation of residual hepatitis C virus in presumed recovered subjects
    Fujiwara K, Allison RD, Wang RY, Bare P, Matsuura K, Schechterly C, Murthy K, Marincola FM, Alter HJ. Hepatology. 2012 Jun 23. doi: 10.1002/hep.25921. [Epub ahead of print]


  1089. Chronic Hepatitis C and Antiviral Treatment Regimens: Where Can Psychology Contribute?
    Evon DM, Golin CE, Fried MW, Keefe FJ. J Consult Clin Psychol. 2012 Jun 25. [Epub ahead of print]


  1090. Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C
    Fox AN, Jacobson IM. Clin Infect Dis. 2012 Jul;55 Suppl 1:S16-24.


  1091. Impact of ribavirin dose on retreatment of chronic hepatitis C patients
    Stern C, Martinot-Peignoux M, Ripault MP, Boyer N, Castelnau C, Valla D, Marcellin P. World J Gastroenterol. 2012 Jun 21;18(23):2966-72.


  1092. Preventive versus
    Huisman EJ, van Hoek B, van Soest H, van Nieuwkerk KM, Arends JE, Siersema PD, van Erpecum KJ. J Hepatol. 2012 Jun 30. [Epub ahead of print]


  1093. Hepatitis C therapy in non-genotype 1 patients: the near future
    Wartelle-Bladou C, Le Folgoc G, Bourlière M, Lecomte L. J Viral Hepat. 2012 Aug;19(8):525-36. doi: 10.1111/j.1365-2893.2012.01634.x.


  1094. Racial Differences in Fibrosis Progression After HCV-Related Liver Transplantation
    Layden JE, Cotler S, Brown KA, Lucey MR, Te HS, Eswaran S, Fimmel C, Layden TJ, Clark NM. Transplantation. 2012 Jul 27;94(2):178-84.


  1095. A Community-Based Cross-Sectional Study: The Association of Lipids with Hepatitis C Seropositivity and Diabetes Mellitus
    Liu JL, Chen JY, Chen CT, Wang JH, Lin CY, Chen PF, Hung CH, Kee KM, Lee CM, Tsai LS, Chen SC, Lin SC, Lu SN. J Gastroenterol Hepatol. 2012 Jun 28. doi: 10.1111/j.1440-1746.2012.07212.x. [Epub ahead of print]


  1096. Assessing Long-Term Treatment Efficacy in Chronic Hepatitis B and C: Between Evidence and Common Sense
    Aghemo A, Lampertico P, Colombo M. J Hepatol. 2012 Jun 27. [Epub ahead of print]


  1097. Peginterferon-?-2b and Ribavirin for Hepatitis C Recurrence Postorthotopic Liver Transplantation
    Gordon FD, Kwo P, Ghalib R, Crippin J, Vargas HE, Brown KA, Schiano T, Chaudhri E, Pedicone LD, Brown RS Jr. J Clin Gastroenterol. 2012 Jun 25. [Epub ahead of print]


  1098. Fatigue Before, During and After Antiviral Therapy of Chronic Hepatitis C: Results from the Virahep-C Study
    Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. J Hepatol. 2012 Jul 1. [Epub ahead of print]


  1099. Cytokinome Profile of Patients with Type 2 Diabetes and/or Chronic Hepatitis C Infection
    Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, Di Stasio M, Paolisso G, Castello G, Colonna G. PLoS One. 2012;7(6):e39486. Epub 2012 Jun 20.


  1100. A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors
    Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, Kleiner DE, Ghany MG, Alter HJ. J Infect Dis. 2012 Jul 20. [Epub ahead of print]


  1101. Altered regional homogeneity in the development of minimal hepatic encephalopathy: a resting-state functional MRI study
    Ni L, Qi R, Zhang LJ, Zhong J, Zheng G, Zhang Z, Zhong Y, Xu Q, Liao W, Jiao Q, Wu X, Fan X, Lu GM. 12;7(7):e42016. Epub 2012 Jul 25.


  1102. Escitalopram for the Prevention of Peginterferon-?2a-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease: A Randomized Trial
    Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T. Ann Intern Med. 2012 Jul 17;157(2):94-103.


  1103. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial
    Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. JAMA. 2012 Jul 18;308(3):274-82. Collaborators (38)


  1104. Increased Risk of Severe Hepatitis C Virus Recurrence After Liver Transplantation in Patients With a T Allele of IL28B rs12979860
    Cisneros E, Baños I, Citores MJ, Duca A, Salas C, Noblejas A, Cañizares M, Millán I, Cuervas-Mons V, Vilches C. Transplantation. 2012 Jul 10. [Epub ahead of print]


  1105. The Performance of Process Measures in Hepatitis C
    Kanwal F, Hoang T, Kramer J, Chrusciel T, El-Serag H, Dominitz JA, Asch SM. Am J Gastroenterol. 2012 Jul 10. doi: 10.1038/ajg.2012.201. [Epub ahead of print]


  1106. Patients' Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection
    Kauf TL, Mohamed AF, Hauber AB, Fetzer D, Ahmad A. Patient. 2012 Jul 10. doi: 10.2165/11633580-000000000-00000. [Epub ahead of print]


  1107. A review on an update of NS5B polymerase hepatitis C virus inhibitors
    Varshney J, Sharma PK, Sharma A. Eur Rev Med Pharmacol Sci. 2012 May;16(5):667-71.


  1108. The Course of Posttransplant Hepatitis C Infection: Comparative Impact of Donor and Recipient Source of the Favorable IL28B Genotype and Other Variables
    Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas-Vorackova F, Charlton MR. Transplantation. 2012 Jul 27;94(2):197-203.


  1109. HCV Infection Prevalence Lower Than Expected among 18-40-Year-Old Injection Drug Users in San Diego, CA
    Garfein RS, Rondinelli A, Barnes RF, Cuevas J, Metzner M, Velasquez M, Rodriguez D, Reilly M, Xing J, Teshale EH. J Urban Health. 2012 Jul 6. [Epub ahead of print]


  1110. A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms
    Krishnan SM, Dixit NM. Antivir Ther. 2012 Jul 18. doi: 10.3851/IMP2251. [Epub ahead of print]


  1111. Efficacy of antiviral therapy for hepatitis C post liver transplant on cyclosporine versus tacrolimus: A systematic review and meta-analysis
    Rabie R, Mumtaz K, Renner EL. Liver Transpl. 2012 Jul 23. doi: 10.1002/lt.23516. [Epub ahead of print]


  1112. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus
    Rocco A, Compare D, Coccoli P, Esposito C, Di Spirito A, Barbato A, Strazzullo P, Nardone G. Gut. 2012 Jul 17. [Epub ahead of print]


  1113. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the realize trial
    Meyer SD, Dierynck I, Ghys A, Beumont M, Daems B, Baelen BV, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G. Hepatology. 2012 Jul 16. doi: 10.1002/hep.25962. [Epub ahead of print]


  1114. HCV in liver transplantation
    Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. Semin Immunopathol. 2012 Jul 25. [Epub ahead of print]


  1115. Laboratory evaluation of rapid test kits to detect hepatitis?C antibody for use in predonation screening in emergency settings
    O'Connell RJ, Gates RG, Bautista CT, Imbach M, Eggleston JC, Beardsley SG, Manak MM, Gonzales R, Rentas FJ, Macdonald VW, Cardo LJ, Reiber DT, Stramer SL, Michael NL, Peel SA. Transfusion. 2012 Jul 23. doi: 10.1111/j.1537-2995.2012.03770.x. [Epub ahead of print]


  1116. Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study
    Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ; for the R.E.V.E.A.L.-HCV Study Group. J Infect Dis. 2012 Aug;206(4):469-477. Epub 2012 Jul 17.


  1117. Long-term antiviral treatment for recurrent hepatitis C after liver transplantation
    Bertuzzo VR, Cescon M, Morelli MC, Di Gioia P, Tamè M, Lorenzini S, Andreone P, Ercolani G, Del Gaudio M, Ravaioli M, Cucchetti A, Dazzi A, D'Errico-Grigioni A, Pinna AD. Dig Liver Dis. 2012 Jul 20. [Epub ahead of print]


  1118. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus
    Feinstone SM, Hu DJ, Major ME. Clin Infect Dis. 2012 Jul;55 Suppl 1:S25-32.


  1119. Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality
    Singal AK, Kuo YF, Anand BS. Eur J Gastroenterol Hepatol. 2012 Jun 24. [Epub ahead of print]


  1120. Effect of discounting on estimation of benefits determined by hepatitis C treatment.
    Messori A, Fadda V, Maratea D, Trippoli S. World J Gastroenterol. 2012 Jun 21;18(23):3032-4.


  1121. Laboratory diagnostics for hepatitis C virus infection
    Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Clin Infect Dis. 2012 Jul;55 Suppl 1:S43-8.


  1122. Global burden of hepatitis C: considerations for healthcare providers in the United States
    Averhoff FM, Glass N, Holtzman D. Clin Infect Dis. 2012 Jul;55 Suppl 1:S10-5.


  1123. Evolving epidemiology of hepatitis C virus in the United States
    Klevens RM, Hu DJ, Jiles R, Holmberg SD. Clin Infect Dis. 2012 Jul;55 Suppl 1:S3-9.


  1124. New perspectives in occult hepatitis C virus infection
    Carreño V, Bartolomé J, Castillo I, Quiroga JA. World J Gastroenterol. 2012 Jun 21;18(23):2887-94.


  1125. Symptomatic Treatment of Interferon-?-Induced Depression in Hepatitis C: A Systematic Review
    Baraldi S, Hepgul N, Mondelli V, Pariante CM. J Clin Psychopharmacol. 2012 Aug;32(4):531-43.


  1126. New perspectives in occult hepatitis C virus infection
    Carreño V, Bartolomé J, Castillo I, Quiroga JA. World J Gastroenterol. 2012 Jun 21;18(23):2887-94.


  1127. Centers for disease control and prevention initiatives to prevent hepatitis C virus infection: a selective update
    Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Clin Infect Dis. 2012 Jul;55 Suppl 1:S49-53.


  1128. Investigation of residual hepatitis C virus in presumed recovered subjects
    Fujiwara K, Allison RD, Wang RY, Bare P, Matsuura K, Schechterly C, Murthy K, Marincola FM, Alter HJ. Hepatology. 2012 Jun 23. doi: 10.1002/hep.25921. [Epub ahead of print]


  1129. Chronic Hepatitis C and Antiviral Treatment Regimens: Where Can Psychology Contribute?
    Evon DM, Golin CE, Fried MW, Keefe FJ. J Consult Clin Psychol. 2012 Jun 25. [Epub ahead of print]


  1130. Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C
    Fox AN, Jacobson IM. Clin Infect Dis. 2012 Jul;55 Suppl 1:S16-24.


  1131. Impact of ribavirin dose on retreatment of chronic hepatitis C patients
    Stern C, Martinot-Peignoux M, Ripault MP, Boyer N, Castelnau C, Valla D, Marcellin P. World J Gastroenterol. 2012 Jun 21;18(23):2966-72.


  1132. Finasteride and Methadone Use and Risk of Advanced Hepatitis C Related Liver Disease
    White DL, Hashmi A, Ramsey DJ, Kuzniarek J, Tavakoli-Tabasi S, El-Serag HB. Dig Dis Sci. 2012 Jun 5. [Epub ahead of print]


  1133. A Population-Based Study of the Epidemiology of Hepatitis C in a North American Population
    Julia U, Bruce TR, Douglas T, Yossel MG. J Hepatol. 2012 Jun 2. [Epub ahead of print]


  1134. Results from a large-scale epidemiologic look-back investigation of improperly reprocessed endoscopy equipment
    Holodniy M, Oda G, Schirmer PL, Lucero CA, Khudyakov YE, Xia G, Lin Y, Valdiserri R, Duncan WE, Davey VJ, Cross GM. Infect Control Hosp Epidemiol. 2012 Jul;33(7):649-56. Epub 2012 May 7.


  1135. A Meta-Analysis of the Existing Knowledge of Immunoreactivity against Hepatitis C Virus (HCV)
    Kim Y, Vaughan K, Greenbaum J, Peters B, Law M, Sette A. PLoS One. 2012;7(5):e38028. Epub 2012 May 31.


  1136. The Burden of Untreated Hepatitis C Virus Infection: A US Patients' Perspective
    El Khoury AC, Vietri J, Prajapati G. Dig Dis Sci. 2012 Jun 5. [Epub ahead of print]


  1137. Increased α-Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4
    Mousa N, Gad Y, Abdel-Aziz A, Abd-Elaal I. Int J Hepatol. 2012;2012:636392. Epub 2012 May 14.


  1138. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents
    Poordad F, Dieterich D. J Viral Hepat. 2012 Jul;19(7):449-64. doi: 10.1111/j.1365-2893.2012.01617.x.


  1139. Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action
    Mukhtar NA, Ayala C, Maher JJ, Khalili M. J Viral Hepat. 2012 Jul;19(7):480-7. doi: 10.1111/j.1365-2893.2011.01568.x. Epub 2011 Dec 18.


  1140. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin
    Guedj H, Guedj J, Negro F, Lagging M, Westin J, Bochud PY, Bibert S, Neumann AU; for the DITTO-HCV study group. J Viral Hepat. 2012 Jul;19(7):488-496. doi: 10.1111/j.1365-2893.2011.01569.x. Epub 2011 Dec 22.


  1141. Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response
    Barut S, Günal O, Erkorkmaz U. Scand J Infect Dis. 2012 Jun 10. [Epub ahead of print]


  1142. Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C
    Cobbold JF, Cox IJ, Brown AS, Williams HR, Goldin RD, Thomas HC, Thursz MR, Taylor-Robinson SD. Hepatol Res. 2012 Jul;42(7):714-20. doi: 10.1111/j.1872-034X.2012.00975.x.


  1143. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C
    Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Am J Gastroenterol. 2012 Jun 12. doi: 10.1038/ajg.2012.137. [Epub ahead of print]


  1144. Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials
    Aghemo A, Degasperi E, Colombo M. Dig Liver Dis. 2012 Jun 11. [Epub ahead of print]


  1145. Hepatitis C Virus-Associated Primary Hepatocellular Carcinoma in Non-cirrhotic Patients
    Albeldawi M, Soliman M, Lopez R, Zein NN. Dig Dis Sci. 2012 Jun 14. [Epub ahead of print]


  1146. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
    Pearlman BL. www.thelancet.com/infectionPublished Online May 29, 2012 DOI:10.1016/S1473- 3099(12)70060-9


  1147. Hepatitis C virus prevention, care, and treatment: from policy to practice
    Ward JW, Valdiserri RO, Koh HK. Clin Infect Dis. 2012 Jul;55 Suppl 1:S58-63.


  1148. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication
    Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R. Hepatology. 2012 Jun 18. doi: 10.1002/hep.25908. [Epub ahead of print]


  1149. Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments
    Enjoji M, Kohjima M, Kotoh K, Nakamuta M. Int J Hepatol. 2012;2012:264017. Epub 2012 Jun 4.


  1150. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1
    Amanzada A, Schneider S, Moriconi F, Lindhorst A, Suermann T, van Thiel DH, Mihm S, Ramadori G. J Med Virol. 2012 Aug;84(8):1208-16. doi: 10.1002/jmv.23323.


  1151. Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1
    Palmer M, Rubin R, Rustgi V; Taribavirin Viral Kinetic Study Group. Aliment Pharmacol Ther. 2012 Jun 19. doi: 10.1111/j.1365-2036.2012.05188.x. [Epub ahead of print]


  1152. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma
    Khattab MA, Eslam M, Mousa YI, Ela-Adawy N, Fathy S, Shatat M, Abd-Aalhalim H, Kamal A, Sharawe MA. Ann Hepatol. 2012 Jul;11(4):487-94.


  1153. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
    Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hézode C, Lim JK, Bronowicki JP, Abrams GA, Bräu N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S. Lancet Infect Dis. 2012 Jun 15. [Epub ahead of print]


  1154. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection
    Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, Folgori A, Rehermann B. Hepatology. 2012 Jun 18. doi: 10.1002/hep.25897. [Epub ahead of print]


  1155. Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients
    Rodríguez-Torres M, Burguera J, Hallman D, Rodríguez-Orengo J, Echeandia M. Ann Hepatol. 2012 Jul;11(4):450-63.


  1156. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection
    Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C. J Clin Virol. 2012 Jun 12. [Epub ahead of print]


  1157. Treating hepatitis C infection by targeting the host
    Salloum S, Tai AW. Transl Res. 2012 Jun;159(6):421-9. Epub 2012 Jan 10.


  1158. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
    Pearlman BL. Lancet Infect Dis. 2012 May 28. [Epub ahead of print]


  1159. Interferon Responsiveness Does not Change in Treatment-Experienced Hepatitis C Subjects: Implications for Drug Development and Clinical Decisions
    Liu J, Florian J, Birnkrant D, Murray J, Jadhav PR. Clin Infect Dis. 2012 May 31. [Epub ahead of print]


  1160. Basic answers to complicated questions for the course of chronic hepatitis C treatment
    Ormeci N, Erdem H. Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3):371-82.


  1161. Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection
    Jin R, Fossler MJ, McHutchison JG, Howell CD, Dowling TC. AAPS J. 2012 Sep;14(3):571-80. Epub 2012 May 26.


  1162. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined
    O'Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Transpl Int. 2012 May 30. doi: 10.1111/j.1432-2277.2012.01498.x. [Epub ahead of print]


  1163. Hepatitis C among Clients of Health Care for the Homeless Primary Care Clinics
    Strehlow AJ, Robertson MJ, Zerger S, Rongey C, Arangua L, Farrell E, O'Sullivan A, Gelberg L. J Health Care Poor Underserved. 2012;23(2):811-33.


  1164. Identifying newly acquired cases of hepatitis C using surveillance: a literature review
    Sacks-Davis R, VAN Gemert C, Bergeri I, Stoove M, Hellard M. Epidemiol Infect. 2012 Jun 1:1-10. [Epub ahead of print]


  1165. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C
    Stättermayer AF, Rutter K, Beinhardt S, Scherzer TM, Stadlmayr A, Hofer H, Wrba F, Steindl-Munda P, Krebs M, Datz C, Trauner M, Ferenci P. J Hepatol. 2012 May 24. [Epub ahead of print]


  1166. A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients
    Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. Hepatology. 2012 May 22. doi: 10.1002/hep.25867. [Epub ahead of print]


  1167. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
    Lee SS, Roberts SK, Berak H, Dusheiko GM, Harley HA, Gane EJ, Husa P, Horsmans YJ, Hadziyannis SJ, Jenny Heathcote E, Messinger D, Tatsch F, Han KH, Ferenci P. Liver Int. 2012 May 24. doi: 10.1111/j.1478-3231.2012.02819.x. [Epub ahead of print]


  1168. Refinement of stopping rules during treatment of hepatitis c-genotype 1 infection with boceprevir combined with peginterferon/ribavirin
    Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, Dinubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP. Hepatology. 2012 May 22. doi: 10.1002/hep.25865. [Epub ahead of print]


  1169. Factors that Predict Response of Patients with HCV Infection to Boceprevir
    Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators. Gastroenterology. 2012 May 21. [Epub ahead of print]


  1170. The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C
    Thomas E, Ghany MG, Liang TJ. Antivir Chem Chemother. 2012 May 16. doi: 10.3851/IMP2125. [Epub ahead of print]


  1171. Association of HCV core antigen seropositivity with long-term mortality in patients on regular hemodialysis
    Kato A, Takita T, Furuhashi M, Fujimoto T, Suzuki H, Maruyama Y, Sakao Y, Miyajima H. Nephron Extra. 2012 Jan;2(1):76-86. Epub 2012 Mar 28.


  1172. Unexpected Maintenance of Hepatitis C Viral Diversity Following Liver Transplantation
    Gray RR, Strickland SL, Veras NM, Goodenow MM, Pybus OG, Lemon SM, Fried MW, Nelson DR, Salemi M. J Virol. 2012 May 23. [Epub ahead of print]


  1173. Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial
    Oliveira LP, de Jesus RP, Boulhosa RS, Mendes CM, Gnoatto MC, Lemaire DC, Toralles MB, Cavalcante LN, Lyra AC, Lyra LG. World J Gastroenterol. 2012 May 14;18(18):2203-11.


  1174. Treatment of Recurrent HCV Infection Following Liver Transplantation: Results of a Multicenter, Randomized, versus placebo, Trial of ribavirin alone as maintenance therapy after one year of Peginterferon Alfa-2A plus Ribavirin
    Calmus Y, Duvoux C, Pageaux G, Wolf P, Rostaing L, Vanlemmens C, Botta-Fridlund D, Dharancy S, Gugenheim J, Durand F, Néau-Cransac M, Boillot O, Chazouillères O, Samelson L, Boudjema K, Samuel D. J Hepatol. 2012 May 18. [Epub ahead of print]


  1175. Rewards program is the best and they have the most direct flights out of Newark. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
    Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J. J Hepatol. 2012 May 18. [Epub ahead of print]


  1176. Cytokines and HCV-Related Disorders
    Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Clin Dev Immunol. 2012;2012:468107. Epub 2012 May 7.


  1177. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population
    Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V, Imbert-Bismut F. J Hepatol. 2012 May 18. [Epub ahead of print]


  1178. Impact of disease severity on health care costs in patients with chronic hepatitis C (CHC) virus infection
    Gordon S, Pockros P, Terrault N, Hoop R, Buikema A, Nerenz D, Hamzeh F. Hepatology. 2012 May 18. doi: 10.1002/hep.25842. [Epub ahead of print]


  1179. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV Coinfection
    Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR. Hepatology. 2012 May 22. doi: 10.1002/hep.25866. [Epub ahead of print]


  1180. Association of chronic hepatitis C with recurrent brief depression
    Carta MG, Angst J, Moro MF, Mura G, Hardoy MC, Balestrieri C, Chessa L, Serra G, Lai ME, Farci P. J Affect Disord. 2012 May 18. [Epub ahead of print]


  1181. Advances in the treatment of hepatitis C virus infection
    Thomas DL. Top Antivir Med. 2012 Apr;20(1):5-10.


  1182. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus
    Barritt AS 4th, Fried MW. Gastroenterology. 2012 May;142(6):1314-1323.e1.


  1183. Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection
    Kwo PY. Therap Adv Gastroenterol. 2012 May;5(3):179-88.


  1184. Circulating Microparticles as Disease-Specific Biomarkers of Severity of Inflammation in Patients with Hepatitis C or Nonalcoholic Steatohepatitis
    Kornek M, Lynch M, Mehta SH, Lai M, Exley M, Afdhal NH, Schuppan D. Gastroenterology. 2012 Apr 23. [Epub ahead of print]


  1185. Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals
    Naggie S, Sulkowski MS. Gastroenterology. 2012 May;142(6):1324-1334.e3.


  1186. New virologic tools for management of chronic hepatitis B and C
    Chevaliez S, Rodriguez C, Pawlotsky JM. Gastroenterology. 2012 May;142(6):1303-1313.e1.


  1187. Anti-hepatitis C virus drugs in development
    Schaefer EA, Chung RT. Gastroenterology. 2012 May;142(6):1340-1350.e1


  1188. The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection
    Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL, Urban TJ, Shianna K, Fellay J, Goodman Z, Noviello S, Pedicone LD, Afdhal N, Sulkowski M, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ. Dig Dis Sci. 2012 Apr 29. [Epub ahead of print]


  1189. Hepatitis C virus therapeutics: at the end of the beginning
    Schooley RT. Top Antivir Med. 2012 Apr;20(1):17-9.


  1190. Estimating incidence rates with misclassified disease status: a likelihood-based approach, with application to hepatitis C virus
    Shebl FM, El-Kamary SS, Shardell M, Langenberg P, Dorgham LS, Maguire JH, Magder LS. Int J Infect Dis. 2012 Apr 27. [Epub ahead of print]


  1191. Viral hepatitis in liver transplantation
    Crespo G, Mariño Z, Navasa M, Forns X. Gastroenterology. 2012 May;142(6):1373-1383.e1.


  1192. The impact of host metabolic factors on treatment outcome in chronic hepatitis C
    Savvoula S, Dimitrios C, George P, Spilios M, Christos T, John G. Gastroenterol Res Pract. 2012;2012:420156. Epub 2012 Apr 22.


  1193. Notes from the field : hepatitis C virus infections among young adults - rural wisconsin, 2010
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 May 18;61:358.


  1194. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-? and ribavirin
    Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Aliment Pharmacol Ther. 2012 May 16. doi: 10.1111/j.1365-2036.2012.05131.x. [Epub ahead of print]


  1195. Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA
    Jewett A, Smith BD, Garfein RS, Cuevas-Mota J, Teshale EH, Weinbaum CM. J Clin Virol. 2012 Jul;54(3):213-7. Epub 2012 May 3.


  1196. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response
    Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, Salimi S, Kheradvar O. Hepat Mon. 2012 Mar;12(3):190-5. Epub 2012 Mar 28.


  1197. Comprehensive analysis for viral elements and il28b polymorphisms in response to peginterferon plus ribavirin therapy in hcv-1b infection
    Maekawa S, Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A, Ohmori T, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N. Hepatology. 2012 May 10. doi: 10.1002/hep.25826. [Epub ahead of print]


  1198. 'Les liaisons dangereuses': Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas
    Marignani M, Fonzo Md, Begini P, Gigante E, Deli I, Pellicelli AM, Gallina S, de Santis E, Delle Fave G, Cox MC. World J Gastrointest Pharmacol Ther. 2012 Apr 6;3(2):21-8.


  1199. Chronic hepatitis C: Treat or wait? Medical decision making in clinical practice
    Niederau C, Hüppe D, Zehnter E, Möller B, Heyne R, Christensen S, Pfaff R, Theilmeier A, Alshuth U, Mauss S. World J Gastroenterol. 2012 Mar 28;18(12):1339-47.


  1200. Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12?weeks of pegylated interferon-?-2a plus ribavirin and RVR
    Restivo L, Zampino R, Guerrera B, Ruggiero L, Adinolfi LE. J Viral Hepat. 2012 May;19(5):346-53. doi: 10.1111/j.1365-2893.2011.01555.x. Epub 2011 Nov 9.


  1201. Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens
    Bonner JE, Esserman D, Evon DM. J Viral Hepat. 2012 May;19(5):316-26. doi: 10.1111/j.1365-2893.2011.01550.x. Epub 2011 Nov 24.


  1202. Response Guided Telaprevir Therapy in Prior Relapsers?: The Role of Bridging Data from Treatment-Naïve and Experienced Subjects
    Liu J, Jadhav PR, Amur S, Fleischer R, Hammerstrom T, Lewis L, Naeger L, O'Rear J, Pacanowski M, Robertson S, Seo S, Soon G, Birnkrant D. Hepatology. 2012 Apr 6. doi: 10.1002/hep.25764. [Epub ahead of print]


  1203. Neuropsychological tools in hepatology: a survival guide for the clinician
    Montagnese S, Schiff S, De Rui M, Crossey MM, Amodio P, Taylor-Robinson SD. J Viral Hepat. 2012 May;19(5):307-15. doi: 10.1111/j.1365-2893.2012.01592.x.


  1204. How can we utilize livers from advanced aged donors for liver transplantation for hepatitis C?
    Uemura T, Nikkel LE, Hollenbeak CS, Ramprasad V, Schaefer E, Kadry Z. Transpl Int. 2012 Apr 6. doi: 10.1111/j.1432-2277.2012.01474.x. [Epub ahead of print]


  1205. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity
    Stepanova M, Lam B, Younossi Y, Srishord MK, Younossi ZM. J Viral Hepat. 2012 May;19(5):341-5. doi: 10.1111/j.1365-2893.2011.01554.x. Epub 2011 Nov 9.


  1206. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response
    Clark PJ, Thompson AJ, Zhu M, Vock DM, Zhu Q, Ge D, Patel K, Harrison SA, Urban TJ, Naggie S, Fellay J, Tillmann HL, Shianna K, Noviello S, Pedicone LD, Esteban R, Kwo P, Sulkowski MS, Afdhal N, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ; for the IDEAL investigators. J Viral Hepat. 2012 May;19(5):332-340. doi: 10.1111/j.1365-2893.2011.01553.x. Epub 2012 Feb 22.


  1207. Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma
    Huang T, Wang J, Cai YD, Yu H, Chou KC. PLoS One. 2012;7(4):e34460. Epub 2012 Apr 6.


  1208. End-stage renal disease and African American race are independent predictors of mild liver fibrosis in patients with chronic hepatitis C infection
    Aslinia FM, Wasan SK, Mindikoglu AL, Adeyemo OA, Philosophe B, Drachenberg C, Howell CD. J Viral Hepat. 2012 May;19(5):371-6. doi: 10.1111/j.1365-2893.2011.01565.x. Epub 2012 Jan 16.


  1209. Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients
    Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, Koike K. World J Gastroenterol. 2012 Mar 28;18(12):1385-90.


  1210. The high comorbidity burden of the hepatitis C virus infected population in the United States
    Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. BMC Infect Dis. 2012 Apr 11;12(1):86. [Epub ahead of print]


  1211. Hepatitis C virus and the brain
    Fletcher NF, McKeating JA. J Viral Hepat. 2012 May;19(5):301-6. doi: 10.1111/j.1365-2893.2012.01591.x.


  1212. The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan
    Russell M, Pauly MP, Moore CD, Chia C, Dorrell J, Cunanan RJ, Witt G, Martin S. Hepatology. 2012 Apr 5. doi: 10.1002/hep.25755. [Epub ahead of print]


  1213. Hepatitis C Treatment Highlights from AASLD 2011
    Cooper C. Clin Infect Dis. 2012 Apr 4. [Epub ahead of print]


  1214. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C
    Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM. Can J Gastroenterol. 2012 Apr;26(4):205-10.


  1215. Recurrent hepatitis C after liver transplantation
    Sheiner P, Rochon C. Mt Sinai J Med. 2012 Mar;79(2):190-8. doi: 10.1002/msj.21300.


  1216. Recurrent diseases following liver transplantation: current concepts
    Petrovic LM. Curr Opin Organ Transplant. 2012 Apr 11. [Epub ahead of print]


  1217. Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan
    Marubashi S, Umeshita K, Asahara T, Fujiwara K, Haga H, Hashimoto T, Hatakeyama K, Ichida T, Kanematsu T, Kitajima M, Kiyosawa K, Makuuchi M, Miyagawa S, Satomi S, Soejima Y, Takada Y, Tanaka N, Teraoka S, Monden M. Clin Transplant. 2012 Apr 16. doi: 10.1111/j.1399-0012.2012.01627.x. [Epub ahead of print]


  1218. Comparison of hepatitis C virus treatment between incarcerated and community patients
    Rice JP, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, Sawyer J, Striker R, Lucey MR. Hepatology. 2012 Apr 13. doi: 10.1002/hep.25770. [Epub ahead of print]


  1219. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C
    Petta S, Ferraro D, Cammà C, Cabibi D, Di Cristina A, Di Marco V, Di Stefano R, Grimaudo S, Mazzola A, Levrero M, Scazzone C, Craxì A. Antivir Ther. 2012 Apr 13. doi: 10.3851/IMP2100. [Epub ahead of print]


  1220. Immediate versus delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis
    Deuffic-Burban S, Castel H, Wiegand J, Manns MP, Wedemeyer H, Mathurin P, Yazdanpanah Y. J Hepatol. 2012 Apr 17. [Epub ahead of print]


  1221. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in taiwan
    Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. PLoS One. 2012;7(4):e34779. Epub 2012 Apr 10.


  1222. The H63D Mutation of the Hemochromatosis Gene is Associated with Sustained Virological Response in Chronic Hepatitis C Patients Treated with Interferon-Based Therapy: A Meta-Analysis
    Li SH, Zhao H, Ren YY, Liu YZ, Song G, Ding P, Ding YP, Wang GQ. Tohoku J Exp Med. 2012;226(4):293-9.


  1223. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
    Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. J Viral Hepat. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x.


  1224. Prevalence of fibromyalgia among patients with chronic hepatitis C infection: relationship to viral characteristics and quality of life
    Mohammad A, Carey JJ, Storan E, Scarry M, Coughlan RJ, Lee JM. J Clin Gastroenterol. 2012 May;46(5):407-12.


  1225. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
    Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G. PLoS One. 2012;7(4):e34372. Epub 2012 Apr 12.


  1226. Hepatitis C virus cryoglobulinemia and non-hodgkin lymphoma
    Jadali Z. Hepat Mon. 2012 Feb;12(2):85-91. Epub 2012 Feb 29.


  1227. Antiviral treatment for cirrhosis due to hepatitis C: a review
    Somasundaram A, Venkataraman J. Singapore Med J. 2012 Apr;53(4):231-5.


  1228. Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels
    Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Hepat Mon. 2012 Feb;12(2):77-84. Epub 2012 Feb 29.


  1229. National patterns and predictors of liver biopsy use for management of hepatitis C
    Groessl EJ, Liu L, Ho SB, Kanwal F, Gifford AL, Asch SM. J Hepatol. 2012 Apr 17. [Epub ahead of print]


  1230. Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office
    Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. Am J Gastroenterol. 2012 Apr 24. doi: 10.1038/ajg.2012.48. [Epub ahead of print]


  1231. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection
    Clark BT, Garcia-Tsao G, Fraenkel L. Patient Prefer Adherence. 2012;6:285-95. Epub 2012 Apr 4.


  1232. Noninvasive methods to assess liver disease in patients with hepatitis B or C
    Castera L. Gastroenterology. 2012 May;142(6):1293-1302.e4.


  1233. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C
    Neuman MG, Schmilovitz-Weiss H, Hilzenrat N, Bourliere M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA, Cohen L. Int J Hepatol. 2012;2012:231210. Epub 2012 Feb 22.


  1234. Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients
    Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, Murata K, Masaki N, Nomura H, Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S. Hepatol Res. 2012 Mar 29. doi: 10.1111/j.1872-034X.2012.01013.x. [Epub ahead of print]


  1235. Development of new IL28B genotyping method using Invader Plus assay
    Kani S, Tanaka Y, Matsuura K, Watanabe T, Yatsuhashi H, Orito E, Inose K, Motojuku N, Wakimoto Y, Mizokami M. Microbiol Immunol. 2012 May;56(5):318-23. doi: 10.1111/j.1348-0421.2012.00439.x.


  1236. Fish to meat intake ratio and cooking oils are associated with hepatitis C virus carriers with persistently normal alanine aminotransferase levels
    Otsuka M, Uchida Y, Kawaguchi T, Taniguchi E, Kawaguchi A, Kitani S, Itou M, Oriishi T, Kakuma T, Tanaka S, Yagi M, Sata M. Hepatol Res. 2012 Mar 29. doi: 10.1111/j.1872-034X.2012.01014.x. [Epub ahead of print]


  1237. Epidemiology of viral hepatitis and hepatocellular carcinoma
    El-Serag HB. Gastroenterology. 2012 May;142(6):1264-1273.e1.


  1238. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
    Welsch C, Jesudian A, Zeuzem S, Jacobson I. Gut. 2012 May;61 Suppl 1:i36-i46.


  1239. Management of non-infectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey
    Terrier B, Krastinova E, Marie I, Launay D, Lacraz A, Belenotti P, de Saint-Martin L, Quemeneur T, Huart A, Bonnet F, Le Guenno G, Kahn JE, Hinschberger O, Rullier P, Diot E, Lazaro E, Bridoux F, Zénone T, Carrat F, Hermine O, Léger JM, Mariette X, Senet P, Plaisier E, Cacoub P. Blood. 2012 Apr 3. [Epub ahead of print]


  1240. HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions
    Cox MC, Aloe-Spiriti MA, Cavalieri E, Alma E, Gigante E, Begini P, Rebecchini C, Delle Fave G, Marignani M. World J Gastrointest Oncol. 2012 Mar 15;4(3):46-53.


  1241. Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C - a randomized phase 2 study
    Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW; for the MK-7009 Protocol 007 Study Group*.Hepatology. 2012 Apr 2. doi: 10.1002/hep.25743. [Epub ahead of print]


  1242. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy
    Giannini EG, Marenco S, Fazio V, Pieri G, Savarino V, Picciotto A. Liver Int. 2012 Apr 4. doi: 10.1111/j.1478-3231.2012.02798.x. [Epub ahead of print]


  1243. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C
    Brennan BJ, Morcos PN, Wang K, Blotner SD, Morrison R, Hagedorn CH, Marbury TC, Sulkowski M, Grippo JF. Aliment Pharmacol Ther. 2012 Apr 3. doi: 10.1111/j.1365-2036.2012.05079.x. [Epub ahead of print]


  1244. Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes
    Oliveira LP, Jesus RP, Boulhosa RS, Mendes CM, Lyra AC, Lyra LG. Clinics (Sao Paulo). 2012;67(3):219-23.


  1245. Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors
    Reddy MB, Morcos PN, Le Pogam S, Ou Y, Frank K, Lave T, Smith P. Antimicrob Agents Chemother. 2012 Apr 2. [Epub ahead of print]


  1246. Managing Viral Hepatitis C: HCV: New Opportunities, High CostTwo new biologics establish a higher standard of care. Managing these agents, however, will be highly complex
    Cawood J. Biotechnol Healthc. 2011 Fall;8(3):26-8.


  1247. Response-guided peginterferon-alpha-2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads
    Sato K, Hashizume H, Yamazaki Y, Horiguchi N, Kakizaki S, Takagi H, Mori M; the Gunma Liver Study Group. Hepatol Res. 2012 Mar 8. doi: 10.1111/j.1872-034X.2012.00997.x. [Epub ahead of print]


  1248. Coping strategies used by patients infected with hepatitis C virus who are facing medication costs
    Sanyal C, Ingram EL, Sketris IS, Peltekian KM, Kirkland S. Can J Hosp Pharm. 2011 Mar;64(2):131-40.


  1249. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies
    Saxena V, Terrault N. Curr Opin Organ Transplant. 2012 Apr 3. [Epub ahead of print]


  1250. Hepatitis C therapy update
    Casey LC, Lee WM. Curr Opin Gastroenterol. 2012 May;28(3):188-92.


  1251. Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation
    Sugawara Y, Tamura S, Yamashiki N, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N. Transplant Proc. 2012 Apr;44(3):791-3.


  1252. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
    Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL. Clin Exp Gastroenterol. 2012;5:11-21. Epub 2012 Feb 14.


  1253. Follow-up of mild alanine aminotransferase elevation identifies hidden hepatitis C in primary care
    Helsper C, van Essen G, Frijling BD, de Wit NJ. Br J Gen Pract. 2012 Mar;62(596):212-6.


  1254. Detection of hepatitis C virus RNA in dried blood spots
    Bennett S, Gunson RN, McAllister GE, Hutchinson SJ, Goldberg DJ, Cameron SO, Carman WF. J Clin Virol. 2012 Mar 12. [Epub ahead of print]


  1255. The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases
    Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Colletta C, Vandelli C, Cmet S, Ceriani E, Smirne C, Toniutto P, Pirisi M. J Med Virol. 2012 May;84(5):747-55. doi: 10.1002/jmv.23259.


  1256. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials
    Lee LY, Tong CY, Wong T, Wilkinson M. Int J Clin Pract. 2012 Apr;66(4):342-55. doi: 10.1111/j.1742-1241.2012.02895.x.


  1257. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
    Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, Mills EJ. Ther Clin Risk Manag. 2012;8:105-30. Epub 2012 Mar 9.


  1258. Economic Burden of Hepatitis C-Associated Diseases: Europe, Asia Pacific, and The Americas
    El Khoury AC, Wallace C, Klimack WK, Razavi H. J Med Econ. 2012 Mar 30. [Epub ahead of print]


  1259. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    Cammà C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, Colombo GL, Di Marco V, Gasbarrini A, Craxì A; on behalf of the WEF Study Group.. Hepatology. 2012 Mar 27. doi: 10.1002/hep.25734. [Epub ahead of print]


  1260. IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation
    Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K. J Gastroenterol Hepatol. 2012 Mar 20. doi: 10.1111/j.1440-1746.2012.07129.x. [Epub ahead of print]


  1261. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus
    Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Miyakawa Y, Kumada H. J Gastroenterol. 2012 Mar 23. [Epub ahead of print]


  1262. Association of hepatitis C virus with insulin resistance: evidences from animal studies and clinical studies
    Badar S, Khubaib B, Idrees M, Hussain A, Awan Z, Butt S, Afzal S, Akram M, Fatima Z, Aftab M, Saleem S, Munir S, Rauff B, Naudhani M, Ali L, Ali M, Rehman I. Hepat Mon. 2012 Jan;12(1):11-5. Epub 2012 Jan 20.


  1263. New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation
    Barritt AS 4th, Darling JM, Hayashi PH. Curr Hepat Rep. 2011 Sep;10(3):179-185.


  1264. Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus
    Verna EC, Valadao R, Farrand E, Pichardo EM, Lai JC, Terrault NA, Brown RS Jr. Liver Transpl. 2012 Apr;18(4):461-7. doi: 10.1002/lt.23376.


  1265. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C
    Perry CM. Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000.


  1266. Hepatic Methionine-enkephalin may interfere with response to antiviral therapy in chronic hepatitis C
    Floreani A, Antoniazzi S, Mescoli C, Bergasa NV. Eur J Gastroenterol Hepatol. 2012 Apr;24(4):427-30.


  1267. The interaction of metabolic factors with HCV infection: does it matter?
    Bugianesi E, Salamone F, Negro F. J Hepatol. 2012;56 Suppl 1:S56-65.


  1268. Early viral load and recipient IL28B rs12979860 genotype are predictors for progression of hepatitis C after liver transplantation
    Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, Mikuz G, Pratschke J, Margreiter R, Vogel W. Liver Transpl. 2012 Feb 2. doi: 10.1002/lt.23402. [Epub ahead of print]


  1269. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients
    Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. Ann Hepatol. 2012 Mar;11(2):179-85.


  1270. Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity
    Welker MW, Reichert D, Susser S, Sarrazin C, Martinez Y, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. PLoS One. 2012;7(2):e30796. Epub 2012 Feb 15.


  1271. Natural History, Risk Factors And Management Of Hepatitis C After Liver Transplantation
    Mukherjee S. Inflamm Allergy Drug Targets. 2012 Feb 2. [Epub ahead of print]


  1272. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients
    Giannelli V, Giusto M, Farcomeni A, Ponziani FR, Pompili M, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, De Martin E, Miglioresi L, Di Paolo D, Fagiuoli S, Merli M; AISF RECOLT-C group study. Transpl Int. 2012 Feb 21. doi: 10.1111/j.1432-2277.2012.01440.x. [Epub ahead of print]


  1273. The role of humoral innate immunity in hepatitis C virus infection
    Tarr AW, Urbanowicz RA, Ball JK. Viruses. 2012 Jan;4(1):1-27. Epub 2012 Jan 5.


  1274. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients
    Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Hayes CN, Tanaka S, Arihiro K, Chayama K. J Gastroenterol. 2012 Feb 18. [Epub ahead of print]


  1275. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk
    Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, Christiansen CL, Weinbaum CM, Southern WN. Dig Liver Dis. 2012 Feb 17. [Epub ahead of print]


  1276. Differential Antigen Specificity of Hepatitis C Virus-Specific Interleukin 17- and Interferon ?-Producing CD8+ T Cells During Chronic Infection
    Grafmueller S, Billerbeck E, Blum HE, Neumann-Haefelin C, Thimme R. J Infect Dis. 2012 Feb 20. [Epub ahead of print]


  1277. Consumption of n-3 Fatty Acids and Fish Reduces Risk of Hepatocellular Carcinoma
    Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, Takashi R, Tanaka Y, Mizokami M, Tsugane S; Japan Public Health Center-based Prospective StudyGroup.. Gastroenterology. 2012 Feb 16. [Epub ahead of print]


  1278. Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-? and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients
    de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martínez MA. PLoS One. 2012;7(2):e31016. Epub 2012 Feb 6.


  1279. Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus mediated liver disease post-transplantation
    Diamond DL, Krasnoselsky AL, Burnum KE, Monroe ME, Webb-Robertson BJ, McDermott JE, Yeh MM, Golib Dzib JF, Susnow N, Strom S, Proll SC, Belisle SE, Purdy DE, Rasmussen AL, Walters KA, Jacobs JM, Gritsenko MA, Camp DG, Bhattacharya R, Perkins JD, Carithers RL Jr, Liou IW, Larson AM, Benecke A, Waters KM, Smith RD, Katze MG. Hepatology. 2012 Feb 13. doi: 10.1002/hep.25649. [Epub ahead of print]


  1280. Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data
    Tomkins SE, Elford J, Nichols T, Aston J, Cliffe SJ, Roy K, Grime P, Ncube FM. J Viral Hepat. 2012 Mar;19(3):199-204. doi: 10.1111/j.1365-2893.2011.01543.x. Epub 2011 Oct 19.


  1281. Outcomes of liver transplantation in HCV-HIV coinfected recipients
    Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, Ragni MV, Barin B, Simon D, Olthoff KM, Johnson L, Stosor V, Jayaweera D, Fung J, Sherman KE, Subramanian A, Michael Millis J, Slakey D, Berg CL, Carlson L, Ferrell L, Stablein DM, Odim J, Fox L, Stock PG; for the HIV-TR Investigators.. Liver Transpl. 2012 Feb 12. doi: 10.1002/lt.23411. [Epub ahead of print]


  1282. Causes of Thrombocytopenia in Chronic Hepatitis C Viral Infection
    Osada M, Kaneko M, Sakamoto M, Endoh M, Takigawa K, Suzuki-Inoue K, Inoue O, Satoh K, Enomoto N, Yatomi Y, Ozaki Y. Clin Appl Thromb Hemost. 2012 Feb 12. [Epub ahead of print]


  1283. Telaprevir for the treatment of hepatitis C
    Forestier N, Zeuzem S. Expert Opin Pharmacother. 2012 Mar;13(4):593-606. Epub 2012 Feb 15.


  1284. Pegylated interferon-associated retinopathy is frequent in HCV patients with hypertension and justifies ophthalmologic screening
    Vujosevic S, Tempesta D, Noventa F, Midena E, Sebastiani G. Hepatology. 2012 Feb 13. doi: 10.1002/hep.25654. [Epub ahead of print]


  1285. Review and management of drug interactions with boceprevir and telaprevir
    Kiser JJ, Burton JR, Anderson PL, Everson GT. Hepatology. 2012 Feb 13. doi: 10.1002/hep.25653. [Epub ahead of print]


  1286. Pegylated interferon-? induced hypoferremia is associated with the immediate response to treatment in hepatitis C
    Ryan J, Altamura S, Devitt E, Mullins S, Lawless M, Muckenthaler M, Crowe J. Hepatology. 2012 Feb 15. doi: 10.1002/hep.25666. [Epub ahead of print]


  1287. The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings
    David B. Rein, PhD; Bryce D. Smith, PhD; John S. Wittenborn, BS; Sarah B. Lesesne, BS; Laura D. Wagner, MPH; Douglas W. Roblin, PhD;Nita Patel, DrPH; John W. Ward, MD; and Cindy M. Weinbaum, MD, MPH. Ann Intern Med. 2012;156:263-270.


  1288. New Protease Inhibitors for the Treatment of Chronic Hepatitis C A Cost-Effectiveness Analysis
    Shan Liu, SM; Lauren E. Cipriano, BSc, BA; Mark Holodniy, MD; Douglas K. Owens, MD, MS; and Jeremy D. Goldhaber-Fiebert, PhD. Ann Intern Med. 2012;156:279-290.


  1289. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007
    Kathleen N. Ly, MPH; Jian Xing, PhD; R. Monina Klevens, DDS, MPH; Ruth B. Jiles, PhD, MPH; John W. Ward, MD; andScott D. Holmberg, MD, MPH. Ann Intern Med. 2012;156:271-278.


  1290. Hepatitis C: The End of the Beginning and Possibly the Beginning of the End.
    Alter HJ, Liang TJ. Annals of Internal Medicine 2012, Feb21. Volume 156 • Number 4 317


  1291. Economic burden of hepatitis C-associated diseases in the United States
    El Khoury AC, Klimack WK, Wallace C, Razavi H. J Viral Hepat. 2012 Mar;19(3):153-60. doi: 10.1111/j.1365-2893.2011.01563.x. Epub 2011 Dec 18.


  1292. Depressive and anxiety disorders in chronic hepatitis C patients: Reliability and validity of the Patient Health Questionnaire
    Navinés R, Castellví P, Moreno-España J, Gimenez D, Udina M, Cañizares S, Diez-Quevedo C, Valdés M, Solà R, Martín-Santos R. J Affect Disord. 2012 Feb 10. [Epub ahead of print]


  1293. Update on alisporivir in treatment of viral hepatitis C
    Flisiak R, Jaroszewicz J, Flisiak I, Lapi?ski T. Expert Opin Investig Drugs. 2012 Mar;21(3):375-82. Epub 2012 Feb 8.


  1294. Serum IL-33 Levels Are Associated with Liver Damage in Patients with Chronic Hepatitis C
    Wang J, Zhao P, Guo H, Sun X, Jiang Z, Xu L, Feng J, Niu J, Jiang Y. Mediators Inflamm. 2012;2012:819636. Epub 2012 Jan 24.


  1295. The Impact of IL28B Genotype on the Gene Expression Profile of Patients with Chronic Hepatitis C Treated with Pegylated Interferon Alpha and Ribavirin
    Younossi ZM, Birerdinc A, Estep M, Stepanova M, Afendy A, Baranova A. J Transl Med. 2012 Feb 7;10(1):25. [Epub ahead of print]


  1296. A Predictive Model of Treatment Outcome in Patients with Chronic HCV Infection Using IL-28B and PD-1 Genotyping
    Ramón VC, Antonio LV, Rebeca AA, Antonio MG, Santiago M, Jesús P, Rosario LR, Paloma SC, Luis R, Rosa PL, Ramón PA, Carlos LL. J Hepatol. 2012 Feb 6. [Epub ahead of print]


  1297. Continuous interferon-?2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
    Roomer R, Bergmann JF, Boonstra A, Hansen BE, Haagmans BL, Kwadijk-de Gijsel S, van Vuuren AJ, de Knegt RJ, Janssen HL. Antivir Ther. 2011 Dec 13. doi: 10.3851/IMP2016. [Epub ahead of print]


  1298. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis
    Aizawa N, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T, Moriwaki E, Shimomura S, Iijima H, Nakamura H, Nishiguchi S. World J Hepatol. 2012 Jan 27;4(1):11-7.


  1299. LD_HCV_TMC435
    Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G. J Hepatol. 2012 Feb 9. [Epub ahead of print]


  1300. Antiviral strategies in hepatitis C virus infection
    Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. J Hepatol. 2012;56 Suppl:S88-S100.


  1301. Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2
    Yamaguchi Y, Tamori A, Tanaka Y, Iwai S, Kobayashi S, Fujii H, Morikawa H, Hagihara A, Enomoto M, Kawada N. Hepatol Res. 2012 Feb 9. doi: 10.1111/j.1872-034X.2011.00956.x. [Epub ahead of print]


  1302. A Phase 1, Randomized, Placebo-Controlled, Three-Day, Dose-Ranging Study of GS-5885, an NS5A Inhibitor, in Patients with Genotype 1 Hepatitis C
    Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. J Hepatol. 2012 Feb 4. [Epub ahead of print]


  1303. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. J Hepatol. 2012 Feb 4. [Epub ahead of print]


  1304. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection
    Cholongitas E, Theocharidou E, Goulis J, Tsochatzis E, Akriviadis E, Burroughs K. Aliment Pharmacol Ther. 2012 Mar;35(6):634-46. doi: 10.1111/j.1365-2036.2012.05000.x. Epub 2012 Feb 8.


  1305. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients
    Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Frei P, Seifert B, Ferrari HA, von Eckardstein A, Müllhaupt B, Geier A; the Swiss Hepatitis C Cohort Study Group. Antivir Ther. 2011 Dec 14. doi: 10.3851/IMP2018. [Epub ahead of print]


  1306. GB virus C: the good boy virus?
    Bhattarai N, Stapleton JT. Trends Microbiol. 2012 Feb 8. [Epub ahead of print]


  1307. Gambarin-Gelwan M, Jacobson IM. Curr Gastroenterol Rep. 2011 Dec 10. [Epub ahead of print]
    Source Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, 1305 York Ave, 4th floor, New York, NY, 10021, USA, mag2046@med.cornell.edu.


  1308. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients
    Butt AA, Kanwal F. Clin Infect Dis. 2012 Jan;54(1):96-104. Epub 2011 Dec 7.


  1309. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
    Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Clin Infect Dis. 2011 Dec 14. [Epub ahead of print]


  1310. Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation
    Maharshak N, Halfon P, Deutsch V, Peretz H, Berliner S, Fishman S, Zelber-Sagi S, Rozovski U, Leshno M, Oren R. World J Gastroenterol. 2011 Dec 7;17(45):5007-13.


  1311. Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients
    Miyamura T, Kanda T, Nakamoto S, Wu S, Fujiwara K, Imazeki F, Yokosuka O. PLoS One. 2011;6(12):e28617. Epub 2011 Dec 12.


  1312. Neutralizing antibody response to hepatitis C virus
    Wang Y, Keck ZY, Foung SK. Viruses. 2011 Nov;3(11):2127-45. Epub 2011 Nov 2.


  1313. Current Perspective of HCV NS5B Inhibitors: A Review
    Patil VM, Gupta SP, Samanta S, Masand N. Curr Med Chem. 2011 Dec 1;18(36):5564-97.


  1314. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
    Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Clin Infect Dis. 2011 Dec 14. [Epub ahead of print]


  1315. HCV and HCC: Clinical Update and a Review of HCC-Associated Viral Mutations in the Core Gene
    Ahmad J, Eng FJ, Branch AD. Semin Liver Dis. 2011 Nov;31(4):347-55. Epub 2011 Dec 21.


  1316. Transmission of hepatitis C virus through transplanted organs and tissue - kentucky and massachusetts, 2011
    Centers for Disease Control and Prevention (CDC).AbstractMMWR Morb Mortal Wkly Rep. 2011 Dec 23;60:1697-700.


  1317. Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B
    Dahari H, Guedj J, Perelson AS, Layden TJ. Curr Hepat Rep. 2011 Jul 2;10(3):214-227.


  1318. Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference?
    Hope V, Parry JV, Marongui A, Ncube F. J Viral Hepat. 2012 Jan;19(1):55-64. doi: 10.1111/j.1365-2893.2010.01415.x. Epub 2011 Jan 7.


  1319. The dependence of viral RNA replication on co-opted host factors
    Nagy PD, Pogany J. Nat Rev Microbiol. 2011 Dec 19. doi: 10.1038/nrmicro2692. [Epub ahead of print]


  1320. Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis C following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype
    Motomura T, Koga E, Taketomi A, Fukuhara T, Mano Y, Muto J, Konishi H, Toshima T, Uchiyama H, Yoshizumi T, Shirabe K, Maehara Y. Hepatol Res. 2011 Dec 19. doi: 10.1111/j.1872-034X.2011.00927.x. [Epub ahead of print]


  1321. A summary of the 18th international symposium on hepatitis C virus and related viruses
    Polyak SJ, Morishima C, Scott JD, Cox A, de Araújo ES, Higgs MR, Loo YM, Golden-Mason L, Lindenbach BD, Baumert TF, Randall G, Gale M Jr. Gastroenterology. 2012 Jan;142(1):e1-5.


  1322. Telaprevir: An oral protease inhibitor for hepatitis C virus infection
    Kim JJ, Culley CM, Mohammad RA. Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33.


  1323. HCV routes of transmission: what goes around comes around
    Alter MJ. Semin Liver Dis. 2011 Nov;31(4):340-6. Epub 2011 Dec 21.


  1324. IL28B polymorphisms influence stage of the liver fibrosis and spontaneousor interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection
    Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, Renda MC, Pitrolo L, Lo Pinto MC, Rizzo M, Fiorenza F, Gerardi C, Grimaudo S, Di Cristina A, Levrero M, Craxi' A. Haematologica. 2011 Dec 16. [Epub ahead of print]


  1325. Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin Therapy
    Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, Kudo M. Digestion. 2011;84 Suppl 1:56-61. Epub 2011 Dec 2.


  1326. Interleukin28B and Inosine Triphosphatase Help to Personalize Hepatitis C Treatment
    Tanaka Y. Digestion. 2011;84 Suppl 1:50-5. Epub 2011 Dec 2.


  1327. What is killing people with hepatitis C virus infection?
    Grebely J, Dore GJ. Semin Liver Dis. 2011 Nov;31(4):331-9. Epub 2011 Dec 21.


  1328. Hepatitis C virus infection and genetic susceptibility to therapy
    Sibbing B, Nattermann J. J Gastrointestin Liver Dis. 2011 Dec;20(4):397-406.


  1329. Determinants of Serum Alpha-Fetoprotein Levels in Hepatitis C Infected Patients
    Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Clin Gastroenterol Hepatol. 2011 Dec 6. [Epub ahead of print]


  1330. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection
    Nehra V, Rizza SA, Talwani R, Temesgen Z. Drugs Today (Barc). 2011 Nov;47(11):829-37.


  1331. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients
    Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. PLoS One. 2011;6(12):e26783. Epub 2011 Dec 2.


  1332. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C-associated cryoglobulinemic vasculitis
    Sneller MC, Hu Z, Langford CA. Arthritis Rheum. 2011 Dec 6. doi: 10.1002/art.34322. [Epub ahead of print]


  1333. Sperm DNA damage in patients with chronic viral C hepatitis
    La Vignera S, Condorelli RA, Vicari E, D'Agata R, Calogero AE. Eur J Intern Med. 2012 Jan;23(1):e19-24. Epub 2011 Sep 3.


  1334. Telaprevir for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther.
    Muir AJ. Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14.


  1335. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C
    Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS; for the HALT-C Trial Group. Liver Int. 2011 Nov 22. doi: 10.1111/j.1478-3231.2011.02686.x. [Epub ahead of print]


  1336. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros PJ, Rodríguez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G. Ann Hepatol. 2012 Jan;11(1):15-31.


  1337. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus
    Patel K, Friedrich-Rust M, Lurie Y, Grigorescu M, Stanciu C, Lee CM, Schiff ER, Häussinger D, Manns MP, Gerken G, Colle I, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG, Zeuzem S. World J Gastroenterol. 2011 Nov 7;17(41):4581-9.


  1338. Specific Detection of Naturally Occurring Telaprevir and Boceprevir (Protease Inhibitors) HCV Resistant Mutants among Treatment Naive Infected Individuals
    Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, Cruz-Rivera MY, Rivera-Osorio P, Vazquez-Pichardo M, Carpio-Pedroza JC, Ruíz-Pacheco JA, Cazares F, Vaughan G. J Clin Microbiol. 2011 Nov 23. [Epub ahead of print]


  1339. Clinical significance of occult hepatitis B virus infection in chronic hepatitis C patients
    Jang JY, Jeong SW, Cheon SR, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Kim HS, Jin SY, Kim YS, Kim BS. Korean J Hepatol. 2011 Sep;17(3):206-12. doi: 10.3350/kjhep.2011.17.3.206.


  1340. Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era
    Poordad F, Chee GM. Curr Gastroenterol Rep. 2011 Nov 22. [Epub ahead of print]


  1341. Female Sex and IL28B, a Synergism for Spontaneous Viral Clearance in Hepatitis C Virus (HCV) Seroconverters from a Community-Based Cohort
    van den Berg CH, Grady BP, Schinkel J, van de Laar T, Molenkamp R, van Houdt R, Coutinho RA, van Baarle D, Prins M. PLoS One. 2011;6(11):e27555. Epub 2011 Nov 15.


  1342. Association between Chronic Viral Hepatitis Infection and Breast Cancer Risk: a Nationwide Population-based Case-control Study
    Su FH, Chang SN, Chen PC, Sung FC, Su CT, Yeh CC. BMC Cancer. 2011 Nov 24;11(1):495. [Epub ahead of print]


  1343. Telaprevir for the treatment of chronic hepatitis C infection
    Muir AJ. Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14.


  1344. Absenteeism and productivity among employees being treated for hepatitis C
    Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH. Am J Manag Care. 2011 Oct;17(10):657-64.


  1345. The natural history of hepatitis C virus infection acquired during childhood
    Robinson JL, Doucette K. Liver Int. 2011 Sep 11. doi: 10.1111/j.1478-3231.2011.02633.x. [Epub ahead of print]


  1346. Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade
    Lai M, Afdhal NH. Am J Gastroenterol. 2011 Dec;106(12):2121-2. doi: 10.1038/ajg.2011.343.


  1347. Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and ?-fetoprotein levels
    Kajiwara E, Ooho A, Yamashita N. Hepatol Res. 2011 Dec 5. doi: 10.1111/j.1872-034X.2011.00916.x. [Epub ahead of print]


  1348. Hepatitis C Virus Infects the Endothelial Cells of the Blood-Brain Barrier
    Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe IA, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, McKeating JA. Gastroenterology. 2011 Nov 30. [Epub ahead of print]


  1349. Ultrasound-based Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients for the detection of hepatic fibrosis in patients with recurrent HCV after liver transplantation: Systematic review and meta-analysis
    Adebajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Liver Transpl. 2011 Dec 5. doi: 10.1002/lt.22460. [Epub ahead of print]


  1350. A seven gene signature of the recipient predicts progression of fibrosis after liver transplantation for hepatitis C infection
    do O NT, Eurich D, Schmitz P, Schmeding M, Heidenhain C, Bahra M, Trautwein C, Neuhaus P, Neumann UP, Wasmuth HE. Liver Transpl. 2011 Dec 5. doi: 10.1002/lt.22475. [Epub ahead of print]


  1351. Very Low Viral Load (VLVL) Relapse Following Treatment of Naïve Patients with Chronic Hepatitis C
    Hoefs JC, Aulakh VS, Ilagan BJ. Dig Dis Sci. 2011 Dec 4. [Epub ahead of print]


  1352. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus
    Tungol A, Rademacher K, Schafer JA. J Manag Care Pharm. 2011 Nov;17(9):685-94.


  1353. Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection
    Osaki R, Nishimura T, Shioya M, Takeuchi T, Okumura Y, Nakahara T, Bamba S, Nakajo S, Fujiyama Y, Andoh A. Mol Med Report. 2011 Nov 1. doi: 10.3892/mmr.2011.655. [Epub ahead of print]


  1354. Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3
    Lee SS, Sherman M, Ramji A, Greenbloom S, Elkashab M, Pluta H, Hilzenrat N, Balshaw R, Usaty C, Myers RP. Aliment Pharmacol Ther. 2011 Nov 2. doi: 10.1111/j.1365-2036.2011.04911.x. [Epub ahead of print]


  1355. Causes and evaluation of mildly elevated liver transaminase levels
    Oh RC, Hustead TR. Am Fam Physician. 2011 Nov 1;84(9):1003-8.


  1356. The role of neutralising antibodies in hepatitis C virus infection
    Edwards V, Tarr AW, Urbanowicz R, Ball J. J Gen Virol. 2011 Nov 2. [Epub ahead of print]


  1357. Novel Approach for Quantification of Hepatitis C Virus in Liver Cirrhosis Using Real-Time Reverse Transcriptase PCR
    Maudar KK, Gandhi P, Mishra PK, Varshney S, Punde R, Bhargav A. J Gastrointest Surg. 2011 Nov 3. [Epub ahead of print]


  1358. Boceprevir
    Rizza SA, Talwani R, Nehra V, Temesgen Z. Drugs Today (Barc). 2011 Oct;47(10):743-51.


  1359. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
    Reddy KR, Belle SH, Fried MW, Afdhal NH, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM. Clin Trials. 2011 Nov 4. [Epub ahead of print]


  1360. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B
    Li S, Hu P, Zhang QQ, Liu YH, Hu HD, Zhang DZ, Ren H. Hepat Mon. 2011 Mar 1;11(3):163-172.


  1361. Recombination in hepatitis C virus
    González-Candelas F, López-Labrador FX, Bracho MA. Viruses. 2011 Oct;3(10):2006-24. Epub 2011 Oct 24.


  1362. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy
    Hung CH, Chen CH, Lu SN, Wang JH, Hu TH, Huang CM, Tsai MC, Lee CM. Antiviral Res. 2011 Oct 28. [Epub ahead of print]


  1363. Implications of rapid virological response in hepatitis C therapy in the US veteran population
    Hwang EW, Thomas IC, Cheung R, Backus LI. Aliment Pharmacol Ther. 2011 Nov 7. doi: 10.1111/j.1365-2036.2011.04903.x. [Epub ahead of print]


  1364. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
    Kwong AD, Kauffman RS, Hurter P, Mueller P. Nat Biotechnol. 2011 Nov 8;29(11):993-1003. doi: 10.1038/nbt.2020.


  1365. Hepatitis C core Ag and its clinical applicability: Potential advantages and disadvantages for diagnosis and follow-up?
    Hosseini-Moghaddam S, Iran-Pour E, Rotstein C, Husain S, Lilly L, Renner E, Mazzulli T. Rev Med Virol. 2011 Nov 24. doi: 10.1002/rmv.717. [Epub ahead of print]


  1366. Economic model of a birth cohort screening program for hepatitis C virus
    McGarry LJ, Pawar VS, Parekh HH, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC. Hepatology. 2011 Dec 2. doi: 10.1002/hep.25510. [Epub ahead of print]


  1367. Role of LDL receptor in the hepatitis c virus life cycle
    Albecka A, Belouzard S, de Beeck AO, Descamps V, Goueslain L, Bertrand-Michel J, Tercé F, Duverlie G, Rouillé Y, Dubuisson J. Hepatology. 2011 Nov 26. doi: 10.1002/hep.25501. [Epub ahead of print]


  1368. Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy
    Lötsch J, Hofmann WP, Schlecker C, Zeuzem S, Geisslinger G, Ultsch A, Doehring A. Pharmacogenomics. 2011 Dec;12(12):1729-40.


  1369. Association between the epidermal growth factor rs4444903 G/G genotype and advanced fibrosis at a young age in chronic hepatitis C
    Falleti E, Cmet S, Fabris C, Bitetto D, Cussigh A, Fornasiere E, Bignulin E, Feruglio C, Mosanghini E, Fontanini E, Pirisi M, Toniutto P. Cytokine. 2011 Nov 26. [Epub ahead of print]


  1370. Hepatitis C and non-Hodgkin lymphoma: The clinical perspective
    Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatology. 2011 Nov 26. doi: 10.1002/hep.25499. [Epub ahead of print]


  1371. Diabetes Mellitus Following Liver Transplantation in Patients With Hepatitis C Virus: Risks and Consequences
    Gane EJ. Am J Transplant. 2011 Nov 28. doi: 10.1111/j.1600-6143.2011.03854.x. [Epub ahead of print]


  1372. Toward the Establishment of a Prediction System for the Personalized Treatment of Chronic Hepatitis C
    Ochi H, Hayes CN, Abe H, Hayashida Y, Uchiyama T, Kamatani N, Nakamura Y, Chayama K. J Infect Dis. 2011 Nov 28. [Epub ahead of print]


  1373. Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study
    Harris HE, Costella A, Amirthalingam G, Alexander G, Ramsay ME, Andrews N; the UK HCV National Register Collaborators. Epidemiol Infect. 2011 Nov 29:1-8. [Epub ahead of print]


  1374. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy
    Farinati F, Giacomin A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Eur J Gastroenterol Hepatol. 2011 Nov 18. [Epub ahead of print]


  1375. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study
    Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T. J Gastroenterol. 2011 Nov 23. [Epub ahead of print]


  1376. 65-gene-based risk score classifier predicts overall survival in hepatocellular carcinoma
    Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24813. [Epub ahead of print]


  1377. Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?
    Berry K, Ioannou GN. Am J Transplant. 2011 Nov 28. doi: 10.1111/j.1600-6143.2011.03853.x. [Epub ahead of print]


  1378. Subtle Hepatocellular Carcinoma: A Persisting Role for Alpha-Fetoprotein Monitoring in High-Risk Patients with Cirrhosis
    Schlansky B, Dobos N, Zaman A. Case Rep Gastroenterol. 2011 Sep;5(3):565-568. Epub 2011 Oct 1.


  1379. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation
    He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, Yang P, Wang BL, Zhang BH, Zhang JY. BMC Cancer. 2011 Nov 22;11(1):492. [Epub ahead of print]


  1380. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development
    Hu L, Zhai X, Liu J, Chu M, Pan S, Jiang J, Zhang Y, Wang H, Chen J, Shen H, Hu Z. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24799. [Epub ahead of print]


  1381. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region
    Kawaoka T, Aikata H, Miyaki D, Murakami E, Azakami T, Takaki S, Nagaoki Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. Hepatol Res. 2011 Nov;41(11):1126-31. doi: 10.1111/j.1872-034X.2011.00853.x.


  1382. Genetic Variation of the IL-28B Promoter Affecting Gene Expression
    Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. PLoS One. 2011;6(10):e26620. Epub 2011 Oct 25.


  1383. Serum HCV RNA level is not associated with insulin resistance and metabolic syndrome in chronic hepatitis C patients with genotype 1 or 2 infection
    Huang HC, Chuang CS, Hsieh YY, Chang TS, Wei KL, Shen CH, Wu CS, Tung SY. Chang Gung Med J. 2011 Sep;34(5):487-95.


  1384. Management of recurrent hepatitis C infection after liver transplantation
    Limaye AR, Firpi RJ. Clin Liver Dis. 2011 Nov;15(4):845-58.


  1385. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C
    Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Aliment Pharmacol Ther. 2011 Oct 28. doi: 10.1111/j.1365-2036.2011.04897.x. [Epub ahead of print]


  1386. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response
    Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N. Hepatology. 2011 Nov;54(5):1538-46. doi: 10.1002/hep.24549.


  1387. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care
    Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, Dillon JF, Forrest E, Fraser A, Gillespie R, Goldberg DJ, Kennedy N, McDonald S, McLeod A, Mills PR, Morris J, Hayes P; on behalf of the Hepatitis C Clinical Database Monitoring Committee.. Hepatology. 2011 Nov;54(5):1547-1558. doi: 10.1002/hep.24561.


  1388. An Italian study on health-related quality of life and fatigue in patients with chronic fatigue syndrome and patients with chronic HCV virus infection: similarities and differences
    Racciatti D, Gorgoretti V, Sepede G, Gambi F, Pizzigallo E. Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3):673-81.


  1389. Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin
    Arends JE, Fransen JH, Hoepelman AI, van Baarle D. Int J Antimicrob Agents. 2011 Oct 3. [Epub ahead of print]


  1390. Chronic viral hepatitis and risk of lymphoid malignancies: A retrospective twelve-year population-based cohort study in Côte d'Or, France
    Proby C, Minello A, Quantin C, Jooste V, Binquet C, Hägi M, Mounier M, Benzenine E, Hillon P, Maynadié M. Dig Liver Dis. 2011 Oct 3. [Epub ahead of print]


  1391. Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C
    Park SH, Kim CH, Kim DJ, Suk KT, Park JH, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Park HY, Kim YB. Clin Biochem. 2011 Sep 28. [Epub ahead of print]


  1392. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy
    Lee C. Arch Pharm Res. 2011 Sep;34(9):1403-7.


  1393. The study of relationship between neutropenia and infection during treatment with peginterferon ? and ribavirin for chronic hepatitis C
    Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. Eur J Gastroenterol Hepatol. 2011 Oct 1. [Epub ahead of print]


  1394. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C
    Golden-Mason L, Bambha KM, Cheng L, Howell CD, Taylor MW, Clark PJ, Afdhal N, Rosen HR; on behalf of the Virahep?C Study Group. Hepatology. 2011 Jul 11. doi: 10.1002/hep.24556. [Epub ahead of print]


  1395. Body piercing and tattoos: a survey on young adults' knowledge of the risks and practices in body art
    Quaranta A, Napoli C, Fasano F, Montagna C, Caggiano G, Montagna MT. BMC Public Health. 2011 Oct 7;11(1):774. [Epub ahead of print]


  1396. High Plasma Interleukin-18 Levels Mark the Acute Phase of Hepatitis C Virus Infection
    Chattergoon MA, Levine JS, Latanich R, Osburn WO, Thomas DL, Cox AL. J Infect Dis. 2011 Oct 7. [Epub ahead of print]


  1397. Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma
    Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura SI, Ohnishi H, Kuwaki K, Toshimori J, Hagihara H, Nouso K, Yamamoto K. Dig Dis Sci. 2011 Oct 12. [Epub ahead of print]


  1398. Retrospective Chart Review to Assess the Relationship Between Depression and Sustained Virological Response From Interferon Treatment for Hepatitis C Virus
    Wackernah RC, Lou M, Park SH. Clin Ther. 2011 Oct 7. [Epub ahead of print]


  1399. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders
    Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24724. [Epub ahead of print]


  1400. Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis
    Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24731. [Epub ahead of print]


  1401. Upper limits of normal for alanine aminotransferase activity in the united states population
    Ruhl E, Everhart JE. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24725. [Epub ahead of print]


  1402. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview
    Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. J Transl Med. 2011 Oct 10;9(1):171. [Epub ahead of print]


  1403. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection
    Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M, Dore GJ, White PA; On behalf of the ATAHC Study Group. Hepatology. 2011 Oct 26. doi: 10.1002/hep.24754. [Epub ahead of print]


  1404. The COBAS(®) TaqMan(®) hepatitis C virus assays: automated systems for accurate and sensitive viral load quantification
    Colucci G, Knobel R. Expert Rev Mol Diagn. 2011 Nov;11(8):793-8.


  1405. Notes from the field: risk factors for hepatitis C virus infections among young adults --- massachusetts, 2010
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Oct 28;60:1457-8.


  1406. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-?2b plus ribavirin
    Ueyama M, Nakagawa M, Sakamoto N, Onozuka I, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Kitazume A, Murakawa M, Nishimura-Sakurai Y, Sekine-Osajima Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M; the Ochanomizu-Liver Conference Study Group. Antivir Ther. 2011;16(7):1081-1091.


  1407. Effects of Anti-Viral Therapy and HCV Clearance on Cerebral Metabolism and Cognition
    Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, Lenkinski R, Afdhal NH. J Hepatol. 2011 Oct 22. [Epub ahead of print]


  1408. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients
    Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, Sakamoto M, Okada SI, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N. Hepatol Int. 2011 Aug 18. [Epub ahead of print]


  1409. Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection
    Wiegand J, Neumann K, Böhm S, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Sarrazin C, Berg T. Clin Infect Dis. 2011 Oct 21. [Epub ahead of print]


  1410. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the HALT-C trial
    Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; The HALT-C Trial Group. Hepatology. 2011 Oct 26. doi: 10.1002/hep.24752. [Epub ahead of print]


  1411. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C
    Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F, Nakayama Y, Kitamura T, Uetake T, Inoue T, Sakamoto M, Okada S, Enomoto N. Hepatol Int. 2011 Aug 17. [Epub ahead of print]


  1412. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma
    Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S. Cancer Chemother Pharmacol. 2011 Oct 28. [Epub ahead of print]


  1413. Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C
    Klibanov OM, Williams SH, Smith LS, Olin JL, Vickery SB. Pharmacotherapy. 2011 Oct;31(10):951-74.


  1414. Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2?weeks after therapy initiation
    Tamai H, Shingaki N, Shiraki T, Tukuda H, Mori Y, Moribata K, Enomoto S, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M. Hepatol Res. 2011 Sep 26. doi: 10.1111/j.1872-034X.2011.00879.x. [Epub ahead of print]


  1415. Conclusion: Evaluation of viral reduction at week 2 after therapy initiation is useful for predicting SVR to low-dose PEG-IFN plus ribavirin therapy.
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2011 Oct;54(4):1127-34. doi: 10.1002/hep.24503. Epub 2011 Aug 19.


  1416. Adding to the toolbox: Receptor tyrosine kinases as potential targets in the treatment of hepatitis C
    Jilg N, Chung RT. J Hepatol. 2011 Jul 22. [Epub ahead of print]


  1417. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E, Zhang Q, Ray AE, Vidaud D, Ripault MP, Boyer N, Bedossa P, Valla D, Vidaud M, Marcellin P. J Hepatol. 2011 Sep 24. [Epub ahead of print]


  1418. Histological Versus Clinical Cirrhosis in Chronic Hepatitis C: Does Race/Ethnicity Really Matter?
    Kohla M, Iwata S, Ea R, Keyhan S, Taylor R, Yu MC, Groshen S, Bonacini M. Dig Dis Sci. 2011 Sep 24. [Epub ahead of print]


  1419. Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C-Related Hepatocellular Carcinoma
    Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Clin Gastroenterol Hepatol. 2011 Aug 4. [Epub ahead of print]


  1420. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD
    Boursier J, Chaigneau J, Roullier V, Lainé F, Sandrini J, Michalak S, Hubert I, Dib N, Oberti F, Bertrais S, Hunault G, Deugnier Y, Rousselet MC, Cavaro-Ménard C, Gallois Y, Aubé C, Calès P; the study group UNAM-METABOL. Eur J Gastroenterol Hepatol. 2011 Sep 7. [Epub ahead of print]


  1421. Host genomics and HCV treatment response
    Clark PJ, Thompson AJ. J Gastroenterol Hepatol. 2011 Sep 14. doi: 10.1111/j.1440-1746.2011.06918.x. [Epub ahead of print]


  1422. The Supplementation of Acetyl-l-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon-? 2b Plus Ribavirin
    The Supplementation of Acetyl-l-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon-? 2b Plus Ribavirin


  1423. Rising burden of Hepatitis C Virus in Hemodialysis Patients
    Khan S, Attaullah S, Ali I, Ayaz S, Naseemullah, Khan SN, Siraj S, Khan J. Virol J. 2011 Sep 13;8(1):438. [Epub ahead of print]


  1424. New therapies for hepatitis C virus infection
    Bacon BR, Khalid O. Mo Med. 2011 Jul-Aug;108(4):255-9.


  1425. Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C
    Cariani E, Critelli R, Rota C, Luongo M, Trenti T, Villa E. J Virol Methods. 2011 Aug 27. [Epub ahead of print]


  1426. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma
    Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. J Viral Hepat. 2011 Oct;18(10):e550-60. doi: 10.1111/j.1365-2893.2011.01468.x. Epub 2011 May 23.


  1427. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response
    Floreani A, Cazzagon N, Boemo DG, Baldovin T, Baldo V, Egoue J, Antoniazzi S, Minola E. Eur J Gastroenterol Hepatol. 2011 Sep 12. [Epub ahead of print]


  1428. A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms
    Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE. Psychosomatics. 2011 Sep-Oct;52(5):433-40.


  1429. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
    Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M. J Viral Hepat. 2011 Oct;18(10):e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.


  1430. Use of HOMA-IR in hepatitis C
    Eslam M, Kawaguchi T, Del Campo JA, Sata M, Abo-Elneen Khattab M, Romero-Gomez M. J Viral Hepat. 2011 Oct;18(10):675-84. doi: 10.1111/j.1365-2893.2011.01474.x. Epub 2011 May 25.


  1431. Psychosocial correlates of alcohol use and reduction for individuals with hepatitis C
    Perzynski AT, McCormick R, Webster NJ, Blixen CE, Kanuch S, Thomas CL, Mullen KD, Dawson NV. J Stud Alcohol Drugs. 2011 Sep;72(5):787-98.


  1432. Future of hepatitis C therapy: development of direct-acting antivirals
    Dore GJ, Matthews GV, Rockstroh J. Curr Opin HIV AIDS. 2011 Sep 3. [Epub ahead of print]


  1433. Comparison of 8 diagnostic algorithms for liver fibrosis in hepatitis C: New algorithms are more precise and entirely non-invasive
    Boursier J, de Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, Calès P; Multicentric groups from SNIFF 32, VINDIAG 7, ANRS/HC/EP23 FIBROSTAR studies. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24654. [Epub ahead of print]


  1434. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation
    Coto-Llerena M, Crespo G, González P, Koutsoudakis G, Miquel R, Navasa M, Forns X, Pérez-Del-Pulgar S. J Hepatol. 2011 Aug 31. [Epub ahead of print]


  1435. Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response
    Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N. Hepatology. 2011 Aug 24. doi: 10.1002/hep.24623. [Epub ahead of print]


  1436. Relative performances of FibroTest, Fibroscan and biopsy for assessing the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard
    Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Le Nahour G, Vaillant JC, Ratziu V, Charlotte F. J Hepatol. 2011 Aug 31. [Epub ahead of print]


  1437. The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study
    Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG, Merat S, Malekzadeh R. PLoS One. 2011;6(8):e23830. Epub 2011 Aug 24.


  1438. Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
    Kenneth E. Sherman, M.D., Ph.D., Steven L. Flamm, M.D., Nezam H. Afdhal, M.D., David R. Nelson, M.D., Mark S. Sulkowski, M.D., Gregory T. Everson, M.D., Michael W. Fried, M.D., Michael Adler, M.D., Ph.D., Hendrik W. Reesink, M.D., Ph.D., Marie Martin, Ph.D., Abdul J. Sankoh, Ph.D., Nathalie Adda, M.D., Robert S. Kauffman, M.D., Ph.D., Shelley George, M.D., Christopher I. Wright, M.D., Ph.D., and Fred Poordad, M.D. for the ILLUMINATE Study Team


  1439. Staying Safe From Hepatitis C: Engaging With Multiple Priorities
    Harris M, Treloar C, Maher L. Qual Health Res. 2011 Aug 25. [Epub ahead of print]


  1440. IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection
    Gonzalez SA, Keeffe EB. Gastroenterol Hepatol (N Y). 2011 Jun;7(6):366-73.


  1441. The cryoglobulinaemias
    Ramos-Casals M, Stone JH, Cid MC, Bosch X. Lancet. 2011 Aug 23. [Epub ahead of print]


  1442. T cell responses in hepatitis C: the good, the bad and the unconventional
    Klenerman P, Thimme R. Gut. 2011 Aug 28. [Epub ahead of print]


  1443. A paradigm shift in the outpatient approach to liver function tests
    Senadhi V. South Med J. 2011 Jul;104(7):521-5.


  1444. Neuropsychological alterations in hepatitis C infection: The role of inflammation
    Senzolo M, Schiff S, D'Aloiso CM, Crivellin C, Cholongitas E, Burra P, Montagnese S. World J Gastroenterol. 2011 Aug 7;17(29):3369-74.


  1445. Viral hepatitis C, active component, U.S. Armed Forces, 2000-2010
    Armed Forces Health Surveillance Center (AFHSC). MSMR. 2011 Aug;18(8):10-4.


  1446. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3
    Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG; for the ACHIEVE-1 and ACHIEVE-2/3 Study Teams. Gut. 2011 Aug 26. [Epub ahead of print]


  1447. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy
    Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, Ferrara MG, Sagnelli E. Dig Liver Dis. 2011 Aug 30. [Epub ahead of print]


  1448. Boceprevir: A User's Guide
    Kwo PY, Zhao R. Clin Liver Dis. 2011 Aug;15(3):537-53.


  1449. The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors
    Membreno FE, Lawitz EJ. Clin Liver Dis. 2011 Aug;15(3):611-26.


  1450. Second-wave Protease Inhibitors: Choosing an Heir
    Ciesek S, von Hahn T, Manns MP. Clin Liver Dis. 2011 Aug;15(3):597-609. Epub 2011 Jun 25.


  1451. Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations
    Khalid O, Bacon BR. Clin Liver Dis. 2011 Aug;15(3):573-83.


  1452. Mixing and matching drugs: what makes sense?
    Welzel TM, Zeuzem S. Clin Liver Dis. 2011 Aug;15(3):657-64.


  1453. Hepatitis C therapy: other players in the game
    Ahn J, Flamm SL. Clin Liver Dis. 2011 Aug;15(3):641-56.


  1454. The NS5A Replication Complex Inhibitors: Difference Makers?
    Gish RG, Meanwell NA. Clin Liver Dis. 2011 Aug;15(3):627-39.


  1455. Naives, nonresponders, relapsers: who is there left to treat?
    Desai AP, Reau N. Clin Liver Dis. 2011 Aug;15(3):483-95.


  1456. Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus
    Hevezi PA, Tom E, Wilson K, Lambert P, Gutierrez-Reyes G, Kershenobich D, Zlotnik A. Autoimmunity. 2011 Aug 24. [Epub ahead of print]


  1457. An overview of emerging therapies for the treatment of chronic hepatitis C
    Ilyas JA, Vierling JM. Clin Liver Dis. 2011 Aug;15(3):515-36.


  1458. The impact of genetic variability on liver disease in the Hispanic/Latin-American population
    Lau-Corona D, Kershenobich D, Gutierrez-Reyes G. Autoimmunity. 2011 Aug 24. [Epub ahead of print]


  1459. Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection
    Holmes JA, Desmond PV, Thompson AJ. Clin Liver Dis. 2011 Aug;15(3):497-513.


  1460. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation
    Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, Niazi M, Ortiz J. World J Hepatol. 2011 Jul 27;3(7):198-204.


  1461. IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection
    IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection


  1462. Interferon-free regimens: the near future, the likely and the not so likely
    Shiffman ML. Clin Liver Dis. 2011 Aug;15(3):665-75. Epub 2011 Jun 25.


  1463. 1990-2010: two decades of interferon-based therapy
    Buti M, Esteban R. Clin Liver Dis. 2011 Aug;15(3):473-82. Epub 2011 Jun 14.


  1464. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective
    McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, I D. J Manag Care Pharm. 2011 Sep;17(7):531-46.


  1465. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. J Hepatol. 2011 Aug 6. [Epub ahead of print]


  1466. Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C (September)
    Foote BC, Spooner LM, Belliveau PP. Ann Pharmacother. 2011 Aug 9. [Epub ahead of print]


  1467. Increased Risk of Severe Recurrence of Hepatitis C Virus in Liver Transplant Recipients of Donation After Cardiac Death Allografts
    Hernandez-Alejandro R, Croome KP, Quan D, Mawardi M, Chandok N, Dale C, McAlister V, Levstik MA, Wall W, Marotta P. Transplantation. 2011 Aug 9. [Epub ahead of print]


  1468. Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapy
    Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Waguri N, Igarashi K, Sugitani S, Takahashi T, Ishikawa T, Kamimura T, Wakabayashi H, Watanabe T, Matsuda Y, Aoyagi Y. Hepatogastroenterology. 2011 May-Jun;58(107-108):965-70.


  1469. Realize the advance in HCV treatment, but remain cautious
    Asselah T. J Hepatol. 2011 Aug 8. [Epub ahead of print]


  1470. Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C: Results From the WIN-R Trial
    Hu KQ, Freilich B, Brown RS, Brass C, Jacobson IM. J Clin Gastroenterol. 2011 Sep;45(8):720-6.


  1471. Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C
    Taskoparan M, Serin E, Gokturk HS, Icer MO, Abaci K, Ozer B, Zumrutdal A, Yilmaz U. Hepatogastroenterology. 2011 May-Jun;58(107-108):875-9.


  1472. A cohort study to investigate hepatocellular carcinoma risk in hepatitis C patients
    Wang CH, Mo LR, Chang KK, Lin RC, Kuo JJ. Hepatogastroenterology. 2011 May-Jun;58(107-108):904-8.


  1473. Hepatitis C virus and the skin
    Al-Ali J, Al-Mutari N, Ahmed el-SF. Hepatogastroenterology. 2011 May-Jun;58(107-108):880-6.


  1474. Hepatorenal Syndrome: Are We Missing Some Prognostic Factors?
    Martinez MO, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Dig Dis Sci. 2011 Aug 18. [Epub ahead of print]


  1475. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study
    Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Hayashi N. J Gastroenterol. 2011 Aug 20. [Epub ahead of print]


  1476. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection
    Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. PLoS One. 2011;6(8):e23218. Epub 2011 Aug 17.


  1477. FibroTest(®) and Fibroscan(®) performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate
    Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Moussalli J, Lebray P, Thabut D, Ratziu V. Clin Res Hepatol Gastroenterol. 2011 Aug 16. [Epub ahead of print]


  1478. Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use
    Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E, Kamili S, Weinbaum CM. J Infect Dis. 2011 Sep;204(6):825-31.


  1479. Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use
    Peña-Orellana M, Hernández-Viver A, Caraballo-Correa G, Albizu-García CE. J Health Care Poor Underserved. 2011;22(3):962-82.


  1480. Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
    Andrade LJ, Atta AM, Atta ML, Mangabeira CN, Paraná R. Braz J Infect Dis. 2011 Aug;15(4):377-81.


  1481. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males
    White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Hepatology. 2011 Aug 19. doi: 10.1002/hep.24618. [Epub ahead of print]


  1482. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy
    D'Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell'era A, Lampertico P, Donato MF, De Nicola S, Prati GM, de Franchis R, Colombo M. Antivir Ther. 2011;16(5):677-84.


  1483. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature
    Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, De Vita S. Autoimmun Rev. 2011 Jul 24. [Epub ahead of print]


  1484. Changes in Depressive Symptoms and Impact on Treatment Course Among Hepatitis C Patients Undergoing Interferon-? and Ribavirin Therapy: A Prospective Evaluation
    Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R. Am J Gastroenterol. 2011 Aug 9. doi: 10.1038/ajg.2011.252. [Epub ahead of print]


  1485. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California
    Telles Dias P, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. BMC Infect Dis. 2011 Aug 2;11(1):208. [Epub ahead of print]


  1486. New hepatitis C therapies in clinical development
    Vermehren J, Sarrazin C. Eur J Med Res. 2011 Jul 25;16(7):303-14.


  1487. Progress toward development of a hepatitis C vaccine with broad shoulders
    Ray R. Sci Transl Med. 2011 Aug 3;3(94):94ps33.


  1488. Chronic hepatitis C
    Jang JY, Chung RT. Gut Liver. 2011 Jun;5(2):117-32. Epub 2011 Jun 24.


  1489. Emerging therapeutic options in hepatitis c virus infection
    Poordad F, Khungar V. Am J Manag Care. 2011 Mar;17(4 Suppl):S123-30.


  1490. Role of the nurse practitioner in the management of patients with chronic hepatitis C
    Olson M, Jacobson IM. J Am Acad Nurse Pract. 2011 Aug;23(8):410-20. doi: 10.1111/j.1745-7599.2011.00603.x. Epub 2011 Mar 31.


  1491. Comparative Analysis of Hepatitis C Recurrence and Fibrosis Progression Between Deceased-Donor and Living-Donor Liver Transplantation: 8-Year Longitudinal Follow-Up
    Jain A, Singhal A, Kashyap R, Safadjou S, Ryan CK, Orloff MS. Transplantation. 2011 Jul 27. [Epub ahead of print]


  1492. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment
    Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. Int J Infect Dis. 2011 Jul 29. [Epub ahead of print]


  1493. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews
    Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Lancet. 2011 Jul 27. [Epub ahead of print]


  1494. Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C
    Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, Schneider G, Sarrazin C. J Clin Virol. 2011 Jul 29. [Epub ahead of print]


  1495. Pregnancy outcomes associated with viral hepatitis
    Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. J Viral Hepat. 2011 Jul;18(7):e394-8. doi: 10.1111/j.1365-2893.2011.01436.x. Epub 2011 Feb 8.


  1496. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy
    Deltenre P, Moreno C, Tran A, Ollivier I, Provôt F, Stanke F, Lazrek M, Castel H, Canva V, Louvet A, Colin M, Glowacki F, Dharancy S, Henrion J, Hazzan M, Noel C, Mathurin P. Aliment Pharmacol Ther. 2011 Jun 20. doi: 10.1111/j.1365-2036.2011.04741.x. [Epub ahead of print]


  1497. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse
    Shoeb D, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R, Sabin CA, Foster GR. Eur J Gastroenterol Hepatol. 2011 Jun 17. [Epub ahead of print]


  1498. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
    Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, Zeuzem S, Negro F. Liver Int. 2011 Jul;31 Suppl 2:4-17. doi: 10.1111/j.1478-3231.2011.02535.x.


  1499. Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-alfa2a and Ribavirin
    Larrey D, Salse A, Ribard D, Boutet O, Hyrailles-Blanc V, Niang B, Pageaux GP, Vaucher E, Arpurt JP, Boulay G, Karlova N, Daures JP; Hepatitis C Network of Languedoc Roussillon (France). Clin Gastroenterol Hepatol. 2011 Jun 6. [Epub ahead of print]


  1500. Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance
    Watanabe T, Konishi I, Shigematsu S, Uesugi K, Joko K, Seike H, Okada S, Miyaoka H, Nakanishi S, Abe M, Matsuura B, Michitaka K, Horiike N, Hiasa Y, Onji M. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00816.x. [Epub ahead of print]


  1501. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review
    Brunasso AM, Puntoni M, Gulia A, Massone C. Rheumatology (Oxford). 2011 Jun 20. [Epub ahead of print]


  1502. Health Utilities and Psychometric Quality of Life in Patients With Early- and Late-Stage Hepatitis C Virus Infection
    Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, Weiss AA, Krahn MD. J Gastroenterol Hepatol. 2011 Jun 16. doi: 10.1111/j.1440-1746.2011.06813.x. [Epub ahead of print]


  1503. Cholesterol and chronic hepatitis C virus infection
    Honda A, Matsuzaki Y. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00838.x. [Epub ahead of print]


  1504. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis
    Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S, Matsuura K, Izumi N. J Gastroenterol. 2011 Jun 17. [Epub ahead of print]


  1505. Telaprevir for previously untreated chronic hepatitis C virus infection
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. N Engl J Med. 2011 Jun 23;364(25):2405-16.


  1506. Telaprevir for retreatment of HCV infection
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. N Engl J Med. 2011 Jun 23;364(25):2417-28.


  1507. Viral hepatitis: Impact of adherence to combination therapy for hepatitis C
    Arase Y. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):248-9.


  1508. Telaprevir Alone or with Peginterferon and Ribavirin Reduces HCV RNA in Patients with Chronic Genotype 2 but Not 3 Infections
    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. Gastroenterology. 2011 May 31. [Epub ahead of print]


  1509. Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses
    Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M. Hepatol Res. 2011 Jun 23. doi: 10.1111/j.1872-034X.2011.00843.x. [Epub ahead of print]


  1510. Acute hepatitis C infection lowers serum lipid levels
    Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, Lauer GM, Chung RT. J Viral Hepat. 2011 Jul;18(7):e366-71. doi: 10.1111/j.1365-2893.2011.01434.x. Epub 2011 Feb 8.


  1511. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1
    Petta S, Di Marco V, Di Stefano R, Cabibi D, Cammà C, Marchesini G, Craxì A. J Viral Hepat. 2011 Jul;18(7):e372-80. doi: 10.1111/j.1365-2893.2011.01439.x. Epub 2011 Feb 22.


  1512. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis
    Fink SA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):285-95.


  1513. Improving surveillance for acute hepatitis C
    Deacon RM, Wand H, Stelzer-Braid S, Treloar C, Maher L. Commun Dis Intell. 2011 Mar;35(1):16-20.


  1514. The Risk of Incident Coronary Heart Disease Among Veterans With and Without HIV and Hepatitis C
    Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Justice AC; for the Veterans Aging Cohort Study. Circ Cardiovasc Qual Outcomes. 2011 Jun 28. [Epub ahead of print]


  1515. Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial
    Maieron A, Metz-Gercek S, Scherzer TM, Laferl H, Fischer G, Bischof M, Gschwantler M, Ferenci P. BMC Res Notes. 2011 Jun 29;4(1):220. [Epub ahead of print]


  1516. Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C
    Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK. Dig Dis Sci. 2011 Jun 25. [Epub ahead of print]


  1517. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
    Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML. J Hepatol. 2011 May 19. [Epub ahead of print]


  1518. Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2011 Jun 30. doi: 10.1002/hep.24503. [Epub ahead of print]


  1519. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, McCarthy JJ. J Hepatol. 2011 Apr 14. [Epub ahead of print]


  1520. Ophthalmological complications in hepatitis C virus infection: Side effect of interferon therapy or a direct role of HCV?
    Pazienza V. Biomed Pharmacother. 2011 May 30. [Epub ahead of print]


  1521. Oral combination therapy: Future hepatitis C virus treatment?
    Hézode C. J Hepatol. 2011 May 19. [Epub ahead of print]


  1522. Efficacy and Safety of Pegylated Interferon in Children and adolescents Infected with Chronic Hepatitis C: A Preliminary Study
    Abdel-Aziz DH, Sabry NA, El-Sayed MH, El-Gazayerly ON. J Pharm Pract. 2011 Apr;24(2):203-10. Epub 2010 Apr 2.


  1523. A sprint to increase response to HCV treatment: expectancies but caution
    Asselah T. J Hepatol. 2011 Jun 30. [Epub ahead of print]


  1524. The tasks of self-managing hepatitis C: The significance of disclosure
    Fry M, Bates G. Psychol Health. 2011 Jul 7. [Epub ahead of print]


  1525. Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease
    Peres WA, Chaves GV, Gonçalves JC, Ramalho A, Coelho HS. Br J Nutr. 2011 Jun 8:1-8. [Epub ahead of print]


  1526. Hepatitis C Reactivation in Patients Who Have Diffuse Large B-Cell Lymphoma Treated With Rituximab: A Case Report and Review of Literature
    Nooka A, Shenoy PJ, Sinha R, Lonial S, Flowers CR. Clin Lymphoma Myeloma Leuk. 2011 May 12. [Epub ahead of print]


  1527. Spontaneous clearance of hepatitis C virus in vertically infected children
    Farmand S, Wirth S, Löffler H, Woltering T, Kenzel S, Lainka E, Henneke P. Eur J Pediatr. 2011 Jul 7. [Epub ahead of print]


  1528. Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes
    Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ. Liver Int. 2011 Aug;31(7):1028-38. doi: 10.1111/j.1478-3231.2011.02549.x. Epub 2011 May 25.


  1529. Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data
    Ladero JM, Martin EG, Fernández C, Carballo M, Devesa MJ, Martínez C, Suárez A, Díaz-Rubio M, Agúndez JA. J Gastroenterol Hepatol. 2011 Jul 1. doi: 10.1111/j.1440-1746.2011.06834.x. [Epub ahead of print]


  1530. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene
    Toyoda H, Kumada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F. J Med Virol. 2011 Sep;83(9):1559-64. doi: 10.1002/jmv.22145.


  1531. Insulin resistance and chronic liver disease
    Kawaguchi T, Taniguchi E, Itou M, Sakata M, Sumie S, Sata M. World J Hepatol. 2011 May 27;3(5):99-107.


  1532. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes
    Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Liver Int. 2011 Jun 7. doi: 10.1111/j.1478-3231.2011.02556.x. [Epub ahead of print]


  1533. Hepatitis C virus infection in USA: an estimate of true prevalence
    Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Liver Int. 2011 Mar 16. doi: 10.1111/j.1478-3231.2011.02494.x. [Epub ahead of print]


  1534. An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C
    O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; and the HALT-C Trial Group. PLoS One. 2011;6(7):e20904. Epub 2011 Jul 8.


  1535. Gaps in the Achievement of Effectiveness of HCV Treatment in National VA Practice
    Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag H, Kramerer JR. J Hepatol. 2011 Jul 11. [Epub ahead of print]


  1536. Diagnosing and treating hepatitis c virus infection
    Schiff ER. Am J Manag Care. 2011 Mar;17(4 Suppl):S108-15.


  1537. Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C
    Burgueño-Montañés C, Pérez-Álvarez R. Arch Soc Esp Oftalmol. 2011 Jun;86(6):193-195. Epub 2011 Apr 29.


  1538. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse
    Lan CL, Guillygomarc'h A, Danielou H, Dréau GL, Lainé F, Védeilhié C, Deugnier Y, Brissot P, Guyader D, Moirand R. J Hepatol. 2011 Jul 11. [Epub ahead of print]


  1539. Improved Responses to Pegylated Interferon alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks
    Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T. Gastroenterology. 2011 Jul 21. [Epub ahead of print]


  1540. Peginterferon Maintenance Therapy in Patients with Advanced Hepatitis C to Prevent Hepatocellular Carcinoma: The Plot Thickens
    Aghemo A, Colombo M. J Hepatol. 2011 Jul 20. [Epub ahead of print]


  1541. Current understanding of insulin resistance in hepatitis C
    Kaddai V, Negro F. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):503-16.


  1542. Mechanisms of non-response to antiviral treatment in chronic hepatitis C
    Chevaliez S, Asselah T. Clin Res Hepatol Gastroenterol. 2011 Jun;35 Suppl 1:S31-41.


  1543. Hepatic steatosis at one year is an additional predictor of subsequent fibrosis severity in liver transplantation recipients with recurrent hepatitis C virus
    Brandman D, Pingitore A, Lai J, Roberts J, Ferrell L, Bass N, Terrault N. Liver Transpl. 2011 Jul 18. doi: 10.1002/lt.22389. [Epub ahead of print]


  1544. Liver stiffness diminishes with antiviral response in chronic hepatitis C
    Hézode C, Castéra L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, Leroy V, Mallat A, Pawlotsky JM. Aliment Pharmacol Ther. 2011 Jul 13. doi: 10.1111/j.1365-2036.2011.04765.x. [Epub ahead of print]


  1545. Effects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study
    Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, Marini SS, Barbeiro HV, Soriano FG, Carrilho FJ, Pereira LM, Alvares-da-Silva MR. Int J Cardiol. 2011 Jul 22. [Epub ahead of print]


  1546. Hyporesponsiveness to pegifn?2b plus ribavirin in patients with hepatitis C-related advanced fibrosis
    Prati GM, Aghemo A, Rumi MG, D'Ambrosio R, Nicola SD, Donato MF, Degasperi E, Colombo M. J Hepatol. 2011 Jul 11. [Epub ahead of print]


  1547. A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment
    Evon DM, Simpson K, Kixmiller S, Galanko J, Dougherty K, Golin C, Fried MW. Am J Gastroenterol. 2011 Jul 19. doi: 10.1038/ajg.2011.219. [Epub ahead of print]


  1548. Pregnancy outcomes associated with viral hepatitis
    Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. J Viral Hepat. 2011 Jul;18(7):e394-8. doi: 10.1111/j.1365-2893.2011.01436.x. Epub 2011 Feb 8.


  1549. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy
    Deltenre P, Moreno C, Tran A, Ollivier I, Provôt F, Stanke F, Lazrek M, Castel H, Canva V, Louvet A, Colin M, Glowacki F, Dharancy S, Henrion J, Hazzan M, Noel C, Mathurin P. Aliment Pharmacol Ther. 2011 Jun 20. doi: 10.1111/j.1365-2036.2011.04741.x. [Epub ahead of print]


  1550. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse
    Shoeb D, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R, Sabin CA, Foster GR. Eur J Gastroenterol Hepatol. 2011 Jun 17. [Epub ahead of print]


  1551. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
    Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, Zeuzem S, Negro F. Liver Int. 2011 Jul;31 Suppl 2:4-17. doi: 10.1111/j.1478-3231.2011.02535.x.


  1552. Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-alfa2a and Ribavirin
    Larrey D, Salse A, Ribard D, Boutet O, Hyrailles-Blanc V, Niang B, Pageaux GP, Vaucher E, Arpurt JP, Boulay G, Karlova N, Daures JP; Hepatitis C Network of Languedoc Roussillon (France). Clin Gastroenterol Hepatol. 2011 Jun 6. [Epub ahead of print]


  1553. Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance
    Watanabe T, Konishi I, Shigematsu S, Uesugi K, Joko K, Seike H, Okada S, Miyaoka H, Nakanishi S, Abe M, Matsuura B, Michitaka K, Horiike N, Hiasa Y, Onji M. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00816.x. [Epub ahead of print]


  1554. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review
    Brunasso AM, Puntoni M, Gulia A, Massone C. Rheumatology (Oxford). 2011 Jun 20. [Epub ahead of print]


  1555. Health Utilities and Psychometric Quality of Life in Patients With Early- and Late-Stage Hepatitis C Virus Infection
    Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, Weiss AA, Krahn MD. J Gastroenterol Hepatol. 2011 Jun 16. doi: 10.1111/j.1440-1746.2011.06813.x. [Epub ahead of print]


  1556. Cholesterol and chronic hepatitis C virus infection
    Honda A, Matsuzaki Y. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00838.x. [Epub ahead of print]


  1557. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis
    Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S, Matsuura K, Izumi N. J Gastroenterol. 2011 Jun 17. [Epub ahead of print]


  1558. Telaprevir for previously untreated chronic hepatitis C virus infection
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. N Engl J Med. 2011 Jun 23;364(25):2405-16.


  1559. Telaprevir for retreatment of HCV infection
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. N Engl J Med. 2011 Jun 23;364(25):2417-28.


  1560. Viral hepatitis: Impact of adherence to combination therapy for hepatitis C
    Arase Y. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):248-9.


  1561. Telaprevir Alone or with Peginterferon and Ribavirin Reduces HCV RNA in Patients with Chronic Genotype 2 but Not 3 Infections
    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. Gastroenterology. 2011 May 31. [Epub ahead of print]


  1562. Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses
    Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M. Hepatol Res. 2011 Jun 23. doi: 10.1111/j.1872-034X.2011.00843.x. [Epub ahead of print]


  1563. Acute hepatitis C infection lowers serum lipid levels
    Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, Lauer GM, Chung RT. J Viral Hepat. 2011 Jul;18(7):e366-71. doi: 10.1111/j.1365-2893.2011.01434.x. Epub 2011 Feb 8.


  1564. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1
    Petta S, Di Marco V, Di Stefano R, Cabibi D, Cammà C, Marchesini G, Craxì A. J Viral Hepat. 2011 Jul;18(7):e372-80. doi: 10.1111/j.1365-2893.2011.01439.x. Epub 2011 Feb 22.


  1565. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis
    Fink SA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):285-95.


  1566. Improving surveillance for acute hepatitis C
    Deacon RM, Wand H, Stelzer-Braid S, Treloar C, Maher L. Commun Dis Intell. 2011 Mar;35(1):16-20.


  1567. The Risk of Incident Coronary Heart Disease Among Veterans With and Without HIV and Hepatitis C
    Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Justice AC; for the Veterans Aging Cohort Study. Circ Cardiovasc Qual Outcomes. 2011 Jun 28. [Epub ahead of print]


  1568. Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial
    Maieron A, Metz-Gercek S, Scherzer TM, Laferl H, Fischer G, Bischof M, Gschwantler M, Ferenci P. BMC Res Notes. 2011 Jun 29;4(1):220. [Epub ahead of print]


  1569. Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C
    Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK. Dig Dis Sci. 2011 Jun 25. [Epub ahead of print]


  1570. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
    Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML. J Hepatol. 2011 May 19. [Epub ahead of print]


  1571. Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2011 Jun 30. doi: 10.1002/hep.24503. [Epub ahead of print]


  1572. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, McCarthy JJ. J Hepatol. 2011 Apr 14. [Epub ahead of print]


  1573. Ophthalmological complications in hepatitis C virus infection: Side effect of interferon therapy or a direct role of HCV?
    Pazienza V. Biomed Pharmacother. 2011 May 30. [Epub ahead of print]


  1574. Oral combination therapy: Future hepatitis C virus treatment?
    Hézode C. J Hepatol. 2011 May 19. [Epub ahead of print]


  1575. Efficacy and Safety of Pegylated Interferon in Children and adolescents Infected with Chronic Hepatitis C: A Preliminary Study
    Abdel-Aziz DH, Sabry NA, El-Sayed MH, El-Gazayerly ON. J Pharm Pract. 2011 Apr;24(2):203-10. Epub 2010 Apr 2.


  1576. Risk factors for the development of depression in patients with hepatitis C taking interferon-?
    Smith KJ, Norris S, O'Farrelly C, O'Mara SM. Neuropsychiatr Dis Treat. 2011;7:275-92. Epub 2011 May 15.


  1577. Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3.
    Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, Healey L, Pulkstenis E, Subramanian GM, McHutchison JG, Sulkowski MS, Zeuzem S, Nelson DR. Clin Gastroenterol Hepatol. 2011 May 13. [Epub ahead of print]


  1578. All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population
    El-Kamary SS, Jhaveri R, Shardell MD. Clin Infect Dis. 2011 Jun 10. [Epub ahead of print]


  1579. Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized controlled trials and implications for the future
    Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A, Buti M, Sheppard F, Ferenci P, Thévenot T. Hepatology. 2011 Jun 14. doi: 10.1002/hep.24480. [Epub ahead of print]


  1580. Importance of Host Genetic Factors HLA and IL28B as Predictors of Response to Pegylated Interferon and Ribavirin
    de Rueda PM, López-Nevot MA, Sáenz-López P, Casado J, Martín-Casares A, Palomares P, Quiles R, Gila A, Romero-Gómez M, Pavón EJ, Muñoz JA, Carazo A, Sanz-Cameno P, Moreno-Otero R, Diago M, León J, Ruiz-Extremera A, Salmerón J. Am J Gastroenterol. 2011 Jun 14. doi: 10.1038/ajg.2011.82. [Epub ahead of print]


  1581. Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?
    Peltekian KM, Bain VG, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Balshaw R, Deschênes M. Ann Hepatol. 2011 Jun 1;10(3):260-9.


  1582. Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large Multicenter Cohort Study
    ReViS-TC Study Group. Transplantation. 2011 Jun 8. [Epub ahead of print]


  1583. Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome
    Miyaaki H, Ichikawa T, Taura N, Miuma S, Shibata H, Isomoto H, Takeshima F, Nakao K. Intern Med. 2011;50(11):1137-41. Epub 2011 Jun 1.


  1584. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C
    Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H. J Infect Dis. 2011 Jul;204(1):84-93.


  1585. Meta-analysis: insulin resistance and sustained virological response in hepatitis C
    Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Aliment Pharmacol Ther. 2011 May 29. doi: 10.1111/j.1365-2036.2011.04716.x. [Epub ahead of print]


  1586. Unmet needs among people reported with hepatitis C, new york city
    Bornschlegel K, Crotty KJ, Sahl S, Balter S. J Public Health Manag Pract. 2011 Jul-Aug;17(4):E9-E17.


  1587. Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
    Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, Kistin M, Brown J, Jenkusky S, Komaromy M, Qualls C. N Engl J Med. 2011 Jun 1. [Epub ahead of print]


  1588. Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study
    Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A. Dig Dis Sci. 2011 Jun 2. [Epub ahead of print]


  1589. Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin
    Garib JR, Garcia GF, Teixeira R, Lima E Silva FD. Scand J Infect Dis. 2011 May 2. [Epub ahead of print]


  1590. Host-based ribavirin resistance influences hepatitis C virus replication and treatment response
    Ibarra KD, Jain MK, Pfeiffer JK. J Virol. 2011 May 4. [Epub ahead of print]


  1591. Hepatitis C virus infected females have a higher risk of advanced fibrosis and graft loss after liver transplantation than males
    Lai JC, Verna EC, Brown RS Jr, O'Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA; for the ConsoRtiUm to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatology. 2011 Apr 28. doi: 10.1002/hep.24390. [Epub ahead of print]


  1592. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection
    Corbetta S, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, Pellegrini C, Beck-Peccoz P, Spada A. Eur J Clin Invest. 2011 Mar 9. doi: 10.1111/j.1365-2362.2011.02498.x. [Epub ahead of print]


  1593. Understanding the host genetics of chronic hepatitis B and C
    Thursz M, Yee L, Khakoo S. Semin Liver Dis. 2011 May;31(2):115-27. Epub 2011 May 2.


  1594. Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: A vicious circle of clinical significance?
    Franceschini L, Realdon S, Marcolongo M, Mirandola S, Bortoletto G, Alberti A. Hepatology. 2011 Apr 29. doi: 10.1002/hep.24394. [Epub ahead of print]


  1595. Hepatitis C virus infection among adolescents and young adults --- massachusetts, 2002--2009
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 May 6;60(17):537-41.


  1596. Hepatitis C-related cirrhosis with sustained prevention of hepatocellular carcinoma recurrence by long-term administration of super-low-dose peginterferon-alpha 2b
    Mamori S, Mamori H. Case Rep Gastroenterol. 2011 Jan 19;5(1):56-62.


  1597. Racial differences in hepatitis C treatment eligibility
    Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; on behalf of the IDEAL Study Team. Hepatology. 2011 Apr 12. doi: 10.1002/hep.24358. [Epub ahead of print]


  1598. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C (HEP-10-2210)
    Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; for the HALT-C Trial Group. Hepatology. 2011 Apr 21. doi: 10.1002/hep.24370.


  1599. Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C
    Yoneda S, Umemura T, Joshita S, Ichijo T, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, Tanaka E; and the Nagano Interferon Treatment Research Group. Hepatol Res. 2011 Apr 19. doi: 10.1111/j.1872-034X.2011.00802.x. [Epub ahead of print]


  1600. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus
    Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR; for the PHOENIX Study Group. Liver Transpl. 2011 May;17(5):528-538. doi: 10.1002/lt.22271.


  1601. Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection
    Huang JF, Chuang YH, Dai CY, Yu ML, Huang CF, Hsiao PJ, Hsieh MY, Huang CI, Yeh ML, Yang JF, Lin ZY, Chen SC, Chuang WL. Hepatol Res. 2011 Apr 19. doi: 10.1111/j.1872-034X.2011.00786.x. [Epub ahead of print]


  1602. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin
    Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM. AIDS. 2011 Apr 18. [Epub ahead of print]


  1603. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination
    Ohara T, Oteki T, Suzuki T, Suzuki M, Matsuzaki Y. Hepatogastroenterology. 2011 Jan-Feb;58(105):133-6.


  1604. The dissociation between the diabetes and both Child-Pugh score and in-hospital mortality in cirrhotic patients due to hepatitis B, hepatitis C, or alcoholic
    Chen YW, Chen HH, Wang TE, Chang CW, Chang CW, Chen WC, Wu CJ. Hepatol Int. 2011 Apr 21. [Epub ahead of print]


  1605. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy
    Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K. J Med Virol. 2011 Jun;83(6):1048-57. doi: 10.1002/jmv.22069.


  1606. IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection
    Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS. PLoS One. 2011 Mar 30;6(3):e18322.


  1607. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)
    Imhof I, Simmonds P. Hepatology. 2011 Apr;53(4):1090-9. doi: 10.1002/hep.24172.


  1608. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon
    Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; for the HALT-C Trial Group. Hepatology. 2011 Apr;53(4):1100-1108. doi: 10.1002/hep.24169.


  1609. Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?
    Carrion AF, Fabrizi F, Martin P. Semin Dial. 2011 Apr 11. doi: 10.1111/j.1525-139X.2011.00851.x. [Epub ahead of print]


  1610. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1
    Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK; on behalf of the CHARIOT Study Group. Hepatology. 2011 Apr;53(4):1109-1117. doi: 10.1002/hep.24180.


  1611. Frequency of HCV infection in renal cell carcinoma patients
    Budako?lu B, Aksoy S, Arslan C, Uyetürk U, Babacan NA, Ozcan MF, Y?ld?z R, Oven BB, Ozdemir NY, Dizdar O, Büyükberber S, Ak?nc? MB, Türker I, Oksüzo?lu B, Altundag K, Zengin N. Med Oncol. 2011 Apr 3. [Epub ahead of print]


  1612. Zinc: A complementary factor in the treatment of chronic hepatitis C? (Review)
    Grüngreiff K, Reinhold D. Mol Med Report. 2010 May-Jun;3(3):371-5. doi: 10.3892/mmr_00000267.


  1613. A new standard of care for the treatment of chronic HCV infection
    Hofmann WP, Zeuzem S. Nat Rev Gastroenterol Hepatol. 2011 Apr 5. [Epub ahead of print]


  1614. Hepatitis C virus NS3/4A protease quasispecies complexity and catalytic efficiency influence responsiveness to peginterferon plus ribavirin treatment in HCV/HIV-co-infected patients
    Aparicio E, Franco S, Parera M, Andrés C, Tural C, Clotet B, Martínez MA. J Virol. 2011 Apr 6. [Epub ahead of print]


  1615. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus
    Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D. J Viral Hepat. 2011 May;18(5):305-15. doi: 10.1111/j.1365-2893.2011.01451.x. Epub 2011 Mar 23


  1616. A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C
    Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y, Oberti F, Dib N, Calès P. Am J Gastroenterol. 2011 Apr 5. [Epub ahead of print]


  1617. Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation
    Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, Martorell J, Navasa M, Forns X. Am J Transplant. 2011 Apr 5. doi: 10.1111/j.1600-6143.2011.03491.x. [Epub ahead of print]


  1618. Differences in circulating MMP-9 levels with regard to viral load and AST:ALT ratio between chronic hepatitis B and C patients
    Helaly GF. Br J Biomed Sci. 2011;68(1):38-42.


  1619. Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes
    Fernandez-Rodriguez CM, Gutierrez ML, Lledó JL, Casas ML. World J Gastroenterol. 2011 Mar 28;17(12):1558-62.


  1620. Occult hepatitis B virus infection: A complex entity with relevant clinical implications
    Larrubia JR. World J Gastroenterol. 2011 Mar 28;17(12):1529-30.


  1621. Host genetics in immune-mediated hepatitis C virus clearance
    Schmidt J, Thimme R, Neumann-Haefelin C. Biomark Med. 2011 Apr;5(2):155-69.


  1622. Prevalence of hepatitis C virus infection among health-care workers: A 10-year survey
    Marconi A, Candido S, Talamini R, Libra M, Nicoletti F, Spandidos DA, Stivala F, Proietti L. Mol Med Report. 2010 Jul-Aug;3(4):561-4. doi: 10.3892/mmr_00000297.


  1623. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
    Hartwell D, Jones J, Baxter L, Shepherd J. Health Technol Assess. 2011 Apr;15(17):1-210.


  1624. Clinical significance of occult hepatitis B virus infection
    Romero M, Madejón A, Fernández-Rodríguez C, García-Samaniego J. World J Gastroenterol. 2011 Mar 28;17(12):1549-52.


  1625. Malnutrion Impairs Interferon Signaling through mTOR and FoxO pathways in Patients with Chronic Hepatitis C
    Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S; Hokuriku Liver Study Group. Gastroenterology. 2011 Mar 30. [Epub ahead of print]


  1626. Genetics in liver disease: new concepts
    Zimmer V, Lammert F. Curr Opin Gastroenterol. 2011 Mar 30. [Epub ahead of print]


  1627. A new era of hepatitis C therapy begins
    Jensen DM. N Engl J Med. 2011 Mar 31;364(13):1272-4.


  1628. Hepatitis C Treatment Completion in Individuals With Psychiatric Comorbidity and Depression
    Gardenier D, Wisnivesky J, McGinn LK, Kronish IM, McGinn TG. Gastroenterol Nurs. 2011 March/April;34(2):102-106.


  1629. Acoustic Liver Biopsy in Patients with Hepatitis C and Advanced Liver Fibrosis Using Endoscopic Ultrasound
    Vegesna A, Nazir A, Chung CY, Kane S, Thomas R, Miller L. Dig Dis Sci. 2011 Apr 1. [Epub ahead of print]


  1630. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis
    Chen JJ, Yu CB, Du WB, Li LJ. Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):122-7.


  1631. Delayed viral clearance of chronic hepatitis C in patients after treatment failure
    Cho SH, Lee SW, Choi SR, Han SY, Roh MH, Lee JH, Jang JS, Baek YH, Kim SY. Gut Liver. 2011 Mar;5(1):110-4. Epub 2011 Mar 16.


  1632. IL28B single nucleotide polymorphisms in the treatment of hepatitis C
    Lange CM, Zeuzem S. J Hepatol. 2011 Mar 24. [Epub ahead of print]


  1633. Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma
    Shin SR, Paik SW, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC. Gut Liver. 2011 Mar;5(1):77-81. Epub 2011 Mar 16.


  1634. High-Dose Pegylated Interferon Alfa and Ribavirin in Non-responder Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial)
    Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. Gastroenterology. 2011 Mar 23. [Epub ahead of print]


  1635. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C
    Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; on behalf of the ITAHEC Study Group. Aliment Pharmacol Ther. 2011 Mar 28. doi: 10.1111/j.1365-2036.2011.04635.x. [Epub ahead of print]


  1636. HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment
    Irshad M, Ansari MA, Singh A, Nag P, Raghvendra L, Singh S, Badhal SS. Hepatogastroenterology. 2010 Nov-Dec;57(104):1529-38.


  1637. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States from 1988-2008
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Clin Gastroenterol Hepatol. 2011 Mar 24. [Epub ahead of print]


  1638. Hepatic encephalopathy: A central neuroinflammatory disorder?
    Butterworth RF. Hepatology. 2011 Apr;53(4):1372-6. doi: 10.1002/hep.24228.


  1639. Increased risk of parkinsonism among patients with cirrhosis: a 7-year follow-up study
    Kang JH, Tsai MC, Lin CC, Lin HL, Lin HC. Liver Int. 2011 May;31(5):685-691. doi: 10.1111/j.1478-3231.2010.02432.x. Epub 2011 Jan 11.


  1640. Validation of the Psychometric Hepatic Encephalopathy Score (PHES) for Identifying Patients with Minimal Hepatic Encephalopathy
    Duarte-Rojo A, Estradas J, Hernández-Ramos R, Ponce-de-León S, Córdoba J, Torre A. Dig Dis Sci. 2011 Apr 3. [Epub ahead of print]


  1641. Regional variations in the concentrations of ketone bodies in cirrhosis and hepatic encephalopathy: a study in patients with TIPSS
    Dabos KJ, Houghton BJ, Pyleris E, Redhead DN, Hayes PC, Salder IH, Plevris JN. Liver Int. 2011 May;31(5):707-11. doi: 10.1111/j.1478-3231.2011.02483.x. Epub 2011 Mar 6.


  1642. Microglia activation in hepatic encephalopathy
    Zemtsova I, Görg B, Keitel V, Bidmon HJ, Schrör K, Häussinger D. Hepatology. 2011 Mar 30. doi: 10.1002/hep.24326. [Epub ahead of print]


  1643. Complications and outcomes in chronic liver disease
    Rahimi RS, Rockey DC. Curr Opin Gastroenterol. 2011 Mar 30. [Epub ahead of print]


  1644. Low-protein diets for hepatic encephalopathy debunked: let them eat steak
    Cabral CM, Burns DL. Nutr Clin Pract. 2011 Apr;26(2):155-9.


  1645. Management of Hepatitis C Antiviral Therapy Adverse Effects
    Sung H, Chang M, Saab S. Curr Hepat Rep. 2011 Mar;10(1):33-40. Epub 2010 Dec 24.


  1646. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more
    Pearlman BL, Traub N. Clin Infect Dis. 2011 Apr;52(7):889-900.


  1647. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?
    Vezali E, Aghemo A, Lampertico P, Colombo M. Clin Res Hepatol Gastroenterol. 2011 Mar 22. [Epub ahead of print]


  1648. Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C
    Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK; EPIC(3) Study Group. Gastroenterology. 2011 Mar 16. [Epub ahead of print]


  1649. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease
    Gisbert JP, Chaparro M, Esteve M. Aliment Pharmacol Ther. 2011 Mar;33(6):619-33.


  1650. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection
    Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, Ahmed A, Lutchman GA, Keeffe EB, Nguyen MH. Hepatology. 2011 Mar 21. doi: 10.1002/hep.24308. [Epub ahead of print]


  1651. Boceprevir for Untreated Chronic HCV Genotype 1 Infection
    Fred Poordad, M.D., Jonathan McCone, Jr., M.D., Bruce R. Bacon, M.D., Savino Bruno, M.D., Michael P. Manns, M.D., Mark S. Sulkowski, M.D., Ira M. Jacobson, M.D., K. Rajender Reddy, M.D., Zachary D. Goodman, M.D., Ph.D., Navdeep Boparai, M.S., Mark J. DiNubile, M.D., Vilma Sniukiene, M.D., Clifford A. Brass, M.D., Ph.D., Janice K. Albrecht, Ph.D., and Jean-Pierre Bronowicki, M.D., Ph.D. for the SPRINT-2 Investigators. N Engl J Med 2011; 364:1195-1206March 31, 2011


  1652. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States from 1988-2008
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Clin Gastroenterol Hepatol. 2011 Mar 24. [Epub ahead of print]


  1653. Gastroenterology. 2011 Mar 24. [Epub ahead of print]
    A Functional Polymorphism in the Epidermal Growth Factor Gene is Associated with Risk for Hepatocellular Carcinoma.


  1654. High-Dose Pegylated Interferon Alfa and Ribavirin in Non-responder Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial)
    Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. Gastroenterology. 2011 Mar 23. [Epub ahead of print]


  1655. Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma
    Shin SR, Paik SW, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC. Gut Liver. 2011 Mar;5(1):77-81. Epub 2011 Mar 16.


  1656. IL28B single nucleotide polymorphisms in the treatment of hepatitis C
    Lange CM, Zeuzem S. J Hepatol. 2011 Mar 24. [Epub ahead of print]


  1657. Delayed viral clearance of chronic hepatitis C in patients after treatment failure
    Cho SH, Lee SW, Choi SR, Han SY, Roh MH, Lee JH, Jang JS, Baek YH, Kim SY. Gut Liver. 2011 Mar;5(1):110-4. Epub 2011 Mar 16.


  1658. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis
    Chen JJ, Yu CB, Du WB, Li LJ. Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):122-7.


  1659. Acoustic Liver Biopsy in Patients with Hepatitis C and Advanced Liver Fibrosis Using Endoscopic Ultrasound
    Vegesna A, Nazir A, Chung CY, Kane S, Thomas R, Miller L. Dig Dis Sci. 2011 Apr 1. [Epub ahead of print]


  1660. Hepatitis C Treatment Completion in Individuals With Psychiatric Comorbidity and Depression
    Gardenier D, Wisnivesky J, McGinn LK, Kronish IM, McGinn TG. Gastroenterol Nurs. 2011 March/April;34(2):102-106.


  1661. A new era of hepatitis C therapy begins
    Jensen DM. N Engl J Med. 2011 Mar 31;364(13):1272-4.


  1662. Genetics in liver disease: new concepts
    Zimmer V, Lammert F. Curr Opin Gastroenterol. 2011 Mar 30. [Epub ahead of print]


  1663. Malnutrion Impairs Interferon Signaling through mTOR and FoxO pathways in Patients with Chronic Hepatitis C
    Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S; Hokuriku Liver Study Group. Gastroenterology. 2011 Mar 30. [Epub ahead of print]


  1664. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection
    Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, Ahmed A, Lutchman GA, Keeffe EB, Nguyen MH. Hepatology. 2011 Mar 21. doi: 10.1002/hep.24308. [Epub ahead of print]


  1665. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: A meta-analysis of two large prospective clinical trials
    D'Heygere F, George C, Van Vlierberghe H, Decaestecker J, Nakad A, Adler M, Delwaide J, Laureys A, Nevens F. J Med Virol. 2011 May;83(5):815-9. doi: 10.1002/jmv.22049.


  1666. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection
    Petta S, Cammà C, Marco VD, Macaluso FS, Maida M, Pizzolanti G, Belmonte B, Cabibi D, Stefano RD, Ferraro D, Guarnotta C, Venezia G, Craxì A. Liver Int. 2011 Apr;31(4):507-15.


  1667. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment
    Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Liver Int. 2011 Apr;31(4):443-60.


  1668. Hepatitis C virus in primary care: survey of nurses' attitudes to caring
    Frazer K, Glacken M, Coughlan B, Staines A, Daly L. J Adv Nurs. 2011 Mar;67(3):598-608.


  1669. Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis
    Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Dig Dis Sci. 2011 Mar 5. [Epub ahead of print]


  1670. Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?
    Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 Mar 3.. [Epub ahead of print]


  1671. Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus
    Pawlotsky JM. Hepatology. 2011 Mar 3. doi: 10.1002/hep.24262. [Epub ahead of print]


  1672. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O. Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.


  1673. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
    Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Nat Rev Gastroenterol Hepatol. 2011 Mar 8. [Epub ahead of print]


  1674. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities
    Dibonaventura MD, Wagner JS, Yuan Y, L'italien G, Langley P, Ray Kim W. J Med Econ. 2011 Mar 9. [Epub ahead of print]


  1675. Second phase HCV RNA decline during telaprevir based therapy increases with drug effectiveness: Implications for treatment duration
    Guedj J, Perelson AS. Hepatology. 2011 Mar 7. [Epub ahead of print]


  1676. Coffee Consumption is Associated with Response to Peginterferon and Ribavirin Therapy in Patients with Chronic Hepatitis C
    Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C Trial Group. Gastroenterology. 2011 Mar 1. [Epub ahead of print]


  1677. Depression in patients with nonalcoholic Fatty liver disease and chronic viral hepatitis B and C
    Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, Nader F, Younossi ZM. Psychosomatics. 2011 Mar-Apr;52(2):127-32.


  1678. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation
    Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M. Liver Transpl. 2011 Mar;17(3):289-98.


  1679. IL-32: A new proinflammatory cytokine involved in HCV-related liver inflammation and fibrosis
    Moschen AR, Fritz T, Clouston AD, Rebhan I, Bauhofer O, Barrie HD, Powell EE, Kim SH, Dinarello CA, Bartenschlager R, Jonsson JR, Tilg H. Hepatology. 2011 Mar 4. doi: 10.1002/hep.24285. [Epub ahead of print]


  1680. Survival After Liver Transplantation Using Hepatitis C Virus-Positive Donor Allografts: Case-Controlled Analysis of the UNOS Database
    Burr AT, Li Y, Tseng JF, Saidi RF, Bozorgzadeh A, Shah SA. World J Surg. 2011 Mar 8. [Epub ahead of print]


  1681. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype
    Neukam K, Nattermann J, Rallón N, Rivero A, Caruz A, Macías J, Vogel M, Benito J, Camacho A, Mira J, Schwarze-Zander C, Barreiro P, Martínez A, Rockstroh J, Soriano V, Pineda J. HIV Med. 2011 Mar 6. [Epub ahead of print]


  1682. HCV RNA decline in the first 24hours exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin
    Laufer N, Bolcic F, Rolón M, Martinez A, Reynoso R, Pérez H, Salomón H, Cahn P, Quarleri J. Antiviral Res. 2011 Mar 1. [Epub ahead of print]


  1683. A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients with Hepatitis C
    Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. Clin Gastroenterol Hepatol. 2011 Mar 10. [Epub ahead of print]


  1684. Non-Invasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients with Chronic Hepatitis C
    Vergniol J, Foucher J, Terrebonne E, Bernard PH, Le Bail B, Merrouche W, Couzigou P, de Lédinghen V. Gastroenterology. 2011 Mar 1. [Epub ahead of print]


  1685. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients
    Patel K, Lucas J, Thompson J, Dubois L, Tillmann H, Thompson A, Uzarski D, Califf R, Moseley M, Ginsburg G, McHutchison J, McCarthy J; for MURDOCK Horizon 1 Study Team. Hepatology. 2011 Mar 4. [Epub ahead of print]


  1686. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients
    Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Hernandez-Quero J, Moreno S, Bernal E, Miró JM, Leal M, Gutierrez F, Portilla J, Pineda JA; on behalf of CoRIS. AIDS. 2011 Mar 3. [Epub ahead of print]


  1687. Insulin Resistance is Independently Associated with Significant Hepatic Fibrosis in Asian Chronic Hepatitis C Genotype 2 or 3 Patients
    Patel K, Thompson A, Chuang W, Lee C, Peng C, Shanmuganathan G, Thongsawat S, Tanwandee T, Mahachai V, Pramoolsinsap C, Cho M, Han K, Shah S, Foster G, Clark P, Pulkstenis E, Subramanian M, McHutchison J. J Gastroenterol Hepatol. 2011 Mar 16. doi: 10.1111/j.1440-1746.2011.06722.x. [Epub ahead of print]


  1688. Genetic variation in IL28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV infected children
    Ruiz-Extremera A, Muñoz-Gámez J, Salmerón-Ruiz MA, de Rueda PM, Quiles-Pérez R, Gila-Medina A, Casado J, Martín AB, Sanjuan-Nuñez L, Carazo A, Pavón EJ, Ocete-Hita E, León J, Salmerón J. Hepatology. 2011 Mar 16. [Epub ahead of print]


  1689. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort
    Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, Kneteman N, Mills EJ. AIDS. 2011 Mar 27;25(6):777-86.


  1690. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study
    Marcellin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Varastet M, Lang JP, Melin P, Cacoub P; for the CheObs Study Group. Liver Int. 2011 Apr;31(4):516-524.Epub 2011 Feb 15.


  1691. Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C
    Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. J Hepatol. 2011 Jan 12. [Epub ahead of print]


  1692. New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Asselah T, Marcellin P. Liver Int. 2011 Jan;31 Suppl 1:68-77.


  1693. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
    Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. J Gastroenterol. 2011 Jan 19. [Epub ahead of print]


  1694. Impact of a sustained virological response on the long-term outcome of hepatitis C
    Alberti A. Liver Int. 2011 Jan;31 Suppl 1:18-22.


  1695. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients
    Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H, Ozaki I, Fujimoto K. World J Gastroenterol. 2011 Feb 21;17(7):914-21.


  1696. Hepatitis C virus infection during pregnancy and the newborn period - are they opportunities for treatment?
    Arshad M, El-Kamary SS, Jhaveri R. J Viral Hepat. 2011 Apr;18(4):229-36. doi: 10.1111/j.1365-2893.2010.01413.x. Epub 2011 Jan 7.


  1697. How to use virological tools for the optimal management of chronic hepatitis C
    de Leuw P, Sarrazin C, Zeuzem S. Liver Int. 2011 Jan;31 Suppl 1:3-12.


  1698. How to assess liver fibrosis in chronic hepatitis C: serum markers or Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients vs. liver biopsy?
    Castera L, Bedossa P. Liver Int. 2011 Jan;31 Suppl 1:13-7.


  1699. Future hepatitis C virus treatment: interferon-sparing combinations
    Gane E. Liver Int. 2011 Jan;31 Suppl 1:62-7.


  1700. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    McHutchison JG. Liver Int. 2011 Jan;31 Suppl 1:29-35.


  1701. Optimal therapy in hepatitis C virus genotypes 2 and 3 patients
    Petta S, Craxì A. Liver Int. 2011 Jan;31 Suppl 1:36-44.


  1702. Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis
    Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY; On Behalf Of The Swiss Hepatitis C Cohort Study Group. J Hepatol. 2011 Jan 11. [Epub ahead of print]


  1703. Sustained virologic response among Latino veterans; does it represent the cure of chronic hepatitis C infection?
    De Jesús J, Nieves-Santiago P, Rodríguez-Pérez F, Toro DH. P R Health Sci J. 2010 Dec;29(4):397-401.


  1704. Immunological/virological peripheral blood biomarkers and distinct patterns of sleeping quality in chronic Hepatitis C patients
    de Almeida CM, de Lima TA, Castro DB, Torres KL, da Silva Braga W, Peruhype-Magalhães V, Teixeira-Carvalho A, Martins-Filho OA, Malheiro A. Scand J Immunol. 2011 Jan 13. [Epub ahead of print]


  1705. Treatment of hepatitis C virus infection in patients with end-stage renal disease
    Liu CH, Kao JH. J Gastroenterol Hepatol. 2011 Feb;26(2):228-39.


  1706. Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony
    Jamma S, Hussain G, Lau DT. Curr Hepat Rep. 2010;9(4):260-269.


  1707. Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads
    Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo C, Fujii H, Minami M, Yasui K, Mitsuyoshi H, Okanoue T, Takehara T, Hiasa Y, Onji M, Yoshikawa T. Hepatol Res. 2011 Feb;41(2):126-32.


  1708. Incidence of Hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study
    Gamage DG, Read TR, Bradshaw CS, Hocking JS, Howley K, Chen MY, Fairley CK. BMC Infect Dis. 2011 Feb 3;11(1):39. [Epub ahead of print]


  1709. Hepatitis C virus Resistance to Protease Inhibitors
    Halfon P, Locarnini S. J Hepatol. 2011 Jan 29. [Epub ahead of print]


  1710. Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C
    Scott JD, Wang CC, Coppel E, Lau A, Veitengruber J, Roy-Byrne P. J Clin Gastroenterol. 2011 Feb 2. [Epub ahead of print]


  1711. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin
    Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. World J Gastroenterol. 2011 Jan 28;17(4):493-8.


  1712. Interferon lambdas: the next cytokine storm
    Kelly C, Klenerman P, Barnes E. Gut. 2011 Feb 8. [Epub ahead of print]


  1713. Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease
    Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Dig Liver Dis. 2011 Feb 8. [Epub ahead of print]


  1714. Epidemic of Sexually Transmitted Hepatitis C Virus Infection Among HIV-Infected Men
    Fierer DS. Curr Infect Dis Rep. 2010 Mar;12(2):118-25.


  1715. Recommendations for the management of mixed Cryoglobulinemia syndrome in Hepatitis C virus-infected patients
    Pietrogrande M, Devita S, Zignego A, et al. Autoimmun Rev. 2011 Feb 5. [Epub ahead of print]


  1716. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy
    Krishnan SM, Dixit NM. PLoS Comput Biol. 2011 Feb 3;7(2)


  1717. Pegylated-interferon-?(2a) in clinical practice: how to manage patients suffering from side effects
    Calvaruso V, Mazza M, Almasio PL. Expert Opin Drug Saf. 2011 Feb 16. [Epub ahead of print]


  1718. Dendritic cells in hepatitis C infection: can they (help) win the battle?
    Dolganiuc A, Szabo G. J Gastroenterol. 2011 Feb 17. [Epub ahead of print]


  1719. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
    Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Proc Natl Acad Sci U S A. 2011 Feb 14. [Epub ahead of print]


  1720. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis
    Petta S, Tripodo C, Grimaudo S, Cabibi D, Cammà C, Di Cristina A, Di Marco V, Di Vita G, Ingrao S, Mazzola A, Marchesini G, Pipitone R, Craxì A. Dig Liver Dis. 2011 Feb 14. [Epub ahead of print]


  1721. Psychiatrists' knowledge and practices in screening and assessment of Hepatitis C for inpatients with severe mental illness
    Lagios K, Deane F. Australas Psychiatry. 2011 Feb 25. [Epub ahead of print]


  1722. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia
    Poordad F, Theodore D, Sullivan J, Grotzinger K. J Med Econ. 2011 Feb 25. [Epub ahead of print]


  1723. Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics
    Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM. Genome Med. 2011 Feb 8;3(2):8. [Epub ahead of print]


  1724. Novel Findings for the Development of Drug Therapy for Various Liver Diseases:Genetic Variation in IL-28B Is Associated With Response to the Therapy for Chronic Hepatitis C
    Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M. J Pharmacol Sci. 2011 Feb 22. [Epub ahead of print]


  1725. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children
    Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Lobritto SJ, Schwarz KB, Robuck PR, Barton B, González-Peralta RP. Hepatology. 2011 Feb 23. [Epub ahead of print]


  1726. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature
    López V, Molina I, Monteagudo C, Jordá E. Int J Dermatol. 2011 Mar;50(3):287-91.


  1727. Assessment of fibrosis and cirrhosis in liver biopsies: an update
    Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Semin Liver Dis. 2011 Feb;31(1):82-90. Epub 2011 Feb 22.


  1728. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future
    Ferenci P. Expert Opin Drug Saf. 2011 Feb 23. [Epub ahead of print]


  1729. Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
    Gaglio PJ, Moss N, McGaw C, Reinus J. Dig Dis Sci. 2011 Feb 19. [Epub ahead of print]


  1730. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-? plus ribavirin therapy in Taiwanese chronic HCV infection
    Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. Genes Immun. 2011 Feb 24. [Epub ahead of print]


  1731. Prevention of virus hepatitis A to E.
    Cornberg M, Manns MP. Internist (Berl). 2011 Feb 23. [Epub ahead of print]


  1732. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; the HALT-C Trial Group. Hepatology. 2011 Mar 3. [Epub ahead of print]


  1733. 'Easy to Treat' genotypes were not created equal. Can rapid virological response (RVR) level the playing field?
    Duarte-Rojo A, Heathcote EJ, Feld JJ. J Hepatol. 2011 Feb 17. [Epub ahead of print]


  1734. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
    Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M; the DITTO-HCV study group. J Hepatol. 2011 Feb 24. [Epub ahead of print]


  1735. Mechanism of action of Ribavirin in a novel hepatitis C virus replication cell system
    Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N. Virus Res. 2011 Feb 11. [Epub ahead of print]


  1736. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b
    Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group. J Med Virol. 2011 Feb 25. doi: 10 [Epub ahead of print]


  1737. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.


  1738. U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for
    Ho SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck-Ytter Y, Decomarmond C, Smith CI, McKee DP, Boyd W, Kulig CC, Bini EJ, Pedrosa MC. Dig Dis Sci. 2011 Jan 11. [Epub ahead of print]


  1739. HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies
    Operskalski EA, Kovacs A. Curr HIV/AIDS Rep. 2011 Jan 11. [Epub ahead of print]


  1740. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
    Tran HA, Jones TL, Ianna EA, Reeves GE. Thyroid Res. 2011 Jan 8;4(1):2. [Epub ahead of print]


  1741. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ, Lee SD. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:96-101.


  1742. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1
    Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N. Eur J Clin Microbiol Infect Dis. 2011 Jan 13. [Epub ahead of print]


  1743. IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations
    Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, Hiraga N, Kawakami Y, Aimitsu S, Kao JH, Kubo M, Tsunoda T, Kumada H, Nakamura Y, Hayes CN, Chayama K. J Gen Virol. 2011 Jan 12. [Epub ahead of print]


  1744. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
    Tran HA, Jones TL, Ianna EA, Reeves GE. Thyroid Res. 2011 Jan 8;4(1):2. [Epub ahead of print]


  1745. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ, Lee SD. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:96-101.


  1746. Hepatitis C virus: How genetic variability affects pathobiology of disease
    Chayama K, Hayes CN. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:83-95.


  1747. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1
    Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N. Eur J Clin Microbiol Infect Dis. 2011 Jan 13. [Epub ahead of print]


  1748. IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations
    Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, Hiraga N, Kawakami Y, Aimitsu S, Kao JH, Kubo M, Tsunoda T, Kumada H, Nakamura Y, Hayes CN, Chayama K. J Gen Virol. 2011 Jan 12. [Epub ahead of print]


  1749. New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Asselah T, Marcellin P. Liver Int. 2011 Jan;31 Suppl 1:68-77.


  1750. Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C
    Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. J Hepatol. 2011 Jan 12. [Epub ahead of print]


  1751. How to use virological tools for the optimal management of chronic hepatitis C
    de Leuw P, Sarrazin C, Zeuzem S. Liver Int. 2011 Jan;31 Suppl 1:3-12.


  1752. Impact of a sustained virological response on the long-term outcome of hepatitis C
    Alberti A. Liver Int. 2011 Jan;31 Suppl 1:18-22.


  1753. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
    Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. J Gastroenterol. 2011 Jan 19. [Epub ahead of print]


  1754. Optimal therapy in hepatitis C virus genotypes 2 and 3 patients
    Petta S, Craxì A. Liver Int. 2011 Jan;31 Suppl 1:36-44.


  1755. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    McHutchison JG. Liver Int. 2011 Jan;31 Suppl 1:29-35.


  1756. Future hepatitis C virus treatment: interferon-sparing combinations
    Gane E. Liver Int. 2011 Jan;31 Suppl 1:62-7.


  1757. How to assess liver fibrosis in chronic hepatitis C: serum markers or Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients vs. liver biopsy?
    Castera L, Bedossa P. Liver Int. 2011 Jan;31 Suppl 1:13-7.


  1758. Immunological/virological peripheral blood biomarkers and distinct patterns of sleeping quality in chronic Hepatitis C patients
    de Almeida CM, de Lima TA, Castro DB, Torres KL, da Silva Braga W, Peruhype-Magalhães V, Teixeira-Carvalho A, Martins-Filho OA, Malheiro A. Scand J Immunol. 2011 Jan 13. [Epub ahead of print]


  1759. Sustained virologic response among Latino veterans; does it represent the cure of chronic hepatitis C infection?
    De Jesús J, Nieves-Santiago P, Rodríguez-Pérez F, Toro DH. P R Health Sci J. 2010 Dec;29(4):397-401.


  1760. Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis
    Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY; On Behalf Of The Swiss Hepatitis C Cohort Study Group. J Hepatol. 2011 Jan 11. [Epub ahead of print]


  1761. Treatment of hepatitis C virus infection in patients with end-stage renal disease
    Liu CH, Kao JH. J Gastroenterol Hepatol. 2011 Feb;26(2):228-39.


  1762. Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony
    Jamma S, Hussain G, Lau DT. Curr Hepat Rep. 2010;9(4):260-269.


  1763. Hepatitis C virus Resistance to Protease Inhibitors
    Halfon P, Locarnini S. J Hepatol. 2011 Jan 29. [Epub ahead of print]


  1764. Incidence of Hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study
    Gamage DG, Read TR, Bradshaw CS, Hocking JS, Howley K, Chen MY, Fairley CK. BMC Infect Dis. 2011 Feb 3;11(1):39. [Epub ahead of print]


  1765. Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads
    Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo C, Fujii H, Minami M, Yasui K, Mitsuyoshi H, Okanoue T, Takehara T, Hiasa Y, Onji M, Yoshikawa T. Hepatol Res. 2011 Feb;41(2):126-32.


  1766. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin
    Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. World J Gastroenterol. 2011 Jan 28;17(4):493-8.


  1767. Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C
    Scott JD, Wang CC, Coppel E, Lau A, Veitengruber J, Roy-Byrne P. J Clin Gastroenterol. 2011 Feb 2. [Epub ahead of print]


  1768. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C
    Pattullo V, Heathcote EJ, Wong DK. Hepatol Int. 2010 Aug 8;4(4):723-31.


  1769. Hepatitis C virus in primary care: survey of nurses' attitudes to caring
    Frazer K, Glacken M, Coughlan B, Staines A, Daly L. J Adv Nurs. 2011 Mar;67(3):598-608.


  1770. Interferon lambdas: the next cytokine storm
    Kelly C, Klenerman P, Barnes E. Gut. 2011 Feb 8. [Epub ahead of print]


  1771. Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease
    Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Dig Liver Dis. 2011 Feb 8. [Epub ahead of print]


  1772. Epidemic of Sexually Transmitted Hepatitis C Virus Infection Among HIV-Infected Men
    Fierer DS. Curr Infect Dis Rep. 2010 Mar;12(2):118-25.


  1773. Recommendations for the management of mixed Cryoglobulinemia syndrome in Hepatitis C virus-infected patients
    Pietrogrande M, Devita S, Zignego A, et al. Autoimmun Rev. 2011 Feb 5. [Epub ahead of print]


  1774. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy
    Krishnan SM, Dixit NM. PLoS Comput Biol. 2011 Feb 3;7(2)


  1775. Pegylated-interferon-?(2a) in clinical practice: how to manage patients suffering from side effects
    Calvaruso V, Mazza M, Almasio PL. Expert Opin Drug Saf. 2011 Feb 16. [Epub ahead of print]


  1776. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis
    Petta S, Tripodo C, Grimaudo S, Cabibi D, Cammà C, Di Cristina A, Di Marco V, Di Vita G, Ingrao S, Mazzola A, Marchesini G, Pipitone R, Craxì A. Dig Liver Dis. 2011 Feb 14. [Epub ahead of print]


  1777. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.


  1778. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
    Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Proc Natl Acad Sci U S A. 2011 Feb 14. [Epub ahead of print]


  1779. Dendritic cells in hepatitis C infection: can they (help) win the battle?
    Dolganiuc A, Szabo G. J Gastroenterol. 2011 Feb 17. [Epub ahead of print]


  1780. Psychiatrists' knowledge and practices in screening and assessment of Hepatitis C for inpatients with severe mental illness
    Lagios K, Deane F. Australas Psychiatry. 2011 Feb 25. [Epub ahead of print]


  1781. Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics
    Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM. Genome Med. 2011 Feb 8;3(2):8. [Epub ahead of print]


  1782. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia
    Poordad F, Theodore D, Sullivan J, Grotzinger K. J Med Econ. 2011 Feb 25. [Epub ahead of print]


  1783. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature
    López V, Molina I, Monteagudo C, Jordá E. Int J Dermatol. 2011 Mar;50(3):287-91.


  1784. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children
    Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Lobritto SJ, Schwarz KB, Robuck PR, Barton B, González-Peralta RP. Hepatology. 2011 Feb 23. [Epub ahead of print]


  1785. Novel Findings for the Development of Drug Therapy for Various Liver Diseases:Genetic Variation in IL-28B Is Associated With Response to the Therapy for Chronic Hepatitis C
    Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M. J Pharmacol Sci. 2011 Feb 22. [Epub ahead of print]


  1786. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-? plus ribavirin therapy in Taiwanese chronic HCV infection
    Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. Genes Immun. 2011 Feb 24. [Epub ahead of print]


  1787. Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
    Gaglio PJ, Moss N, McGaw C, Reinus J. Dig Dis Sci. 2011 Feb 19. [Epub ahead of print]


  1788. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future
    Ferenci P. Expert Opin Drug Saf. 2011 Feb 23. [Epub ahead of print]


  1789. Assessment of fibrosis and cirrhosis in liver biopsies: an update
    Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Semin Liver Dis. 2011 Feb;31(1):82-90. Epub 2011 Feb 22.


  1790. Prevention of virus hepatitis A to E.
    Cornberg M, Manns MP. Internist (Berl). 2011 Feb 23. [Epub ahead of print]


  1791. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; the HALT-C Trial Group. Hepatology. 2011 Mar 3. [Epub ahead of print]


  1792. Mechanism of action of Ribavirin in a novel hepatitis C virus replication cell system
    Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N. Virus Res. 2011 Feb 11. [Epub ahead of print]


  1793. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
    Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M; the DITTO-HCV study group. J Hepatol. 2011 Feb 24. [Epub ahead of print]


  1794. 'Easy to Treat' genotypes were not created equal. Can rapid virological response (RVR) level the playing field?
    Duarte-Rojo A, Heathcote EJ, Feld JJ. J Hepatol. 2011 Feb 17. [Epub ahead of print]


  1795. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b
    Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group. J Med Virol. 2011 Feb 25. doi: 10 [Epub ahead of print]


  1796. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.


  1797. Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus
    Pawlotsky JM. Hepatology. 2011 Mar 3. doi: 10.1002/hep.24262. [Epub ahead of print]


  1798. Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?
    Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 Mar 3.. [Epub ahead of print]


  1799. Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis
    Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Dig Dis Sci. 2011 Mar 5. [Epub ahead of print]


  1800. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O. Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.


  1801. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
    Tran HA, Jones TL, Ianna EA, Reeves GE. Thyroid Res. 2011 Jan 8;4(1):2. [Epub ahead of print]


  1802. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses
    Houghton M. Immunol Rev. 2011 Jan;239(1):99-108.


  1803. Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy
    Gonzalez SA, Keeffe EB. Front Biosci. 2011 Jan 1;16:225-50.


  1804. Hepatitis C virus replication and potential targets for direct-acting agents
    O'Leary JG, Davis GL. Therap Adv Gastroenterol. 2010 Jan;3(1):43-53


  1805. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients
    Burney T, Dusheiko G. Expert Rev Anti Infect Ther. 2010 Dec 14


  1806. Evaluation of a New; Rapid Test for Detecting HCV Infection; Suitable for Use with Blood or Oral Fluid
    Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M. J Virol Methods. 2010 Dec 20


  1807. Dietary History and Physical Activity and Risk of Advanced Liver Disease in Veterans with Chronic Hepatitis C Infection
    White DL, Richardson PA, Al-Saadi M, Fitzgerald SJ, Green L, Amaratunge C, Anand M, El-Serag HB. Dig Dis Sci. 2010 Dec 28.


  1808. Thrombocytopenia in chronic hepatitis C
    Olariu M, Olariu C, Olteanu D. J Gastrointestin Liver Dis. 2010 Dec;19(4):381-5.


  1809. Current therapies for chronic hepatitis C
    Ferguson MC. Pharmacotherapy. 2011 Jan;31(1):92-111.


  1810. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-?-2a and ribavirin in HIV/HCV co-infected patients
    Vachon Marie-Louise C; Factor Stephanie H; Branch Andrea D; Fiel Maria-Isabel; Rodriguez-Torres Maribel; Bräu Norbert; Sterling Richard K; Slim Jihad; Talal Andrew H; Dieterich Douglas T; Sulkowski Mark S. Journal of hepatology 2011;54(1):41-7. 2. 2010.


  1811. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C
    Asselah T. J Hepatol. 2010 Dec 15.


  1812. Lymphocytosis as a predictor of poor response to treatment of hepatitis C
    Martinez-Camacho A, Khaoustov VI, Adam E, Lewis DE, Tavakoli-Tabasi S, Yoffe B. Gastroenterol Clin Biol. 2010 Dec 22.


  1813. Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy
    Bortoletto G, Campagnolo D, Mirandola S, Comastri G, Severini L, Pulvirenti FR, Alberti A. J Clin Virol. 2010 Dec 29. [Epub ahead of print]


  1814. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes
    Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, Alter HJ, Herrine SK, Liang TJ, Hoofnagle JH, Heller T. Aliment Pharmacol Ther. 2010 Dec 29. [Epub ahead of print]


  1815. Impact of hepatitis C in mortality in patients on hemodialysis
    Rabanal CP, Zevallos JC, Cusato RC. J Bras Nefrol. 2010 Dec;32(4):337-341.


  1816. Hepatitis C virus: Up to the minute
    Roche B, Samuel D. Liver Transpl. 2010 Oct;16(S2):S26-S35.


  1817. Transfusion-transmissible viral infections among US military recipients of whole blood and platelets during Operation Enduring Freedom and Operation Iraqi Freedom
    Hakre S, Peel SA, O'Connell RJ, Sanders-Buell EE, Jagodzinski LL, Eggleston JC, Myles O, Waterman PE, McBride RH, Eader SA, Davis KW, Rentas FJ, Sateren WB, Naito NA, Tobler SK, Tovanabutra S, Petruccelli BP, McCutchan FE, Michael NL, Cersovsky SB, Scott PT. Transfusion. 2010 Oct 7. [Epub ahead of print]


  1818. Seizures During Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C: Observations From the WIN-R Trial
    Ahmed F, Jacobson IM, Herrera JL, Brand M, Wasserman RB, Fixelle AM, Rustgi VK, Albert C, Brown R, Brass C; for the WIN-R Study Group. J Clin Gastroenterol. 2010 Oct 6. [Epub ahead of print]


  1819. Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis
    Russo MW. Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):535-9.


  1820. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C
    Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. Hepatology. 2010 Aug 20. [Epub ahead of print]


  1821. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C
    Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A. Pharmacol Res. 2010 Oct 9. [Epub ahead of print]


  1822. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
    de Bruijne J, Bergmann JF, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J, Tong X, Li J, Treitel MA, Hughes EA, van Lier JJ, van Vliet AA, Janssen HL, de Knegt RJ. Hepatology. 2010 Aug 19. [Epub ahead of print]


  1823. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy
    Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Aliment Pharmacol Ther. 2010 Oct;32(8):969-83. . Epub 2010 Aug 15.


  1824. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
    Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Hepatology. 2010 Jul 29. [Epub ahead of print]


  1825. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
    Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. BMC Gastroenterol. 2010 Sep 9;10(1):103. [Epub ahead of print]


  1826. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy
    Tuma P, Medrano J, Resino S, Vispo E, Madejón A, Sánchez-Piedra C, Rivas P, Labarga P, Martín-Carbonero L, Barreiro P, Soriano V. Antivir Ther. 2010;15(6):881-6.


  1827. Use of Statins in Patients with Chronic Hepatitis C
    Andrus MR, East J. South Med J. 2010 Sep 2. [Epub ahead of print]


  1828. Patient-to-patient transmission of hepatitis C virus (HCV) during colonoscopy diagnosis
    Gonzalez-Candelas F, Guiral S, Carbo R, Valero A, Vanaclocha H, Gonzalez F, Bracho MA. Virol J. 2010 Sep 8;7(1):217. [Epub ahead of print


  1829. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France
    Larsen C, Bousquet V, Delarocque-Astagneau E, Pioche C, Roudot-Thoraval F; the HCV surveillance steering committee, the HCV surveillance group and Jean-Claude Desenclos. J Med Virol. 2010 Oct;82(10):1647-1654.


  1830. Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy
    François C, Descamps V, Brochot E, Bernard I, Canva V, Mathurin P, Castelain S, Duverlie G. J Med Virol. 2010 Oct;82(10):1640-6.


  1831. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis
    Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N. J Gastroenterol. 2010 Sep 10. [Epub ahead of print]


  1832. The impact of smoking on incident type 2 diabetes in a cohort with hepatitis B but not hepatitis C infection
    Wang CS, Chang TT, Yao WJ, Wang ST, Chou P. Viral Hepat. 2010 Aug 31. [Epub ahead of print]


  1833. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial
    Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Psychosomatics. 2010 Sep;51(5):401-8.


  1834. von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4
    Pramhas S, Homoncik M, Ferenci P, Ferlitsch A, Scherzer T, Gangl A, Peck-Radosavljevic M. Antivir Ther. 2010;15(6):831-9.


  1835. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C
    Rao GA, Pandya PK. Gastroenterology. 2010 Sep 9. [Epub ahead of print]


  1836. Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities
    Maher L, White B, Hellard M, Madden A, Prins M, Kerr T, Page K. Vaccine. 2010 Sep 7. [Epub ahead of print]


  1837. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics
    Guedj J, Neumann AU. J Theor Biol. 2010 Sep 10. [Epub ahead of print]


  1838. Intensified peginterferon alfa-2a/ribavirin therapy for patients with HCV genotype 1, weight >/=85 kg and high viral load: randomized trial
    Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA; PROGRESS Study Investigators. Gastroenterology. 2010 Sep 2. [Epub ahead of print]


  1839. A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon ? and Ribavirin
    Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A, Ignaccolo L, Vadalà G, Misseri M, Maiorca D, Mastrosimone G, Judica A, Palermo F. J Clin Gastroenterol. 2010 Sep 8. [Epub ahead of print]


  1840. Hepatitis C virus infection: A "liaison a trois" amongst the virus, the host, and chronic low-level inflammation for human survival
    Barnaba V. J Hepatol. 2010 Jun 25. [Epub ahead of print]


  1841. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; the HALT-C Trial Group. Gut. 2010 Jul 30. [Epub ahead of print]


  1842. Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV- and HCV-Coinfected Patients
    Chary A, Winters MA, Kottilil S, Murphy AA, Polis MA, Holodniy M. J Infect Dis. 2010 Aug 2. [Epub ahead of print]


  1843. Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression
    Maluf DG, Archer KJ, Villamil F, Stravitz RT, Mas V. Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):445-58.


  1844. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis
    Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Int J Infect Dis. 2010 Jul 31. [Epub ahead of print]


  1845. Comparison of Immune Restoration in Early versus Late Interferon Alpha Therapy against Hepatitis C Virus
    Abdel-Hakeem MS, Bédard N, Badr G, Ostrowski M, Sékaly RP, Bruneau J, Willems B, Heathcote EJ, Shoukry NH. J Virol. 2010 Jul 28. [Epub ahead of print]


  1846. Acute Hepatitis C: Diagnosis and Management
    McLean OR, Herrera JL. PRACTICAL GASTROENTEROLOGY • SEPTEMBER 2007;31:66-77.


  1847. Management of Hepatitis C Virus Infection
    Tran LC, Woods AR, Herrera JL. Drug Benefit Trends 2004;16:266-276.


  1848. Hepatitis C: Who should be treated?
    Smith JR, Herrera JL. PRACTICAL GASTROENTEROLOGY • SEPTEMBER 2002;26:14-21.


  1849. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C
    Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK; International Hepatitis Interventional Therapy Group. Am J Gastroenterol. 2003 Nov;98(11):2354-62.


  1850. Increased prevalence of depression in hepatitis C infection patients
    Hjerrild S, Renvillard SG, Leutscher PD, Videbech P. Ugeskr Laeger. 2010 Jun 21;172(25):1889-1893.


  1851. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros
    Masuzaki R, Yoshida H, Omata M. Dig Liver Dis. 2010 Jul;42 Suppl 3:S281-6.


  1852. New Frontiers of HCV Therapy in HIV/HCV Co-infection
    Amorosa VK. Curr HIV/AIDS Rep. 2010 Jun 20. [Epub ahead of print]


  1853. Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy
    Hofer H, Aydin I, Neumueller-Guber S, Mueller C, Scherzer TM, Staufer K, Steindl-Munda P, Wrba F, Ferenci P. J Viral Hepat. 2010 Jun 21. [Epub ahead of print]


  1854. Gender influence on treatment of chronic hepatitis C genotype 1
    Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, Ferraz ML, Silva AE. Rev Soc Bras Med Trop. 2010 Jun;43(3):217-23.


  1855. Treatment options for HCV nonresponders and relapse patients
    Pearlman BL, Sjogren MH. Gastroenterol Hepatol (N Y). 2010 Mar;6(3 Suppl 6):1-12.


  1856. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
    Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Carlos Lopez-Talavera J, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Hepatology. 2010 May 14. [Epub ahead of print]


  1857. Treatment of Hepatitis C in Renal Transplantation Candidates: A Single-Center Experience
    Werner T, Aqel B, Balan V, Byrne T, Carey E, Douglas D, Heilman RL, Jorge. Transplantation. 2010 Jun 22. [Epub ahead of print]


  1858. Evidence for separation of HCV subtype 1a into two distinct clades
    Pickett BE, Striker R, Lefkowitz EJ. J Viral Hepat. 2010 Jun 21. [Epub ahead of print]


  1859. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
    Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS. Hepatology. 2010 Jun 1. [Epub ahead of print]


  1860. Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; and the HALT?C Trial Group. Hepatology. 2010 May 14. [Epub ahead of print]


 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.